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Abstract:  
 
Tracking Parkinson’s -The PRoBaND study (Parkinson's Repository of Bio samples 
and Networked Datasets)  
 
There is a wide variation in the phenotypic expression, progression rates, therapy response 
and complications in Parkinson’s disease (PD). The primary research objective in this thesis 
was to analyse the variation in the 4 domains of phenotypic expression i.e. motor, non-motor, 
cognitive, and quality of life in a subset of early onset Parkinson’s disease (EOPD) patients 
from the PRoBaND study, in the United Kingdom. The secondary objective was to explore 
the factors responsible for this variation or heterogeneity in the clinical characteristics. 
 
Linking genotypes with phenotypes, besides evaluating environmental risk factors and 
iatrogenic influences, represents one mechanism of understanding this variation in the 
phenotypic expression of PD.  
 
We found subtle but significant variation across all domains of symptoms examined in this 
thesis by classifying patients into groups according to motor subtype, gender, age at diagnosis 
and heritability of the parkinsonian trait, despite statistically insignificant differences in risk 
factors such as head trauma, exposure to pesticides (including herbicides, insecticides, 
fungicides and fumigants), heavy metals, caffeine and a past history of oophorectomy (in 
females) with the exception of smoking (p=0.046) and exposure to solvents, which were 
more common in males compared to females (p<0.001).  
 
There were differences in the prevalence of motor symptoms such as balance problems being 
more prevalent in the postural instability gait difficulty (PIGD) subtype compared to the 
tremor dominant PD (TDPD) and ‘Mixed’ motor subtypes both subjectively (p<0.001) and 
objectively (p<0.001). Other axial problems such as speech difficulties and freezing were also 
more prevalent in those with the PIGD phenotype compared to the other motor subtypes both 
subjectively (p=0.004, p<0.001) and objectively (p=0.002, p<0.001). There was also 
variation in the prevalence of motor complications such as dyskinesia (p<0.001) and dystonia 
(p=0.020), being more prevalent in the PIGD subtype compared to other motor subtypes. 
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The prevalence of certain non-motor symptoms such as pain (p=0.022) and features of 
gastrointestinal dysfunction e.g. prandial bloating (p=0.024) and constipation (p=0.022) were 
more commonly reported by females compared to males. 
 
There were also differences in the prevalence of cognitive impairment (p=0.049) and 
neurobehavioural characteristics such as anxiety (p=0.002) and depression (p=0.006), after 
the diagnosis of PD, being more prevalent in PIGD compared to other motor subtypes. 
  
Finally, these differences contributed  to the variation in the independence of activities of 
daily living scores which were lower in those with the PIGD phenotype compared to other 
motor subtypes (p<0.001).  
 
There were some differences in exposure to environmental risk factors for PD but not 
sufficient to explain all the variation. Iatrogenic influences from drugs contributed in part to 
the phenotypic variation. 10% of the cases in the EOPD cohort tested positive for mutations 
in one of three genes screened i.e. LRRK2, GBA and Parkin; their DNA remains banked and 
there is scope to test these cases for mutations in other genes, relevant to PD, in the future.  
There were too small numbers of cases in each subgroup to draw definite conclusions about 
the exact influence of genes on the overall phenotypic variation but differences between 
Parkin mutation carriers and gene test negative ‘controls’ such as early age of onset and long 
disease duration were obvious. 
 
PRoBaND is linked to other similar research studies in the UK, with the stated aim of sharing 
datasets, in the hope that larger numbers of patients and their DNA samples will increase the 
power, in statistical terms, to test hypotheses about the role of genetic markers in influencing 
the course and expression of symptoms. 
 
Our current understanding of PD as a complex trait suggests both genetic and environmental 
influences (including iatrogenic factors if patients are treated) play a role in the phenotypic 
expression of this condition. A lot more remains to be explored to improve our understanding 
of the finer details and molecular mechanisms underlying the variation in this disease.  
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Chapter 1.  The natural history of treated Parkinson’s disease 
  
 
 
 
In 1817 James Parkinson described the first cases of a disease that now bears his name but he 
mainly described the motor features of a condition that can have manifestations across 
several domains including cognitive, autonomic, psychiatric and behavioural on a vast non-
motor landscape. A broader description and understanding of how the disease unfolds over 
time and affects the body systems across the successive stages of this disorder is central to the 
process of treating patients afflicted by Parkinson’s disease (PD) in order that all the medical 
issues that merit attention are addressed without losing focus on the core disabilities arising 
from the motor dysfunction. 
 
The management of PD has changed over the last 200 years from Charcot’s use of anti-
cholinergics to treat his patients, as documented by his student Ordenstein in his doctoral 
thesis[1], to the breakthrough of finding the oral dopamine precursor ‘gold drug’ levodopa [2] 
following the discovery by Hornykiewicz of extensive reduction of dopamine in the brains of 
patients with PD [3]. 
 
While undoubtedly showing a beneficial effects on the core motor symptoms of bradykinesia, 
rigidity and tremor, some have argued that drug therapy has not changed the natural history 
of PD as mortality from the condition is not affected, there is no evidence that drug therapy 
can delay the onset of non-motor features such as dementia and even the response to some 
motor features such as falls is negligible[4]. Perhaps the finding that levodopa has limited 
beneficial effects on the non-motor symptoms of PD could be related to the involvement of 
biochemical pathways besides the dopaminergic neurotransmitter system in these 
manifestations of the condition[5]. The central pathology in PD though, is related to the loss 
of dopaminergic neurons in the substantia nigra and the accumulation of alpha-synuclien in 
neurons has a key role in the neurodegenerative process but how this process begins is still a 
matter of debate. Mutations in the gene coding for alpha-synuclein can cause PD but this is 
very rare.[6] Even mutations in other genes that can cause a phenotype of PD account for 
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only a minority of the total cases of PD; the majority of cases being currently labelled 
‘idiopathic’ PD. This may change in the years to come as our understanding of the pathogenic 
mechanisms evolves. 
 
Systematic reviews are one way of gathering all the data and evidence from studies 
previously conducted to obtain a broader view of how the natural history of PD evolves while 
allowing for standard treatment to be instituted. 
 
 
Parkinson’s disease on a timescale: A systematic review. 
 
 
Abstract  
 
Background 
Parkinson’s disease is the second most common neurodegenerative disorder affecting the 
elderly. In common with other neurodegenerative disorders it is a progressive condition. The 
progression of the motor symptoms of Parkinson’s disease with time is well documented. 
Non-motor symptoms usually emerge earlier on a time scale while cognitive problems 
emerge later. Disability in general increases with time and this may reflect cumulative 
deficits across motor, non-motor and cognitive domains.  
Objective  
To review the literature and summarize the data from large case series of both untreated and 
treated Parkinson’s disease to evaluate the progression rates in motor disability, the 
prevalence rates in non-motor symptoms, the changes in mortality data and the quality of life 
scores in these patients on a timescale.  
Data Sources  
Publications selected were based on original papers that had been abstracted in major online 
medical databases.  
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Study Selection 
Publications cited are those meeting inclusion and criteria described below that shed light on 
the variation in the progression of motor and the prevalence of non-motor symptoms in 
untreated and treated Parkinson’s disease, the standardised mortality ratios and quality of life 
of these patients that were published between Sep 1966 and Jan 2013. 
Data Extraction  
Data were primarily extracted from peer-reviewed literature appearing on Medline, Embase 
and Cochrane library. 
Data Synthesis  
Searches were limited to humans studies published in English. Hand searches were 
performed if references in the papers cited other sources that were missed on electronic 
searching.  
Conclusion  
The data available from this systematic review has helped us simulate the natural history of 
Parkinson’s disease. This can serve as a tool for comparison of the prospective data that will 
become available from current and future observational studies of Parkinson’s disease.  
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1.1 Introduction 
 
Parkinson’s disease first described in detail by James Parkinson in the early nineteenth 
century is a relentlessly progressive neurodegenerative disorder[7]. More recently, there is 
increased recognition that the underlying pathology in PD involves extranigral structures 
causing a host of problems affecting multiple body systems across motor, non-motor and 
cognitive domains. It is widely recognized that clinical progression of PD is 
multidimensional and is a function of time. Age at disease onset, duration of disease and 
pharmacological treatment with levodopa and dopamine agonists to a large extent determine 
the evolution of the global disability in PD. However genetic influences also contribute to the 
variation in progression rates of PD and several monogenic causes of autosomal dominant 
and recessive PD have been described.  
 
1.2 Methods 
 
1.2.1 Criteria for considering studies for this review 
 
i. Types of studies: A search for all studies describing 20 or more subjects with PD 
(clinically diagnosed PD patients, with or without controls, including treated and untreated 
cases) was performed. Both cross-sectional and longitudinal studies were included. 
Convenience samples and cohorts restricted by certain demographic factors such as age or 
institution were also accepted. 
ii. Types of participants: Diagnosis of PD required confirmation by an experienced 
physician, from history, examination and relevant investigations. Alternative diagnoses were 
excluded e.g. progressive supranuclear palsy, multiple system atrophy, and parkinsonism 
secondary to cerebrovascular disease or drugs. The progression of the disease should have 
been described over at least 1 year. No age group was excluded. 
iii. Types of outcome measures: The main outcome measure was the description of 
progression of motor and/or non-motor symptoms of Parkinson’s disease with time whether 
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treatment was commenced or not. Mortality rates in PD, causes of mortality, quality of life in 
PD and monogenetic causes of PD were also evaluated.  
iv. Search methods for identification of studies: Ovid databases (Medline, Old Medline, 
Embase, Embase Classic), were searched combining medical subheadings progression, 
Parkinson* disease using the boolean operator AND; limiting the searches to humans and 
English language. Duplicate searches were then removed. Separate searches were conducted 
in the Cochrane library. Hand searches were performed for studies cited under references of 
review articles that were not located with electronic searches of databases mentioned above. 
v. Scope of the review: Natural history of PD is affected by treatment with levodopa and 
progression rates in studies after 1967 when levodopa became available as the standard 
medical treatment will reflect treatment effects. Long term data on untreated cases post 1967 
is very limited but where available is included. Studies in selected populations e.g. elderly are 
included. Surgical interventions are not considered as they are beyond the remit of this 
review. The focus of this review remains the change in symptoms as a function of disease 
duration hence studies not indicating disease duration are excluded. 
 
1.2.2 Data collection and analysis 
 
i. Selection of studies: We identified 3738 abstracts in Ovid databases Medline and Embase; 
9 abstracts in Cochrane library combining MeSH disease progression, Parkinson* disease 
with the boolean operator AND. Limiting the abstract searches to English removed 209 
abstracts; restricting the studies to humans rejected 485 abstracts and removing duplicate 
entries between the Medline and Embase databases removed 771 entries.  Of the remaining 
abstracts, 136 abstracts fulfilled the inclusion criteria of case series containing 20 or more 
patients with Parkinson’s disease and enough information available to document the 
progression of Parkinson’s disease for at least 1 year. 
ii. Description of studies: Case series containing 20 or more subjects in which sufficient 
clinical features were present to diagnose Parkinson’s disease having excluded alternative 
diagnoses, reasonable descriptions of measures of disease progression were given, and 
enough information was available to assess response to treatment if this had been initiated,  
were summarized. 
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Figure 1.1 PRISMA diagram showing the process of paper selection for this systematic 
review. 
 
1.3 Results 
 
We summarize the key papers included in this review looking at 5 domains: cognitive, motor, 
non-motor, quality of life and morbidity/mortality in PD. Large scale studies of genetic cases 
of PD are limited but where available are included (all alphabetically listed in Tables). 
 
 
3747 abstracts 
3053 abstracts 
3538 abstracts 
2282 abstracts 
136 abstracts 
 
Limit studies 
to English  
 
 
Limit studies 
to humans 
 
 
Remove 
duplicates 
 
 > 20 patients, 
describing 
disease 
progression 
over 1 year 
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1.3.1 The natural history of untreated Parkinson’s disease  
 
Since the introduction of levodopa by Cotzias in 1967 as a standard treatment for PD there 
are only a few studies which can describe the natural history of drug naïve PD patients for 
brief periods before standard treatment is commenced[2]. In the pre-levodopa era Hoehn and 
Yahr’s seminal study of 856 parkinsonian patients seen at Columbia-Presbyterian medical 
center  from 1949-1964 included 672 patients with ‘primary parkinsonism’ or idiopathic 
Parkinson’s disease. The mean age at onset of disease was 55.3 years (range 17-89y) and men 
outnumbered women in a ratio of 2:1 (males 60.1%). Majority of the patients presented with 
a tremor (70.4%, 129/183) but non-motor presentations with pain, depression and 
paraesthesia were also recognized (13.1%)[8].  
 
1.3.2 Variable progression in motor disability and prevalence of non-motor symptoms 
 
1.3.2.1 Progression of motor dysfunction and prevalence of motor complications 
 
     a. Motor dysfunction 
 
Measuring progression of any symptom, sign or disability over time and comparing the 
available data from other sources requires the use of an instrument (scale) that is valid, 
consistent and reproducible. More importantly the use of disease specific scales is preferred 
to generic scales due to different disease and population characteristics. We will present the 
data using scale(s) that are used in current clinical practice for each symptom as opposed to 
historical scales in order that a comparison of data from the various studies included in this 
review can be made. A general discussion for sources of variance in results follows at the end 
and where necessary after an analysis of the data in each domain. A brief description of what 
each scale purports to measure is given prior to presenting the results. Details on the use of 
the various scales mentioned is beyond the remit of this review but a reference will be 
provided for each scale so that the reader is directed to a more detailed description on its 
application. 
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Progression of motor symptoms has historically been measured using several scales including 
Hoehn and Yahr (HY), Columbia University rating scale and Webster to name a few. More 
recently Unified Parkinson’s disease rating scale (UPDRS) and its adaptation Movement 
Disorder Society UPDRS (MDS-UPDRS) scales have become standard instruments for 
measuring motor symptom progression. Nevertheless HY scale for its simplicity continues to 
be used alongside the UPDRS and we have summarized our data from the studies included in 
this review using both instruments where available (Table 1.1). Those studies which lasted 
for less than 52 weeks such as TVP-1012 in Early Monotherapy for Parkinson's 
Disease Outpatients (TEMPO) (25 weeks) are not included as they do not meet the inclusion 
criterion for duration of observation but exceptions have been made where studies that have 
historical importance such as Earlier versus Later Levodopa Therapy in Parkinson Disease 
(ELLDOPA) (42 weeks) have been included. 
The HY scale measures unilateral (HY-1) versus bilateral involvement (HY-2), normal 
balance versus postural instability with independence in daily activities (HY-3), and the 
ability to walk with assistance (HY-4) versus wheelchair dependency (HY-5). A modified 
version of this scale that is currently in use allows for intermediate stages 1.5 where axial 
involvement is present and 2.5 where disease is bilateral and mild but postural imbalance 
occurs. 
HY staging records progression of motor disability on a categorical (non-parametric) scale as 
opposed to UPDRS Part 3 which records motor disability on a relatively continuous scale 
(parametric) from 0-108. UPDRS consists of 4 parts with the first 3 parts containing 44 
questions each scored on a 0-4 scale (total for first 3 parts 0-176) and part 4 contains 11 
questions and the total scores on part 4 can range from 0-23. Part 1 records mentation, 
behaviour and mood, part 2 records activities of daily living, part 3 records the motor 
disability and part 4 records complications of therapy. A modified version of this currently in 
use (MDS-UPDRS) extends the motor disability scale (part 3) to record the motor 
examination, in particular the tremor, in more detail so that the range of score extends from 0-
136. 
The annual rate of progression from the studies included in this review is 1.5 to 5.3 points on 
the UPDRS3 scale. (Table 1.1) The variation is accounted for partly by the fact that 
dopaminergic treatments have been commenced in these patients at various times after 
diagnosis singly or in combination. This pattern reflects standard clinical practice wherein 
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patients are commenced on treatment based on patient and physician preference, usually 
when motor disability becomes significant, and this point in time varies. Most of the evidence 
about annual rates of progression in the post levodopa era comes from drug trials which have 
a placebo arm and in particular those trials conducted after 1987 when the UPDRS scale, the 
most commonly used research tool to evaluate drug treatments in PD, in its current form 
came into use. In the pre-levodopa era one of the most remarkable pieces of evidence comes 
from Hoehn and Yahr’s original case series (n=672) which in contrast documented the 
progression of motor disability step-by-step on the HY scale in years. The average duration in 
stage 1 was three years, stage 2 six years, stage 3 seven years, stage 4 nine years and stage 5 
fourteen years[8]. In the post levodopa era a study of a similar magnitude in terms of 
longitudinal follow up is the Sydney multicenter study (n=126). From this longitudinal study 
the reported average times spent in HY stage 1 and stage 2 (by those who entered the study at 
these stages, 65.8%) was 3.5 y, in stage 3 was 7 years and in stage 4 was 6 years.(Table 1.1) 
No statistically significant differences were found comparing the 15 year HY staging data 
from the Sydney mulitcenter study (patients treated with levodopa) with the 15 year data 
from the original Hoehn and Yahr’s pre-levodopa era study (p> 0.05)  suggesting that 
although levodopa improves symptoms in the first few years, the disease probably continues 
to progress at the same rate with or without levodopa [9]. 
As opposed to real time data computational Markov modelling to estimate the step-by-step 
progression rates from H&Y stages I to II, II to III, and III to IV or V has also been used  in 
newly diagnosed cases (n=71).Stages IV and V were grouped together because of the 
sparseness of cases. Annual progression rates were first calculated and the inverse of each 
progression rate was then used to calculate the average time spent in stages I, II and III. The 
average duration in stages I was 2.8 years, II was 6.6 years and III was 1.4 years. The average 
delay time until progression to stage IV or V was therefore about 11 years[10] compared to 
16 years in the Hoehn Yahr series[8]. 
The rate of progression of motor disability as well as age of onset is prognostically important 
and is one of the factors that have an impact on the quality of life in PD. There was an 
increased hazard ratio for death (1.4), disability (2.7) and cognitive impairment (4.3) with 
each 10 unit increase on the UPDRS scale. Age at study entry increased the hazard ratios to 
49.1 for death, 4.76 for disability and 90.0 for cognitive impairment at age 60 years [11]. 
Earlier onset of postural instability (HY stage 3) reflecting a relatively faster rate of 
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progression had a significant impact on the quality of life in a representative study of PD 
patients (n=132) [12]. 
Data from studies using instruments that are not used in current clinical practice/research 
protocols such as University of California Los Angeles (UCLA) and New York University 
(NYU) scales have not been included for purposes of comparison. 
Based on motor phenotypes those presenting without tremor also called postural instability 
gait difficulty (PIGD) have a faster rate of progression of motor disability [8, 13, 14]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
Table 1.1 Progression of motor dysfunction in Parkinson’s disease with time (papers listed 
alphabetically in table). 
 
Study (Year) N UPDRS 3* 
(annual 
increment) 
Time spent in HY stages  
HY 1 HY2  HY3  HY4  HY5 
Alves et al (2005) [15] 232   3.3   5.1-9.3y    
Hely et al (1999) 
†
[16] 149    3.5y
‡
 7y
‡
 6y
‡
   
Hoehn et al (1967) [8] 183  3y
†
 6y
†
 7y
†
 9y
†
 14y
†
 
Jankovic et al (2001)[13] 297  1.39
§
      
PSG (1996) 
¶
[17] 66
P
 5.3      
Liou et al (2008) [10] 37  2.8y 6.6y 1.4y   
Louis et al (1999) [18] 237 1.5 -3.6       
Lopez et al (2010) [19] 43
L
 
21
N
 
3.9
\\
 
       2.9
\\
 
     
Marttila et al (1977) [20] 419  2.9y 2.6y 2y 4.2y  
PSG (1993) 
**
[21] 57
P
 3.62 
 
     
PSG (2004) 
††
[22] 70
P
 5.2 
‡‡
      
Schrag et al (2007) [23] 145 3.3      
Shults et al (2002)
£ 
[24] 16
P
 5       
N=number of cases, UPDRS3= Unified Parkinson’s disease rating scale Part 3, *= annual increase, HY= 
Hoehn Yahr stage ,  †= Sydney Multicenter study, ‡ median , PSG=Parkinson Study Group,  ¶ 
=Lazebamide study, 
P 
= in placebo arm, 
L
 = L-DOPA arm, 
N
= non-LDOPA arm,  § for ‘off’ state , \\ after 
1st year,
 **
 DATATOP study, †† ELLDOPA study, ‡‡ 42 weeks ,  £ Coenzyme Q10 study 
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b. Motor complication rates 
 
Motor complications inevitably occur in the later stages of PD and in fact dyskinesias 
occurring with levodopa are considered to be one of the characteristics of idiopathic 
Parkinson’s disease. Dyskinesias are involuntary abnormal movements which can affect any 
part of the body. This term encompasses both choreiform and dystonic movements. These 
may be related to dopamine levels in the body such as with ‘peak dose dyskinesia’ but in the 
later stages of PD this relationship becomes more complex. Freezing or motor block is an 
episodic inability (usually lasting seconds) to generate effective stepping in the absence of 
any known cause other than parkinsonism or high-level gait disorders[25]. Rapid changes 
from an ‘on’ state when medication is working well to ‘off’ state when medication effects 
have largely dissipated are called ‘on’ ‘off’ fluctuations while a more gradual transition from 
‘on to ‘off’ is called wearing ‘off’. Motor complications can be recorded and their severity 
assessed in individual patients with UPDRS or MDS-UPDRS part 4. This part of the UPDRS 
records dyskinesia , ‘on’ ‘off’ fluctuations and wearing ‘off’ but does not record freezing 
which is recorded in part 3 of the scale. Data from cross-sectional studies is useful when 
determining the prevalence of these complications in a population (Table 1.2). Prospective 
studies have shown that motor complications increase with disease duration and are also 
related to initial treatment (levodopa vs. others) (odds ratio OR 3.87), age at onset (OR 0.90), 
and sex (OR 12.87) [26]. 
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Table 1.2 Prevalence of motor complications of the disease on a time scale (papers listed 
alphabetically in table). 
Study (Year) N Dur. Dyskinesia FOG ‘On’ ‘Off’* Wearing ‘off’ 
Hauser et al (2007)[27] 42
R
 
27
L
 
10y 
52.4% 
77.8% 
  62.5%
†
 
72.0%
†
 
Hely et al (1994)‡ [28] 62NL 
64
L
 
5y 27.4% 
54.7% 
  41% 
37% 
Holloway et al (2004) 
[29] 
151
P
 
150
L
 
4y 
37% 
81% 
56% 
38% 
10% 
12% 
71% 
94% 
Korczyn et al (1997) 
[30] 
168
R
 
167
B
 
3y 
7.7% 
7.2 % 
   
Lopez et al (2010) [19] 
 
 
 
 
  43
L
 
 
 
21
N
 
 
 
 
3y 
 
34.9% 
4.8% 
16.3% 
0% 
34.9% 
0% 
 
 
 
 
5y 
 
51.2% 
9.5% 
30.2% 
4.8% 
65.1% 
19% 
7y 
 
53.6% 
35.7% 
42.9% 
42.9% 
82.1% 
37.5% 
10y 
84% 
46.2% 
76% 
61.5% 
96% 
92.3% 
Montastruc et al (1994) 
[31] 
29
L
 
31
N
 
3y 
48.3%  
12% 
  34.5% 
40% 
Poewe et al (1986) [32] 35
L
 6y 54%  6% 52% 
Rascol et al (2000) [33] 179
R
 
89
L
 
5y 20%  
45%  
32% 
25% 
 
 
23% 
34% 
Rinne et al (1989) [34] 25
L
 
5
l
 
27
Ll
 
20l
L
 
 
4y 
64% 
0% 
19% 
20% 
16% 
0% 
14% 
20% 
 52% 
0% 
7% 
20% 
Ruiz et al (2004) [35] 36
L
 
 
23
N
 
3y 5% 
25% 
8% 15% 
10% 
 
5y 
40% 
20% 
27% 45% 
20% 
Ruiz et al (2012) [26] 
 
25
L
 
20
N
 
7y 60% 
45% 
52% 
35% 
88% 
50% 
 
10y 
72% 
50% 
76% 
60% 
96% 
85% 
 
N= number, Dur= duration in years, FOG=freezing of gait, R= Ropinirole, L=Levodopa, 
‡ 
Sydney 
multicenter study, NL= non-levodopa medication, P=Pramipexole, B=Bromocriptine, l=lisuride * ‘on’ 
‘off’ includes ‘off’ period dystonia †mild wearing ‘off’ 
 
33 
 
1.3.2.2 Non-motor symptoms of Parkinson’s disease on a timeline 
 
Although James Parkinson may not have recognized the importance of non-motor symptoms 
(NMS) in the disease that bears his name, describing Paralysis Agitans “with the senses and 
intellect being uninjured”, these symptoms are very common in PD. 98.6% of 1072 
consecutive patients with PD in the PRIAMO (Parkinson and non motor symptoms) study 
reported the presence of non-motor symptoms[36]. These symptoms affect patients’ quality 
of life, perception of disability levels [37] and most importantly can precede the diagnosis of 
PD by years which may provide an important time window for neuroprotective interventions 
(Table3). 
Non-motor presentations of PD have been recognized for a long time [8] and are perhaps 
more common than previously thought. In 433 cases with pathologically proven PD, 91 
(21%) had exclusively non-motor symptoms at presentation to their general practitioner. Of 
the NMS, pain was the most frequent, seen in 53% of these cases, urinary symptoms were 
present in 16.5%, depression or anxiety in 12.1% [38]. 
a. Pre-motor symptoms  
 
A concept of pre-motor PD has emerged from imaging and pathological evidence of cell loss 
in the nigrostriatal dopaminergic system preceding the diagnosis of PD. By the time patients 
fulfil the diagnostic criteria for the diagnosis of PD, which are biased towards motor 
symptoms, there may be degeneration of  about 50-60% of neurons in the substantia 
nigra[39]. The duration of the premotor phase following the onset of neuronal cell death is 
variable, but from pathological and radiological estimates has been considered to be between 
3 and 5.5 years although in individual cases this can be more than a decade[40-43]. 
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Table 1.3 Pre-motor symptoms in Parkinson’s disease (papers grouped alphabetically in 
table). 
Study (Year) Olf. 
%/OR 
(yrs.*) 
RLS/EDS 
OR 
(yrs.*) 
RBD 
% 
(yrs.*) 
Constip. 
OR 
(yrs.*) 
Auto. 
OR 
(yrs.*) 
Dep/Psy 
OR 
(yrs.*) 
Abbott et al (2001) 
[44]   N=6790  
   2.7-4.5 
(12y) 
  
Gao et al (2011)[45] 
N=107,668 
   5m, 2.1f 
( 6y) 
  
Savica et al (2009) 
[46]   N= 202 
   3.0 
(>20y) 
  
Haehner et al (2007) 
[47]   N=30 
7% 
(4y) 
     
Ponsen et al (2004) 
[48]   N=361 
10%  
(2y) 
     
Ponsen et al (2010 
[49]  N=361 
12%  
(5y ) 
     
Ross et al (2008) 
[50]  N=2,267 
OR 5.2 
(4y) 
     
Olson et al (2000) 
[51]  N=92 
  14.1% 
(3y) 
   
Postuma et al (2009) 
[52]  N=93 
  16% 
5y 
   
Schenck et al (1996) 
[53] N=29 
  38% 
(13y) 
   
Gao et al (2007) 
[54] N=32,616 
    3.8
§
 
(14y) 
 
Fang et al (2010) 
[55]  N=279,958 
     2.7 
(11y) 
Santamaria et al 
(1986) [56] N=34 
     14.7 % 
(5y) 
Schuurman et al 
(2002) [57] N=1358 
     3.1 
(10y) 
Shiba et al (2000) 
[58] N=392 
     1.4
d
, 2.1
a
 
(5y) 
Taylor et al (1999) 
[59]  N=148 
     3.0 
(22y) 
Abbott et al (2005) 
[60]  N=3078 
 3.3 
(8y) 
    
Olf= olfactory dysfunction, RLS= Restless legs syndrome/ EDS= excessive daytime sleepiness, RBD= 
REM sleep behaviour disorder, Constip=constipation, Auto= Autonomic symptoms, Dep/Psy = 
Depression/Psychosis, yrs.*= years before diagnosis of PD, N=number of subjects, OR=odds ratio, § 
erectile dysfunction, m= male, f=female , d= depression, a = anxiety 
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Large prospective population-based registries have provided valuable information on the 
odds ratio of developing Parkinson’s disease with non-motor symptoms such as olfactory loss 
that predate the motor symptoms and may be a useful screening tool to detect those at high 
risk for development of PD in later life. 
Olfactory dysfunction was found to increase the odds ratio of developing PD in the next 4 
years by 5.2 in the large Honolulu-Asia Aging (HAA) study (n=2,267) [50] and roughly 
about 1 in 8 with olfactory dysfunction in another series (n=361) went to develop PD over the 
next 5 years [49] . Nevertheless not all those who have idiopathic olfactory dysfunction went  
on to develop PD. Some have therefore argued diagnosing premotor Parkinson's disease 
using a two-step approach combining olfactory testing and dopamine transporter (DAT 
SPECT) imaging [61]. 
Another report emerging, from the HAA study (n=3078, age 71-93y), reported the risk of 
developing Parkinson's disease in men with excessive daytime sleepiness was considerably 
higher than in those without (odds ratio, 3.3) (95% CI = 1.4 to 7.0; p = 0.004) after 8 years 
[60].   
Constipation has also been thought of as a pre-motor symptom in Parkinson’s disease even 
though this is a common symptom in otherwise normal people and depends a lot on prevalent 
dietary patterns. In the Honolulu Heart Program, follow up of 6790 men aged 51-75 years, 
over a 12 year period, showed the incidence of developing Parkinson's disease increased with 
decreasing numbers of bowel movements per day. Men with <1 bowel movement/day had a 
2.7-fold excess risk of PD versus men with 1/day (95% CI: 1.3, 5.5; p = 0.007) and this risk 
almost doubled when compared with men with 2/day (95% CI: 1.7, 9.6; p = 0.001) [44]. 
Other studies have also suggested a 2-5 fold increased risk of developing PD up to 20 years 
later in those with otherwise unexplained constipation compared to those with normal bowel 
habits[45, 46]. 
The association between preceding psychiatric disorders and PD using a case control design 
has also been evaluated. The frequency of psychiatric disorders was higher in cases than in 
control subjects at 5 years follow up; the odds ratio was 2.1 for anxiety disorders (95% 
confidence interval [CI] 1.3–3.2; p=0.001), 1.4 for depressive disorders (95% CI 0.8–2.6; p 
=0.3), and 2.4 for both anxiety disorders and depressive disorders occurring in the same 
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individual (95% CI 1.2–4.8; p= 0.02)[58].Other studies have also suggested an increased risk 
with odds ratio of 2-3 [55, 59]. 
REM sleep behaviour disorder preceding PD has been well documented [51]. The first 
comprehensive report of RBD as a predictor of neurodegenerative disease found that 38% of 
29 male patients had developed a parkinsonian disorder 5 years after the diagnosis of 
idiopathic RBD [53]. A study of 93 patients with RBD diagnosed with polysomnography 
over 5 years showed that about 16% went on to develop parkinsonism[52]. 
Autonomic symptoms such as erectile dysfunction have been reported up to 14 years before 
developing PD. Men with otherwise unexplained erectile dysfunction were 3.8 times more 
likely to develop PD (n=200) during the follow-up than were those with very good erectile 
function(n=32,416) (relative risk = 3.8, 95% confidence interval: 2.4, 6.0; p < 0.0001)[54].  
 
   b. NMS after diagnosis of PD 
 
As with motor dysfunction the proportion of patients experiencing non-motor symptoms is a 
function of time. (Table 1.4) A survey of a very large cohort of PD patients (n=10,101) 
showed that the percentage of people with PD experiencing NMS increased with the duration 
of the disease and there was an inverse correlation between the prevalence of NMS and 
quality of life (PDQ-8 scale) [62].  
 
1. Olfactory Dysfunction in PD   
 
Olfactory dysfunction is very common in PD but under reported by patients to their doctors. 
72 % of PD patients were unaware of a smell disorder before testing; those who were aware 
had significantly lower test scores objectively compared to established norms[63]. Olfactory 
dysfunction is present in up to 90% of PD patients ultimately but comparison across studies is 
restricted with some studies using tests recording odour identification, odour discrimination, 
odour thresholds and variable cut-offs in the tests utilized. 
There are several different tests to measure olfactory acuity in PD. It is important to 
understand what is being measured by a test under consideration as it is not possible to make 
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a direct comparison between two studies reporting results using different tests. Some 
olfactory tests are used for odour identification(OI) e.g. University of Pennsylvania Smell 
Identification test (UPSIT), some measure odour discrimination(OD) egg Düsseldorf Odour 
Discrimination Test,  some record olfactory thresholds (OT) such as phenyl ethyl alcohol       
(PEA) or elecrogustatometry  while others such as Sniffin Sticks
® 
(Burghart GmbH, Wedel, 
Germany) detect all three. UPSIT (and its versions such as brief smell identification test, 
BSIT, and cross cultural smell identification test, CCSIT) and Sniffin' Sticks
®
 test are the best 
validated tests in PD. For a detailed description of the test procedures and cut-offs please see  
Doty et al, 1984[64] and Hummel et al ,1997[65].  
Previously olfactory dysfunction has been reported to be independent of disease duration 
[63], however, more recent reports suggest olfactory dysfunction correlates with disease 
duration [66, 67] . We included studies that provide a measure of disease duration as 
described in the inclusion criteria. (Table 1.4) 
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Table 1.4 Olfactory dysfunction in Parkinson’s disease on a time scale (papers listed 
alphabetically in table). 
Study (Year) N 
 
Olfactory dysfunction (%) Test 
Duration (years) 
(mean or range as provided by authors) 
 0-5y 5-10y 10-15y 15-20y  
Boesveldt et al 
(2008) [68] 
404 65%† 
(0-44y) 
SS 
Doty et al 
(1988) [63] 
81   38 % d 
(12y) 
 UPSIT 
Double et al 
(2003) [69] 
49 82% 
(0-1y) 
   B-SIT 
Haehner et al 
(2008) [47] 
400  52 %
e
 
 45 % d 
(7y) 
  SS 
Ramjit et al 
(2010) [66] 
 
58 
 
 
 
 
 8 % a 
8 % 
b
 
47 % 
c
 
33 % 
d 
(11y) 
 UPSIT 
Ward et al 
(1983) [70]  
72  39% 
(10y) 
  PEMEC 
Amyl acetate 
4 odorants 
N= number of cases , † 65% had deficits in olfactory identification while 42% had deficits in olfactory 
discrimination, SS-Sniffin Sticks, UPSIT-University of Pennsylvania Smell Identification test, B-SIT – 
brief smell identification test, * both anosmic and hyposmic, not age-adjusted for norms. a= mild 
hyposmia, b=moderate hyposmia, c=severe hyposmia, d=anosmia, e= any degree of hyposmia f= 
hyposmia or anosmia, PEMEC=phenylethylmethylethyl carbinol, 4 odorants: coffee, cinnamon, cherry 
and strawberry. Note: Studies not documenting duration of PD have been excluded.   
 
 
The results of olfactory identification tests can be conditioned by cultural backgrounds, so it 
is important that the odorants used, as well as the odours suggested as possible answers, 
belong to the cultural background of the population which is tested. Therefore modifications 
of UPSIT for different ethnic populations have more recently been used in PD [67]. 
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It is obvious that there are grades of olfactory loss from mild to severe hyposmia (also called 
microsmia) and anosmia. Most patients in PD have some degree of olfactory loss and there 
are reports that suggest that this is more likely to be in the mild-moderate end of the spectrum 
in early disease (<5 years) and severe hyposmia to anosmia later in the disease (> 10 years) 
[63] [66]. However, Double et al (2003) did not demonstrate any significant differences in 
olfactory dysfunction in the PD cohort across Hoehn Yahr stages I-III with an average 
disease duration of 1 year [69].  
The cut-offs for defining hyposmia, normosmia and anosmia have varied from study to study 
both because of varying methodology used to detect odour deficits and the use of age 
matched controls to define limits of normal olfactory acuity that decreases with age. 
 
2. Autonomic symptoms in PD  
 
The range of autonomic symptoms that patients with PD experience is wide and includes 
gastrointestinal, cardiovascular and urinary dysfunction. These symptoms like other NMS are 
usually under reported. However when patients are asked to fill in questionnaires for 
autonomic symptoms the prevalence of these problems becomes evident. 89 % of PD patients 
(n=48) had at least one autonomic symptom from constipation, erectile dysfunction, bladder 
dysfunction, dysphagia and orthostatic dizziness, compared to 43% of healthy control 
subjects (n=32) in a questionnaire based survey (p < 0.05)[71]. Since then more structured 
instruments for recording the prevalence and severity of autonomic symptoms in PD have 
become available. 
Scales for Outcomes in Parkinson's disease – Autonomic (SCOPA–Aut) is a validated 
questionnaire in PD for recording the presence of most autonomic symptoms. It contains 23 
items in six domains: gastrointestinal functioning (7 items), urinary functioning (6 items), 
cardiovascular functioning (3 items), thermoregulatory functioning (4 items), pupillomotor 
functioning (1 item), and sexual functioning (2 items for men and 2 items for women). For 
further details on test performance and scoring please refer to Visser et al, 2004 [72]. 
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Table 1.5 Autonomic symptoms in PD with disease duration (papers listed alphabetically in 
table). 
 
Study (Year) N  Dur. Constip. Bladder Sexual 
 
OS Hyperh. Sialo. 
 
Edwards et al 
(1991) [73] 
19* 
79† 
2.7y  
8.4y 
5%  
35% 
    74%  
69% 
Korchounov et 
al (2005) [74] 
532 
 
6.2y 58.6% 
 
22.4% 
 
17.5% 
 
29.5% 
 
23.5% 
 
 
Magerkurth et 
al (2004) [75] 
141 6.3y  45%  64%
 m
 
 
48%  46%   
Muller et al 
(2013) [76] 
31* 
140† 
2.1y  
2.4y  
41.9% 
33.6% 
51.6% 
36.4% 
 
 
25.8% 
30.0% 
 41.9% 
37.1% 
Ramjit et al 
(2010) [66] 
58 11y 67.3%   10%
‡
   
Sakakibara et 
al (2001) [77] 
115 6y 63% 
f
 
69% 
m
 
42% 
f
 
54% 
m
 
84% 
f
 
83%
 m
 
  
 
 
Siddiqui et al  
( 2002) [78] 
44 8.3y 20.4% 
 
68.2% 
 
70%
 m
 
 
11-66%  52.3% 
Singer et al 
(1992) [71] 
48 8y 43.9 % 45.8% 60%
 m
 21.9%   
Verbaan et al 
(2007) **[79] 
420 10.5 
y 
50% 67% - 
90% 
 4-56% 
 
 73% 
 
N=number of cases, Dur. = duration of disease, ** those scoring >1 on the items for SCOPA-AUT, 
Bladder = bladder dysfunction (this includes urinary urgency) Sexual = Sexual dysfunction (this includes 
erectile dysfunction) OS = orthostatic symptoms (this includes syncope), Hyperh. = hyperhidrosis, Sialo. = 
sialorrhoea, m= males, f= females, *treated with dopaminergic medications, † drug naive, ‡ drop of 
systolic blood pressure of 20mm Hg on standing 
 
 
 
 
 
Some of these autonomic problems may be either iatrogenic or exacerbated by anti-
parkinsonian medication. Higher doses of dopaminergic medication were related to more 
autonomic problems in a study of 420 patients with PD [79]. Autonomic symptom severity 
was associated with other NMS including depressive symptoms, cognitive dysfunction, 
psychiatric complications, night-time sleep disturbances, and excessive daytime sleepiness 
(all p values < 0.01) [76]. 
 
The prevalence of autonomic symptoms in PD has been reported to be between 14-80% [80] 
but this is largely based on reports looking at one domain of autonomic dysfunction and 
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perhaps a true estimate is difficult to quantify into a single figure given that the frequency and 
prevalence of individual autonomic symptoms varies so widely (Table 1.5). The prevalence 
can vary from 25% for orthostatic symptoms to 51% for urinary dysfunction very early in the 
disease (2 years from diagnosis) to 56% for orthostatic symptoms and up to 87% for urinary 
dysfunction (nocturia) late in the disease (10 years from diagnosis) [76, 79] . 
Constipation, which is a prominent pre-motor symptom as well, is variably defined in PD 
studies as being frequency of bowel movement less often than one per day (normal being 
greater than three stools per week) to less than three per week [73], but other studies also base 
their definition on stool consistency and frequency of straining. While constipation is not the 
only symptom of gastrointestinal dysfunction in PD, defecatory dysfunction (i.e. straining, 
incomplete evacuation) is reported as the predominant disorder of bowel function in PD 
rather than decreased frequency [73]. Other symptoms of gastrointestinal dysfunction 
including bloating, abdominal pain, nausea, vomiting, heartburn and dysphagia can also 
concomitantly present in 10-50% of patients [73]. 
Hoehn & Yahr (H&Y) stage, disease duration, age at onset and various therapy combinations 
all show significant correlations with autonomic dysfunction scores. However, PD patients 
show higher autonomic dysfunction scores than controls, even in the mild disease stages of 
the disease suggesting autonomic dysfunction as an inherent feature of PD [74].  
 
3. Depression/Anxiety  
 
Depression may precede or follow the motor symptoms of PD. Depending on the study 
designs, diagnostic criteria and the scale used for recording the symptoms, the prevalence of 
depression in PD is reported to be between 7 and 70% (Table 1.6), higher prevalence in 
hospital based cohorts may reflect a selection bias, towards the more severely affected 
individual requiring hospital placements. Minor depressive symptoms are present in a higher 
proportion of patients (70%) [81] in some series; the proportion of patients fulfilling DSM 
III/IV criteria for major depression is relatively lower in the range (13-30%) [82-86] in most 
series suggesting that the mild to moderate severity of the spectrum is the predominant 
phenotype encountered in clinical practice. In Starkstein’s series major depression was 
commoner than minor depression however this was a hospital clinic based series as opposed 
to a community based series and it is argued that hospital based series in general can be 
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biased towards the more severe spectrum of the disease because those with minor symptoms 
would be less likely to seek medical attention in a hospital [85]. Most of the evidence about 
the prevalence comes from cross-sectional studies and it is difficult to make an exact 
comparison when different diagnostic criteria and instruments to detect depression and other 
psychiatric co-morbidities are employed. In Giladi’s series (n=172) depression was 
associated with progression of the disease measured on the HY scale and earlier age at 
disease onset [87] and while the correlation between HY stage and depression was borne out 
in the larger (n=1449) German Study on the Epidemiology of Parkinson's Disease with 
Dementia (GEPAD) series but the correlation with disease onset didn’t hold true. Females 
were more commonly affected than men with PD as in the general population. The 
importance in recognizing depression is that it is perhaps the variable with the most 
significant impact on the quality of life in PD [88].  
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Table 1.6 Psychiatric problems in PD with disease duration (papers listed alphabetically in 
table). 
 
Study 
(Year) 
Number 
 
Dur. 
 
                  Psychiatric co-morbidity in PD Scale/ 
Criteria 
Major 
depres. 
Dysthymia Minor 
depres. 
Anxiety Hypomania 
Bieliauskas et 
al (1989) 
N=33 [81] 
 
9y 
   
70%
 
 
  
MMPI- D, 
HDRS 
Brown et al 
(1990) 
N=40 [89] 
 
11y 
   
25% 
 
 
12.5 % 
 
PSE-10, 
ICD-9 
Cole et al 
(1996) 
N=31[82] 
 
8y 
 
13% 
 
 
10% 
 
   
6.5 % 
 
 
DSM III R 
Dissanayaka 
et al (2010) 
N=79 [90] 
 
8.2y 
 
11% 
 
6% 
 
6% 
 
25% 
3% 
  
DSM-IV 
Giladi et al 
(2000) 
N=172 [87] 
 
11y 
 
33% 
     
DSM-IV 
Leentjens et al 
(2012) 
N=132 
N=118 
[91] 
 
 
6.4y 
10y 
    
 
9% 
23% 
  
 
HARS, 
DSM-IV 
Mayeux et al 
(1981) 
N=55 [83] 
 
9y 
 
3.6% 
     
BDI 
Riedel et al 
(2010) 
N=1449 [92] 
 
5.8y 
 
25.2% 
    
MADRS 
DSM IV 
Schrag et al 
(2001) 
N=97 [84] 
 
5.8y 
 
19.6%* 
     
BDI 
Starkstein et al 
(2007) 
N=173 [85] 
 
6.4y 
 
30%  
 
20%  
 
10%  
  
HDS, 
DSM IV 
Tandberg et 
al (1996) 
N=245 [86] 
 
8y 
 
7.7 %  
    
MADRS, 
BDI 
Depres.= depression MMPI D Minnesota Multiphasic Personality Inventory D scale , HDRS- Hospital 
Depression Rating Scale, PSE 10 (Present State Examination, 10th edition), ICD 9- International system 
for classification of diseases , 9th edition,  DSM III R= Diagnostic and Statistical Manual, 3rd edition, 
Revised ;  BDI=Beck Depression inventory,  * BDI>17 which signifies >borderline depression, DSM IV- 
Diagnostic and Statistical Manual, 4thedition, HARS- Hospital Anxiety Rating scale, HDS- Hamilton 
Depression rating scale , MADRS- Montgomery-Asberg depression rating scale. Note: Only studies 
utilizing set diagnostic criteria and rating scales included. 
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Anxiety is a common neuropsychiatric symptom in PD occurring in 9-25% of patients 
(Tables 1.6) and seems commoner in the later stages of disease (HY) however patients 
meeting criteria for Generalized Anxiety Disorder are considerably less. Anxiety also affects 
quality of life and adds to the complexity of PD [90].  
 
4. Restless Legs Syndrome (RLS) 
 
Restless legs is a common symptom in PD and can affect 0-25% of patients.(Table 1.7) 
Earlier studies may not be truly representative of the prevalence of RLS in PD due to possible 
misdiagnosis of nocturnal dyskinesia and akathisia that often occur in PD patients with 
RLS[93]. The use of validated criteria such as International RLS Study Group (IRLSSG) is 
therefore recommended. The Memory and Morbidity in Augsburg Elderly (MEMO) study 
provided a background rate of about 0.1%-10% in a community based cohort of people> 55 
years without PD. This is significantly lower than the prevalence of RLS in PD. RLS 
symptoms are present in other parkinsonian disorders but much less frequent than in PD[94]. 
RLS is associated with periodic leg movements of sleep which contribute to the disrupted 
sleep pattern of these patients. The role of dopamine in the pathophysiologic mechanisms of 
RLS is supported by the improvement of symptoms with dopaminergic drugs.  
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Table 1.7 Prevalence of restless legs symptoms in PD with disease duration (papers listed 
alphabetically in table). 
Study 
(Year) 
 
N 
                      Duration of PD Diagnostic 
criteria 
0-5y 5-10y 10-15y 15-20y 
Bhalsing et al 
(2013) [94] 
134 
 
11.9% 
(4.6y) 
 
 
   
IRLSSG 
Gomez-
Esteban et al 
(2007) [95] 
114  21.9%
 
(7.1y) 
  IRLSSG 
Krishnan et al 
(2003) [93] 
126  7.9% 
(5.4y) 
  IRLSSG 
Nomura et al 
(2006) [96] 
165  12% 
(10y) 
  IRLSSG 
Ondo et al 
(2002) [97] 
303 20.8% 
(>4.5y) 
IRLSSG 
Peralta et al 
( 2009) [98] 
113  24% 
(9y) 
  IRLSSG 
Tan et al 
( 2002) [99] 
125  0% 
(5.5y) 
  IRLSSG 
N=number of cases, International RLS Study Group (IRLSSG) 
 
 
 
 
5. REM sleep behaviour disorder (RBD) 
 
The diagnostic criteria for RBD, in the International Classification of Sleep Disorders 
(ICSD), include movements of limbs or body associated with dream mentation and at least 
one of the following: potentially harmful sleep behaviour, dreams that appear to be “acted 
out”, or sleep behaviour that disrupts sleep continuity. PSG is not mandatory in these criteria. 
However, for two reasons studies with clinically probable RBD have not been included. First, 
reliable information from bed partners is not available in all patients. Second, patients with 
PD who are taking dopaminergic medication may show a variety of abnormal nocturnal 
motor and non-motor behaviours such as confusional states, hallucinatory episodes, and 
severe PLMS, which may be mistaken for RBD episodes in interviews. Previous studies 
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identified a poor sensitivity for RBD in clinical interviews in patients with PD as opposed to 
patients without PD [100, 101].  
 
Table 1.8 Prevalence of REM sleep behaviour disorder (RBD) symptoms in PD with disease 
duration (papers listed alphabetically in table). 
 
Study 
(Year) 
N                           Duration of PD Instrument 
used 
0-5y 5-10y 10-15y 15-20y 
Gagnon et al 
(2002) [102] 33  
58%* 
(7.7y) 
  
PSG 
Postuma et al 
(2008) [103] 
36  
58%* 
(5.7 y) 
  
PSG 
Romenets et al 
(2012) [104] 
98  
55%* 
(5.3y) 
  
PSG 
Sixel Doring et 
al (2011) [100] 457  
46%* 
(8.7y) 
  
PSG 
Vendette et al 
(2007) [105] 34  
53%* 
(5.2y) 
  
PSG 
* based on polysomnographic (PSG) recordings. Note: Studies where diagnosis of RBD was not  
based on REM sleep phase documented on PSG associated with the movements are not included. 
 
 
 
Sleep dysfunction was even recognized by James Parkinson his essay the Shaking Palsy [7]. 
Night time sleep disturbances are common in PD, affecting up to 90% of PD patients[106] 
but only about half the patients had told their doctor of nocturnal problems[107].The most 
common sleep disorders reported by the patients with PD were frequent awakening (sleep 
fragmentation) and early awakening [108]. Nocturia, difficulty in turning over in bed, painful 
leg cramps, vivid dreams/nightmares, back pain, limb/facial dystonia and leg jerks are the 
main causes of nocturnal awakening in PD patients[109]. Both RLS and RBD disrupt sleep 
which can contribute to excessive day time sleepiness the following day. 
The estimated prevalence of excessive daytime sleepiness (EDS) in PD patients varies from 
20 to 50%. EDS may be due to the nocturnal disturbances, medication effects or a 
combination of both [110].   
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Finally to summarize the prevalence of NMS in PD is nearly universal. Non-motor symptom 
scale (NMSS) is a validated composite measure of the problems. The total NMSS scores 
were higher in patients with PD than those with other forms of parkinsonism that may look 
similar such as drug induced parkinsonism [111].  
However many of the non-motor symptoms can be consequences of drug therapies as well 
and it may sometimes be difficult to disentangle the contribution of iatrogenic mechanisms 
from purely disease related phenomena in PD. 
 
1.3.2.3 Prevalence of cognitive impairment in Parkinson’s disease with time 
 
In keeping with previous epidemiological studies recording the prevalence of other NMS in 
PD, the estimated prevalence rates of cognitive dysfunction in PD will vary depending upon 
the data collection methods, the population under study, scales used and the definition of 
dementia utilized in the study protocol (Table 1.9). The reported prevalence rates of dementia 
mostly from cross-sectional studies vary from 13 % at 3.5 years [112]  to 78% at 17 years 
from disease onset [113] (DSM-III criteria). Two longitudinal studies have provided 
invaluable information about prevalence of dementia in PD from early to late stage disease 
and this data roughly reflects the figures available from cross-sectional studies. 17% of 
incident patients in a population-representative incident cohort developed dementia over 5 
years. (CamPaIGN study, n = 126) [114].  The Sydney Multicentre Study found the 
prevalence of dementia increased with disease duration, from 24% at baseline to 80% at 20 
years, but the evolution of dementia within PD occurred at around 70 years of age, regardless 
of the time of PD onset [115]. 
The association with increased disease duration was also confirmed in a study of young onset 
PD patients. However, dementia within PD could occur much earlier than 70 years (range 41-
78 years). After a median disease duration of 18 years, cognitive impairment sufficient for a 
diagnosis of dementia was found in only 19% of patients (n=98) (13% of those younger than 
60 years and 43% of those 60 years or older). Age, reflecting disease duration, was the most 
important factor for development of dementia, but female sex and positive family history of 
parkinsonism also had some positive predictive value [116].  
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The variation in the results of these 2 important studies reflects not only the differences in the 
tools used for the diagnosis of dementia (Tables 1.9a and 1.9b) but also the inherent 
differences of the populations studied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
Table1.9a Prevalence of dementia in PD with disease duration (papers listed alphabetically in 
table). 
Study 
(Year) 
N 
Duration of disease Instrument/ 
Criteria 
1y 2-5y 6-10y 11-19y 20y 
Aarsland et al 
(2001) [117] 
N=171  
 
25.1% 
(4.2y) 
   
MMSE, DRS, NPB 
DSM-III-R criteria 
Aarsland et al 
(2003) [113] 
N=224 
  
26% 
(9y) 
78.2% 
(17y) 
 
MMSE,UPRS m, 
GBSS 
DSM-III-R criteria 
Balzer-
Geldsetzer et 
al ⃰ (2011) 
N=604 [118] 
  
13.8% 
(6.8y) 
  
NPB 
Emre criteria for PDD 
Evans et al 
(2011) 
N=132 [12] 
  
35% 
(6.2y) 
  
MMSE 
DSM IV criteria 
Hobson et al 
(2004) [119] 
N=86 
 
35.3% 
(4y) 
   
CAMCOG 
DSM-IV criteria 
Mahieux et al 
(1998) [120] 
N=81 
  
23.4% 
(8.3y) 
  
NPB 
DSM-III-R criteria 
Marttila al 
(1976) [121] 
N=421 
  
29% 
(7.2y) 
  
 
Celesia & Wanamaker 
criteria (1972) 
Mayeux et al 
(1992) [122] 
N=179 
  
 
41.3% 
(5.7y) 
  
NPB 
 
Mayeux et al 
(1988) [123] 
N=339 
  
 
11% 
(7y) 
  
MMMSE 
DSM-III criteria 
Melcon et al 
(1997) [124] 
N=51 
  
15.7% 
(7.6y) 
  DSM-III-R criteria 
Mindham et al 
(1982) [125] 
N=40 
  
40% 
(9y) 
  
NPB 
GPRUIS criteria 
(1970). 
Mutch et al 
(1986) [126] 
N=252 
  
11% 
(7y) 
  MMSE <5/10 
Reid et al  
(2011) † [115] 
N=108 
24% 
(baseline) 
30% 
(3y) 
38% 
(5y) 
67% 
(10y) 
80% 
(15y) 
NPB 
DSM IV criteria 
For legend see continuation of this table on next page (Table 1.9b) 
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Table 1.9b Prevalence of dementia in PD with disease duration (continuation of Table 1.9a) 
Study 
(Year) 
N 
Duration of disease Instrument/ 
Criteria 
 
1 y 
 
2-5 y 6-10 y 11-19 y 20 y 
Schrag et al 
(1998 )[116] 
N=149 of 
YOPD 
   
 
19% 
(18y) 
 BTCT 
Riedel et al 
(2008) [127] 
N=873 
  
28.6% 
(6.7y) 
  
MMSE, CDR, PANDA 
DSM-IV criteria 
Snow et al 
(1989) [128] 
N=55 
  
20% 
(8y) 
  MMSE<7/10 
Sutcliffe et al 
(1995) [129] 
N=353 
  
41.1% 
(8y) 
  MMSE <25/30 
Wang et al 
(1996) [112] 
N=23 
 
13% 
(3.5y) 
   
CASI, CDR 
DSM-III-R criteria 
N= number  of patients at the start of the study .⃰DEMPARK study,† Sydney multicentre study, MMSE-
Mini-Mental State Examination , DRS- Dementia Rating Scale, NPB- Neuropsychological battery, DSM-
III-R Diagnostic and Statistical Manual  3
rd
 edition Revised, UPDRSm- the mentation item from the 
mental subscale of the Unified Parkinson Disease Rating scale , GBSS- Gottfries-Bråne-Steen scale,  PDD- 
Parkinson’s disease dementia, CAMCOG- Cambridge Cognition Examination, DSM IV- Diagnostic and 
Statistical Manual 4
th
 edition,  MMMSE- Modified Mini-Mental State Examination , DSM-III Diagnostic 
and Statistical Manual 3
rd
 edition, GPRUIS- General Practice Research Unit Interview Schedule criteria, 
BTCT- brief telephone cognitive test ¸ CDR – Clinical Dementia Rating Scale , PANDA- 
Parkinson Neuropsychometric Dementia Assessment (PANDA), CASI-Cognitive Abilities Screening 
Instrument. 
 
 
 
 
 
1.3.3 Quality of Life in PD (QoL) 
 
Measuring the QoL in Parkinson’s disease in the past has been done with generic instruments 
such as The Barthel index and the modified Baecke questionnaire but these are not specific to 
PD and are a hindrance when comparing results from studies using different questionnaires. 
We have therefore included studies that have used a disease-specific measure.   
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The 39 item Parkinson’s disease Questionnaire PDQ-39 and 8 item PDQ-8 have been 
specifically designed for use with individuals with Parkinson's disease and has shown validity 
and reliability. The PDQ-8 is derived from the 39-item. A higher score indicates poorer 
quality of life (for details on scoring please see Jenkinson et al, 1997 [130]). These scales also 
incorporate measures of activities of daily living (ADL). 
In a prospective multicentre UK based study looking at self-reported quality of life in a 
cohort of 198 drug naïve PD patients over 18 months, the self-reported health status scores in 
all eight domains of the PDQ‐39 and the overall PDQ‐39 summary index worsened 
significantly (p<0.01) in patients left untreated [131]. Therefore patient preference about 
improving and maintaining quality of life may counterbalance the traditional  physicians’ 
perspective of delaying levodopa based treatments in the hope of delaying onset of motor 
complications like dyskinesia and ‘on’ ‘off’ fluctuations. 
Disability, postural instability, and cognitive impairment had the greatest influence on QoL in 
Parkinson's disease [132]. In other studies QoL also depended on daily dosage of levodopa, 
disease duration, disease progression, sex, tremor scores, clinical fluctuations as measured by 
UPDRS part IV and the H–Y stage of disease. These factors taken together account for the 
variation in QoL scores [133,134].  
Therefore, addressing all these factors that affect the patients QoL should become an 
important focus of treatment of PD [133]. 
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Table 1.10 Variation in quality of life scores in PD with disease duration (papers listed 
alphabetically in table). 
 
Study (Year) N Duration HY / UPDRS 3  PDQ 8*/ PDQ39
† 
 
Carod-Artal et al 
(2007) [134] 
144 6.6y 2 40.7
†
 
Chapuis et al (2004) 
[135] 
143 9.1y 2 36.5
†
 
Cubo et al (2002) 
[136] 
158 8.1y 2.2 48.8
†
 
Gomez- Esteban et al 
(2007) [137] 
110 7.6y 24.73 
UPDRS 3 
41.3
†
 
Grosset et al (2007) 
[131] 
198 
 
4y 1.6 18
†
at baseline
ǂ
 
31
†
at 9 months
ǂ
 
43
†
at 18 months
ǂ
 
Klepac et al (2007) 
[138] 
111 5y 25 
UPDRS 3 
47
†
 
Michalowska et al 
(2005) [139] 
60 8y 2.7 32.1
†
 
Navarro-Peternella et 
al. (2012) [140] 
40 8.4y 2.5 35.45
†
 
Rahman et al  
(2008) 
130 12.1y 2.6 25.2 HY<2.5
†
 
39.6 HY>3
†
 
Schrag et al  
(2000) [132] 
92 5.3y 2.35 30
†
 
Slawek et al  
(2005) [133] 
100 6.7y 2.6 34
†
 
Zach et al  
(2004) [141] 
141 11.9y 2.5
§
 35.3
†
 
Zhao et al  
(2008) [142] 
183 4.6y 2.3 27.5* 
N=number of cases, Y= years, 
ǂ 
in drug naïve patients who remained without any treatment over 18 
months (n=61), 
§ 
between HY stage II and III. 
 
 
 
1.3.4 Morbidity and Mortality  
 
1.3.4.1 Standardised mortality ratios 
 
The effect of Parkinson's disease on mortality, and whether anti-parkinsonian medication 
impacts this, has been long debated.  
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Standardised mortality ratios (SMRs) are estimated from the ratio of observed to expected 
number of deaths. Mortality rates in general in PD cohorts are greater than the general 
population when matched for age and gender (Table 1.11a). 
In the pre-levodopa era (1949-64) Hoehn and Yahr’s cohort of PD patients (n=672) the mean 
age of disease onset was 55.3 years, mean duration of illness was 9.7 years and SMR was 2.9 
[8]. 
In the post-levodopa era Barbeau in one of the early studies found no significant difference in 
the SMR compared to the pre-levodopa era. However,  most studies have found a reduction 
of death rate during long-term levodopa treatment and this effect can be seen even at 20 years 
post diagnosis [143]. 
Using regression modelling, to assess the impact of the timing of levodopa administration 
during the course of illness on mortality, while statistically controlling for other factors (i.e., 
patient selection for levodopa treatment, and independent predictors of survival), risk of death 
following initiation of levodopa was significantly reduced (p < 0.001), regardless of pre-
levodopa duration of illness. At no point in time was levodopa treatment associated with 
increased mortality, arguing against levodopa toxicity [144]. 
Using a modified  Gompertz function and data on mortality from 6 studies [116, 145-149]               
of SMR in PD and life expectancy in the UK from the Office of National Statistics, the 
calculated  estimated age specific life expectancies in patients with PD compared with the 
general population were 38 (SD 5) years for onset between 25 and 39 years compared with 49 
(SD 5) years; 21 (SD 5) years for onset between 40 and 64 years compared with 31 (SD 7) 
years; and 5 (SD 4) years for onset age > or = 65 years compared with 9 (SD 5) years [150].  
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Table 1.11a Mortality ratios (observed: expected deaths) in PD with disease duration (papers 
listed alphabetically in table). 
 
Study 
(Year) 
 
N 
Mortality ratio.  Observed: Expected deaths 
(Duration of disease in years) 
< 5y 5-9 y 10-19 y >=20 y 
Barbeau et al 
(1976) [151] 
80  2.4 
(6y) 
  
Ben-Shlomo et al 
(1995) [148] 
220    2.6 
(20y) 
Cedarbaum et al 
(1987) [152] 
100   1.9 
(16y) 
 
 
Curtis et al 
(1984) [153] 
176  1.5 
(6y) 
2.59 
(12y) 
 
Diamond et al 
(1989) [154] 
54  1.8-2.2 
(6y) 
  
Duarte et al 
(2013) [143] 
273    1.39 
(20y) 
Ebmeier et al 
(1990) [155] 
267 2.3 
(3.5y) 
   
Hely et al (1999) ⃰
[16] 
108   1.58 
(10y) 
 
Hoehn & Yahr 
(1967) [8] 
672  2.9 
(9.4y) 
  
Herlofson et al 
(2004) [146] 
245  1.5 
(8y) 
  
Louis et al 
(1997) [156] 
288  2.7 
(8.8y) 
  
Marttila et al 
(1977) [157] 
349  1.8 
(7y) 
  
Morgante et al 
(2000) [147] 
59  2.3 
(8y) 
  
Rinne et al 
(1980) [158] 
349 1.1-1.7 
(2-3y) 
1.9 
(9y) 
  
Schrag et al 
(1998) [116] 
JP=10 
YOPD=139 
  2.0 
(18y) 
3.0 
(24y) 
Shaw et al 
(1980) [159] 
178  1.5 
(6 y) 
  
Sweet et al 
(1975) [160] 
100 1.9 
(5y) 
   
Tison et al 
(1996)† [149] 
24  3.43 
(5y) 
  
JP= Juvenile parkinsonism (age at onset <21y) YOPD= Young onset Parkinson’s disease (age at 
onset<40y), ⃰ Sydney Multicentre study, † PAQUID study 
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Table 1.11b Causes of mortality in Parkinson’s disease (papers listed alphabetically in table). 
 
Study (Year) 
N 
                           Causes of death by system/disease (%) 
 
Respiratory 
disease* 
Heart 
disease 
Cancer CVD PD Other Unknown 
 
Ben Shlomo et 
al (1995) 
N=220 [148] 
 
16.4 
 
23.1 
 
4.6 
 
16.9 
 
- 
 
39 
 
- 
Ben Shlomo et 
al (1998) 
N=624 [161] 
 
4 
 
26 
 
12.5 
 
10 
 
40 
 
7.5 
 
- 
Beyer et al 
(2001) [162] 
N=84 
 
24 
 
18 
 
17 
 
9.5 
 
- 
 
32.2 
 
- 
D’Amelio et al 
(2006) [163] 
N=59 
 
27 
 
35 
 
7 
 
20 
   
Fall et al  
(2003) [164] 
N=170 
 
23 
 
13 
 
8 
 
6 
   
Hely et al   
(1999) [16] 
N=108 
 
30 
 
21 
 
19 
 
16 
 
5 
 
6 
 
3 
Morgante et al 
(2000) [147] 
N=59 
 
15 
 
17 
 
<1 
 
13.5 
 
- 
 
10 
 
- 
Pennington et 
al (2010) 
[165] 
N=143 
 
11 
 
12 
 
12 
 
9 
 
29 
 
27 
 
- 
N=Number of cases, CVD= cerebrovascular disease, PD- Parkinson’s disease , *Respiratory disease 
includes pneumonia. 
 
 
1.3.4.2 Causes of mortality in Parkinson’s disease 
 
The 5 most common causes of mortality in PD are cardiovascular, respiratory, 
cerebrovascular disease, cancer and advanced stage PD combining the results from 8 studies 
reporting causes of mortality in PD. (Table 1.11b, Figure 1.2). Not surprisingly 
cardiovascular disease, reflecting the trend in the general populations from the Western 
world, was the most common cause of death in PD. This reflects the findings from a recent 
longitudinal 20 year study of PD as well [143] but results from other studies are variable 
(Table 1.11b).  
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The variation in the results partly reflects the different methods used when conducting 
mortality studies. Death certificates documenting proximate cause(s) of death are often 
prepared in a hospital or hospice setting not laced with research methodology, thus leading to 
a possible under reporting of the terminal diagnosis as underlying co-morbidities may be 
multiple, and in some cases a positive diagnosis given to the patient may not be proven at 
autopsy. The level of accuracy of the diagnoses documented on death are subject to variation 
in different countries and in different time periods within the same country reflecting 
different reporting patterns[162]. In a more general sense the underlying heterogeneity of the 
population and environments in which those populations live reflecting different life styles 
may also contribute to variation in e.g. the proportion of patients dying with cardiovascular 
disease. 
             
                  
 
Figure 1.2 summarizes the data on mortality in Parkinson’s disease from the 8 studies 
included in Table 1.11b. 
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1.3.5 Comparison with the Mendelian inherited forms of Parkinson’s disease  
 
The three most common mutations linked to PD are the autosomal dominant GBA, LRRK 2 
gene mutations and autosomal recessive Parkin gene mutations. PINK1, DJ1 and ATP13A2 
gene mutations are rarer. 
Homozygous mutations in the glucocerebrosidase gene (GBA) cause Gaucher's disease and 
heterozygous mutations are a risk factor for PD. A study evaluating the frequency of GBA 
mutations in British patients affected by PD (n=790) compared with normal controls (n=257), 
matched for age and ethnicity reported that the frequency of GBA mutations in PD patients 
(4.18%) was significantly higher (p = 0.01; odds ratio = 3.7; 95% confidence interval = 1.12-
12.14) when compared to controls (1.17%). The phenotype of mutation carriers with PD 
comprised an early onset of the disease, the presence of hallucinations in 45% and symptoms 
of cognitive decline or dementia in 48% of patients. Pathological examination revealed 
widespread and abundant alpha-synuclein pathology in all GBA mutation carriers (n=17) who 
had autopsies.  This large study with  genotype/phenotype/pathological analyses showed that 
mutations in GBA are found in British subjects at a higher frequency than any other known 
Parkinson's disease gene [166]. 
Mutations in the LRRK2 gene, coding for leucine rich repeat kinase 2, cause autosomal 
dominant Parkinson's disease. The LRRK2 phenotype was defined on the basis of 59 motor 
and non-motor symptoms in 356 patients with LRRK2-associated PD and compared with the 
symptoms of 543 patients with pathologically proven idiopathic PD. A worldwide population 
study showed the frequency of the commonest LRRK2 mutation, Gly2019Ser, was found in 
1% of patients with sporadic PD and 4% of patients with hereditary PD; the frequency was 
highest in the Middle East and higher in southern Europe than in northern Europe. The risk of 
PD for a person who inherits the LRRK2 Gly2019Ser mutation was 28% at age 59 years, 51% 
at 69 years, and 74% at 79 years. The LRRK2 phenotype (n=356) showed motor symptoms 
(e.g., disease severity, rate of progression, occurrence of falls, and dyskinesia) and non-motor 
symptoms (e.g., cognition and olfaction) were more benign than those of idiopathic PD 
(n=543) [167].  
A wide variety of mutations in the Parkin gene (PARK2) are responsible for autosomal 
recessive parkinsonism. The phenotype of Parkin gene mutation carriers is characterized by 
early onset (before age 40) of disease, marked response to levodopa treatment and levodopa-
58 
 
induced dyskinesia. In 35 mostly European families with early onset autosomal recessive 
parkinsonism with Parkin gene mutations mean age at onset was 38 +/- 12 years however in 
many patients except for early age of onset, the phenotype is indistinguishable from that of 
idiopathic PD[168]. 
Table 1.12 Phenotypes of LRRK2, GBA and Parkin mutation carriers with Parkinson’s 
disease (papers listed alphabetically). 
Study 
(Year) 
N 
Gene Age of 
onset 
(mean) 
Rate of 
progression 
Dystonia Dopamine 
response 
LID Cognitive 
problems 
Healy et 
al  
(2008) 
[167] 
N= 321 
LRRK2 
 
 
58.1y 
 
HY I: 4 y 
HY II : 7.2 y 
HY III: 9.4 y 
HY IV:12.6 y 
HY V: 15.6 y 
42% 89% good 
9% 
modest 
3% poor 
11% 
(5 y) 
58% 
(8y) 
23% 
(14 y) 
 
Lucking 
et al 
(2000) 
[169] 
N=54 
Parkin 
 
32y HY I: 11 y 
HY II : 19 y 
HY III: 26 y 
HY IV: 40 y 
HY V: 15.6 y 
58% 72% good 77% 
(5y) 
<1 % 
(17 y) 
Neumann 
et al 
(2009) 
[166] 
N=31 
GBA 
 
52.7y - - 90% good - 48% 
(12y) 
N=Number of cases, LID= levodopa induced dyskinesia, LRRK2= Leucine rich repeat kinase 2 gene, 
Parkin= Parkin gene, GBA= Glucocerebrosidase gene, HY= Hoehn Yahr stage. Note: Studies including 
less than 20 cases not included as per study protocol. 
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1.4 Discussion 
 
Our knowledge about the natural history of Parkinson’s disease, until recently, came from 
studies which have used the date of presentation to the clinician as a starting point. These 
studies have therefore predominantly focussed on the clinical phase of the disease, when 
nearly 80% of dopamine stores have already been depleted [170, 171]. We know that 
Parkinson’s disease has a preclinical and a premotor phase. To understand more about these 
phases of the illness we may have to rely on epidemiological studies using population based 
cohorts such as from the HAA study. 
Whilst there are numerous reports documenting the progression of the motor symptoms of 
PD, there are not many longitudinal studies about the evolution of non-motor symptoms in 
this disease after the onset of motor dysfunction. However we know from previous studies 
that non-motor features such as hyposmia, constipation, erectile dysfunction, depression, 
daytime somnolence and REM sleep behaviour disorder, can precede the motor symptoms of 
PD, sometimes by many years (Table 1.3).  A critical appraisal of these premotor symptoms 
suggest they could be used as biomarkers of a preclinical PD phenotype. Some studies have 
combined clinical, genetic and neuroimaging investigations to study the premotor phase in 
subjects at high risk for developing PD such as hyposmic individuals (Parkinson's Associated 
Risk Study) [172]. 
Cognitive dysfunction, although not recognized by James Parkinson, thought to be one of the 
most important features of PD in late stages is a function of time, chronologically analogous 
to the progression of motor disability. The most compelling piece of evidence for this comes 
from the longitudinal Sydney Multicentre study; over 20 years the proportion of patients 
developing dementia increased from 24% to 80% in surviving patients[115]. 
The rates of progression of motor, non-motor and cognitive symptoms vary in individuals but 
in general there is a cumulative disability and this invariably affects patients’ quality of life. 
(Table 1.10) 
The importance of predicting who develops PD cannot be more emphasized than by stating 
that if future neuroprotective drugs are going to make a difference in the relentless cascade of 
neurodegeneration that follows once the pathologic burden of alpha-synuclein aggregates in 
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the brain reaches a critical mass, these drugs will have to target a population of patients 
where the disease process is not yet entrenched. 
Once PD is diagnosed it is well recognized by clinicians and patients that it is a progressive 
condition. In order to make management decisions regarding treatments offered to patients, 
clinicians assess and record the progression of motor disability so that medications are 
tailored to disease stage. Besides using validated scales, such as UPDRS, for recording 
disease progression, there have been efforts to find alternative methods to do this in vivo. 
Nuclear medicine imaging provides one such tool for measuring disease progression, 
assessing the rate of loss of presynaptic dopaminergic neurons although this relationship may 
not be linear due to the possible confounding effects of concomitant dopaminergic 
medications and therefore better biomarkers of disease progression are required.  
The factors affecting the rates of progression of motor and non-motor symptoms have not 
been elucidated sufficiently to explain all the variation. Dopaminergic and other medications 
alter the natural history of PD as they decrease morbidity, mortality and improve quality of 
life [173] but the variation in progression is too large to be explained by medication effects 
alone. Environmental influences, besides drugs, and cultural differences may affect the 
subjective perception of disability but objective differences probably reflect the underlying 
heterogeneity of the populations studied. Although a perfect understanding of all the factors 
that underlie the variability in PD is limited, over the last 15 years our understanding of the 
genetic influences in PD has become clearer. While genetic causes account for only a small 
proportion of the total cases of PD, subtle genetic differences between individuals (single 
nucleotide polymorphisms) at several loci in the human genome probably explain a lot of  the 
variation in the expression of PD. Gene-gene and gene-environment interactions may explain 
more of this  variation than the influence of single genes e.g. polymorphisms in the N-acetyl 
transferase 2 gene which codes for an enzyme responsible for the biotransformation of 
exogenous neurotoxins, results in a slower rate of metabolism of these detrimental influences 
from the body. This can lead to greater vulnerability to neurotoxins and to a higher 
susceptibility of PD [174]. 
Recent studies suggest genetic factors may also underlie the variability in cognitive and 
motor dysfunction [175]. Further genetic differences in the activities of dopamine 
metabolizing enzymes could influence both the individual response to therapy and the risk of 
early motor disturbances with MAOB and COMT inhibitors [176]. An argument can 
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therefore be made that patient heterogeneity reflecting genetic differences as well as 
environmental influences interacting with human genes may underlie the variability in other 
aspects of PD as well. 
 
1.5 Conclusion 
 
Although differences in methodologies and reporting of the results make a direct comparison 
of all studies not possible, it is quite clear from the evidence provided that progression of 
motor symptoms, signs and disability on a time scale is nearly universal in PD despite the 
individual variation. Non-motor symptoms are abundant and some precede the development 
of the motor-symptoms by years while others like cognitive problems show a cumulative 
prevalence, which on a chronological timeline would parallel the progressive motor disability  
that these patients experience, such that by 20 years the vast majority of surviving patients 
show scores on neuropsychological batteries compatible with a diagnosis of dementia. 
 
Search strategy 
 
I. For Medline and Embase 
 
1. parkinson*.mp. [mp=ti, ab, ot, nm, hw, ps, rs, ui, an, sh, tn, dm, mf, dv, kw] 
2. disease progression.mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, sh, tn, dm, mf, dv, kw]  
3. 1 and 2 
4. limit 3 to English language 
6. limit 4 to human 
8. remove duplicates from 5 
 
II. For Cochrane Library using advanced search  
MeSH parkinson* disease AND disease progression 
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Chapter 2. Alpha-synuclein as a molecular biomarker of Parkinson’s 
disease 
 
 
 The official National Institute of Health (United States) definition of a biomarker is: "a 
characteristic that is objectively measured and evaluated as an indicator of normal biologic 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention" 
[177]. Clinical, genetic, blood and cerebrospinal fluid (proteomics, transcriptomics, 
metabolomics), and neuroimaging biomarkers may provide useful tools in the diagnosis of 
Parkinson’s disease (PD) and in measuring disease progression and response to 
therapies[178]. The diagnostic value of these biomarkers lies in their ability to help 
differentiate PD from its mimics and to predict who is at a risk for PD. The prognostic role of 
clinical biomarkers such as the motor subtype and cognitive impairment in PD is recognized 
[114, 179] and the value of biochemical markers such as serum levels of advanced oxidized 
protein products that could participate in the development of parkinsonian neurodegeneration 
as a prognostic marker of PD duration is an area of potential research[180]. 
 
 
         
Figure 2.1 shows the categories of biomarkers for Parkinson’s disease under investigation. 
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Biomarkers used as diagnostic tests, prognostic tools, or surrogate endpoints must not only 
have biologic relevance but also a strong linkage to the clinical outcome of interest [180].  
 
i. Clinical biomarkers 
 
a. Olfactory dysfunction  
Olfactory dysfunction is near-universal in PD [181] and may predate the clinical diagnosis of 
PD by years. Recent data indicate that over 95% of patients with PD present with significant 
olfactory loss. Thus, olfactory dysfunction could be considered a reliable biomarker of the 
disease.  There is poor performance of PD patients on odour discrimination, odour detection 
and odour identification tasks. As significant olfactory impairment is found early in the 
disease process, olfactory tests may be useful. However,  it is not a specific bio-marker as 
olfactory dysfunction has been documented in other neurological disorders such as 
Alzheimer's disease, multiple sclerosis, Huntington's disease and old age  [182].  
 
b. REM sleep behaviour disorder 
 
Rapid eye movement (REM) sleep behaviour disorder (RBD) is a parasomnia characterized 
by vivid dreams associated with simple or complex motor behaviours during REM sleep. The 
polysomnographic (PSG) features of RBD include increased electromyographic tone and 
dream enactment behaviour during REM sleep [183].   
REM sleep without atonia (RWA) shows abnormal muscle activation during REM sleep 
during PSG without manifest behaviours may represent preclinical forms of RBD  is more 
common in PD than RBD[102]. RBD or RWA is present in 25 to 50% of PD patients[184]. 
 
Probable RBD (based on informant response to the questionnaire) is more frequent in PD 
than essential tremor  and could suggest the diagnosis of PD in a tremulous patient[185] but 
RBD is not specific to PD and can occur concomitantly with other alpha-synucleinopathies 
including  Lewy body dementia and multiple system atrophy[186]. 
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 c. Restless legs syndrome 
 
Restless legs syndrome (RLS) is marked by a tendency to keep moving the legs accompanied 
by a premonitory urge and dysesthesias that occur at rest and are alleviated by movement. 
Symptoms occur in a circadian manner  being  most prominent in the evening hours and 
when lying in bed to sleep[184]. Despite the observations suggesting that RLS may be a 
dopaminergic deficiency state given that it responds to dopamine agonists, it is clear that RLS 
differs pathologically from PD as the  dopaminergic dysfunction does not involve neuronal 
degeneration and likely involves dopaminergic pathways other than the nigrostriatal pathway 
that is involved in PD[187]. RLS is also not specific to PD and can be associated with several 
other disorders such as such as iron deficiency, pregnancy, medications, chronic renal failure, 
leprosy, peripheral neuropathy and systemic sclerosis[188-192]. Although the symptoms of 
RLS are relatively common in patients with PD; however, at present there is no evidence that 
RLS symptoms early in life predispose to the subsequent development of PD. There is some 
evidence to suggest that RLS may be a secondary phenomenon, in some cases this may bear a 
relation to their low ferritin levels. [97].  
 
d. Constipation 
 
Gastrointestinal symptoms that are significantly more prevalent in PD patients include dry 
mouth, drooling, dysphagia, constipation and defecatory dysfunction. Constipation and 
defecatory dysfunction precede motor manifestations and can be therefore be included 
amongst other non-motor symptoms such as hyposmia and RBD that can be considered as 
bio-markers of pre-motor PD. Gastroparesis symptoms may also precede motor 
manifestations but like other autonomic manifestation these symptoms are also not specific to 
PD [193].  
 
e. Family history of PD 
 
Family history is consistently identified as an independent risk factor for PD in systematic 
reviews and meta-analyses [194, 195] . There is a broad range of risk estimates reported 
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ranging from 4 to 40 times higher amongst relatives of people with PD [59, 196-198]. It is 
likely that biases in collecting data and variation in study designs have contributed to this 
large range of reported risk, however, these studies all concur with the multifactorial 
hypothesis of PD, in which inherited genes interact with environmental influences to 
determine the overall risk of an individual developing PD over his lifetime.  
 
ii. Genetic biomarkers 
 
Genetic biomarkers in the form of disease causing genes or risk-modifying variants, can 
define the risk of an individual developing a disease, and allow stratification of patient 
populations according to the underlying molecular defect [199]. However, the case load of 
monogenic causes of PD is small overall and the aetiology in the majority of patients with 
sporadic or hereditary forms of PD remains unknown in most populations [200]. The 
relationship of genotype to phenotype in complex traits such as Parkinson’s disease is also 
not straightforward as the heterogeneity in the clinical expression of PD is too large to be 
explained by a mutation in a single gene and perhaps there are other yet unidentified 
biological influences besides environmental factors that modify phenotypic expression. 
Nevertheless in individual cases and families with PD the genetic carrier status of the 
proband can be tested to inform about prognosis and inheritance risks.  
 
iii. Neuroimaging biomarkers 
 
Midbrain/nigral structural abnormalities can be demonstrated in vivo with both trans cranial 
sonography (TCS) and diffusion tensor magnetic resonance imaging (DT-MRI) while 
positron emission tomography (PET) and single photon emission computed tomography 
(SPECT) ligands exist to demonstrate dopamine terminal dysfunction[201].  
To confirm the diagnosis of degenerative parkinsonism, the PET ligand [18F]-DOPA for 
estimating dopaminergic neurotransmission by estimating striatal aromatic amino acid 
decarboxylase (AADC) activity , SPECT ligands 
123I fluopane and βCIT for dopamine 
transporter imaging  and 11C- or 18F-dihydrotetrabenazine PET ligands for measuring  the 
density of vesicular monoamine transporter (VMAT2). 
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These radiotracers are markers of dopamine storage capacity, vesicular monoamine and 
dopamine transporter availability. While dopaminergic neuronal loss leads to motor 
disability, non-dopaminergic neurotransmitter dysfunction is implicated in non-motor 
symptoms including sleep disturbance, fatigue, depression, dementia, and autonomic 
dysfunction. PET and SPECT utilizing different ligands, than those used to interrogate 
dopaminergic transmission, exist and can be used to evaluate the function of monoaminergic 
and cholinergic circuits in the brain. 
Several other imaging biomarkers using other ligands such as [18F] deoxygluose for 
mitochondrial bioenergetics, [18F]BMS for mitochondrial complex-1, [11C](R)-PK11195 for 
microglial activation, also exist [202].  
 
The central pathology in PD however revolves around alpha-synculein and currently no 
imaging bio-marker exists to visualize alpha-synuclein aggregates in neurons compared the 
Pittsburgh binding agent for amyloid aggregation in Alzheimer’s disease. New frontiers in 
PD imaging to fill this void may evolve over the next few years to decades. 
 
iv. Biochemical biomarkers 
 
Several research groups have investigated a variety of clinical, imaging or biochemical 
assays, alone or in combination, to find a clinically useful biomarker of PD. It has been 
argued that perhaps the most promising is the assay of alpha-synuclein in the diagnosis and 
its accumulation in the prognosis of Parkinson disease. At present, detection protocols are 
still being refined, so that this is a process in evolution [203].  
We conducted a systematic review of alpha-synuclein in body’s tissues excluding the central 
nervous system and bio-fluids to investigate its utility as a potential biomarker of PD. 
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Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson’s 
disease - a systematic review. 
 
 
  
Abstract  
  
Background  
 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder that 
affects the elderly, with a prevalence of approximately 1% among those older than 65 
years. PD is neuropathologically characterized as an alpha-synucleinopathy. Alpha-
synuclein aggregates accumulate in Lewy bodies, which are the pathological hallmark 
of PD. However, alpha-synuclein containing inclusions in PD are not restricted to the 
central nervous system, but can also be stained in several peripheral tissues and alpha-
synuclein monomers and oligomers are detected in various body fluids. 
  
Objective 
 
To conduct a systematic review of available evidence for the utility of alpha-synuclein 
as a peripheral biomarker of PD. 
  
Methods 
  
Search strategy  
PUBMED (1948 to May 26, 2013), Embase (1974- May 26, 2013), the Cochrane 
Library (up to May 26, 2013), LILACS (up to May 26, 2013) and  CINAHL (up to 
May 26, 2013) were searched for studies of alpha-synuclein in peripheral tissues or 
body fluids in PD patients. 
 
Selection criteria Reports containing more than 5 subjects (patients and controls) were 
included where PD was diagnosed during life using predefined criteria, and the study 
found evidence of alpha-synuclein in peripheral tissues or body fluids. 
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Data analysis 
  
Sensitivity and specificity of individual tests were calculated comparing PD cases with 
healthy controls, and did not include cases with incidental Lewy body disease. 
  
  
Results 
 
A total of 49 studies fulfilled the search criteria. Peripheral tissues such as colonic 
mucosa showed a sensitivity of 42-90% and a specificity of 100% ; labial salivary 
glands showed 66% sensitivity and 100% specificity; submandibular salivary glands 
showed sensitivity and specificity of 100%; skin biopsy showed 19% sensitivity and 
80% specificity in detecting alpha-synuclein pathology. CSF alpha-synuclein had 71-
94% sensitivity and 25-53% specificity for distinguishing PD from controls. Plasma 
alpha-synuclein had 48-53% sensitivity and 69-85% specificity in sporadic PD. 
Variability was at least in part methodological (e.g. assay techniques included enzyme 
linked immunosorbent assay (ELISA), Western blots and Luminex assays). 
  
Conclusion  
 
Alpha-synuclein is often present in peripheral tissues in PD, but tissues with the 
highest sensitivity and specificity (e.g. vagus and sympathetic ganglia) are difficult to 
access for biopsy. Endoscopic gastrointestinal biopsy may offer a relatively less 
invasive option while maintaining high sensitivity. However the confounding factor of 
incidental Lewy body disease and the non-specificity of alpha-synuclein to PD remain 
major obstacles in test interpretation. Body fluids are less reliable than solid tissue 
samples for differentiating alpha-synucleinopathies from other diseases or normal 
controls. 
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2.1 Introduction  
 
  
The synucleins include alpha-, beta- and gamma-synuclein, and are a family of small, 
soluble proteins expressed primarily in neurons, but also found in lower 
concentrations in other tissues. Alpha-synuclein was first identified in human brain 
tissue during the ultrastructural study of amyloid plaques in patients with Alzheimer’s 
disease in the early 1990’s. Detailed analysis of the amino acid sequence in an 
amyloid preparation revealed a second component, in addition to the major A-beta 
fragment that was already known. It was called NAC (non A-beta component) and its 
precursor was named NACP (NAC precursor) [204]. A computer homology search 
established that the human NACP gene, which codes for alpha-synuclein, was 
homologous to the rat synuclein gene and mapped to chromosome 4q21 [205]. The 
human NACP gene was therefore redesignated as SNCA. 
  
2.1.1 Structure of alpha-synuclein 
  
Alpha-synuclein is formed of a varying number of amino acids as a result of alternative 
splicing of the SNCA gene. Alpha-synuclein 140 represents the whole transcript and is the 
major variant. Shorter forms have 126, 112, or 98 amino acids[206]. The 140 variant retains 
all the sites that undergo post-translational protein modification, while the shorter forms do 
not, and may be at the greatest risk of abnormal aggregation. Alpha-synuclein 140 has an N-
terminal helix, a central helix and an unorganized, negatively charged C-terminal [206]. The 
N-terminal helix is characterized by lipid affinity that anchors alpha-synuclein to membranes 
and assembles lipoprotein complexes, while the hydrophobic central region is prone to 
intermolecular interactions, which may promote the aggregation of soluble alpha-synuclein 
monomers into insoluble oligomers and polymers[207]. Deletion or disruption of this region 
blocks this abnormal aggregation. The C-terminal charge qualitatively influences the kinetics 
of alpha-synuclein aggregation. The higher its content in negative amino acid residues, the 
lower the aggregation rate of alpha-synuclein thereby countering the pro-aggregatory 
potential of the central region[208]. 
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2.1.2 Physiological role of alpha-synuclein 
  
Alpha-synuclein accounts for as much as 1% of total protein in soluble cytosolic brain 
fractions, suggesting a significant role in neuronal function [209]. Physiologically the 
normal protein modulates the stability of the neuronal membrane, and it may also 
integrate presynaptic signalling and membrane trafficking via vesicular transport 
[210]. In experimental physiological conditions an extended monomeric conformation 
is its intrinsic state, but extreme environmental sensitivity causes alternative 
conformations, both physiological (e.g. monomeric alpha-helix and beta-sheet rich 
species, and dimers) and pathological (e.g. oligomers, polymerization into fibrils), the 
latter developing into the cytoplasmic inclusions (Lewy neurites and Lewy bodies) 
that mark disease states [211]. 
  
2.1.3 Mechanisms of abnormal alpha-synuclein aggregation 
  
Alpha-synuclein belongs to the intrinsically disordered protein class. Environmental agents 
such as neurotoxins and genetic mutations may induce alpha-synuclein misfolding [212]. 
Alternative splicing of the SNCA gene may result in variations in protein structure, altering its 
aggregating propensity. Further protein modification after mRNA translation can occur by 
phosphorylation, ubiquitination, nitration, and truncation. All of these changes may result in 
oligomer formation and accumulation [206]. The mechanisms proposed to describe the 
neurotoxicity of alpha-synuclein and its aggregates include mechanical distortion of cellular 
compartments/processes, toxic gain of function, or loss of physiological function, and such 
mechanisms may be synergistic [213]. 
  
2.1.4 CNS distribution of alpha-synuclein aggregates 
  
Alpha-synuclein inclusions are deposited in both dopaminergic and non-dopaminergic 
neurons, and in glia [207]. In PD and dementia with Lewy bodies (DLB), these 
inclusions are present both in cell bodies and the axonal processes of neurons and glia, 
as two morphologically distinct entities: Lewy bodies and Lewy neurites. In multiple 
system atrophy (MSA), the inclusions are seen as glial cytoplasmic inclusions (GCI) 
and in the neuronal cytoplasm. In neuroaxonal dystrophy (also called neuronal brain 
iron accumulation type 2), the inclusions are present as axonal spheroids [214]. 
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2.1.5 Lewy bodies, Lewy neurites and alpha-synuclein in PD 
  
Aggregated alpha-synuclein is the major component of Lewy bodies, the 
neuropathological hallmark of PD [215]. Besides the substantia nigra in the midbrain, 
Lewy bodies also are found in other brain regions, such as the dorsal motor nucleus of 
the vagus, the nucleus basalis of Meynert, the locus coeruleus and more diffusely in 
the brain in the later stages of PD [215]. Lewy bodies have a diameter of 5 to 25 
microns, and a dense eosinophilic core with a surrounding halo [216]. Lewy neurites 
contain filaments similar to those of Lewy bodies [217]. Point mutations and 
multiplications in the SNCA gene cause autosomal dominant PD, further supporting 
the pathogenic role of alpha-synuclein in PD [6]. However, aggregation of alpha-
synuclein is also a marker of other neurodegenerative diseases (the synucleinopathies) 
including DLB, the Lewy body variant of Alzheimer's disease, MSA, and 
neurodegeneration with brain iron accumulation type 1 [207]. 
  
2.1.6 Measurement of alpha-synuclein and detection of Lewy bodies 
  
Alpha-synuclein is also present in red blood cells, cerebrospinal fluid, plasma and 
saliva, in both monomeric and oligomeric forms, challenging previous concepts that it 
may be a purely intracellular protein [218, 219]. Measurement of both monomeric and 
oligomeric forms in body fluids uses techniques such as ELISA or Western blots. 
Lewy bodies can be visualized in neurons of the central and autonomic nervous 
system from biopsies taken from various tissues including the gastrointestinal 
submucosa and salivary glands. Traditional staining shows these to be eosinophilic, 
but alpha-synuclein immunohistochemistry (antibodies to the amino- and carboxyl-
terminal sequences) is now the standard method of localizing Lewy bodies and Lewy 
neurites in tissue specimens [220]. Proteomic identification by comparative mass 
spectrometry has identified around 40 other proteins including several kinases and 
ligases that may be involved in alpha-synuclein aggregation in the Lewy bodies [221]. 
  
2.1.7 Distribution of alpha-synuclein in Parkinson’s disease 
  
The molecular basis of PD is closely linked to the abnormal aggregation of alpha-
synuclein and factors affecting its conformation [217]. A pre-symptomatic phase of 
PD is well recognized, involving neurodegeneration in the substantia nigra 
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progressing to a critical threshold [222] but extra-cerebral pathology accompanies or 
even predates this, raising the possibility of pre-symptomatic detection from 
peripheral tissues [223]. 
  
2.1.8 Distribution of alpha-synuclein in the healthy elderly 
  
Lewy bodies are present in autopsy brain specimens in 10 to 12% of people aged over 
60 years without clinical parkinsonism [224], raising a potential problem for the 
interpretation of alpha-synuclein as a marker of pre-symptomatic or early PD. An 
alternative interpretation is that such Lewy bodies reflect age-related change in alpha-
synuclein, without clinical significance to the development of PD, sometimes referred 
to as incidental Lewy body disease (iLBD) [225]. 
Alpha-synuclein also aggregates in a wider group of neurodegenerative conditions, 
such as DLB and MSA, and we excluded studies that were restricted to those other 
diseases. 
  
  
2.2 Methods 
2.2.1 Criteria for considering studies for this review 
  
i. Types of studies 
  
A search for all studies of alpha-synuclein inclusions in tissues other than the brain or 
spinal cord, or monomers/oligomers of alpha-synuclein in body fluids was performed. 
The material sampled could include ante-mortem biopsy tissue, body fluid or autopsy 
tissue specimen. Studies limited to alpha-synuclein pathology only in the central 
nervous system, review articles, letters in reply to another original article (unless 
presenting original data), abstracts without full articles, and studies without controls 
were excluded. 
  
ii. Types of participants 
We included reports where tissue samples were collected either during life or post-mortem in 
5 or more subjects (clinically diagnosed PD patients with controls). Patients were included 
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provided their diagnosis was made by an experienced movement disorder physician, such that 
history, examination and investigation excluded alternative diagnoses. 
iii. Types of outcome measure 
The main aim was to review alpha-synuclein as an in vivo marker of PD, from accessible 
peripheral specimens (fluids and tissues). The primary outcome measure was the proportion 
of patients diagnosed clinically as PD, who had a tissue level of alpha-synuclein (detected by 
various immunochemical methods) that was statistically different from controls. 
2.2.2 Search methods for identification of studies 
Ovid databases (PUBMED and Embase) were searched combining medical sub 
headings [MeSH] Parkinson* disease and alpha-synuclein combined with the boolean 
operator AND, limiting the searches to humans and English language. Duplicate 
searches were then removed. Separate searches were conducted in CINAHL, the 
Cochrane library and LILACS using the same strategy. References in all relevant 
papers were hand searched for additional publications. 
  
2.2.3 Data collection 
  
Abstract matching to the selection criteria was performed independently by 2 authors 
(NM,DS) and resolution of differences by a third author (KG). 6281 abstracts were identified 
in Ovid databases Medline and Embase, 232 from CINAHL, 3 abstracts in the Cochrane 
library and 3 abstracts in LILACS. Limiting to human studies removed 1951 abstracts and 
restricting to English language removed a further 182; removing duplicates excluded a further 
148 abstracts. Additional hand searching from references identified provided a further 20 
abstracts. Of the remaining 4020 abstracts, 49 fulfilled the criteria of 5 or more PD patients 
and/or controls, with information available to assess for alpha-synuclein levels in peripheral 
body fluids or tissues. (Figure 2.2) 
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Figure 2.2 PRISMA diagram showing the process of paper selection for this systematic 
review. 
 
Records 
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foreign language 
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Abstracts after duplicates removed 
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 Unable to locate 
full text of article* 
  
N=10 
  
Records  
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articles 
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N= 3 
Full text articles 
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Pooled data for 
synucleinopathies 
N= 1 
Methods or 
statistics not 
described 
completely 
N= 3 
 
Search PUBMED, Cochrane Library, 
CINAHL, LILACS 
N=4330 
* includes conference 
proceedings, poster 
presentations and abstracts 
without full text articles 
† Michell et al (2005) is 
included in Table 1 and 
Table 2 separately. 
Studies of alpha-
synuclein in CNS 
tissues only 
N= 4 
Letter replies to 
original articles 
N=5 
 
Abstracts 
excluded on 
screening  
 
N= 3927 
Diagnosis of PD 
not established 
N= 11 
Less than 5 
subjects 
N= 1 
Additional 
records identified 
by hand searches  
 
N=20 
 
Studies included 
in final analysis 
 
N= 49† 
 
† Michell et al (2005) paper 
is included in Table 2.1a and 
Table 2.2a. 
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2.3 Results 
 
  
The results of all the studies that fulfilled the inclusion criteria for this systematic 
review are tabulated in Table 2.1a and 2.1 b for solid tissues and in Table 2.2a and 
2.2b for body fluids in chronological order with calculations of sensitivity and 
specificity where available. 
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Table 2.1a Summary of 20 studies of alpha-synuclein pathology in solid tissues outside the 
central nervous system in humans. 
Authors 
(year) 
 
Specimen  
(type of study) 
PD 
(n) 
Contro
ls 
(n) 
iLBD 
(n) 
Methods Alpha-synuclein 
positive 
cases/total  
Sensitivity 
( %) 
Specificity 
(%) 
PD versus 
Controls 
Iwanaga et 
al (1999) 
[226] 
 
Cardiac plexus, 
sympathetic 
ganglia 
(post-mortem) 
11 25 7 IHC Positive in  
PD 9/11, iLBD 
7/7 
PD 9/11, iLBD 
5/7 
PD 88, 
71-100 
iLBD 
100 
Duda et al 
(1999) [227] 
Olfactory 
mucosa 
(post-mortem) 
5 11 NA IHC PD 5/5,  
Controls 11/11 
100 0 
Michell et al 
(2005) [228] 
Skin 
(ante-mortem) 
16 
 
5 
 
NA 
 
IHC 
 
PD 3/16  
Controls 1/5  
19 80 
 
Braak et al 
(2006) [223] 
Gastric 
myenteric 
plexus (post-
mortem) 
3 5 2 IHC PD 3/3 
iLBD 2/2 
Controls 0/5 
      PD 100 
 iLBD 100  
100 
 
Fujishiro et 
al (2008) 
[229] 
Heart 
(post-mortem) 
14 4 11 IHC PD 14/14 
 iLBD 7/11 
PD 100 
iLBD 63  
100 
Lebouvier et 
al (2008) 
[230] 
Colonic tissue 
(ante-mortem) 
5 5 NA IHC PD 4/5 
Controls 0/5 
80 100 
Orimo et al  
(2008)[231] 
Cardiac 
sympathetic 
nervous system   
(post-mortem) 
10 10 20 IHC PD 6/10 
iLBD 18/20 
Controls 0/10 
    PD 60 
   iLBD 90         
 
 
100 
Orimo et al 
(2008) [232] 
 
Cardiac  
sympathetic  
nervous system 
(post-mortem) 
3
a
 
 
3 0 IHC PD 3/3 
Controls 0/3 
       100 100 
Beach et al 
(2009) [233] 
Olfactory 
mucosa 
(post-mortem) 
58 69 21 IHC PD 55/58 
iLBD 14/21 
Controls 5/69 
    PD 95 
   iLBD 67 
 
91 
Ghebermed
hin et al 
(2009) [234] 
Heart 
b
 
(post-mortem) 
5 2 7 IHC PD 3/5 
iLBD 2/2 
      PD 60 
 iLBD 100  
100 
Witt et al  
(2009) [235] 
Olfactory 
mucosa  
(ante-mortem) 
7 25 NA IHC PD 0/7  0 NA 
PD=Parkinson’s disease; iLBD=incidental Lewy Body disease; IHC=immunohistochemistry; NA=not 
applicable or not available; 
a
 PD patients with SNCA duplication, 
b
 epicardium, myocardium and 
conduction system, 
c 
larynx, primary bronchus, lung 
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Table 2.1b is a continuation of Table 2.1a 
Authors 
(year) 
Specimen  
(type of 
study) 
PD 
(n) 
Controls 
(n) 
iLBD 
(n) 
Methods Alpha-synuclein 
positive 
cases/total  
(p value) 
Sensitivity 
( %) 
Specificity 
(%) 
PD versus 
Controls 
Beach et al 
(2010) [236] 
Multiple body 
sites 
(post-mortem) 
17 23 7 IHC PD (12/15 
sympathetic 
ganglia, 11/15 
vagus, 11/17 
gastrointestinal 
tract, 1/8 
respiratory tract
 c
, 
2/9 endocrine 
system
 d
, 1/8 
genitourinary 
tract). 
PD  
(sympathet
ic ganglia 
80;vagus 
73; 
gastrointes
tinal tract 
65; 
respiratory 
tract 12; 
endocrine 
system 22; 
genitourina
ry tract 12)  
 
NA 
Del Tredeci 
et al (2010) 
[237] 
Submandibula
r salivary 
glands, 
autonomic 
ganglia, vagus 
(post-mortem) 
9 
 
19 3 IHC Salivary glands: 
PD 9/9, iLBD 2/3, 
Controls 0/18  
Superior cervical 
ganglion: PD 9/9, 
iLBD 2/3, 
Controls 0/8 
Vagus: PD 9/9, 
iLBD 2/3, 
Controls 0/18 
PD 100 
iLBD 66  
 
PD 100 
iLBD 66  
 
 
PD 100 
iLBD 66  
 
100 
 
 
100 
 
 
 
100 
Lebouvier et 
al  (2010) 
[238] 
Colonic tissue 
(ante-mortem) 
29 10 NA IHC PD 21/29 72 100 
Cersosimo 
et al (2011) 
[239] 
Labial salivary 
glands 
(ante-mortem) 
3 3 NA IHC PD 2/3  
Controls 0/3  
 
66 100 
Pouclet et al 
(2012) [240] 
Rectal/ 
Colonic tissue 
(ante-mortem) 
26 9 NA IHC PD (rectum 6/26, 
descending colon 
11/26,  
ascending colon 
17/26) 
rectum 23, 
descending 
colon 42, 
ascending 
colon 65 
100 
Shannon et 
al (2012) 
[241] 
Colonic tissue 
(ante-mortem) 
10 23 NA IHC PD 9/10 
Controls 0/23 
 90 100 
Beach et al 
(2013) [242] 
Sub-
mandibular 
salivary gland 
(post-mortem) 
28
e
 50 5 IHC PD 28/28 
iLBD 0/5 
Controls 0/50 
PD 100 
iLBD 0 
100 
 
Mu et al  
(2013) [243] 
Cervical part 
of vagus, 
pharyngeal 
plexus 
(post-mortem) 
10 4 NA IHC PD 10/10 
Controls 0/4 
         100 
 
      100 
Pouclet et al 
(2012) [240] 
Colonic 
submucosa 
(ante-mortem) 
9 10 NA IHC PD 5/9 
Controls 0/10 
        55       100 
 
 
d
 adrenal, thyroid, parathyroid, testis and ovary ,
e  
included 3 patients who met neuropathological criteria 
for PSP 
 
78 
 
Table 2.2a Summary of 30 studies of alpha-synuclein in body fluids in humans. 
Authors 
(year) 
 
Specimen  
 
PD 
(n) 
Controls 
(n) 
Methods Alpha-synuclein  
PD versus 
controls 
(p value) 
Sensitivity 
( %) 
Specificity 
(%) 
Borghi et al 
(2000) [244] 
CSF 12 10 IP and 
WB 
NS NA NA 
Li et al (2002) 
[245] 
 
Platelets 13 11 WB NS NA NA 
El Agnaf et al 
(2006) [246] 
Plasma 34 27 ELISA Higher in PD 
(p=0.002) 
53 85 
Miller et al  
(2004) [247] 
Blood 1 6 WB Higher in PD 
(p<0.0001) 
NA NA 
Michell et al 
(2005) [228] 
Platelets 12 5 WB NS 100 0 
Tan et al (2005) 
[248] 
Leukocyte
s 
80 80 mRNA 
using 
PCR 
NS NA NA 
Lee et al 
(2006)[249] 
Plasma 105 51 ELISA Higher in PD 
(p<0.001) 
NA NA 
Tokuda et al 
(2006)  [250] 
CSF 33 38 ELISA Lower in PD 
(p<0.001) 
NA NA 
Li et al (2007) 
[251] 
Plasma 27 11 WB Lower in PD 
(p=0.001) 
NA NA 
Papachroni et al 
(2007) [252] 
Plasma 31sPD 
20 fPD 
26  WB  
 
Higher in fPD 
(p<0.001) 
48 sPD 
90 fPD 
69 
Fuchs et al 
(2008) [253] 
Blood 
mononucle
ar cells 
36 79 RTPCR 
ELISA 
Related to 
genotype, see text 
NA NA 
Ohrfelt et al 
(2009) [254] 
CSF 15 55 ELISA NS NA NA 
 
 
Duran et al 
(2010) [255] 
Plasma 95 
 
60 ELISA Higher in PD 
(p=0.0229) 
NA NA 
Hong et al (2010) 
b, c   
[256] 
CSF 117 132 Luminex 
assay 
Lower in PD 
(p<0.001) 
93† 39† 
Shi et al (2010) 
b, 
d 
[257] 
CSF 126 137 Luminex 
assay 
Lower in PD 
(p<0.001) 
92‡ 38‡ 
Brighina et al 
(2010) [258] 
Lympho- 
monocytes 
78 78 ELISA NS NA NA 
Mata et al 
(2010) [259] 
Plasma 86 78 Luminex 
assay 
NS NA NA 
Foulds et al 
(2011) [260] 
Plasma 32 30 ELISA NS NA NA 
Parnetti et al 
(2011) [261] 
CSF 38 32 ELISA Lower in PD 
(p<0.05) 
94 25 
Yanamandra et al 
(2011) [262] 
Plasma 
a
 39 
(EOPD 
27 
LOPD 
12) 
23 WB  Higher monomers 
in PD, 
(EOPD p<0.0001) 
(LOPD p<0.05) 
NA NA 
PD=Parkinson’s disease; CSF=cerebrospinal fluid; NA=not applicable or not available; 
IP=Immunoprecipitation; WB=Western blot; 
a  
antibodies to alpha-synuclein, ELISA=enzyme linked 
immunosorbent assay; mRNA=messenger RNA; NS= non-significant difference; PCR=polymerase chain 
reaction; sPD=sporadic PD; fPD=familial PD; RTPCR= real time polymerase chain reaction 
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Table 2.2b is a continuation of Table 2.2a 
Authors 
(year) 
 
Specimen  
 
PD 
(n) 
Controls 
(n) 
Methods Alpha-synuclein 
PD versus 
controls 
(p value) 
Sensitivity 
( %) 
Specificity 
(%) 
Pchelina et al 
(2011) [263] 
Leukocyte
s 
8 
LRRK2 
33 sPD 
18 WB Lower in LRRK2 
vs. sPD (p<0.02) 
and controls 
(p<0.05) 
NA NA 
 
 
 
Mollenhauer et al  
(2011) [264] 
CSF 257 47
e
 ELISA Lower in PD 
(p=0.0002) 
71 53 
Devic et al (2011) 
[265] 
Saliva 24 25 WB NS NA NA 
 
Park et al 
(2011) [266] 
CSF,  
Plasma 
23 29 ELISA 
 
Higher CSF 
oligomers in PD 
(p=0.039) 
Total  levels in 
CSF and plasma: 
NS 
NA NA 
Foulds et al 
(2012) 
f 
 [267] 
CSF 39 20 ELISA NS NA NA 
 
 
Gorostidi et al 
(2012) [268] 
 
Plasma 134 sPD  
32 
LRRK2 
109 ELISA Lower in sPD 
(p=0.010) 
NS in LRRK2 
NA NA 
 
 
Hall et al 
g
 
(2012) [269] 
CSF 90 107 Luminex  Lower in PD 
(p<0.01) 
NA NA 
Smith et al 
(2012) [270] 
Serum 14 9 ELISA NS NA NA 
Besong-Agbo et 
al  (2013) [271] 
 
Serum 62 46 ELISA Lower in PD 
(p<0.05) 
NA NA 
 
 
Mollenhauer et al 
(2013) [272] 
CSF 78 48 ELISA Lower in PD 
(p=0.002) 
NA NA 
b 
Data sets overlap ; 
c 
excluding cases with RBC contamination of CSF, 
d
 excluding cases with RBC 
contamination of CSF and age<50 years, EOPD=early onset PD; LOPD=late onset PD; LRRK2=leucine 
rich repeat kinase 2 positive; 
e
 normal controls, normal pressure hydrocephalus and progressive 
supranuclear palsy cases, 
f
 post-mortem collection of CSF,  
g
 excluding CSF samples with hemoglobin 
levels greater than 1000 ng/L  
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2.4 Discussion 
 
A tissue biomarker for PD would be useful for diagnosis and disease monitoring, 
which might include assessing the effects of potentially neuroprotective therapy [273]. 
Such a biomarker might supplement or replace current screening approaches for early 
markers of pre-motor PD such as olfactory loss [172]. The attractiveness of alpha-
synuclein as a potential biomarker for PD is clear from the large numbers of studies 
identified. Its pathological accumulation (whether intrinsically cytotoxic, or protective 
as a mechanism to eliminate damaged cellular components) is linked closely to the 
degenerative process [274, 275]. However, its presence in different forms, and within 
several tissues and fluids, adds complexity when evaluating it as a biomarker. In 
addition there are variations in case definition and disease duration within the studies 
reviewed, as well as the types of control cases included, and in the laboratory methods 
in detecting the various forms of alpha-synuclein. We will now discuss these various 
facets. 
 
Firstly, the potential clinical setting of alpha-synuclein measurement varies between 
studies. As abnormal alpha-synuclein accumulation is a marker of a group of diseases 
called synucleinopathies, it should more readily distinguish PD from tauopathies such 
as progressive supranuclear palsy or Alzheimer’s disease, but would not distinguish so 
easily from DLB or MSA, unless tissue distribution or levels in body fluids differed 
significantly. The inclusion of age-matched controls is important in such studies, since 
incidental Lewy bodies may be present with ageing and in the absence of a disease 
state, although the existence of preclinical PD is an added challenge of interpretation. 
Accordingly, we used normal controls (which were usually age and sex-matched) to 
determine sensitivity and specificity of tissue and fluid specimens in our analysis, and 
summarised but did not include data from cases defined as incidental Lewy body 
disease in these calculations. Secondly, studies that have been done so far are 
exclusively cross-sectional; monitoring disease progression by measuring peripheral 
alpha-synuclein levels in longitudinal studies has not been reported. 
  
Compared to other potential biomarkers related to dopaminergic neurons, such as 
dopamine metabolites and dopamine transporters which are influenced by the dynamic 
responses to dopamine deficiency in the synaptic system and the use of dopamine 
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replacement therapies, alpha-synuclein may be considered as a more stable marker 
reflective of disease severity and progression, as it temporally and spatially aggregates 
in the brain with disease progression. 
 
We first looked at the distribution of alpha-synuclein aggregates in peripheral tissues, 
in patients with PD, which could be obtained for diagnostic purposes and found that it 
is extensively distributed in several body tissues [236].While the presence of 
pathological alpha-synuclein in all peripheral tissues is included in this systematic 
review, information from tissues that are generally inaccessible to sample collection in 
vivo, but has been obtained from autopsy, is more relevant to the understanding of the 
pattern of distribution of alpha-synuclein in PD, and less relevant to its consideration 
as a practically useful biomarker. Therefore to aid in deciding the clinical usefulness 
of a tissue specimen for detecting alpha-synuclein pathology and the ease of obtaining 
the specimen for practical purposes we divided the results into those studies that 
required solid tissue from a biopsy/autopsy specimen and those analysing body fluids. 
Amongst solid tissue specimens the peripheral nervous system offered samples with 
the highest sensitivity, ranging from 73 to 100% for vagus nerve [236, 237], 60 to 
88% for cardiac sympathetic ganglia [226, 231], 100% for superior cervical ganglion 
[237] and 100% for the submucosal nervous plexus in the stomach [223], but all 
studies were very small (between 3 and 15 cases). While specificity in these studies 
where healthy controls were included was 100% [223, 226, 231, 237], these studies 
also included cases of iLBD [223, 226, 231, 236, 237], which showed the presence of 
alpha-synuclein aggregates in a similar proportion of cases to PD [223, 226, 231, 237]. 
The presence of alpha-synuclein inclusions in these tissues is therefore not a reliably 
specific marker of PD; rather it is a marker of alpha-synuclein aggregation. While 
some consider iLBD to be a pre-morbid stage of PD [276], involving the concept of a 
threshold of Lewy body accumulation, an alternative interpretation is held by others, 
that such Lewy bodies reflect age-related change in alpha-synuclein, without clinical 
significance to disease development [225]. The detection of alpha-synuclein 
aggregates outside the brain (e.g. epicardial fat [277] , gastric tissue [278] and 
abdomino-pelvic autonomic plexuses in the general population [279] )during life has 
extended the spectrum of incidental alpha-synuclein inclusions or immunoreactivity. 
While iLBD has traditionally been defined by post-mortem diagnosis from brain tissue 
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(on the basis of Lewy bodies in the substantia nigra and/or locus coeruleus without a 
clinical diagnosis of PD in life) [280], it does not cover the discovery of abnormal 
alpha-synuclein inclusions in peripheral tissues in living patients (in whom brain 
specimens have not been obtained). We therefore propose the term incidental alpha-
synuclein aggregates (iAA) qualified by location: iAA-C for central nervous system 
such as the brain and spinal cord and iAA-P for alpha-synuclein aggregates in 
peripheral tissues. Whether iAA-P is pathological or not is entirely dependent on the 
interpretation of iAA-C, also called iLBD, as a preclinical disease state or an age-
related phenomenon.  
  
Peripheral nervous tissue showed high rates of detection of alpha-synuclein pathology 
in PD patients, but the practicality of obtaining some of the tissues studied (e.g. 
cardiac) is limited. Biopsy specimens from more accessible sites such as the colonic 
mucosa had moderate to high sensitivity (42-90%) and 100% specificity compared to 
healthy controls [230, 238, 240, 241]; submandibular and labial salivary glands also 
showed high sensitivity (66 to 100%) and specificity (100% versus normal controls), 
but again in very small studies (3 to 9 patients) [237, 239]. Biopsies of olfactory 
mucosa showed mixed results (sensitivity 0-100%, n=12) [227, 235]. Other tissues 
such as skin had low sensitivity in detecting alpha-synuclein pathology [228]. 
  
Alpha-synuclein is found normally in all blood cells including red blood cells, 
leukocytes, platelets, and body fluids including CSF, saliva and plasma [245, 248, 
262, 265, 281]. The presence of alpha-synuclein in its various conformations in body 
fluids, compared to normal controls, therefore requires measuring concentration 
differences, to determine a cut-off value, in order to develop a diagnostic test or a 
biomarker for an alpha-synucleinopathy. 
  
Conflicting results are reported for plasma alpha-synuclein levels. In 5 studies 
comparing total plasma alpha-synuclein between PD and controls, 2 reported elevated 
levels in PD [246, 249]; one found decreased levels in PD [251], and one found no 
significant difference [266]. Two studies reported no difference in oligomeric plasma 
alpha-synuclein (suggested as the neurotoxic species) [266, 282] while one study 
reported higher levels of antibodies to monomeric alpha-synuclein in PD [262]. There 
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was no difference in phosphorylated plasma alpha-synuclein (which is present in 
Lewy bodies) between PD cases and controls [260]. 
 
While the observation that alpha-synuclein may be actively secreted from 
degenerating neurons into CSF suggested potential utility as a biomarker of PD, 
results are no more consistent than for plasma. Decreased CSF alpha-synuclein levels 
in PD patients compared to controls [250, 256, 261, 264, 283], increased levels (of 
oligomeric alpha-synuclein) [264] and no significant difference [244, 254, 267] are all 
reported. For CSF alpha-synuclein, contamination from red blood cells which are a 
major source of alpha-synuclein [218, 281] requires consideration, but only 4 of 9 
studies corrected for this factor. A further contributor to variation is reflected in a 
review of 242 studies up to 2005, which identified that only 75 studies (31%) used 
standardized commercial antibodies to alpha-synuclein, and dilution and antigen 
unmasking protocols varied between studies, even when the same antibody was 
employed [284]. 
  
None of the studies we reviewed examined alpha-synuclein as a marker of disease 
progression, which is consistent with negative findings from a systematic review of 
biomarkers relating to disease progression in PD [285]. 
  
 
2.5 Conclusion 
 
  
It is clear that neither plasma nor CSF alpha-synuclein is presently a reliable marker of 
PD. This differs from alpha-synuclein in solid tissue samples of enteric and autonomic 
nervous system, which have potential as a surrogate marker of brain synucleinopathy, 
while recognising the important difference between such changes being incidental (or 
pre-clinical) or manifest. As such a single bio-marker, for example alpha-synuclein 
may not have clinical utility and it is probably the combination of a biochemical 
biomarker such as peripheral tissue alpha-synuclein, neuroimaging biomarker such as 
FP-CIT SPECT and clinical biomarkers such as olfactory dysfunction that may 
provide clues to diagnosing early PD. Clearly there is an unmet demand for better 
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tools that could be used as biomarkers that are practical and cost- effective in 
screening targeted populations. 
 
Index terms 
  
Medical Subject Headings (MeSH): Parkinson* disease; Alpha-synuclein 
MeSH check words: Humans, English 
  
 Search Strategy 
  
i. For Pubmed/Embase 
  
1. parkinson*.mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, sh, tn, dm, mf, dv, kw] 
2. alpha-synuclein.mp. [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, sh, tn, dm, mf, dv, kw] 
3. 1 and 2 
4. limit 3 to "PubMed not Medline" [Limit not valid in Embase; records were retained] 
5. limit 4 to humans 
6. limit 5 to English language 
7. remove duplicates from 6 
8. limit 7 to full text 
  
 ii. For Cochrane Library using advanced search 
  
MeSH parkinson* disease AND alpha-synuclein 
  
iii. For CINAHL using advanced search 
  
S1: alpha-synuclein AND parkinson* disease 
Limiters - English Language; Exclude MEDLINE records; Human; 
  
Search modes - Boolean/Phrase; Interface - EBSCO host .Search Screen - Advanced Search. 
Database - CINAHL Plus with Full Text; PsycINFO 
  
iv. For LILAC 
  
Search Parkinson* disease AND alpha-synuclein 
Limiters- English Language; Exclude Medline records; Human 
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Chapter 3. Clinical research protocol of PRoBaND 
 
 
 
 
 
 
3.1 Introduction 
 
 Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting 
the elderly and the numbers of people affected with PD, in countries of Western Europe, are 
projected to double by 2030 [286, 287]. This will have implications for the distribution of 
health care resources and more importantly it will be an economic burden on the patient and 
society [288]. Our understanding of the pathogenesis of PD, though still incomplete, changed 
significantly with the discovery of alpha-synuclein aggregation in Lewy bodies, the 
neuropathological hallmark of this disease [289]. Further confirmation of the central role of 
alpha-synuclein in the pathogenesis of PD was the finding of a specific mutation in the gene 
that codes for alpha-syunclein, SNCA, in some families with PD [6]. Mendelian genetics 
though, can only explain a small proportion of the total number of PD cases, and it is more 
likely that PD is a complex trait with both gene-gene and gene-environment interactions 
[290]. There is a need to find biomarkers that can help in diagnosing PD ,monitoring disease  
progression and determining response to therapy, given that we know that  there is a pre-
symptomatic phase where therapeutic  interventions may have a better chance to affect the 
course of the disease [199]. 
  
3.2 Study design 
  
The study is carried out in accordance with the World Medical Association Declaration of 
Helsinki (1964) and is funded by Parkinson’s UK. Ethics approval for the study was obtained 
from the West of Scotland multi-centre research ethics committee (reference 11/AL/0163, 
protocol 52504/1). 
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3.2.1 Study objectives 
  
Primary objective: 
 
To define the variation or heterogeneity in the clinical phenotypes of Parkinson’s disease. 
 
Secondary objectives: 
 
i. To relate the variation in the clinical phenotype of PD to the underlying genotype of 
patients. 
ii. To support related studies evaluating genetic, serum and imaging biomarkers for the 
diagnosis and progression of PD. 
  
3.2.2 Study cohort 
  
PRoBaND is the largest prospective, observational, multicentre study of PD in the United 
Kingdom (UK). We are recruiting 2000 patients with recent onset PD, defined as those 
diagnosed with PD in the last 3 years and  240 cases with early onset PD, defined as those 
with age at onset less than 50 years. We will also recruit 750 first degree unaffected relatives 
of patients with recent onset PD and 90 first degree relatives of cases with early onset who 
will serve as internal controls. 
 
Inclusion criteria 
 
A.  Subjects with a diagnosis of PD 
  
i. Diagnosis of PD, based on UK Brain Bank criteria and made within the preceding 3 years 
(‘recent onset cases’) or diagnosed at under 50 years (‘under 50 years cases’) 
ii. Age ≥18 to < 90years 
iii. Subject is able and willing to provided informed consent. 
iv. Subjects are allowed to enter the study after they have started anti-parkinsonian 
medication. 
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B.  Subjects who are first degree (unaffected) relatives of recruited PD patients 
  
i. Age ≥18 to < 90years 
ii. Resident in the United Kingdom and able to access one of the PRoBaND study centres. 
iii. Subject is able and willing to provided informed consent. 
  
Exclusion criteria 
 
A.  Subjects with a diagnosis of PD 
  
i. Subject has severe comorbid illness that would prevent full study participation 
ii. Subject has features indicating another type of degenerative parkinsonism, e.g. progressive 
supranuclear palsy 
iii. Drug-induced parkinsonism (drug-unmasked PD is allowed) 
iv. Symmetrical lower body parkinsonism attributable to significant cortical and/or 
subcortical cerebrovascular disease (patients with ‘incidental’ small vessel disease on brain 
imaging are allowed). 
v. Negative or normal functional imaging of the presynaptic dopamine system 
vi. The presence of UK Brain Bank exclusion criteria will be recorded at baseline, allowing 
for the presence of 1 or 2 exclusion criteria (e.g. dopamine antagonist Drug used; more than 
one affected relative) (if justified e.g. by abnormal SPECT). 
  
B.     Subjects who are first degree (unaffected) relatives of recruited PD patients 
  
i. Subject has severe comorbid illness that would prevent study participation 
ii. Subject already has a diagnosis of PD. 
 
3.2.3 Recruitment sites 
  
60 sites in the UK that provide standard care to PD patients as part of the National Health 
Service (NHS) have been selected for the PRoBaND study. Once approval has been obtained 
from the research and development (R & D) unit of the local health board and the local ethics 
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committee, the PRoBaND executive committee grants approval for site activation provided it 
is satisfied that a trained movement disorder specialist is involved in the provision of care of 
the PD patients and supervises the local staff recruiting subjects and administering study 
protocols. Unlike drug trials, there is no site initiation visit. But local principal investigator 
(PI) ensures research staff has undergone necessary training to ensure compliance with good 
ethical practice and NHS protocols. Verification of data acquisition, bio specimen collection 
and receipt across the multiple centres is reviewed on a weekly basis at the data co-ordinating 
centre, Glasgow, to ensure data validity. 
  
3.2.4 Data acquisition, storage and validation 
  
Data capture is by local medical and nursing staff, including PD nurse specialists where 
available at the various recruiting centres. Data recording is done directly on a secure and 
anonymised web-based electronic data capture system linked to the website 
www.clinbase.co.uk , but a paper case report form (CRF) is also available for centres unable 
to use the electronic-system. Missing and erroneous data points are pursued at the data co-
ordinating center at Glasgow and information relayed to the study investigators to complete 
missing data points or rectify the erroneous data entries. Genetic data will be generated, 
analysed and stored at the central laboratory in Cardiff.  
  
3.2.5 Clinical assessments 
  
These are carried out at the local hospitals by trained medical staff where subjects have been 
recruited from and attend clinics for their routine clinical care. The study involves face to 
face interviews and clinical assessments recorded on standardised scoring sheets and 
validated scales to document the motor, non-motor, cognitive, behavioural features and 
therapy response of the enrolled subjects (Table 3.1). Blood samples are collected at baseline 
for DNA testing and serum samples are stored at -80
o
 centigrade in the central laboratory in 
Cardiff for proteomic analyses. Study follow up visits are spaced at 6 monthly intervals and 
for patient convenience are designed to overlap with their routine clinic visits (Figure 3.1) 
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Table 3.1 Clinimetric scales that are used during the study protocol (on the left) and 
biomarkers recorded or envisaged as add-ons to PRoBaND (on the right). 
 
Clinical assessment Scale  Biomarker  Modality 
 
 
Motor MDS-UPDRS  Imaging CT, MRI, FP-CIT 
SPECT 
Cognitive MOCA  Serum Alpha-synuclein 
Autonomic 
 
 
SCOPA-Aut 
 
Constipation 
questionnaire 
 
BP & HR recording 
Genetic LRRK2, GBA, 
Parkin, PINK1 
Sleep ESS, PSS    
RBD RBD questionnaire   
NMS NMSS    
Olfaction UPSIT   
Neurobehavioral HADS    
Personality BFI   
Quality of Life PDQ8 , EQ5D    
Past Medical and 
Family history 
 
 
Structure 
questionnaires 
  
Environmental 
exposures 
MERQ-PD-B    
MDS-UPDRS –Movement disorder society- Unified Parkinson’s disease rating scale, CT- computed 
tomographic scan, MRI- magnetic resonance imaging, FP-CIT- SPECT- Iodine-123 fluoropropyl single 
photon emission computed tomographic scan, MOCA –Montreal cognitive assessment scale, SCOPA-Aut- 
Scales for Outcomes in PD- Autonomic, ESS- Epworth sleepiness scale, PSS- Parkinson’s disease 
sleepiness scale, RBD- Rapid eye movement sleep behaviour disorder, NMSS- non-motor symptoms 
severity scale, UPSIT- University of Pennsylvania Identification test, HADS- Hospital Anxiety and 
depression scale, BFI- Big Five Inventory, PDQ 8-Parkinson’s disease questionnaire 8 item, EQ5D-
EuroQol questionnaire, MERQ PD-B- Mini Environmental Risk Questionnaire for Parkinson's disease 
patients baseline. 
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Figure 3.1 shows the timings of the visits and the assessments performed in the early onset 
Parkinson’s disease (EOPD) arm of the study. 
 
 
 
   
3.2.6 Blood sampling and genetic analysis 
  
LRRK2 and GBA mutation carrier status will be tested in all PD patients. Parkin (PARK 2) 
mutations will be screened in early onset PD patients in the first phase with PINK1 mutation 
screening later.   
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3.2.7 Proteomic analysis 
 
Serum samples are collected at study entry (visit 0) for the early onset cases and stored for 
proteomic analyses at -80
o
 centigrade as described above. Alpha-synuclein has been 
investigated as a biomarker for PD [260] as have the isoforms of DJ1 protein [291]. These 
and other proteins that alpha-synuclein interacts with would be potential candidates for 
investigation as biochemical biomarkers. Using biomarkers to disentangle the different types 
of parkinsonism has been investigated [292] and there is a proteomic biomarker programme 
based in London and Oxford linked to our study. 
 
3.2.8 Statistical analysis 
  
The sample size for the bigger PRoBaND study has been calculated based on known 
incidence rates of PD and clinic activity levels in the NHS. This calculation was initially 
based on 24 recruiting sites. The number of centres has since increased, but we have left the 
target numbers unchanged, to allow for any delays in centre initiation and other 
contingencies. The study was designed to have a minimum of 240 patients in the EOPD arm 
of the study. Some patients who were recently diagnosed with PD also met eligibility criteria 
for inclusion in the EOPD arm. Inclusion of these additional patients (n=86) in the EOPD 
arm increased the sample size to 326. This was done assuming there would be data missing at 
the end of the study and those with >25% of questionnaires incomplete would be excluded 
from statistical analysis. 50 patients with incomplete datasets were therefore excluded, as no 
data imputation was allowed by protocol. This left us with datasets from 276 patients 
available for statistical analysis and the subsequent chapters in this thesis deal only with these 
patients with EOPD (Figure 3.2), except where indicated (Chapters 4 and 13). Consort 
diagrams, as an aid to explain how many case record forms were available prior to each 
statistical analysis, are shown at the beginning of the results section in each  individal chapter 
from 4 to14 (Figures 4.1, 5.1,  6.1, 7.1, 8.1, 9.1, 10.1, 11.1, 12.1, 13.1, 14.1).  
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Figure 3.2 shows the disoposition of cases prior to data analysis. No data imputation was 
allowed. Those who had incomplete questionnaires were not included in data analysis. 
  
Since PD is a multifaceted disorder, there are many possible ways to define subtypes. For 
example, PD subtypes may be based on motor features (e.g. tremor dominant vs. postural 
instability gait difficulty), age at diagnosis (less than 40 years vs. greater than 40 years), 
gender (males vs. females) and heritability of the parkinsonian trait (familial PD vs. sporadic 
PD). The onset of PD was defined, in line with previous studies as the time of diagnosis, not 
the retrospective report of first symptoms which is subject to a recall bias [293]. Familial PD 
was also defined in line with previous studies, as those cases showing a positive family 
history compatible with the diagnosis of Parkinsonism in at least one first or second degree 
relative [166]. Where a Mendelian pattern of inheritance in familial cases, either autosomal 
Initial recruitment 
target 
N= 240 
Incomplete 
questionnaires 
N = 50 
Additional cases 
recrutited 
N = 86 
Full dataset 
available 
N = 276 
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dominant (across generations) or autosomal recessive (skipping generations but siblings may 
be affected), is obvious the term hereditary PD has been used [294].  While recognising that 
there may be several other ways of classifying EOPD patients e.g. by genotype, within the 
broader framework of this thesis, to analyse for the variation or heterogeneity in the clinical 
phenotype of EOPD patients with respect to historical and examination findings, all cases 
will be classified in 4 ways i.e. according to motor subtype, sex, age at diagnosis of PD and 
family history of PD.  
 
In order to provide a uniform methodology, the computational models for statistical analysis 
and presentation of results (in tabulated form) using the ‘4 way classification’ (Figure 3.3), 
described above, will be applied in all chapters of this thesis, except where specifically 
indicated. 
 
               
Figure 3.3 shows the 4 ways in which the early onset Parkinson’s disease (EOPD) cases will 
be classified in all the chapters of this thesis, except where indicated. 
 
3.2.9 Collaboration 
  
Harmonization of datasets assists collaborative research. PRoBaND has adopted the common 
data elements (CDEs) of the National Institute for Neurological Diseases and Stroke 
(NINDS)  [295]. The NINDS plans to enforce the use of CDEs in future US government 
funded PD research, which often includes international sites, e.g. the Parkinson Progression 
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Marker Initiative (PPMI) project.  This will enhance compatibility and longevity of the 
datasets that will become available from the PRoBaND study. 
 
In the UK we have linked up with Oxford Discovery Project, Cardiff Neurological Disease 
Bio bank and Neurogenetics Research Study (CANDAS), the NILS (Non-motor International 
Longitudinal Study) and the Brain Bank at Imperial College, London for tissue banking. 
(Figure 3.4) 
                
 
Figure 3.4 shows the ‘hub and spoke’ model of the PRoBaND study where sub-studies 
(rectangular boxes) link to the main study (circle) and collaboration with other similar studies 
(ovals) is supported, NILS=Non-motor international longitudinal study, CANDAS= Cardiff 
Neurological Disease Bio bank and Neurogenetics Research Study, BRAIN BANK= Imperial 
College, London, Brain Bank, DISCOVERY= Oxford Parkinson disease centre Discovery 
project. 
 PRoBaND 
Pain 
sub-study 
Respiratory 
sub-study 
Gastro. 
Sub-study 
MRI 
sub-study 
       
         NILS 
    
BRAIN BANK 
     
     CANDAS 
     
DISCOVERY 
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3.2.10 Supporting future research 
  
Data will be made available to support other research and audit projects in Parkinson’s 
disease.  Such data sharing will be stripped of personal identifiers, including date of birth and 
detail of family history. Access to such datasets will be on application to the executive 
committee chair. All studies seeking to use data and/or blood or serum samples will require 
ethics approval. 
  
3.3 Discussion 
  
PRoBaND seeks to establish a networked dataset of historical and clinical features of a large 
cohort of PD patients, establish patterns and variations in the phenotypes, acquire serum 
samples for proteomic analyses and collect DNA samples from all individuals to lay the 
groundwork for linking phenotypes with genotypes of these individuals. This is a process in 
evolution and will require a detailed analysis of the genomes of these individuals. Beyond 
traditional Sanger sequencing, genomic technologies have evolved over the last decade to 
include genome wide association studies (GWAS) which can indicate regions in the human  
genome that can confer the risk of disease and next generation sequencing ,such as exome 
sequencing, that can pinpoint novel genes that contain mutations [296]. In GWAS, the 
identification of genetic risk factors for the development of PD is achieved by analyzing as 
many as 500,000 different single-nucleotide polymorphisms (SNPs) in large groups of 
sporadic PD patients (a few thousands) and healthy individuals, and comparing SNP 
frequencies in the two groups. If certain variants are more frequent in PD patients, they are 
considered to be “associated” with the disease. These genetic variants are used to indicate the 
region of the human genome where the PD-causing change is likely to be situated.[297] 
  
In the first phase we aim to test for Mendelian genes causing PD which will include LRRK2 
[298] , GBA[299] and Parkin [300] with  PINK1 [301]  tested later, only in those with early 
onset disease. 
 
Mendelian genes though account for less than 10% of the total cases of PD in the general 
population [302]. Mutations in the 4 genes that will be tested in the PRoBaND cohort are 
recognised as rare causes of PD but common variants in these genes and other related genes 
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may serve as susceptibility loci [303]. Single nucleotide polymorphisms (SNPs) at several 
genetic loci probably account for a substantial part of the variation in the clinical phenotypes 
of PD, however, a great deal of these common variants of small effect remain to be 
discovered [290]. In the second phase of our study we therefore aim to expand the use of 
genomic technologies to enhance our understanding of the genetic risks to individuals with 
PD. Sequencing for SNPs across the genome will serve as the goal of the second phase in the 
protocol. All DNA samples will be genotyped using the Illumina Human Core Exome array, 
supplemented with custom content. This will allow the analysis of approximately 250,000 
common and 250,000 rare variants, plus over 27,000 custom variants selected because of 
their previous implication in a range of neurodegenerative, neurological, and psychiatric 
disorders [304, 305]. 
 
There will be a large number of SNPs identified in these loci and using public databases such 
as dbSNP we can filter the information to analyse which variants can influence the 
phenotypes comparing cases with controls [306]. 
  
The genetic basis of sporadic late onset PD is not clearly understood and this is likely to be a 
complex trait where genetic as well as environmental influences play a role through gene 
environment interactions although the molecular pathways for this have not been elucidated 
[307]. 
  
Finding a blood biomarker would be a very convenient way of diagnosing and recording 
progression of a disease process. Alpha-synuclein levels in the blood have been tested for use 
as a biomarker but the data so far have been less than convincing in establishing its utility for 
this purpose due the large variation in the results reported. However since alpha-synuclein is 
intimately linked to the pathogenesis of PD, either a specific confirmation of alpha-synuclein 
or a panel of plasma biomarkers that involves proteins that interact with alpha-synuclein 
would have to be investigated to determine whether this hypothesis is true or not. 
PRoBaND’s ‘hub and spoke’ model (Figure 3.4) allows for this and a group based in London 
with expertise in tandem mass spectrometry and ELISA based protocols is in the process of 
commencing work on this. 
  
Imaging biomarkers that are more economical and readily accessible to physicians than 
currently available modalities such as FP-CIT SPECT scans are needed. The nuclear 
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medicine scans currently in use are neither specific for PD, to differentiate it from atypical 
parkinsonism, nor can they be used to monitor disease progression or response to therapy. An 
imaging sub-study of PRoBaND is in place to start enrolling patients in one of the largest 
ever brain scanning studies in patients with PD. This will involve magnetic resonance image 
(MRI) scans of the brain at high resolution in 300 patients from the original PRoBaND cohort 
and an additional 100 people who will serve as normal controls. The data collected will be 
used to create a ‘virtual brain bank’ which will supplement the detailed clinical subtyping of 
PD that PRoBaND provides and this will be accessible to researchers all over the world to 
use as a platform for identifying novel imaging markers for PD. 
  
Several other sub-studies linking with the hub include research teams looking at pain 
pathways, gastrointestinal dysfunction and respiratory disturbances in PD to provide an in-
depth and comprehensive assessment of factors that could have an impact on the quality of 
life in PD. 
 
Our study has similarities with other large cohort studies in PD such as the United States 
Parkinson’s Progression Markers Initiative (PPMI) multicenter study  (n=600 ) [308] , 
however, PRoBaND is a much larger multi-faceted study (n=3080) and is not limited to drug-
naïve PD cases like PPMI but has a broader base and serves as a hub for several allied sub-
studies in PD. So, while acknowledging some of our goals such as finding biomarkers for PD 
are shared with PPMI and other similar studies, PRoBaND offers a platform for researchers 
across the world to access datasets, DNA and bio samples of  a large cohort of prospectively 
followed patients in order to better understand this disease and there is an unlimited scope for 
collaboration. 
  
3.4 Conclusion 
  
We have been successful in establishing a large effective clinical research network actively 
recruiting cases to a combined clinical-laboratory program, evaluating variation in the clinical 
expression of PD, which will be studied in relation to genetic influences, and offer a platform 
for finding serum and imaging biomarkers for this disorder. Collaboration with other groups 
in this scientific endeavour has been actively pursued in order to improve our understanding 
of PD and we anticipate that our ground work lays down the path for future research in the 
pathogenesis and treatment of this disease. 
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 Chapter 4. Variation in premotor symptoms and other risk factors in 
EOPD 
 
 
 
4.1 Objective 
 
The objective in this chapter is to analyse the variation in the pre-motor characteristics and 
risk factors in a cohort of patients with early onset Parkinson’s disease from the PRoBaND 
study.  
 
4.2 Introduction 
 
Parkinson’s disease (PD) is recognised to have a pre-motor phase that may start several years, 
if not decades, before the classical motor features that are part of the diagnostic criteria[309] 
develop. Anxiety, depression, REM sleep behaviour disorder (RBD), olfactory loss and 
constipation have been considered pre-motor characteristics in PD[310]. Head injury and 
oophorectomy have been found to have an increased odds ratio of being associated with the 
subsequent development of PD in meta-analyses of epidemiological studies while smoking 
and caffeine consumption are reported to have a negative association with the future risk of 
developing PD [194, 311]. 
 
The study protocol of PRoBaND allowed for olfaction, constipation and RBD symptoms to 
be recorded using standard questionnaires prospectively, rather than retrospectively, hence 
the data on variation in these 3 symptoms have been presented in Chapter 7 which deals with 
all non-motor symptoms, rather than here.  
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4.3 Methods  
 
Patients attended 6 monthly clinic visits as per study protocol described in detail in Chapter 3. 
They were asked to fill in questionnaires for demographic data at baseline (visit 0); physical 
parameters such as weight, height and blood pressure were recorded at the same visit. Data 
required for Movement Disorder Society Unified Parkinson's disease rating scales (MDS-
UPDRS) scores were collected at study visit 1 and a modified mini environmental risk 
questionnaire for Parkinson’s disease patients’ baseline (MERQ-PD-B) at study visit 2. This 
is one of the standard forms for collecting such information incorporating common data 
elements (CDE) suggested by the National Institute of Neurological Disorders and Stroke 
(NINDS). An overview of all PD CDE recommendations can be found in the PD CDE 
Highlight Summary document on their website [295].The MERQ-PD form was used to 
collect information for exposure to environmental risk factors such as head injury, 
consumption of caffeine and past history of oophorectomy in females. The MERQ-PD-B 
form was modified to include additional questions about pre-motor symptoms i.e. depression 
and anxiety prior to the diagnosis of PD. Head injury for the purposes of this study was 
defined as that causing either loss of consciousness or  conscussion as diagnosed by a doctor. 
 
To analyse for the variation in clinical phenotype of PD with respect to historical and 
examination findings all cases with EOPD were classified in 4 ways as outlined in chapter 3. 
First patients were classified according to motor subtypes i.e. tremor dominant PD (TDPD), 
postural instability gait difficulty (PIGD) and ‘Mixed’ or ‘Indeterminate’, terms 
interchangeably used hereafter, subtypes based on their UPDRS scores  according to a 
mathematical formula that incorporates MDS-UPDRS Part 2 (UPDRS2) and MDS-UPDRS 
Part 3 (UPDRS3) scores [312]. Tremor score is calculated as the mean score of the MDS-
UPDRS elements describing tremor in the left column (0–4 for each item) of Table 4.1. PIGD 
score is calculated as the mean score for the posture, gait and instability while walking 
elements in the right column (0–4 for each item) of Table 4.1. 
 
The ratio of the mean MDS-UPDRS tremor score (11 items, left column Table 4.1) to the 
mean UPDRS PIGD score (5 items, right column Table 4.1) was used to define TDPD motor 
subtype (ratio ≥1.5), PIGD motor subtype (ratio ≤1), and ‘Mixed’ or ‘Indeterminate’ motor 
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subtype (ratios >1.0 and <1.5). In addition, patients who had a positive mean in the numerator 
and a zero in the denominator were classified as TDPD; patients with a zero in the numerator 
and a positive mean in the denominator were classified as PIGD, and patients with zeroes in 
both the numerator and denominator were classified as ‘Mixed’. 
 
Table 4.1 Elements of the Movement Disorder Society Unified Parkinson’s disease rating 
(MDS-UPDRS) scale used in calculating Tremor and PIGD scores. 
Tremor score PIGD score 
MDS- UPDRS Part 2 MDS- UPDRS Part 2 
1. Tremor 1. Walking and balance 
 2. Freezing 
MDS- UPDRS Part 3 MDS- UPDRS Part 3 
2. Postural tremor RUE 3. Gait 
3. Postural tremor LUE 4. Freezing of gait 
4. Kinetic tremor RUE 5. Postural stability 
5. Kinetic tremor LUE  
6. Rest tremor RUE  
7. Rest tremor LUE  
8. Rest tremor RLE  
9. Rest tremor LLE  
10. Rest tremor lip/jaw  
11. Rest constancy  
RUE= Right upper extremity, LUE=left upper extremity, RLE=Right lower extremity,  
LLE=Left lower extremity. Adapted from [312].  
 
Further analyses looking at variation in the clinical phenotype involved 3 additional methods 
of subtyping cases: by gender, age at onset and heritability of the parkinsonian trait i.e. those 
with a positive family history of PD compared to those with no family history of PD. 
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Finally, considering that the most important risk factor for PD is a positive family history of 
PD [194] we analysed the hereditary patterns within the EOPD cohort by classifying patients 
into 2 groups, those who at age at onset of PD symptoms ≤ 40 years and those with age at 
onset of PD symptoms > 40 years to consider whether the cut-off of 40 years to define EOPD 
in other studies made a  significant difference to the results from our study, where we have 
used 50 years as the cut-off to define EOPD.    
 
Statistical analysis:  
 
Descriptive data are presented as median and inter-quartile range (IQR) as data in most 
instances failed tests of normality (Shapiro Wilk). Kruskal Wallis test was used for inter- 
group comparisons of numerical data in scenarios where cases where classified into 3 groups 
e.g. motor subtypes, with post hoc comparisons between groups using Mann Whitney U if the 
Kruskal Wallis test statistic showed a significant difference between the 3 groups. Mann 
Whitney U test was used for inter-group comparisons of numerical data where cases were 
classified into 2 groups e.g. males and females. Chi square tests or Fisher’s exact tests were 
used for comparing groups for categorical data, with post-hoc tests as appropriate.  
 
All statistical analyses were two-sided and significance level was set at 5%. Statistical tests 
were performed using Prism software (version 4.0 for Windows; CA, USA) and SPSS 
(version 23 for Windows, IL, USA). 
 
4.4 Results 
 
210 patients had completed all questionnaires relevant to this analysis and are included here 
(Figure 4.1). The median age at the time of registration was 52.5 years (inter-quartile range, 
IQR, 47.4-56.6) and median disease duration was 7.5 years (IQR 3.7-11.5). Slightly more 
than half of the patients were males and the vast majority were Caucasians (Figure 4.2).  
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Figure 4.1 shows the disoposition of cases prior to data analysis for this chapter. No data 
imputation was allowed. Those who had incomplete questionnaires relevant to this analysis 
were not included. 
 
Initial recruitment 
target 
N = 240 
Incomplete 
questionnaires 
N = 116 
Additional cases 
recrutited 
N = 86 
Full dataset 
available 
N = 210 
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Figure 4.2 shows the demographic profile of the early onset PD cohort (n=210) used in this 
analysis, with proportion of cases on the y-axis and demographic characteristics on the x-
axis. 
 
 
Other demographic variables of these 210 patients are presented in Table 4.2.  Those with 
missing data in the questionnaires analysed in this chapter (n=66) were not included and 
imputation of missing data was not used, in order to avoid drawing erroneous conclusions 
from the results of the statistical analysis. 
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Table 4.2 Demographic profile of the early onset PD patients (n=210) 
 analysed in this section who had completed all relevant questionnaires. 
Variable Median (Inter-quartile range) 
Number of cases 210 
Age (at registration, in years) 52.5 (47.4-56.6) 
Sex (males) 52.5% 
Height (metres) 1.7 (1.7-1.8) 
Weight (kg) 79.2 (65.6-95.2) 
Handedness (right) 89.4% 
Married 69.2% 
Employed (at the time of diagnosis) 89.9% 
Ethnicity 
 
      Caucasian 94.8% 
      Asian 3.3% 
      African 0% 
      Caribbean 0.5% 
Disease duration (years) 7.5 (3.7-11.5) 
IQR= inter-quartile range.  Data are presented as median (inter-quartile range) except  
where indicated 
 
 
The variation in some of the important pre-motor characteristics and risk factors in patients 
classified by motor subtype is shown in Figures 4.3 and 4.4. There were 116 cases that were 
classified as TDPD, 79 cases were classified as PIGD and 15 cases were classified in the 
‘Mixed’ motor subtype (Table 4.3).  
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Figure 4.3 shows the prevalence of head injury and smoking, antedating the diagnosis of 
Parkinson’s disease (PD), in the EOPD cohort of PRoBaND on the y-axis and the motor 
subtype of the patients on the x-axis. The top of the boxes represent the proportion of cases 
who were either smokers or reported head injury, as indicated on the y-axis, and the whiskers 
represent the 95% confidence limits of proportion. 
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Figure 4.4 shows the prevalence of anxiety and depression, antedating the diagnosis of 
Parkinson’s disease, as pre-motor characteristics in the EOPD cohort of PRoBaND on the y-
axis and the motor subtype of the patients on the x-axis. The top of the boxes represent the 
proportion of cases who reported either anxiety or depresion, as indicated on the y-axis, and 
the whiskers represent the 95% confidence limits of proportion. 
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Patients in the PIGD were older (p<0.001) and had longer disease duration (p<0.001) 
compared to the other motor subtypes. Post hoc tests showed significant differences in age 
between TDPD and PIGD (p<0.001), PIGD and ‘Mixed’ (p=0.011) but were not significant 
between TDPD and ‘Mixed’ (p=0.993). The differences in disease duration on post hoc tests 
showed significant differences between TDPD and PIGD (p=<0.001) but not between PIGD 
and ‘Mixed’ (p=0.087) or between TDPD and ‘Mixed’ (p=0.303).  
  
There were no statistically significant differences in the prevalence of pre-motor features 
such as depression and anxiety or risk factors such as head injury, caffeine intake and 
smoking in between cases classified by motor subtype (Table 4.3)  
 
 
Table 4.3 Variation in pre-motor characteristics and risk factors for Parkinson’s disease in  
patients (n=210) classified by motor subtype. 
 
Variable    TDPD 
 median (IQR)  
   PIGD 
median (IQR)  
‘Mixed’ 
 median (IQR) 
p- 
value 
Number of cases 116 79 15 - 
Age* (years) 51.2 
 (46.0-54.7) 
55.0  
(50.0-59.4) 
51.2  
(45.9-52.3) 
<0.001 
Sex (males) 65.5% 59.5% 60.0% 0.675 
Duration
†
 (years) 5.7 (2.9-10.1) 9.5 (5.4-15.1) 7.7 (3.9-11.2) <0.001 
Anxiety 
‡
 15.5% 12.7% 20.0% 0.719 
Depression 
‡
  17.2% 16.5% 26.7% 0.628 
Head injury 
‡
 25.0% 22.8% 20.0% 0.879 
Caffeine 
‡§
  4.5 (3-8) 6 (3-8) 6 (4-6) 0.485 
Smoking * 29.3% 35.4% 33.3% 0.661 
Oophorectomy *  3.4% 0 0 NA 
* Age at registration, † disease duration, ‡ prior to diagnosis of PD, ‡§ coffee/tea cups per day.  
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There were 132 males and  78 females in the analysed cohort (Table 4.4).Classifying patients 
by gender showed more males were exposed to cigarette smoke compared to females 
(p=0.046) but there were no statistically significant differences in other risk factors or pre-
motor features analysed in between the two groups (Figures 4.5 and 4.6, Table 4.4) 
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Figure 4.5 shows differences between males (on the left) and females (on the right) in the 
prevalence of pre-motor features and risk factors in the EOPD cohort of PRoBaND. The top 
of the boxes represent the proportion of cases who reported anxiety, depression or head injury 
antedating the diagnosis of Parkinson’s disease, as indicated on the y-axis, and the whiskers 
represent the 95% confidence limits of proportion. 
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Figure 4.6 shows differences between males (on the left) and females (on the right) in 
caffeine intake (on y-axis) in the EOPD cohort (p=0.178) of PRoBaND. The line in the centre 
of the boxes represent the medians, the ends of the whiskers 2 standard deviations on either 
side and outliers are represented by dark circles. 
 
Table 4.4 Variation in pre-motor characteristics and risk factors in patients (n=210) classified 
by gender. 
 
Variable Males 
median (IQR) 
Females 
median (IQR) 
p- 
value 
Number of cases 132 78 - 
Age* (years) 52.5 (47.4-56.7) 52.2 (47.4-56.5) 0.906 
Duration
†
 (years) 7.7 (3.7-11.6) 6.7 (3.3-11.3) 0.362 
Anxiety 
‡
 15.9% 12.8% 0.688 
Depression 
‡
  17.4% 17.9% 1.000 
Head injury 
‡
 25.0% 21.8% 0.620 
Caffeine 
‡§
  5 (3-8) 5 (3.5-6.8) 0.178 
Smoking 
‡
 37.1% 23.1% 0.046 
Oophorectomy 
‡
  NA 2.6% NA 
* Age at registration, † disease duration, ‡ prior to diagnosis of PD, ‡§ coffee/tea cups per day 
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There were 50 cases that had been diagnosed before the age of 40 years and 160 cases that 
were diagnosed with PD after the age of 40 years in the EOPD cohort analysed (Table 4.5). 
Those diagnosed with PD before the age of 40 years had a longer disease duration (p=0.031) 
compared to those diagnosed after the age of 40 years in this cohort of EOPD patients but 
there were no statistically significant differences between any of the pre-motor features and 
risk factors analysed between the two groups (Figure 4.7 and Table 4.5). 
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Figure 4.7 shows differences between those diagnosed with Parkinson’s disease (PD) at or 
before the age of 40 years (on the left) and those diagnosed after the age of 40 years (on the 
right) in the prevalence of  pre-motor features and risk factors in the EOPD cohort of 
PRoBaND. The top of the boxes represent the proportion of cases who reported anxiety, 
depression or head injury antedating the diagnosis of PD, as indicated on the y-axis, and the 
whiskers represent the 95% confidence limits of proportion. 
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Table 4.5 Variation in pre-motor characteristics and risk factors in patients (n=210) 
 classified by age at onset of PD. 
 
Variable  Age onset ≤ 40 yrs. 
     median (IQR)  
Age onset > 40 yrs. 
     median (IQR)     
p- 
value 
Number of cases 50 160 - 
Age* (years) 47.2(41.6-51.9) 53.5(49.7-57.0) <0.001 
Sex (Males) 72% 60% 0.135 
Duration
†
 (years) 8.4(4.7-15.0) 7.2(3.1-11.2) 0.031 
Anxiety 
‡
 14.0% 15.0% 1.000 
Depression 
‡
  18.0% 17.5% 1.000 
Head injury 
‡
 28.0% 22.5% 0.449 
Caffeine 
‡§
  4.5(3-8) 5(3-8) 0.203 
Smoking 
‡
 34.0% 31.3% 0.730 
Oophorectomy 
‡
  0% 2.5% NA 
* age at registration, † disease duration, ‡ prior to diagnosis of PD, ‡§ coffee/tea cups per day 
 
 
 
 
 
52 patients had a family history of PD affecting one or more relatives while 158 patients had 
no family history of PD and were classified as sporadic PD (Table 4.6).  There were no 
differences between age, disease duration, pre-motor characteristics or any of the risk factors 
analysed between those with a positive family history of PD compared to those with negative 
family history of PD (Figure 4.8 and Table 4.6) 
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Figure 4.8 shows differences between those with a positive family history of Parkinson’s 
disease (PD), left box of each pair, and those with a negative family history of PD, right box 
of each pair, in the prevalence of pre-motor features and risk factors in the EOPD cohort of 
PRoBaND. The top of the boxes represent the proportion of cases who reported anxiety, 
depression or head injury antedating the diagnosis of PD, as indicated on the y-axis, and the 
whiskers represent the 95% confidence limits of proportion. None of the differences were 
significant as shown overlapping confidence intervals in the figure and by p-values >0.05 for 
the comparisons in Table 4.6. 
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Table 4.6 Variation in pre-motor characteristics and risk factors in patients (n=210) 
 classified by family history of PD. 
 
Variable Positive FH 
median (IQR) 
Negative FH 
median (IQR) 
p- 
value 
Number of cases 52 158 - 
Age* (years) 52.0 (47.4-55.9) 52.7 (47.5-56.6) 0.586 
Sex (Males) 63.5% 62.7% 1.000 
Duration
†
 (years) 6.0 (3.7-11.3) 7.6 (3.7-11.7) 0.602 
Anxiety 
‡
 7.7% 17.1% 0.117 
Depression 
‡
  15.4% 18.4% 0.681 
Head injury 
‡
 26.9% 22.8% 0.575 
Caffeine 
‡§
  5.5 (3.0-7.8) 5.0 (3-8) 0.368 
Smoking 
‡
 40.4% 29.1% 0.169 
Oophorectomy 
‡
  1.9% 1.9% 1.000 
FH = family history, IQR = inter-quartile range, * Age at registration, † disease duration, ‡ prior to 
diagnosis of PD, ‡§ coffee/tea cups per day 
 
 
 
 
There was no statistically significant difference in the family history, as a risk factor for PD, 
between those aged less than 40 years at diagnosis PD and those aged greater than 40 years at 
diagnosis in the EOPD cohort (Figure 4.9 and Table 4.7) 
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Figure 4.9 shows differences in family history of Parkinson’s disease (PD) between those 
diagnosed at or before the age of 40 years (on the left) and those diagnosed with PD after the 
age of 40 years (on the right) in the EOPD cohort of PRoBaND. The top of the boxes 
represent the proportion of cases who reported other family members having been diagnosed 
with PD, as indicated on the y-axis, and the whiskers represent the 95% confidence limits of 
proportion. None of the differences were significant as shown by overlapping confidence 
intervals and p-values > 0.05 in Table 4.7 for the comparisons. 
 
Table 4.7 Family history (as an indication of genetic risk) in EOPD 
 
Family history Age of onset ≤ 40y Age of onset > 40y p-value 
Number of cases  50   160 - 
Parent(s) affected 12.0% 13.1% 1.000 
Sibling(s) affected 0% 1.3% NA 
Parent(s) or sibling(s) 
affected 
12.0% 14.4% 0.816 
1 family member affected 20.0% 18.1% 0.835 
2 family members affected 2.0% 5.0% 0.689 
3 family members affected 4.0% 1.3% 0.241 
 Any family history of PD 26.0% 24.4% 0.852 
PD= Parkinson’s disease 
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4.5 Discussion   
 
The age at onset of PD is variable. In general, individuals with onset of parkinsonian 
symptoms i.e. tremor, rigidity, bradykinesia, postural instability or combinations thereof, 
before the age of 20 years are considered to have juvenile onset PD (JOPD) [313], those with 
onset before the  age of 40 or 50 years are classified as having early onset PD (EOPD) or 
young onset PD (YOPD) [314, 315] and those with onset after the age of 50 years are 
considered to have late onset PD (LOPD) [316]. A cohort of EOPD patients from the larger 
PRoBaND study are the subject of analysis of the variation in the clinical expression of PD in 
this thesis. 
 
There is evidence that the neurodegenerative process that ultimately leads to the death of 
neurons in PD begins many years, perhaps as long as 5-20 years, before the onset of motor 
manifestations. Recognizing the early signs of PD, years before the characteristic motor signs 
appear [317], would be ideal for investigating the role of neuroprotective therapies in such 
cases, to offset or delay the development of the debilitating effects of PD on mobility and 
quality of life [318]. Additionally, there can be challenges in diagnosing EOPD when 
presentation to the general practitioner is with a slight intermittent tremor in a relatively 
young and otherwise fit person, leading to delays in arriving at the right diagnosis by as many 
as 15 months compared to LOPD [319]. These considerations make it an interesting 
proposition to establish whether certain pre-motor features that might act as red flags in 
someone with an otherwise ordinary looking tremor segregate with some clinical subtypes of 
PD but not others within the broader rubric of EOPD.  
 
Over the years researchers have recognized several clinical subtypes of PD [320]. Classifying 
patients into subtypes by predominant motor presentation [179], gender [321] , age of onset 
[322] and heritability PD [323] can allow for comparison to be made particularly when trying 
to establish the variation in phenotypic characteristics of the group. Zetusky et al established 
the idea of clinical subtyping patients with PD because of prognostic implications as they 
demonstrated in their study of PD patients (n=334), deterioration in mental status was 
correlated with the PIGD subtype while the TDPD subtype was associated with relative 
preservation of mental status, earlier age at onset, family history of parkinsonism, and 
generally a more favourable prognosis [324]. Identification of such subtypes may have 
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important implications, not only for the reasons mentioned above, but also for generating 
pathogenic hypotheses and future therapeutic strategies tailored to particular subtypes [325, 
326].  
 
In the data set we analysed there were no significant differences in the prevalence of any of 
the pre-motor features considered here, classifying patients by motor subtype (Table 4.3), 
gender (Table 4.4) age at onset (Table 4.5) or family history of PD (Table 4.6). This can be 
interpreted in two ways, first that the whole EOPD cohort that was analysed here was very 
homogeneous, due to a pre-selection bias, to begin with and therefore the differences in the 
prevalence of these pre-motor features were not significant or that the differences reported by 
others [327, 328] are so small that our sample size (n=210) when dichotomised into 2 or 
divided into 3 groups has small number of cases in each category and the statistical tests used 
don’t have enough power to detect any significant differences.  
 
Furthermore, the only significant differences detected in the risk factors considered here was 
in the prevalence of smoking between males and females (p=0.046) as well as the reports of 
oophorectomy in women only in the TDPD motor subtype and those diagnosed with PD after 
the age of 40 years, when comparing analogous subtypes (Tables 4.3 to 4.5). The higher 
incidence of smoking  in males is a secular trend in the general population in both Scotland 
and England and could be explained by the higher prevalence of risk taking behaviours in 
males, while recognising the fact prevalence is also affected by cultural factors [329, 330]. 
The prevalence recorded in our cohort was generally higher than previously reported figures 
from NHS patients both for males (37.1% vs. 25.3%) and females (23.1% vs. 20.0%) [331]. 
The higher figures in our sample could be due to the fact that the population cohort in 
Simpson et al’s paper has a different demographic profile and also due to the fact that our 
cohort has an inherent pre-selection bias, referred to above, that is an unavoidable fact of 
most clinic based studies. But the interesting statistic that merits attention is the almost 2:1 
ratio of smokers between males and females when considered in the context of smoking 
being considered a protective influence on the development of PD as reported from 
epidemiological surveys. If smoking were indeed a protective influence rather than an 
association, one would expect lesser number of males in this cohort to be affected by PD; 
however, our results replicate the well reported finding of more males to be affected by PD 
than females (Table 4.4). Bilateral oophorectomies are usually performed as part of a 
procedure, hsyterosalpingo-oophorectomy, and this radical procedure is performed more in 
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older women than younger women as prevalence of hormone driven malignancies increases 
with age [332].  This could explain the findings from our study. However, it would not 
explain why only women in the TDPD cohort reported oophorectomies, but it would be 
unreasonable to jump to conclusions or make educated guesses given the total number of 
women who reported oophorectomies in the whole cohort is small. It would also be 
unreasonable to dismiss it altogether before analysing this finding in a larger study. 
 
One can therefore surmise that environmental risk factors of PD considered here, except 
oophorectomy, don’t contribute significantly to the classification of patients by clinical 
subtypes. Therefore, as a corollary, influence of genetic factors, the underlying biologic 
makeup, iatrogenic influences or the distribution of alpha-synuclein in the brain may have a 
greater role to play than environmental factors in the divergence of trajectories in the 
prognosis, as used in its broadest meaning, of the clinical subtypes of PD. 
 
The strongest associations with later diagnosis of PD amongst all risk factors, genetic or 
environmental, in a recent meta-analysis were  a family history of a  first-degree or any 
relative with PD (odds ratio [OR], 3.23; 95% confidence interval [CI], 2.65–3.93 and OR, 
4.45; 95% CI, 3.39–5.83) [194]. A positive family history of PD, particularly when traced 
across more than one generation, would suggest a hereditary trait passed on from parent to 
offspring in their genes. A hereditary trait therefore has connotations of a genetic aetiology. 
Our results did not show any significant difference in the family histories between those with 
age of onset of PD before 40 years of age and those who had onset of PD symptoms after the 
age of 40 years in the EOPD cohort (Table 4.7), to suggest that more cases in one group or 
the other had hereditary parkinsonism. One could therefore, on the basis of these results,  
argue that the arbitrary cut-off of 40 years, as opposed to 50 years, in defining EOPD, with 
the tacit assumption that cases with PD diagnosed before the age 40 years as opposed to 50 
years are likely to have a genetic basis to PD, is an artificial construct. The counter argument 
could be that the numbers in our study are relatively small to draw such a conclusion and that 
autosomal recessive genes like Parkin usually have an earlier age of onset and no family 
history of PD in the previous generation.  
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4.6 Conclusion 
 
There were no statistically significant differences in the pre-motor symptoms such as anxiety 
or depression and environmental risk factors such as head injury and caffeine consumption 
between the clinical subtypes in the EOPD cohort. Smoking was more prevalent in males 
compared to females whilst oophorectomy was only reported by women in the TDPD motor 
subtype and those with aged 40 years or older at onset of PD, when comparing to analogous 
subtypes. Family histories suggesting a hereditary nature of PD did not differ between those 
diagnosed before or after the age of 40 years in our EOPD cohort.  
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Chapter 5. Variation in motor symptoms of EOPD 
 
 
 
 
5.1 Objective 
 
The objective in this chapter is to analyse the variation in the motor symptoms in a cohort of 
patients with early onset Parkinson’s disease from the PRoBaND study. 
 
5.2 Introduction 
 
The diagnostic criteria for Parkinson’s disease (PD) have always been biased in favour of its 
motor manifestations, not only because these were the first to be recognized as a distinct 
symptom complex by James Parkinson [7], but also due to the fact that these protean 
manifestations contribute significantly to the disability caused by the condition. There are 
several motor subtypes of PD. Tremor dominant PD (TDPD) and postural instability gait 
difficulty (PIGD) represent two ends of the spectrum and some patients have features that 
have semblance to both motor subtypes yet don’t meet the formal criteria for either, hence 
classified as ‘Mixed’ or ‘Indeterminate’, terms used interchangeably. There are only 
hypothesised biological differences between these motor subtypes but we know from clinical 
observations they certainly have different disease trajectories and responses to treatment, 
hence it sounds logical to use this framework as one of the ways of classifying PD patients.  
 
 
5.3 Methods 
 
Patients attended 6 monthly clinic visits as per study protocol described in detail in Chapter 3. 
They were asked to fill in questionnaires for demographic data at baseline (visit 0). Data 
required for MDS-UPDRS scores and Hoehn Yahr (HY) staging were recorded at study visit 
1. Historical presenting features were recorded from case notes in the case report form (CRF) 
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at study visit 2 as per study protocol. Problems affecting balance and speech subjectively and 
objectively were recorded from MDS-UPDRS part 2 and MDS-UPDRS part 3 respectively. 
 
The motor scores recorded by the clinician on MDS-UPDRS part 3 were in a practically 
defined ‘on’ state. It was not considered convenient for patients enrolled in the study to 
withhold their anti-parkinson medications in the morning to induce an ‘off’ state as their 
clinic visits could have been scheduled anytime between 9:00 am and 4:30 pm and this would 
risk putting patients through a difficult phase for hours together if their ‘off’ state was 
disabling. A practically defined ‘on’ state for the purpose of this non-interventional study was 
defined as patients taking their normally prescribed anti-parkinson medications, including 
rescue medications, at their pre-scheduled times to have sufficient dopamine leves in their 
system to function as closely possible as they would in their normal daily lives. 
 
To analyse the variation in the motor phenotype of PD with respect to historical and 
examination findings all cases with EOPD were classified in 4  ways: according to motor 
subtypes (TDPD, PIGD and ‘Mixed’), gender, age at onset of PD symptoms and heritability 
of the Parkinsonian trait as described in Chapter 4.  
 
Levodopa equivalent daily dose (LEDD) dose was calculated using the following dose 
equivalence: Levodopa 100 mg = Controlled Release Levodopa 70 mg = Ropinirole 5 mg = 
Rotigotine 5mg = Pramipexole 1mg (salt) = Bromocriptine 10mg = Pergolide 1mg = 
Cabergoline 1 mg = Selegiline 10mg = Zelapar 1.25mg = Rasagiline 1 mg as baseline = 
10mg Apomorphine (visit 0). All medication equivalent doses, levodopa equivalent units 
(LEU) as mg/day, were added together to obtain LEDD. Where a COMT inhibitor was used, 
this would add 30% to the levodopa dose used to calculate LEDD [333, 334] .  
 
Statistical analysis: 
Descriptive data are presented as median and inter-quartile range (IQR) as data in most 
instances failed tests of normality (Shapiro Wilk). Kruskal Wallis test was used for inter-
group comparisons of numerical data in scenarios where cases where classified into 3 groups 
e.g. motor subtypes with post hoc comparisons between groups using Mann Whitney U if the 
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Kruskal Wallis test statistic showed a significant difference between the 3 groups, correcting 
for multiple comparisons in the post hoc tests with Dunn’s correction. Mann Whitney U test 
was used for inter-group comparisons of numerical data where cases were classified into 2 
groups e.g. males and females. Chi square tests or Fisher’s exact tests were used for 
comparing groups for categorical data, with post-hoc tests as appropriate. 
 
Generalised linear modelling, based on ANCOVA, was used with age, disease duration and 
LEDD as covariates to determine the effect of the motor subtype, gender, age at onset and 
hereditary versus sporadic parkinsonism (independent variables) on the UPDRS part 3 scores 
(dependent variable). Age and disease duration were used as covariates in the statistical 
models to determine the effect of the motor subtype, gender, age at onset and hereditary 
versus sporadic parkinsonism (independent variables) on the HY stage (dependent variable). 
Logarithmic transformations (base 10) of numerical data were used where tests of normality 
(Shapiro Wilk) failed.  
 
All statistical analyses were two-sided and significance level was set at 5%. Statistical tests 
were performed using Prism software (version 4.0 for Windows; CA, USA) and SPSS 
software (version 23 for Windows; IL, USA). 
 
5.4 Results 
 
276 patients with EOPD (age of onset <50 years) from the PRoBaND study who had 
completed all questionnaires relevant to the data analysis in this chapter were included 
(Figure 5.1).  
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Figure 5.1 shows the disoposition of cases prior to data analysis for this chapter. No data 
imputation was allowed. Those who had incomplete questionnaires relevant to this analysis 
were not included. 
 
The median age at the time of registration was 51.4 years (inter-quartile range, IQR, 46.9-
56.3) and median disease duration was 6.8 years (IQR 2.7-11.5). Two- thirds of the patients 
were males and the vast majority were Caucasians (Figure 5.2). Other demographic variables 
of these 276 patients are presented in Table 5.1 
 
 
 
 
 
 
Initial recruitment 
target 
N = 240 
Incomplete 
questionnaires 
N = 50 
Additional cases 
recrutited 
N = 86 
Full dataset 
available 
N = 276 
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Figure 5.2 shows the demographic profile of the early onset PD cohort (n=276) used in this 
analysis with proportion of cases on the y-axis and demographic characteristics on the x-axis. 
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Table 5.1 Demographic profile of the early onset PD patients (n=276)  
analysed in this section who had completed all relevant questionnaires. 
Variable Median (IQR) 
Number of cases 276 
Age (at registration, in years) 51.4 (46.9-56.3) 
Sex (males) 67.7% 
Height (metres) 1.7 (1.7-1.8) 
Weight (kg) 75.0 (58.0-90.0) 
Handedness 85.8% 
Married 66.9% 
Employed (at the time of diagnosis) 89.9% 
Ethnicity  
      Caucasian 93.8% 
      Asian 3.6% 
      African  0% 
     Caribbean 0.4% 
Others (including Romas) 0.4% 
Disease duration (years) 6.8 (2.7-11.5) 
IQR = inter-quartile range.   
 
 
The variation in the presenting features, motor symptoms, medication requirements, UPDRS 
motor scores and Hoehn Yahr staging in patients classified by motor subtype is shown below  
(Figures 5.3 and 5.4, Table 5.2).  
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Figure 5.3 shows the unified Parkinson’s disease rating scale part 3 (UPDRS 3) scores (on the 
y-axis) and the motor subtype (on the x-axis). The line in the centre of the boxes represent the 
medians, the ends of the whiskers 2 standard deviations on either side and outliers are 
represented by dark circles. UPDRS 3 scores were significantly higher in those with PIGD 
(n=100) compared to those with ‘Mixed’ (n=21) motor subtype (p=0.014) when corrected for 
age, disease duration and medication usage but not to TDPD (n=155). 
 
Figure 5.4 shows the Hoehn Yahr (HY) stage (on the y-axis) and the motor subtype (on the x-
axis) of the patients. The top of the boxes represent the medians and the whiskers the inter-
quartile ranges (bottom whisker is hidden in the box). The HY stage was significantly lower 
in those with TDPD (n=155) compared to those with the PIGD (n=100) motor subtype when 
corrected for age and disease duration (p<0.001). 
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Table 5.2 Variation in motor symptoms, medication requirements, UPDRS 3 score and 
Hoehn Yahr staging in patients (n=276) classified by motor subtype. 
Variable    TDPD 
median (IQR) 
   PIGD 
median (IQR) 
Mixed 
median (IQR) 
p- 
value 
Number of cases 155 100 21 - 
Age* ( years) 50.4 (45.1-54.3) 54.6 (48.8-59.8) 49.6 (46.9-52.5) <0.001 
Sex (males) 64.1% 59% 65% 0.356 
Duration (years) 5.1 (2.0-9.6) 9.1 (4.6-15.0) 7.4 (2.5-11.8) <0.001 
Side of onset (r) 48.5% 56.3% 38.9% 0.355 
Presenting features (based on clinical notes at the time of diagnosis of PD)  
  Resting tremor 80.3% 59.3% 77.8% 0.003 
  Bradykinesia 84.1% 78.5% 83.3% 0.583 
  Rigidity 78.9% 85.2% 83.3% 0.511 
  Post. instability 14.4% 28.6% 11.1% 0.028 
Balance problems
†
   77.4% 95.0% 85.7% <0.001 
Balance problems
‡
  21.3% 56.0% 23.8% <0.001 
Speech problems
†
   65.8% 83.0% 57.1% 0.004 
Speech problems
‡
 56.8% 75.0% 42.9% 0.002 
LEDD (mg/day) 599 (300-965) 840 (532-1043) 738 (538-1053) 0.003 
UPDRS 3 scores 22 (14-36) 27 (19-38) 15 (10-21) 0.014 
Hoehn Yahr stage 2.0 (1.0-2.0) 2.0 (2.0-3.0) 1.5 (1.0-2.0) <0.001 
TDPD = tremor dominant Parkinson’s disease, PIGD = postural instability gait difficulty, IQR = inter-
quartile range, * Age at registration, (r) = right side, † = subjective from MDS-UPDRS Part 2, ‡ = 
objective from MDS-UPDRS Part 3, LEDD = levodopa equivalent daily dose, UPDRS 3 = MDS-UPDRS 
scale Part 3 
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There were significant differences in the presenting features of the 3 motor subtypes with 
resting tremor, as expected and by definition, being most common in the TDPD group 
compared to other motor subtypes (p=0.003) and postural instability least prevalent at 
presentation in the ‘Mixed’ motor subtype (p=0.024) (Table 5.1) although it is important to 
point out that the 4 cardinal features required to diagnose  PD i.e. resting tremor, 
bradykinesia, rigidity and postural instability were present at diagnosis in all groups, albeit in 
varying proportions. Post hoc tests, showed the differences in the prevalence of resting 
tremor at presentation to be present between TDPD and PIGD motor subtypes (p=0.001) with 
no statistically significant differences between TDPD and ‘Mixed’ motor subtypes (p=0.759) 
or between PIGD and ‘Mixed’ motor subtypes (p=0.183).  Post hoc tests for postural 
instability, deemed by the clinician to be present at diagnosis, showed significant differences 
between TDPD and PIGD (p=0.018) with no statistically significant differences between 
TDPD and ‘Mixed’ motor subtypes (p=0.707) or between  PIGD and ‘Mixed’ motor subtypes 
(p=0.146).  
 
 There were also significant differences in the prevalence of balance problems at the time of 
assessment in the PRoBaND study both subjectively, based on UPDRS Part 2 (p<0.001) and 
objectively, based on UPDRS Part3 (p<0.001) in between the three motor subtypes, these 
being most prevalent in the PIGD group (Table 5.1). Post hoc tests of subjective balance 
problem showed the differences to be present only between TDPD and PIGD (p<0.001) but 
not between TDPD and ‘Mixed’ (p=0.573) or PIGD and ‘Mixed’ (p=0.141). Post hoc tests of 
objective balance problems showed the differences between TDPD and PIGD (p=<0.001) 
and PIGD and ‘Mixed’ (p=0.009) but not between TDPD and ‘Mixed’ (p=0.781).  
 
Further, there were significant differences in the prevalence of speech problems both 
subjectively (p=0.004) and objectively (p=0.002) in between the groups, these being most 
prevalent in the PIGD group (Table 5.1). Post hoc tests showed that speech problems 
subjectively were more prevalent in the PIGD group compared to the TDPD group (p=0.003) 
and PIGD compared to the ‘Mixed’ group (p=0.017) but there were no significant differences 
between the TDPD group and the ‘Mixed’ group (p=0.470) (Figure 5.5). Post hoc tests 
showed that speech problems objectively were more prevalent in the PIGD group compared 
to the TDPD group (p=0.003) and PIGD compared to the ‘Mixed’ group (p=0.007) but there 
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were no significant differences between the TDPD group and the ‘Mixed’ group (p=0.250) 
(Figure 5.5).  
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Figure 5.5 shows the proportion of patients who had speech problems (subjectively) on the 
Unified Parkinson’s disease rating scale Part 2 (on the y-axis) and their motor subtype (on the 
x-axis). The top of the boxes represent the proportion of cases with speech problems, as 
indicated on the y-axis, and the whiskers represent the 95% confidence limits of proportion. 
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Figure 5.6 shows the proportion of patients who had balance problems (objectively) on the 
Unified Parkinson’s disease rating scale Part 3 (on the y-axis) and their motor subtype (on the 
x-axis). The top of the boxes represent the proportion of cases with balance problems, as 
indicated on the y-axis, and the whiskers represent the 95% confidence limits of proportion. 
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There were also significant differences between 3 groups in UPDRS 3 scores (p=0.014) and 
Hoehn Yahr stages (p<0.001) after correcting for differences in age, disease duration and 
LEDD in statistical models (Table 5.2). 
 
Post hoc tests, with Dunn’s correction for multiple comparisons, showed the differences in 
UPDRS 3 to be present between PIGD and ‘Mixed’ motor subtypes with significantly lower 
UPDRS 3 scores in the ‘Mixed’ motor subtype while the HY stages showed significant 
differences to be between TDPD and PIGD groups. 
 
Speech problems were more prevalent in males compared to females both subjectively based 
on UPDRS 2 and objectively based on UPDRS 3 scoring but there were no statistically 
significant differences between males and females on any of the motor signs at presentation 
or problems that developed later on (Table 5.3) including their UPDRS3 scores (Figure 5.7), 
HY stages (Figure 5.8) or the proportion of males and females classified by motor type (5.9) 
 
 
Figure 5.7 shows the unified Parkinson’s disease rating scale part 3 scores (on the y-axis) and 
the gender (on the x-axis). The line in the centres of the boxes represent the medians, the ends 
of the whiskers 2 standard deviations on either side and outliers are represented by dark 
circles. No significant differences were found between males (n=177) and females (n=99) 
(p=0.549) 
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Table 5.3 Variation in motor symptoms, medication requirements, UPDRS 3 score and 
Hoehn Yahr staging in patients (n=276) classified by gender. 
 
Variable          Males 
   median (IQR) 
      Females 
    median (IQR) 
p- 
value 
Number of cases           177           99 - 
Age(at registration, in years)      51.7 (46.5-56.8)     51.1 (47.2-55.6) 0.968 
PD duration (years)      7.3 (2.8-11.5)     6.5 (2.6-11.9) 0.737 
Side of onset (right)           50.7%         50.0% 0.922 
Presenting features (based on clinical notes at the time of diagnosis of PD)  
          Resting tremor           72.7%        73.2% 0.941 
          Bradykinesia         79.2%       87.5% 0.118 
          Rigidity         82.8%       79.0% 0.481 
          Postural instability         21.2%      14.5% 0.222 
Motor subtype  
      TDPD        59.3%     50.5% 0.156 
      PIGD        33.3%     41.4% 0.180 
     ‘Mixed’         7.3%    8.1% 0.824 
Balance problems (subjective)        85.9%     81.8% 0.372 
Balance problems (objective)       29.9%     41.4% 0.053 
Speech problems (subjective)       78.0%     59.6% 0.001 
Speech problems (objective)       67.8%     52.5% 0.012 
LEDD (mg/day) 760 (400-1030) 600 (328-986) 0.136 
UPDRS 3 scores      24 (15-37)     22 (15-35) 0.549 
Hoehn Yahr stage       2.0 (1.5-2.5)     2.0 (1.3-2.5) 0.639 
TDPD = tremor dominant Parkinson’s disease, PIGD = postural instability gait difficulty, IQR = inter-
quartile range, * Age at registration, (r) = right side, † = subjective from MDS-UPDRS Part 2, ‡ = 
objective from MDS-UPDRS Part 3, LEDD = levodopa equivalent daily dose, UPDRS 3 = MDS-UPDRS 
scale Part 3 
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Figure 5.8 shows the Hoehn Yahr stage (on the y-axis) and gender (on the x-axis) of the 
patients. The top of the boxes represent the medians and the whiskers the inter-quartile 
ranges. No significant differences were found between males (n=177) and females (n=99) 
(p=0.871) 
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Figure 5.9 shows the motor subtype (on the y-axis) and their gender (on the x-axis) of the 
patients (n=276) in the EOPD cohort of the PRoBaND study. The top of the boxes represent 
the proportion of cases of each motor subtype, as indicated on the y-axis, and the whiskers 
represent the 95% confidence limits of proportion. There were no significant differences in 
the proportion of those classified as TDPD (p=0.156), PIGD (p=0.180) or ‘Mixed’ (p=0.824) 
between the 2 genders. 
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There was no difference in the proportion of cases classified as TDPD (p=0.170), PIGD 
(p=0.712) or ‘Mixed’ (p=0.063) between those diagnosed with PD aged less than (or equal 
to) 40 years compared to those diagnosed after the age of 40 years in the EOPD cohort after 
correcting for age in the statistical model (Figure 5.10). There were no other statistically 
significant  differences in between the 2 subgroups in the UPDRS3 scores (Figure 5.11), 
Hoehn Yahr stages (Figure 5.12) or the prevalence of motor manifestations either at 
presentation or those that developed later on (Table 5.4). 
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Figure 5.10 shows the proportion of patients with the tremor dominant Parkinson’s disease 
(TDPD), postural instability gait difficulty (PIGD) and “Mixed” motor subtypes on the y-axis 
and age at onset of PD symptoms on the x-axis of the patients  (n=276) in the EOPD cohort 
of the PRoBaND study. The top of the boxes represent the proportion of cases of each motor 
subtype, as indicated on the y-axis, and the whiskers represent the 95% confidence limits of 
proportion. There were no significant differences in the proportion of cases classified as 
TDPD (p=0.170), PIGD (p=0.712) or ‘Mixed’ (p=0.063) between those age at diagnosis ≤ 40 
years and those with age at diagnosis > 40 years. 
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Table 5.4 Variation in motor symptoms, medication requirements, UPDRS 3 score and 
Hoehn Yahr staging in patients (n=276) classified age at onset of PD. 
 
Variable   Age onset  ≤ 40 years                     
    median (IQR) 
 Age onset > 40 years 
     median (IQR) 
p- 
value 
Number of cases   64     212 - 
Age (at registration, in years) 44.6 (40.2-50.8) 52.9 (48.8-57.0) <0.001 
Sex (Males)   67.2% 63.2% 0.561 
PD duration (years)   7.9 (3.7-15.0)  6.6 (2.5-11.3) 0.707 
Side of onset (right)  52.0%   50.3% 0.802 
Presenting features (based on clinical notes at the time of diagnosis of PD)  
       Resting tremor    73.1%   72.0% 0.971 
       Bradykinesia    85.1%   81.1% 0.546 
       Rigidity    82.4%   81.4% 0.854 
       Postural instability    19.2%   18.6% 0.952 
Motor subtype  
       TDPD    48.1%    58.7% 0.170 
       PIGD     32.7%    35.5% 0.712 
       Mixed     13.5%    5.8% 0.063 
Balance problems (s)    90.6%   81.8% 0.118 
Balance problems (o)   35.9%   33.2% 0.717 
Speech problems (s)    79.7%  68.7% 0.093 
Speech problems (o)   71.9%   59.3% 0.071 
LEDD (mg/day) 700 (363-998) 715 (400-1008) 0.659 
UPDRS 3 scores 25 (18-40)   23 (14-34) 0.725 
Hoehn Yahr stage 2.0 (1.0-2.5) 2.0 (1.5-2.5) 0.871 
TDPD = tremor dominant Parkinson’s disease, PIGD = postural instability gait difficulty, IQR = inter-
quartile range, * Age at registration, (r) = right side, † = subjective from MDS-UPDRS Part 2, ‡ = 
objective from MDS-UPDRS Part 3, LEDD = levodopa equivalent daily dose, UPDRS 3 = MDS-UPDRS 
scale Part 3 
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Figure 5.11 shows the unified Parkinson’s disease rating scale part 3 scores (on the y-axis) 
and the age at onset of PD (on the x-axis). The line in the centre of the boxes represent the 
medians, the ends of the whiskers 2 standard deviations on either side and outliers are 
represented by dark circles. No significant differences were found between those with age at 
onset of PD ≤ 40 years (n=64) compared to those with age at onset of PD > 40 years (n=212) 
(p=0.725) 
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Figure 5.12 shows the Hoehn Yahr stage (on the y-axis) and the age at onset of PD (on the x-
axis). The top of the boxes represent the medians and the whiskers the inter-quartile ranges. 
No significant differences were found between those with age at onset of PD ≤ 40 years 
(n=64) compared to those with age at onset of PD > 40 years (n=212) (p = 0.871) 
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The only differences in the motor presentation of those with a positive family history of PD 
compared to cases with no family history of PD were that resting tremor at presentation, as 
one of the 4 cardinal signs of PD when using Queen Square Brain Bank criteria for diagnosis, 
was more commonly found in those with hereditary PD (p=0.005) while bradykinesia at 
presentation was more commonly present in those with sporadic PD (p=0.030) (Table 5.5). 
There were no other statistically significant  differences in between the 2 subgroups in the 
UPDRS3 scores (Figure 5.13), Hoehn Yahr stages (Figure 5.14), motor subtypes (Figure 
5.15) or the prevalence of motor manifestations either at presentation or those that developed 
later on (Table 5.5).  
 
 
 
 
 
 
 
Figure 5.13 shows the Unified Parkinson’s disease rating scale Part 3 score of the cases (on 
the y-axis) and their family history (FH) of Parkinson’s disease (on the x-axis). The line in 
the centre of the boxes represent the medians, the ends of the whiskers 2 standard deviations 
on either side and outliers are represented by dark circles. No significant differences were 
found between those with a positive family history of PD (n=64) compared to those with no 
family history of PD (n=212) (p=0.987) 
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Table 5.5 Variation in motor symptoms, medication requirements, UPDRS 3 score and 
Hoehn Yahr staging in patients (n=276) classified by family history. 
Variable Positive FH 
median (IQR) 
Negative FH 
median (IQR) 
p- 
value 
Number of cases 64 212 - 
Age(at registration, in years) 52.2 (47.3-56.8) 51.2 (46.9-56.1) 0.582 
Sex (Males) 65.6% 63.7% 0.776 
PD duration (years) 6.7  (3.5-12.1) 6.8  (2.5-11.3) 0.312 
Side onset (right) 55.4.% 49.2% 0.485 
Presenting features (based on clinical notes at the time of diagnosis of PD)  
          Resting tremor 84.5% 68.3% 0.005 
          Bradykinesia 73.2% 85.1% 0.030 
          Rigidity 80.4% 82.0% 0.692 
          Postural instability 18.5% 18.9% 0.952 
Motor subtype  
       TDPD 56.3% 56.1% 0.987 
       PIGD  34.4% 36.8% 0.724 
       Mixed  9.4% 7.1% 0.543 
Balance problems (subjective) 80.3% 84.9% 0.686 
Balance problems (objective) 36.4% 33.0% 0.507 
Speech problems (subjective) 66.7% 72.6% 0.398 
Speech problems (objective) 69.7% 59.9% 0.132 
LEDD (mg/day) 824 (460-1033) 655 (400-1000) 0.135 
UPDRS 3 scores 23 (15-36) 23 (15-35) 0.987 
Hoehn Yahr stage 2.0 (1.5-2.0) 2.0 (1.5-2.5) 0.333 
TDPD = tremor dominant Parkinson’s disease, PIGD = postural instability gait difficulty, IQR = inter-
quartile range, * Age at registration, (r) = right side, † = subjective from MDS-UPDRS Part 2, ‡ = 
objective from MDS-UPDRS Part 3, LEDD = levodopa equivalent daily dose, UPDRS 3 = MDS-UPDRS 
scale Part 3 
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Figure 5.14 shows the Hoehn Yahr stage (on the y-axis) and the family history of PD (on the 
x-axis). The line in the centre of the boxes represent the medians, the ends of the whiskers 2 
standard deviations on either side and outliers are represented by dark circles. No significant 
differences were found between those with familial PD (n=64) compared to those with 
sporadic PD (n=212) (p=0.333) 
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Figure 5.15 shows the proportion of patients with the tremor dominant Parkinson’s disease 
(TDPD), postural instability gait difficulty (PIGD) and “Mixed” motor subtypes on the y-axis 
and family history (FH) of PD on the x-axis of the patients  (n=276) in the EOPD cohort of 
the PRoBaND study. The top of the boxes represent the proportion of cases of each motor 
subtype, as indicated on the y-axis, and the whiskers represent the 95% confidence limits of 
proportion. 
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5.5 Discussion 
 
Patients with PD show marked heterogeneity in their motor features not only in relation to the 
motor subtype but also some differences when classifying patients by gender, age at onset of 
PD and hereditary versus sporadic PD. 
 
This variation in the motor presentation could have several possible explanations. Some have 
hypothesized that TDPD and PIGD motor subtypes of PD might be due to differential iron 
load within different basal ganglia structures in the brain [335]. Others have suggested that 
abnormal oscillatory activity in different neuronal circuits, some localised to the basal 
ganglia, might explain the differences in the motor presentations [336].  
 
Pathological specimens from post-mortem studies have demonstrated that the motor subtypes 
may have different morphological lesion patterns. PIGD cases showed more severe cell loss 
in the ventrolateral part of substantia nigra pars compacta that projects to the dorsal putamen 
than the medial part projecting to caudate nucleus and anterior putamen. Reduced 
dopaminergic input causes overactivity of the GABA ergic inhibitory striatal neurons 
projecting via the "indirect loop" to substantia nigra zona reticulata and medial pallidum 
leading to inhibition of the glutamatergic thalamo-cortical motor loop and reduced cortical 
activation. TDPD cases showed more severe neuron loss in medial than in lateral substantia 
nigra zona compacta and damage to the retrorubral field A8, containing only few tyrosine 
hydroxylase and dopamine transporter immunoreactive neurons. The retrorubral field A8 that 
is rather preserved in PIGD [337] .  
 
Gender differences have been reported in motor symptoms [327] with resting tremor at 
presentation more common in women. We didn’t find this difference in the EOPD cohort but 
we found speech problems less prevalent in women compared to men both subjectively 
(p=0.001) and objectively (p=0.012) as recorded on the UPDRS part 2 and 3 scores. The 
gender differences may be related to the effects of female sex hormones such as estradiol on 
synaptic plasticity, neurotransmission, neurodegeneration, and cognitive circuits in the brain 
leading to notable sex differences in the incidence and manifestations of several central 
nervous system disorders, including Parkinson's disease [338].  
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The age at onset can influence the motor phenotype of PD. Tremor at presentation is reported 
to be twice as common in those with older onset as compared to those with younger onset, the 
prevalence increasing linearly with age at onset of PD [339]. Those with younger age at onset 
also have a longer disease course and slower progression [314]. Our results did not show that 
tremor (p=0.971), bradykinesia (p=0.546), rigidity (p=0.854) or postural instability (p=0.952) 
as presenting features were more common in those diagnosed with PD before the age of 40 
years compared to those diagnosed after the age of 40 years in the EOPD cohort. There was 
also no significant difference in the Hoehn Yahr stage between those diagnosed with PD 
before the age of 40 years compared to those diagnosed after the age of 40 years (p=0.871) 
when corrected for age and disease duration, suggesting the rate of motor progression was 
similar in the two groups. This is not in concurrence with Schrag et al’s [314] observations 
probably due to the fact that the populations analysed in the two studies are different. Their 
cohort had 10 with juvenile parkinsonism (onset before age 21 years) and the rest of 139 
cases had age of onset between 21 to 40 years. Those with juvenile parkinsonism very likely 
either had Parkin mutations or had secondary parkinsonism due to some other aetiology such 
as SCA mutations  as idiopathic Parkinson’s disease is quite rare in that age group in clinical 
practice. None was genetically tested to rule out other causes of parkinsonism except one 
who had a SCA3 mutation. 
 
A smaller prospective study comparing familial PD (n=50) with sporadic PD (n=50), after 
excluding those cases with genetic mutations causing PD (n=9) reported similar motor signs 
and symptoms between the 2 groups suggesting that either the topographic distribution of the 
neurodegenerative process in the brain leading to the parkinsonian clinical syndrome could be 
similar  in these 2 groups or the aetiologies could be similar [340]. A larger study of familial 
PD (n=40) and sporadic PD (n=1277) also reported similarities in the phenotypic 
characteristics, such as tremor as the initial motor symptom and asymmetric parkinsonism 
during disease course, of the two groups with similar conclusions [341].  Our results also 
showed no major differences in between the 2 subgroups, as previously reported, but in our 
cohort tremor at presentation was more common in those with familial PD (p=0.005) while 
bradykinesia at presentation was more common at presentation in those with sporadic PD 
(p=0.030). The definition of familial PD in the larger study (with 10 or more affected 
members) was different from ours where any family history of PD in first relations across 3 
generations was considered as inherited trait. 
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5.6 Conclusion 
 
The differences in the 3 motor subtypes, as one would expect, showed differences in the 
prevalence of tremor and postural instability but there were also other significant differences 
of note between TDPD and PIGD motor subtypes. Speech problems both subjectively and 
objectively were most prevalent in the PIGD subcases. This would not be surprising if speech 
is considered a midline or axial problem that would go hand in hand with other axial 
problems such as problems with balance. UPDRS 3 scores after correcting for age, disease 
duration and LEDD were the lowest in the TDPD cases. There were also some notable 
differences when cases were classified by gender, with males experiencing more speech 
problems both subjectively and objectively despite no significant differences in age or disease 
duration. More patients who had age at onset of PD less than 40 years had the PIGD motor 
subtype whereas more patients who had onset of PD after age of 40 years in the EOPD cohort 
had the TDPD phenotype.  
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Chapter 6. Variation in motor complications in EOPD 
 
 
 
 
6.1 Objective 
 
The objective in this chapter is to analyse the variation in the prevalence of motor 
complications in a cohort of patients with early onset Parkinson’s disease. 
 
 
6.2 Introduction 
 
Motor complications in the form of levodopa induced dyskinesia, ‘off’ period dystonia, ‘on’ 
‘off’ fluctuations and freezing of gait are often seen either as a complication of long-term 
dopaminergic therapy or difficult to treat problems that do not respond well to changes in 
medications, nevertheless, cause problems that significantly affect the quality of life of these 
patients. These complications typically develop after 4-6 years of therapy, and affect 
approximately half of all patients but there is a recognised heterogeneity in the prevalence 
and severity of these complications in the population of patients with PD. 
 
6.3 Methods 
 
Patients attended 6 monthly clinic visits as per study protocol described in detail in Chapter 3. 
They were asked to fill in questionnaires for demographic data and anti-parkinsonian 
medication requirements in levodopa equivalent untis (LEU) in mg/day, at baseline (visit 0). 
Levodopa equivalent daily dose (LEDD) was calculated using the formula described in 
Chapter 5. Data required for MDS-UPDRS Part 4 (UPDRS4) scores for evaluation of 
complications of dopaminergic therapy including the presence of dyskinesia, ‘on’ ‘off’ 
fluctuations, ‘off’ dystonia were recorded at study visit 1. Freezing was recorded from 
clinician completed UPDRS3 forms. 
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To analyse the variation in motor complications of PD with respect to historical and 
examination findings all cases with EOPD were classified in 4  ways: according to motor 
subtypes (TDPD, PIGD and ‘Mixed’) , gender , age at onset of PD symptoms and heritability 
of the Parkinsonian trait as described in Chapter 4.  
 
Statistical analysis: 
 
Descriptive data are presented as median and inter-quartile range (IQR) as data in most 
instances failed tests of normality (Shapiro Wilk). Kruskal Wallis test was used for inter-
group comparisons of numerical data in scenarios where cases where classified into 3 groups 
e.g. motor subtypes with post hoc comparisons between groups using Mann Whitney U if the 
Kruskal Wallis test statistic showed a significant difference between the 3 groups. Mann 
Whitney U test was used for inter-group comparisons of numerical data where cases were 
classified into 2 groups e.g. males and females. Chi square tests or Fisher’s exact tests were 
used for comparing groups for categorical data, with post-hoc tests as appropriate. 
 
In generalised linear models, based on  ANCOVA,  age, disease duration and LEDD were 
used as covariates to determine the effect of the motor subtype, gender, age at onset and 
family history of PD (independent variables) on the UPDRS4 scores (dependent variables). 
Logarithmic (base 10) transformations of numerical data were used where tests of normality 
(Shapiro Wilk) failed. 
 
We used binary logistic regression to determine the effect of age, disease duration, motor 
subtype, family history and LEDD (covariates) on the dependent variable i.e. presence or 
absence of dyskinesia. A smiliar model was used to determine the effect of these covraiates 
on the other dependent variable i.e presence or absence of dystonia. 
 
All statistical analyses were two-sided and significance level was set at 5%. Statistical tests 
were performed using Prism software (version 4.0 for Windows; CA, USA) and SPSS 
software (version 23 for Windows; IL, USA). 
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6.4 Results 
 
276 patients had completed all questionnaires relevant to this analysis and are included here 
(Figure 6.1). Their demographic details have been presented in Table 5.1 in Chapter 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 shows the disoposition of cases prior to data analysis for this chapter. No data 
imputation was allowed. Those who had incomplete questionnaires relevant to this analysis 
were not included. 
 
The variation in the rates of motor complications such as dyskinesia (Figure 6.2) and dystonia 
(Figure 6.3), medication requirements and UPDRS4 scores in patients, classified by motor 
subtype, is shown in Table 6.1. 
 
Initial recruitment 
target 
N = 240 
Incomplete 
questionnaires 
N = 50 
Additional cases 
recrutited 
N = 86 
Full dataset 
available 
N = 276 
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Figure 6.2 shows the proportion of patients who had dyskinesia as recorded on the unified 
Parkinson’s disease rating scale Part 4 (on the y-axis) and their motor subtype (on the x-axis). 
The top of the boxes represent the proportion of cases with dyskinesia, as indicated on the y-
axis, and the whiskers represent the 95% confidence limits of proportion. 
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Figure 6.3 shows the proportion of patients who had dystonia as recorded on the unified 
Parkinson’s disease rating scale Part 4 (on the y-axis) and their motor subtype (on the x-axis). 
The top of the boxes represent the proportion of cases with dystonia, as indicated on the y-
axis, and the whiskers represent the 95% confidence limits of proportion. 
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Table 6.1 Variation in motor complications of Parkinson’s disease in patients (n=276) 
classified by motor subtype. 
 
Variable   TDPD 
median (IQR) 
  PIGD 
median (IQR) 
Mixed subtype 
median (IQR) 
p- 
value 
Number of cases 155 100 21 - 
Age* (in years) 50.4 (45.1-54.3) 54.6 (48.8-59.8) 49.6 (46.9-52.5) <0.001 
Sex (males) 64.1 % 59.0 % 65.0 % 0.356 
Duration
†
 (years) 5.1 (2.0-9.6) 9.1 (4.6-15.0) 7.4 (2.5-11.8) <0.001 
Dyskinesia 25.8 % 59.6 % 42.9 % <0.001 
On-off fluctuations 47.7 % 66.7 % 52.4 % 0.016 
Dystonia 33.5 % 40.8 % 57.1 % 0.093 
Freezing (s)  41.9 % 74.0 % 52.4 % <0.001 
Freezing (o)  12.3 % 47.0 % 28.6 % <0.001 
LEU (mg/day) 599 (300-965) 840 (532-1043) 738 (538-1053) 0.003 
UPDRS4 2 (0-6) 5 (2-10) 4 (0-10) 0.117 
* Age at registration, † disease duration, IQR = inter-quartile range, (s) = subjective from MDS-UPDRS 
Part 2, (o) = objective from MDS-UPDRS Part 3, LEU = levodopa equivalent untis, UPDRS4 = MDS-
UPDRS Part 4 score 
 
 
 
 
Post hoc calculations showed dyskinesia more prevalent in the PIGD group compared to 
TDPD (p<0.001) but not between TDPD and ‘Mixed’ (p=0.121) or between PIGD and 
‘Mixed’ (p=0.175) motor subtypes.  
 
On-off fluctuations were also more prevalent in the PIGD group compared to TDPD 
(p=0.004) but not between TDPD and ‘Mixed’ (p=0.817) or between PIGD and ‘Mixed’ 
(p=0.318) on post hoc tests. 
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Freezing as reported subjectively, as recorded on MDS-UPDRS Part 2, was more prevalent in 
PIGD compared to TDPD (p<0.001) but not between TDPD and ‘Mixed’ (p=0.482) or 
between PIGD and ‘Mixed’ motor subtypes (p=0.066) on post hoc tests. This was replicated 
in the prevalence of freezing, as recorded objectively, on MDS-UPDRS Part 3 between PIGD 
and TDPD (p<0.001) but not between TDPD and Mixed (p=0.087) or between PIGD and 
‘Mixed’ (p=0.150) on post hoc tests. 
 
Medication requirements in LEU (mg/day) were highest in the PIGD group compared to 
TDPD (p<0.001) but not between TDPD and Mixed (p= 0.134) or between PIGD and 
‘Mixed’ (p=0.616) on post hoc tests. 
 
Classifying patients by gender showed that there were no differences between males and 
females in medication requirements in LEU (mg/day) as shown in Figure 6.4, MDS-UPDRS 
Part 4 scores (Figure 6.5) or any of the other complications of treatment (Table 6.2). 
 
 
 
 
Figure 6.4 shows the medication requirements as levodopa equivalent units (LEU) in mg/day 
(on the y-axis) and the gender (on the x-axis). No significant differences were found between 
males (n=177) compared to females (n = 99) (p=0.136). 
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Figure 6.5 shows the unified Parkinson’s disease rating scale part 4 scores (on the y-axis) and 
the gender (on the x-axis). The line in the centre of the boxes represent the medians, the ends 
of the whiskers 2 standard deviations on either side and outliers are represented by dark 
circles. No significant differences were found between males (n=177) compared to females 
(n=99) (p=0.886). 
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Table 6.2 Variation in motor complications of Parkinson’s disease in patients (n=276) 
classified by gender. 
 
Variable 
 
            Males 
         median (IQR) 
         Females 
      median (IQR) 
p- value 
Number of cases          177          99 - 
Age * (years)     51.7 (46.5-56.8)    51.1 (47.2-55.6) 0.968 
Duration† (years)     7.3 (2.8-11.5)    6.5 (2.6-11.9) 0.737 
Dyskinesia 37.3 % 42.4 % 0.402 
On- Off fluctuations 53.1 % 57.6 % 0.474 
Dystonia 37.9 % 37.4 % 0.937 
Freezing (subjective) 53.7 % 55.6 % 0.763 
Freezing (objective) 27.7 % 23.2 % 0.419 
LEU (mg/day) 760 (400-1030) 600 (328-986) 0.136 
UPDRS 4 3 (0-8) 4 (0-8) 0.886 
* age at registration, † disease duration, IQR =  inter-quartile range, (s) = subjective from MDS-UPDRS 
Part 2, (o) = objective from MDS-UPDRS Part 3, LEU= levodopa equivalent untis, UPDRS4= MDS-
UPDRS Part 4 score 
 
 
 
 
 
 
There were also no differences between those diagnosed with PD aged less than (or equal to) 
of 40 years compared to those diagnosed after the age of 40 years in the EOPD cohort in 
medication requirements recorded in LEU (mg/day) as shown in Figure 6.6, MDS-UPDRS 
Part 4 scores (Figure 6.7) or any of the other complications of treatment (Table 6.3). 
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Figure 6.6 shows the medication requirements as levodopa equivalent units (LEU) in mg/day 
(on the y-axis) and the age at onset in years (on the x-axis). No significant differences were 
found between those with age at onset of PD ≤ 40 years (n=64) compared to those with age at 
onset of PD > 40 years (n=212) (p=0.659). 
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Figure 6.7 shows the unified Parkinson’s disease rating scale part 4 scores (on the y-axis) and 
the age at onset in years (on the x-axis. The line in the centre of the boxes represent the 
medians, the ends of the whiskers 2 standard deviations on either side and outliers are 
represented by dark circles. No significant differences were found between those with age at 
onset of PD ≤ 40 years (n=64) compared to those with age at onset of PD > 40 years (n=212) 
(p=0.275). 
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Table 6.3 Variation in motor complications of Parkinson’s disease in patients (n=276) 
classified by age at onset. 
Variable    Age at onset ≤ 40 years 
         median(IQR) 
 Age at onset > 40 years 
        median(IQR) 
p- value 
Number of cases  64    212 - 
Age* (years) 44.6 (40.2-50.8) 52.9 (48.8-57.0) <0.001 
Sex (males)  67.2% 63.2% 0.561 
Duration† (years)  7.9 (3.7-15.0) 6.6 (2.5-11.3) 0.707 
Dyskinesia 20.0 % 39.9 % 0.148 
On-off fluctuations 40.0 % 55.1 % 0.564 
Dystonia 33.3 % 37.6 % 0.579 
Freezing (subjective) 40.0 % 54.8 % 0.357 
Freezing (objective) 6.7 % 27.0 % 0.283 
LEU (mg/day) 700 (363-998) 715 (400-1008) 0.659 
UPDRS4 4 (0-9) 3 (0-8) 0.275 
* age at registration, † disease duration, IQR= interquartile range.  Data are presented in median (inter-
quartile range) except where indicated, (s) = subjective from MDS-UPDRS Part 2, (o) = objective from 
MDS-UPDRS Part 3, LEU= levodopa equivalent units, UPDRS4= MDS-UPDRS Part 4 score 
 
 
 
 
 
 
The only difference in the motor complications between those with a positive family history 
of PD and those with a negative family history of PD was the prevalence of dystonia being 
higher in those in the former category (p=0.020) as shown in Table 6.4. There was no 
difference in the medication requirements (Figure 6.8), MDS-UPDRS Part 4 scores (Figure 
6.9) or any of the other motor complications of PD between the 2 groups (Table 6.4). 
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Figure 6.8 shows the medication requirements as levodopa equivalent units (LEU) in mg/day 
(on the y-axis) and the family history (FH) of Parkinson’s disease (on the x-axis). No 
significant differences were found between those with familial PD (n=64) compared to those 
with sporadic PD (n=212) (p=0.135). 
 
 
 
Figure 6.9 shows the unified Parkinson’s disease rating scale part 4 scores (on the y-axis) and 
the family history (FH) of Parkinson’s disease (on the x-axis). The line in the centre of the 
boxes represent the medians, the ends of the whiskers 2 standard deviations on either side and 
outliers are represented by dark circles. No significant differences were found between those 
with familial PD (n=64) compared to those with sporadic PD (n=212) (p=0.785). 
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Table 6.4 Variation in motor complications of Parkinson’s disease in patients (n=276) 
classified by family history. 
 
Variable Positive FH 
median (IQR) 
Negative FH 
median (IQR) 
p- value 
Number of cases 64 212 - 
Age* (years) 52.2 (47.3-56.8) 51.2 (46.9-56.1) 0.582 
Sex (males) 65.6 % 63.7 % 0.776 
Duration (years) 6.7 (3.5-12.1) 6.8 (2.5-11.3) 0.312 
Dyskinesia 47.0 % 36.3 % 0.082 
On- Off fluctuations 54.5 % 54.2 % 0.777 
Dystonia 48.5 % 34.0 % 0.020 
Freezing (subjective) 53.0 % 54.5 % 0.979 
Freezing (objective) 18.2 % 28.3 % 0.127 
LEU (mg/day) 824 (460-1033) 655 (400-1000) 0.135 
UPDRS 4 5 (1-8) 3 (0-8) 0.785 
FH= family history, * Age at registration, † disease duration, IQR = inter-quartile range.  Data are 
presented in median (inter-quartile range) except where indicated, (s) = subjective from MDS-UPDRS 
Part 2, (o) = objective from MDS-UPDRS Part 3, LEDD = levodopa equivalent units, UPDRS4 = MDS-
UPDRS Part 4 score 
 
 
Binary logistic regression analyses showed that the only variables that had a significant effect 
on the presence or absence of dyskinesia were disease duration (p<0.001), the PIGD motor 
subtype (p=0.009) and the HY stage (p=0.016). All the other covraiates tested in this model 
i.e age (p=0.244), gender (p=0.304), family history (p=0.107) and LEDD (p=0.350) had no 
significant effect on the presence of dyskinesia. 
 
Using analogous binary logistic regression analyses, the only variables that had a significant 
effect on the presence or absence of dystonia were the Mixed motor subtype (p=0.013) and 
the HY stage (p=0.010). All the other covraiates tested in this model i.e age (p=0.543), 
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disease duration (p=0.682), gender (p=0.611), family history (p=0.073) and LEDD (p=0.342) 
had no significant effect on the presence of dystonia. 
 
 
6.5 Discussion: 
 
 
The development of motor complications in approximately half of patients treated with 
levodopa after 5-6 years had been recognised in the early years after the introduction of this 
drug as standard therapy for treating parkinsonian symptoms [160] but the development of 
motor fluctuations is also influenced by the total daily dose of levodopa.  The proportion of 
patients affected with motor fluctuations at 5 years could be as low as 20 % with prescription 
of lower total daily doses of levodopa [342].  
 
The relationship of motor subtypes to the prevalence of developing motor complications has 
been reported before. Multivariate logistic regression analysis demonstrated that TDPD was 
associated with a reduced risk of levodopa induced dyskinesia, independent of other risk 
factors, such as age at the onset of PD, the duration and dose of levodopa [343]. We also 
found that motor complications such as dyskinesia (p<0.001), 'on' 'off' fluctuations (p= 0.004) 
and freezing (p<0.001) were more prevalent in the PIGD group compared to the TDPD group 
however there were no significant differences between the Mixed subtype and TDPD or 
PIGD. This would not be surprising if one considers that TDPD and PIGD represent ends of a 
spectrum with ‘Mixed’ representing a sub-group that has features of both and can be 
imagined to lie somewhere in the middle of that spectrum.  
 
Some have argued that postural instability with falling (PIF) and freezing of gait (FOG) are 
distinct subtypes within the postural PIGD group [344]. While this remains a point of debate 
what is clear is that FOG is most prevalent in the PIGD motor subtype compared to TDPD 
and ‘Mixed’. The following  four models have been proposed to underlie the episodic nature 
of FOG: (1) The threshold model assumes that FOG occurs when the accumulation of various 
motor deficits reinforce each other to a point of motor breakdown; (2) the interference model 
proposes that FOG represents an inability to deal with concurrent cognitive, limbic, and 
motor input, causing an interruption of locomotion; (3) the cognitive model views FOG as 
induced by a failure to process response conflict, leading to behavioural indecision; and (4) 
the decoupling model sees FOG as a disconnection between preparatory programming and 
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the intended motor response as a result of which automatic movement generation gets stuck 
[345], it is probably a mix of these all hypothetical model that will explain the variation in 
FOG with motor subtype. Cases with the PIGD motor subtype have the greatest motor 
problems, disability (as shown in  Chapter 5) and cognitive impairment (as shown in Chapter 
8) , after correcting for the effects of age and disease duration,  compared to TDPD and 
‘Mixed’ phenotypes.  Therefore to summarise it is probably the depletion of motor and 
cognitive reserves and an increasingly complex response to levodopa with disease 
progression that will leads to the emergence of FOG [345].  
 
Of all the motor complications dyskinesia is reported to be the most common [346]. Our 
study however, showed that FOG, as recorded objectively on MDS-UPDRS Part 3, was the 
most common documented complication in the whole EOPD cohort (73.9%) followed by 
dystonia (62.3%), dyskinesia (60.9%) and ‘on’ ‘off’ fluctuation (45.3%), as documented on 
MDS-UPDRS Part 3 . This has obviously to be interpreted in the light of disease duration of 
this cohort which was 6.5 years (median), inter-quartile range 2.6-11.9 years, and medication 
usage in LEDD 682.5mg/day (median), inter-quartile range 368.8-1000.0 mg/day. 
 
There are gender differences in the development of peak dose dyskinesia. Multivariate 
logistic regression analysis was used to show that independent predictors for the occurrence 
of peak dose dyskinesia besides higher dose of levodopa  and longer duration of treatment 
were female sex and earlier age at onset of PD [347]. We did not find any statistically 
significant differences in the prevalence of dyskinesia (p= 0.402) or any of the motor 
complications subjectively or objectively between the genders. 
 
The age at onset can influence the rate of motor complications in  PD. Patients with a 
younger age at onset are reported to exhibit higher risk of dyskinesia or dystonia compared to 
older age of PD onset [339], however,  our results didn’t show any differences in the rates of 
either dyskinesia (p=0.148) or dystonia (p=0.579) between those diagnosed with PD before 
the age of 40 years compared to those diagnosed after the age of 40 years. This is probably 
due to the fact that the population analysed in Wickremaratchi et al’s study had a different 
demographic profile including a mix of EOPD and LOPD cases whereas our study cohort 
was more homogeneous as it included only EOPD cases. The mean age at assessment in that 
study compared to the cohort analysed here was 65 years vs. 51.5 years, mean age at onset 56 
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years vs. 43.5 years, mean disease duration was 9 years vs. 7.9 years and mean motor 
UPDRS Part 3 score was 28 vs. 26. 
 
We found dystonia to be more prevalent in those with a family history of PD compared to 
those with sporadic PD (P=0.020). Patients with Parkin mutations more commonly present 
with dystonia and have a positive family history of PD [348]. This can be a possible 
explanation for the statistically significant differences in the prevalence of dystonia between 
the 2 sub-groups given that medication usage in LEDD was not significantly different. 
 
 
 
6.6 Conclusion 
 
Factors that are responsible for the variation in the prevalence of motor complications of PD 
include duration of disease, duration of levodopa treatment, cumulative and levodopa daily 
dose, earlier age at onset of disease, female sex, and possibly genetic factors but differences 
in the methods used to assess the presence of these complications (self-reporting versus 
objective assessment), the setting (hospital or community based clinic versus research 
protocol) and different patient populations may also contribute to some of the variation in 
reported prevalence rates. 
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Chapter 7. Variation in non-motor symptoms in EOPD 
  
 
 
7.1 Objective 
 
The objective in this chapter is to analyse the variation in the non-motor symptoms in a 
cohort of patients with early onset Parkinson’s disease. Olfaction data will be analysed and 
presented separately in Chapter 8. 
 
7.2 Introduction 
 
PD has traditionally been viewed as a motor syndrome arising from nigrostriatal 
dopaminergic denervation, however, there is sufficient evidence to indicate that PD is a 
multisystem neurodegenerative disorder with dozens of non-motor symptoms [349]. The 
recognition of  non-motor symptoms (NMS) in PD is important not only because these are 
widely prevalent but also because NMS have a direct negative impact on health-related and 
perceived quality of life in PD, sometimes this effect can be larger than that due to the motor 
disability in these patients [350]. 
 
7.3 Methods 
Patients attended 6 monthly clinic visits as per study protocol described in detail in Chapter 3. 
They were asked to fill in questionnaires for demographic data at baseline (visit 0), physical 
examination to record changes in blood pressure with posture as a measure of orthostatic 
hypotension was recorded at the same visit. Data required for documenting other features of 
autonomic dysfunction including orthostatic symptoms, gastrointestinal, genitourinary, 
sudomotor, temperature intolerance were collected from patient filled validated 
questionnaires such as: scales for outcomes in PD-autonomic (SCOPA-AUT) [72] , 
gastroparesis cardinal symptom index (GCSI)  [351] and non-motor symptom assessment 
scale for Parkinson's disease (NMSS) [352] at visit 1( 0-6 months). The prevalence of restless 
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legs symptoms, unexplained pain and fatigue as significant non-motor symptoms that impact 
on the perceived quality of life by patients [353, 354] were also recorded from the NMSS 
questionnaire.  
Excessive day time sleepiness, rapid eye movement sleep behaviour disorder (RBD) 
symptoms and sleep dysfunction were also recorded at visit 1 using 3 validated instruments 
Epworth sleepiness scale (ESS) [355], Parkinson's disease sleep scale (PDSS) [356] and 
Rapid eye movement (REM) sleep behaviour disorder (RBD) questionnaire [357].  
 
In order to analyse variation in the  non-motor phenotype of PD with respect to historical and 
examination findings all cases with EOPD were classified in 4  ways: according to motor 
subtypes (TDPD, PIGD and ‘Mixed’), gender, age at onset of PD symptoms and family 
history of PD as described in Chapter 4.  
 
Statistical analysis: 
 
Descriptive data are presented as median and inter-quartile range (IQR) as data in most 
instances failed tests of normality (Shapiro Wilk). Kruskal Wallis test was used for inter-
group comparisons of numerical data in scenarios where cases where classified into 3 groups 
e.g. motor subtypes with post hoc comparisons between groups using Mann Whitney U if the 
Kruskal Wallis test statistic showed a significant difference between the 3 groups. Mann 
Whitney U test was used for inter-group comparisons of numerical data where cases were 
classified into 2 groups e.g. males and females. Chi square tests or Fisher’s exact tests were 
used for comparing groups for categorical data, with post-hoc tests as appropriate. 
 
All statistical analyses were two-sided and significance level was set at 5%. Statistical tests 
were performed using Prism software (version 4.0 for Windows; CA, USA) and SPSS 
software (version 23 for Windows; IL, USA). 
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7.4 Results 
 
276 patients had completed all questionnaires relevant to this analysis and are included here 
(Figure 7.1). Their demographic details have been presented in Table 5.1 in Chapter 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 shows the disoposition of cases prior to data analysis for this chapter. No data 
imputation was allowed. Those who had incomplete questionnaires relevant to this analysis 
were not included. 
 
 
 
 
 
Initial recruitment 
target 
N = 240 
Incomplete 
questionnaires 
N = 50 
Additional cases 
recrutited 
N = 86 
Full dataset 
available 
N = 276 
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The variation in the prevalence of non-motor symptoms in these patients, classified by motor 
subtype, is presented in Tables 7.1a and 7.1b. There were no statistically significant 
differences in the prevalence of autonomic (Figure 7.2), gastrointestinal (Figure 7.3), 
genitourinary, sleep dysfunction (Figures 7.4 to 7.6), fatigue or pain symptoms between the 
three motor subtypes (Tables 7.1a and 7.1b) 
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Figure 7.2  shows the proportion of patients who had orthostatic hypotension on examination, 
defined as a drop of 20 mm Hg in the systolic blood pressure and/or 10 mm Hg in the 
diastolic blood pressure within 3 minutes of standing from a lying position (on the y-axis) 
and their motor subtype (on the x-axis). The top of the boxes represent the proportion of 
cases with orthostatic hypotension, as indicated on the y-axis, and the whiskers represent the 
95% confidence limits of proportion. 
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Figure 7.3 shows the proportion of patients who reported constipation, as recorded on the 
SCOPA-AUT questionnaire (on the y-axis) and their motor subtype (on the x-axis). The top 
of the boxes represent the proportion of cases who reported constipation, as indicated on the 
y-axis, and the whiskers represent the 95% confidence limits of proportion. 
 
 
 
Figure 7.4 shows the Epworth sleepiness scale score (on the y-axis) and the motor subtype 
(on the x-axis). The line in the centre of the boxes represent the medians, the ends of the 
whiskers 2 standard deviations on either side and outliers are represented by dark circles. No 
significant differences were found between thoses with TDPD (n=155), PIGD (n=100) or 
‘Mixed’ (n=21) motor subtype (p=0.064). 
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Table 7.1a Variation in non-motor symptoms in patients (n=276) classified by motor subtype. 
 
Variable    TDPD  
median (IQR)  
   PIGD 
median (IQR)  
Mixed 
 median (IQR) 
p- 
value 
Number of cases 155 100 21  
Age* ( in years) 50.4 
(45.1-54.3) 
54.6 
(48.8-59.8) 
49.6 
(46.9-52.5) 
<0.001 
Sex (males) 67.7 %  59.0 %  65 %  0.356 
Duration (years) 5.1 (2.0-9.6) 9.1 (4.6-15.0) 7.4 (2.5-11.8) <0.001 
Autonomic symptoms  
Orthostatic symptoms  47.1 % 54.0 % 61.9 % 0.317 
Orthostatic 
hypotension†  
4.0 % 11.1 % 5.0 % 0.082 
Hyperhidrosis (day) 45.8 % 45.0 % 42.9 % 0.965 
Hyperhidrosis (night) 51.6 % 56.0 % 47.6 % 0.696 
Cold  intolerance  50.3 % 50.0 % 61.9 % 0.587 
Heat intolerance 47.7 % 47.0 % 47.6 % 0.993 
Gastrointestinal symptoms  
Dysphagia 31.6 % 38.0 % 23.8 % 0.360 
Prandial bloating 30.3 % 30.0 % 28.6 % 0.986 
Constipation 45.2 % 60.0 % 42.9 % 0.053 
Incontinence (faecal) 7.1 % 9.0 % 0 % 0.349 
TDPD = tremor dominant Parkinson’s disease, PIGD = postural instability gait difficulty, * Age at 
registration, IQR= inter-quartile range, †orthostatic hypotension was defined as fall in systolic blood 
pressure of 20 mm Hg or more or diastolic blood pressure of 10 mm Hg or more on standing.  
 
 
 
 
There were no statistically significant differences in the NMSS total scores between the three 
motor subtypes (p=0.155) as shown in Table 7.1b and figure 7.7. 
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Table 7.1b Variation in non-motor symptoms in patients (n=276) classified by motor subtype 
(continuation of Table 7.1a) 
 
Variable    TDPD 
median (IQR)  
   PIGD 
median (IQR)  
Mixed  
 median (IQR) 
p- 
value 
Number of cases 155 100 21 - 
Genitourinary dysfunction  
Bladder dysfunction* 93.5 % 98.0 % 100.0 % 0.140 
Erectile dysfunction (m) 46.7 % 50.8 % 38.5 % 0.697 
Anorgasmia (f) 32.0 % 51.2 % 50.0 % 0.158 
Incontinence (urinary) 34.8 % 40.0 % 23.8 % 0.343 
Sleep dysfunction  
 RBD
†
 symptoms 36.8 % 46.0 % 38.1 % 0.334 
 Disrupted sleep‡ 51.7 % 38.4 % 55.0 % 0.092 
 EDS§  32.3 % 40.0 % 33.3 % 0.442 
 Restless legs symptoms 65.6 % 73.7 % 55.0 % 0.179 
Pain (unexplained) 35.8 % 46.5 % 45.0 % 0.129 
Fatigue 76.8 % 80.8 % 85.0 % 0.590 
NMSS total score 36 (21-65) 48 (25-77) 43 (26-84) 0.155 
TDPD = tremor dominant Parkinson’s disease, PIGD = postural instability gait difficulty, *Bladder 
dysfunction= difficulty retaining urine, feeling bladder not completely empty, weak stream, pis en deux  
or nocturia, (m) = males, (f) = females. RBD = Rapid eye movement sleep behaviour disorder, †RBD 
questionnaire score ≥ 5, ‡ using Parkinson’s disease sleep scale (PDSS) score > 100, § EDS = excessive 
daytime sleepiness using Epworth sleep scale (ESS) score ≥ 11, NMSS = non-motor symptom scale. 
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Figure 7.5 shows the REM sleep behaviour disorder scale score (on the y-axis) and the motor 
subtype (on the x-axis). The line in the centre of the boxes represent the medians, the ends of 
the whiskers 2 standard deviations on either side and outliers are represented by dark circles. 
No significant differences were found between thoses with TDPD (n=155), PIGD (n=100) or 
‘Mixed’ (n=21) motor subtype (p=0.256). 
 
 
 
Figure 7.6 shows the Parkinson’s disease sleep scale score (on the y-axis) and the motor 
subtype (on the x-axis). The line in the centre of the boxes represent the medians, the ends of 
the whiskers 2 standard deviations on either side and outliers are represented by dark circles. 
PDSS scores were significantly greater in those with TDPD (n=155) compared to PIGD 
(n=100) (p=0.031). 
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Figure 7.7 shows the non-motor symptoms scale score (on the y-axis) and the motor subtype 
(on the x-axis). The line in the centre of the boxes represent the medians, the ends of the 
whiskers 2 standard deviations on either side and outliers are represented by dark circles. No 
statistically significant differences in the NMSS total scores were found between thoses with 
TDPD (n=155), PIGD (n=100) or ‘Mixed’ (n=21) motor subtype (p=0.155). 
 
The prevalence of some gastrointestinal, genitourinary and pain symptoms showed gender 
differences as shown in Table 7.2a and 7.2b. Both bladder and bowel incontinence (Figure 
7.8) were more commonly reported by females. 
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Figure 7.8 shows the proportion of patients who reported bladder or bowel incontinence, as 
recorded on the SCOPA-AUT questionnaire (on the y-axis) and their gender (on the x-axis). 
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Table 7.2a Variation in non-motor symptoms in patients (n=276) classified by gender 
 
Variable    Males 
     median (IQR)  
    Females 
     median (IQR)  
p- value 
Number of cases 177 99 - 
Age*  (years)       51.7 (46.5-56.8)     51.1 (47.2-55.6) 0.968 
Disease duration (years)       7.3 (2.8-11.5)      6.5 (2.6-11.9) 0.737 
Autonomic symptoms  
    Orthostatic symptoms 48.6 % 54.5 % 0.342 
    Orthostatic hypotension† 7.3 % 5.1 % 0.613 
    Hyperhidrosis (day) 43.5 % 48.5 % 0.425 
    Hyperhidrosis (night) 48.6 % 60.6 % 0.056 
    Cold  intolerance  49.7 % 53.5 % 0.543 
    Heat intolerance 45.8 % 50.5 % 0.450 
Gastrointestinal symptoms  
     Dysphagia 39.5 % 22.2 % 0.003 
     Prandial bloating 25.4 % 38.4 % 0.024 
     Constipation 45.2 % 59.6 % 0.022 
     Incontinence (faecal) 5.6 % 10.1 % 0.226 
* Age at registration, IQR= inter-quartile range, † orthostatic hypotension defined as fall in systolic blood 
pressure of 20 mm Hg or more or diastolic blood pressure of 10 mm Hg or more on standing  
 
 
 
There were no statistically significant differences in the NMSS total scores between the two 
genders (p=0.743) as shown in Table 7.2b and figure 7.9. 
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Table 7.2b Variation in non-motor symptoms in patients (n=276) classified by gender 
(continuation of Table 7.2a) 
 
Variable     Males 
     median (IQR)  
       Females 
median (IQR)  
p- value 
Number of cases  177  99 - 
Genitourinary dysfunction  
     Bladder dysfunction¶ 96.0 % 94.9 % 0.669 
     Erectile dysfunction  52.5 % NA - 
     Anorgasmia (females) NA 65.7 % - 
     Incontinence (urinary) 28.2 % 49.5 % <0.001 
Sleep dysfunction  
    RBD** symptoms  41.2 % 38.4 % 0.642 
    Disrupted sleep‡  47.5 % 43.4 % 0.520 
    EDS §  37.9 % 30.3 % 0.208 
    Restless legs symptoms 64.4 % 69.7 % 0.373 
Pain (unexplained) 34.5 % 48.5 % 0.022 
Fatigue 75.7 % 79.8 % 0.437 
NMSS total score 41 (24-70) 36 (24-73) 0.743 
IQR = inter-quartile range,¶Bladder dysfunction= difficulty retaining urine, feeling bladder not 
completely empty, weak stream, pis en deux or nocturia. M= males, F= females. RBD = Rapid eye 
movement behaviour disorder, **RBD questionnaire score ≥ 5, ‡ using Parkinson’s disease sleep scale 
(PDSS) score >100, § EDS= excessive daytime sleepiness using Epworth sleep scale (ESS) score ≥ 11, 
NMSS = non-motor symptom scale. 
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Figure 7.9 shows the non-motor symptoms scale score (on the y-axis) and the gender (on the 
x-axis). The line in the centre of the boxes represent the medians, the ends of the whiskers 2 
standard deviations on either side and outliers are represented by dark circles. No statistically 
significant differences in the NMSS total scores were found between males (n=177) and 
females (n=99) (p=0.743). 
 
There were no differences in most of the non-motor symptoms between those diagnosed with 
Parkinson’s disease aged less than (or equal to) 40 years compared to those diagnosed after 
the age of 40 years as shown in Tables 7.3a and 7.3b including sexual dysfunction (Figure 
7.10). 
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Figure 7.10 shows the proportion of patients who reported erectile dysfunction or 
anorgasmia, as recorded on the SCOPA-AUT questionnaire (on the y-axis) and their age at 
diagnosis of PD (on the x-axis). 
167 
 
 
Table 7.3a Variation in non-motor symptoms in patients (n=276) classified by age at onset  
of PD. 
Variable Age onset ≤ 40 yrs. 
     median (IQR) 
Age onset > 40 yrs. 
     median (IQR)     
p- 
value 
Number of cases    64      212 - 
Age* ( in years) 44.6 (40.2-50.8) 52.9 (48.8-57.0) <0.001 
Sex (males)    67.2 %  63.2 % 0.561 
Disease duration (years)    7.9 (3.7-15.0)   6.6 (2.5-11.3) 0.707 
Autonomic symptoms  
   Orthostatic symptoms 57.8 % 48.1 % 0.196 
   Orthostatic hypotension 
¶
 9.5 % 5.7 % 0.385 
   Hyperhidrosis (day) 45.3 % 45.3 % 0.997 
   Hyperhidrosis (night) 57.8 % 51.4 % 0.369 
   Cold  intolerance  54.7 % 50.5 % 0.511 
   Heat intolerance 51.6 % 46.3 % 0.454 
Gastrointestinal symptoms  
    Dysphagia 40.6 % 30.8 % 0.158 
    Prandial bloating 29.7 % 29.9 % 0.939 
    Constipation 42.2 % 52.8 % 0.136 
    Incontinence (faecal) 6.3 % 7.5 % 0.726 
* Age at registration, IQR = interquartile range, ¶ orthostatic hypotension defined as fall in systolic blood 
pressure of 20 mm Hg or more or diastolic blood pressure of 10 mm Hg or more on standing.  
 
 
 
 
There were no statistically significant differences in the NMSS total scores between the two 
groups (p=0.227) as shown in Table 7.3b and Figure 7.11. 
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Table 7.3b Variation in non-motor symptoms in patients (n=276) classified by age at onset  
of PD (continuation of Table 7.3a) 
 
Variable Age onset ≤ 40 yrs. 
     median (IQR) 
Age onset > 40 yrs. 
     median (IQR)     
p- 
value 
Number of cases    64      212 - 
Genitourinary dysfunction  
     Bladder dysfunction✝ 93.8 % 96.3 % 0.395 
     Erectile dysfunction(m) 65.1 % 57.5 % 0.374 
     Anorgasmia (f) 33.3 % 47.4 % 0.248 
     Incontinence (urinary) 29.7 % 37.4 % 0.240 
Sleep dysfunction  
     RBD**symptoms  40.6 % 40.1 % 0.940 
    Disrupted sleep‡  49.2 % 46.4 % 0.694 
    EDS §  40.6 % 33.5 % 0.295 
    Restless legs symptoms 74.6 % 65.7 % 0.186 
Pain(unexplained) 44.4 % 39.1 % 0.452 
Fatigue 76.2 % 79.7 % 0.549 
NMSS total score 45 (26-74) 37 (23-70) 0.227 
✝Bladder dysfunction = difficulty retaining urine, feeling bladder not completely empty, weak stream,  
pis en deux or nocturia. (m) = males, (f) = females. RBD = Rapid eye movement behaviour disorder, 
**RBD questionnaire score ≥ 5, ‡ using Parkinson’s disease sleep scale (PDSS) score > 100, § EDS = 
excessive daytime sleepiness using Epworth sleep scale (ESS) score ≥ 11, NMSS = non-motor symptom 
scale. 
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Figure 7.11 shows the non-motor symptoms scale (NMSS) score (on the y-axis) and age at 
onset of PD (on the x-axis). The line in the centre of the boxes represent the medians, the 
ends of the whiskers 2 standard deviations on either side and outliers are represented by dark 
circles. No statistically significant differences in the NMSS total scores were found between 
those with age at onset of PD ≤ 40 years (n=64) compared to those with age at onset of PD > 
40 years (n=212) (p=0.227). 
 
Classifying patients into those with a positive family history of PD and those with a negative 
family history of PD also showed no differences in most non-motor symptoms except one 
autonomic symptom i.e. prandial bloating (Figure 7.12) which was more commonly reported 
by those with a positive family history (p= 0.036) as shown in Table 7.4a and 7.4b. 
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Figure 7.12  shows the proportion of patients who reported prandial bloating and dysphagia, 
as recorded on the SCOPA-AUT questionnaire (on the y-axis) and their family history (FH) 
of PD (on the x-axis).  
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Table 7.4a Variation in non-motor symptoms in patients (n=276) classified by family history  
of PD.  
 
Variable      Positive FH 
    median (IQR)  
     Negative FH 
       median (IQR)  
p- 
value 
Number of cases  64 212 - 
Age* (years) 52.2 (47.3-56.8) 51.2 (46.9-56.1) 0.582 
Sex (males) 65.6 %  63.7 % 0.776 
Disease duration (years) 6.7 (3.5-12.1) 6.8 (2.5-11.3) 0.312 
Autonomic symptoms  
  Orthostatic symptoms 51.5 % 50.0 % 0.661 
  Orthostatic hypotension 
¶
 6.1 % 1.9 % 0.087 
  Hyperhidrosis (day) 47.0 % 44.8 % 0.771 
  Hyperhidrosis (night) 50.0 % 53.8 % 0.597 
  Cold  intolerance  50.0 % 51.9 % 0.629 
  Heat intolerance 43.9 % 48.6 % 0.497 
Gastrointestinal symptoms  
  Dysphagia 25.8 % 35.4 % 0.190 
  Prandial bloating 39.4 % 26.9 % 0.036 
  Constipation 45.5 % 51.9 % 0.357 
  Incontinence (faecal) 6.1 % 7.5 % 0.726 
FH = family history, * age at registration, IQR = inter-quartile range.  ¶ orthostatic hypotension defined 
as fall in systolic blood pressure of 20 mm Hg or more or diastolic blood pressure of 10 mm Hg or more 
on standing  
 
 
 
 
There were no statistically significant differences in the NMSS total scores between the two 
groups (p=0.831) as shown in Table 7.4b and Figure 7.13. 
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Table 7.4b Variation in non-motor symptoms in patients (n=276) classified by family history  
of PD. (continuation of Table 7.4a) 
 
Variable      Positive FH 
    median (IQR)  
      Negative FH 
       median (IQR)  
p- 
value 
Number of cases  64 212 - 
Genitourinary dysfunction  
  Bladder dysfunction✝ 97.0 % 95.3 % 0.584 
  Erectile dysfunction (males) 56.8 % 57.0 % 0.979 
  Anorgasmia (females) 40.9 % 45.5 % 0.705 
  Incontinence (urinary) 30.3 % 37.3 % 0.380 
Sleep dysfunction  
  RBD **symptoms  37.5 % 41.0 % 0.613 
  Disrupted sleep‡  40.6 % 47.6 % 0.324 
  EDS§  37.5 % 34.4 % 0.653 
  Restless legs symptoms 75.0 % 63.7 % 0.093 
Pain(unexplained) 43.8 % 38.2 % 0.427 
Fatigue 73.4 % 78.3 % 0.416 
NMSS total score 41 (26-70) 39 (23-73) 0.831 
FH = family history, IQR = inter-quartile range,✝Bladder dysfunction = difficulty retaining urine, 
feeling bladder not completely empty, weak stream, pis en deux or nocturia.  RBD = Rapid eye movement 
sleep behaviour disorder, **RBD questionnaire score ≥ 5, ‡ using Parkinson’s disease sleep scale (PDSS) 
score > 100, § EDS= excessive daytime sleepiness using Epworth sleep scale (ESS) score ≥ 11, NMSS = 
non-motor symptom scale. 
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Figure 7.13 shows the non-motor symptoms scale score (on the y-axis) and the family history 
(FH) of PD (on the x-axis). The line in the centre of the boxes represent the medians, the ends 
of the whiskers 2 standard deviations on either side and outliers are represented by dark 
circles. No statistically significant differences in the NMSS total scores were found between 
those with familial PD (n=64) compared to those with sporadic PD (n=212) (p=0.831).  
 
7.5 Discussion 
 
Non-motor symptoms of PD are legion and increasingly being recognised by clinicians as a 
source of considerable distress in the daily lives of these patients. The Parkinson and non-
motor symptoms (PRIAMO) study report suggested that the mean number of non-motor 
symptoms per patient can be 7-8 (range, 0-32) [36]. The PRIAMO study investigators used a 
semistructured interview to determine the prevalence of NMS. We used the validated NMSS 
to determine the prevalence of NMS in our cohort as it is free from floor and ceiling effects 
[358]. The PRIAMO study (n=1072) reported a near universal presence (98.6%) of NMS in 
their cohort. We found similar results and all of our patients (n=269) had at least one NMS to 
report. NMSS has nine domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual 
problems, attention/memory, gastrointestinal, urinary, sexual function and “miscellany” 
[352].  The “miscellany” domain of the NMSS contains questions about pain, olfaction, 
weight changes and hyperhidrosis. Based on this scale the prevalence of NMS in each of 
these domains for the whole cohort (n=269) was: cardiovascular (51%) , sleep/fatigue (67%), 
mood/cognition (48%), perceptual problems (29%), attention/memory ( 61%), 
gastrointestinal (41%), urinary (65%), sexual function (38%) and “miscellany” (49%). 
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However, some of these domains contain questions that overlap the boundaries of the human 
body’s anatomical and physiological systems. The autonomic nervous system, for example, 
innervates several organs in the body including the cardiovascular system, skin and bowel. 
Autonomic system dysfunction can have several manifestations including orthostatic 
hypotension, anhidrosis and constipation [359]; we have therefore considered questions from 
the NMSS [352] and SCOPA-Aut [72]  related to these organ systems under one domain 
when classifysing the EOPD cohort according to clinical subtypes (Tables 7.1-7.4). The sleep 
domain of NMSS has only 4 questions [352] but we considered this barely useful to assess 
either excessive daytime sleepiness or nocturnal sleep disorders without exploring the 
potential causes. We used more detailed and validated scales such as the RBD questionnaire 
(using a cutoff score> 5) [357], Parkinson’s disease sleep scale (PDSS) using a cutoff score 
>100 [360] and Epworth sleep scale (ESS) using a cutoff score >=11[355] to document 
specific problems in sleep (Tables 7.1-7.4). Sexual and urinary dysfunction are considered as 
two separate domains in NMSS, however, we considered these symptoms under one domain 
(genitourinary) as the anatomical and physiological substrates for these symptoms are 
intimately linked (Tables 7.1-7.4). 
 
In addition to the motor disability of PD non-motor symptoms such as depression, anxiety, 
fatigue, confusion, autonomic disturbance particularly urinary incontinence and sensory 
symptoms such as pain were the major predictors of QoL. This has implications for the 
medical management of PD if QoL is an important therapeutic endpoint [353].  
 
There are reported differences in the prevalence of non- motor symptoms in between the 
motor subtypes of PD. Some features such as hyper salivation and dribbling are significantly 
more common in those with the PIGD subtype than in those with TDPD [361]. Our results, 
however, showed no statistically significant differences in the prevalence of autonomic, 
gastrointestinal, genitourinary, sleep dysfunction, fatigue or pain symptoms between the three 
motor subtypes (Tables 7.1a and 7.1b). The previous study reported findings from a cohort of 
LOPD with different demographic characteristics, hence, is not directly comparable to our 
study. 
 
Gender based differences in the prevalence of non- motor symptoms has also been reported.  
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Male patients are reported to more frequently complain of sexual dysfunction and 
taste/smelling difficulties significantly more frequently than female patients [328]. The 
prevalence of pain as a symptom in patients with PD ranges from 30 to 70% [362-365] . 
While some reports have suggested no differences in the prevalence of pain between genders 
[366], others have reported pain to be more prevalent in female patients [367] . We also 
found pain to be more commonly reported by females than males in the EOPD cohort 
(p=0.022). The higher prevalence of pain may be related to perceptual differences of pain 
between genders or lower pain thresholds in females[368]. It is recognised that although pain 
experienced by patients may have several causes including comorbidities such as 
osteoarthritis, cases with PD can have pain without an identifiable cause, some clinicians use 
the terms ‘non-PD pain’ and  ‘PD pain’ to delineate these two entities [369]. Our study also 
showed other differences in between the two sexes with more females reporting urinary 
incontinence (p<0.001), prandial bloating (p=0.024) and constipation (p=0.022) compared to 
males who had a higher prevalence of dysphagia (p=0.003).  
 
The age of onset of PD is reported to influence the development of non-motor symptoms. 
Old-age at onset is characterized by more olfactory and sensory symptoms, autonomic 
symptoms and sleep [370]. Our results didn’t show any differences in between autonomic or 
sleep symptoms however sexual dysfunction was more commonly reported by females in the 
older age group (p=0.022).  
 
The prevalence of non-motor symptoms in familial cases of PD compared to sporadic cases 
has not been reported. We found no difference in the prevalence of non-motor symptoms 
between the 2 sub-groups except prandial bloating was more commonly reported by those 
with a family history of PD (p=0.036). The significance of this, if any, remains undetermined.  
 
7.6 Conclusion 
 
 Non-motor symptoms are common in parkinsonian patients in varying proportions. Unlike 
motor symptoms the determinants of the heterogeneity in most non- motor symptoms are 
largely unknown, with exceptions such as cognitive problems (analysed in Chapter 10). 
Nevertheless the recognition and management of non-motor symptoms is important because 
of their significant influence on the quality of life of affected patients. 
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Chapter 8. Variation in olfactory function in EOPD. 
 
 
  
 
 
8.1 Objective 
 
The primary objective of our work here was to assess olfaction in a cohort of EOPD cases in 
order to determine the degree or grading of olfactory loss according to motor subtype, age at 
onset and heritability of the parkinsonian trait. A secondary objective was to analyse the 
correlation between olfactory, cognitive, motor and non- motor symptom scores. 
 
 
8.2 Introduction 
 
Olfactory dysfunction is an important and early feature of Parkinson’s disease (PD) [371]. 
The degree of olfactory loss is however variable and is differentially impaired in distinct 
parkinsonian syndromes [372]. It is also well accepted that PD has a pre-motor phase and 
olfactory loss is a recognised feature of this phase [373]. Current diagnostic criteria for PD 
[317] have an emphasis on cardinal motor features, but non-motor symptoms including the 
loss of sense of smell may precede the motor presentation by several years [50]. Olfactory 
dysfunction is therefore under study as a biomarker, or screening tool, for premotor PD, in 
combination with other prodromal features identified through questionnaires and simple 
motor tasks [374]. This is less invasive and less expensive than other modalities, such as 
functional dopamine brain scanning.[375] A simple ‘scratch and sniff’ test such as the 
University of Pennsylvania smell identification test (UPSIT) has been applied in selected 
populations e.g. relatives of those affected with PD who have an increased risk of developing 
PD [374] . There is some evidence that olfactory dysfunction in PD differs according to 
motor subtype, being more evident in patients with tremor dominant PD (TDPD) than in 
postural instability gait difficulty motor subtype (PIGD) [376, 377] . These studies had a mix 
of cases of early onset PD (EOPD) and late onset PD (LOPD) and no study has looked 
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specifically at EOPD cases. EOPD differs from late onset PD (LOPD) by having slower 
motor progression, a longer disease course, and greater preservation of cognitive function, 
but earlier motor fluctuations and dyskinesia [378]. It is also more likely that EOPD cases 
have a genetic basis to the underlying aetiology compared to LOPD cases when considering 
genes like Parkin. [169] 
 
 
8.3 Methods 
 
Early onset PD cases (age <50 years at diagnosis) based on UK Brain Bank criteria [317], 
enrolled in the PRoBaND study were included. Patients with features indicating other types 
of degenerative parkinsonism e.g. progressive supranuclear palsy, drug-induced or vascular 
parkinsonism, and those with normal presynaptic dopamine imaging (performed in selected 
cases on clinical grounds) were excluded. All patients had demographic data, relevant past 
medical history, vital signs, diagnostic features at presentation, medication history and family 
history recorded. Smell testing was performed using the British version of the UPSIT, a 40-
odour ‘scratch and sniff’ test. 
 
Classification of cases: All cases were classified into TDPD, PIGD and ‘Mixed’, based on 
UPDRS part 2 (history) and part 3 (examination) scores, was done as explained in detail in 
Chapter 4. Further exploratory analysis involved classifying cases by age of onset at PD and 
family history of PD (hereditary vs. sporadic PD). In all classes cases were grouped by 
gender as differences in olfactory acuity based on gender are well recognised. 
 
Definitions of normosmia and olfactory dysfunction: Standard definitions were applied to 
grade olfactory performance as follows: anosmia - UPSIT scores<19 for both males and 
females); hyposmia- UPSIT scores 19-33 inclusive in men, and 19-34 inclusive in women; 
and normosmia - UPSIT scores >34 for men and >35 for women. Hyposmia was sub-
categorized as mild - UPSIT scores of 30-33 inclusive in men, and 31-34 inclusive in 
women); moderate - UPSIT scores of 26-29 inclusive in men, and 26-30 inclusive in women), 
and severe (UPSIT scores of 19-25, inclusive, in men and women).[379]  
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Statistical analyses: The UPSIT scores (dependent variable) were compared using a 
generalised linear model, based on ANCOVA, using age and disease duration as covariates 
and motor subtype and gender as fixed factors (independent variables) . Logarithmic 
transformations (log10) were obtained prior to fitting the data in the statistical model where it 
failed a test of normality (Shapiro Wilk). Chi-square tests were used for categorical variables. 
Those with age at diagnosis ≤ 40 years and those with age at diagnosis > 40 years were also 
compared using a similar generalised linear model described above and Fisher’s exact test for 
categorical data. Associations among the different measures were tested using correlation 
analyses (Pearson for parametric, Spearman for non-parametric). All statistical analyses were 
two-sided and significance level was set at 5%. Statistical tests were performed using 
MINITAB software (version 16 for Windows; PA, USA) and SPSS software (version 23 for 
Windows; IL, USA). 
 
8.4 Results 
 
213 patients had filled in all the booklets from the UPSIT, relevant to this analysis and are 
included here (Figure 8.1).  
There were 136 males (63.6 %) and 77 females (34.4%), median age 52.1 years (interquartile 
range, IQR, 47.5-56.6 years), median disease duration 7.3 years (IQR 3.0-11.4 years). The 
median UPSIT score was 21 out of 40 (IQR 16-28) for the entire cohort. Females scored 
higher (median 27, IQR 20-30) than males (median 19, IQR 14-25, p<0.0001). (Figure 8.2) 
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Figure 8.1 shows the disoposition of cases prior to data analysis for this chapter. No data 
imputation was allowed. Those who had incomplete questionnaires relevant to this analysis 
were not included. 
 
 
 
 
 
 
Initial recruitment 
target 
N = 240 
Incomplete smell 
test booklets 
N = 113 
Additional cases 
recrutited 
N = 86 
Full olfaction data 
available 
N = 213 
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Figure 8.2 shows box-whisker plots of the scores on the University of Pennsylvania smell 
identification test 40 item version (UPSIT) on the y-axis versus gender on the x-axis. The line 
in the centre of the boxes represent the medians, the ends of the whiskers 2 standard 
deviations on either side and outliers are represented by dark circles. Females obtained higher 
scores compared to males (p<0.0001). 
 
There were no statistically significant differences in the UPSIT scores between the TDPD, 
PIGD and ‘Mixed’ motor subtypes (p=0.523) (Figures 8.3 and 8.4). 
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Figure 8.3 shows box-whisker plots of the scores on the University of Pennsylvania smell 
identification test 40 item version (UPSIT) on the y-axis versus motor subtype of males 
(n=136) on the x-axis. The line in the centre of the boxes represent the medians, the ends of 
the whiskers 2 standard deviations on either side and outliers are represented by dark circles. 
No statistically significant differences in the UPSIT scores were found between the three 
motor subtypes amongst males (p=0.454). 
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Figure 8.4 shows box-whisker plots of the scores on the University of Pennsylvania smell 
identification test 40 item version (UPSIT) on the y-axis versus motor subtype in females on 
the x-axis. The line in the centre of the boxes represent the medians, the ends of the whiskers 
2 standard deviations on either side and outliers are represented by dark circles. No 
statistically significant differences in the UPSIT scores were found between the three motor 
subtypes amongst females (p=0.765). 
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The proportion of patients with normosmia, 3 grades of hyposmia and anosmia classified by 
motor subtype is shown in Table 8.1.  
 
Table 8.1 Olfactory status in patients (n=211) classified by motor subtype and gender. 
Olfactory status* TDPD  
median (IQR) 
PIGD  
median (IQR) 
‘Mixed’  
median (IQR) 
Number of cases 117 79 15 
Age* ( in years) 50.9 (46.0-54.3) 54.9 (49.8-59.8) 46.7 (41.5-51.0) 
Sex (males) 66.1 % 59.3 % 68.8 % 
Duration (years) 5.5 (2.4-9.8) 9.1 (4.9-15.0) 7.5 (2.4-11.0) 
UPSIT score 
M: 20 (16-24) 
F: 26 (20-30) 
M: 17 (14-25) 
F: 28 (20-30) 
M: 17 (11-22.2) 
F: 24 (22-28) 
Normosmia 
M: 5.1% 
F: 12.5% 
M: 0 % 
F: 6.1 % 
M: 8.3 % 
F: 0 % 
Mild hyposmia 
M: 5.1 % 
F: 17.5 % 
M: 10.9 % 
F: 24.2 % 
M: 0 % 
F: 33.3 % 
Moderate hyposmia 
M: 11.5 % 
F: 22.5 % 
M: 8.7 % 
F: 30.3 % 
M: 16.7 % 
F: 0 % 
Severe hyposmia 
M: 32.1 % 
F: 32.5 % 
M: 26.1 % 
F: 15.2 % 
M: 16.7 % 
F: 66.7 % 
Anosmia 
M: 46.2 % 
F: 15.0 % 
M: 54.3 % 
F: 24.2 % 
M: 58.3 % 
F: 0 % 
Total (hyposmia or 
anosmia) 
M: 94.9 % 
F: 87.5 % 
M: 100 % 
F: 93.9 % 
M: 91.7 % 
F: 100 % 
TDPD = Tremor dominant Parkinson’s disease, PIGD-PD = Postural instability gait difficulty dominant 
Parkinson’s disease, *using gender based cut-off scores from the University of Pennsylvania Smell 
Identification 40 item test, M = male, F = female. 
 
 
There were no statistically significant differences in the UPSIT scores between those with 
age at onset ≤ 40 years compared to those with age at onset > 40 years (p=0.243). The 
proportion of patients with normosmia, 3 grades of hyposmia and anosmia classified by age 
at diagnosis of PD in Table 8.2 and in Figures 8.5 and 8.6. 
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Subgroup analysis showed males with a relatively earlier onset of disease (≤ 40 years of age) 
had lower UPSIT total scores (median 22, IQR 16-28) compared to females (median 28, IQR 
20-30) (p= 0.0179). This trend persisted in those with later onset of disease (> 40 years of 
age) with females achieving higher scores on UPSIT (median 26, IQR 20-30) compared to 
males (median 19, IQR 14-24) (p<0.001)  
 
 
Table 8.2 Olfactory status in patients (n=211) classified by age at onset of PD and 
gender. 
Olfactory status*  Age onset ≤ 40 yrs.  
median (IQR) 
Age onset >40  years 
median (IQR) 
Number of cases    45      166 
Age
†
 ( in years) 46.7 (41.5-51.0) 53.1 (49.4-57.2) 
Sex (males) 69.6 % 62.1 % 
Disease duration (years) 8.2 (3.6-15.1) 6.9 (2.8-11.2) 
UPSIT scores 
M: 21 (16-28) 
F:  28 (20-30) 
M: 18 (14-24) 
F: 26 (20-30) 
Normosmia 
M: 0 % 
F: 15.4 % 
M: 4.9 % 
F: 7.9 % 
Mild hyposmia 
M: 12.1 % 
F: 15.4 % 
M: 4.9 % 
F: 22.2 % 
Moderate hyposmia 
M: 18.2 % 
F: 30.8 % 
M: 8.7 % 
F: 23.8 % 
Severe hyposmia 
M: 21.2 % 
F: 30.8 % 
M: 31.1 % 
F: 25.4 % 
Anosmia 
M: 48.5 % 
F: 7.7 % 
M: 50.5 % 
F: 20.6 % 
Total (hyposmia or 
anosmia) 
M: 100 % 
F: 84.6 % 
M: 95.1 % 
F: 92.2 % 
* using gender based cut-off scores provided in the University of Pennsylvania Smell Identification test 
kit (40 item) British version. † age at registration, M = male, F = female. 
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Figure 8.5 shows the proportion of male patients with varying grades of hyposmia and 
anosmia in those with age of diagnosis ≤ 40 years (n=64), in the left 4 bars, and in those with 
age of diagnosis > 40 years (n=214), in the right 4 bars in the graph. [Note: Normosmic cases 
are not shown.] 
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Figure 8.6 shows the proportion of female patients with varying grades of hyposmia and 
anosmia in those with age of diagnosis ≤ 40 years (n=64), in the left 4 bars, and in those with 
age of diagnosis > 40 years (n=214), in the right 4 bars in the graph. [Note: Normosmic cases 
are not shown.] 
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There were no statistically significant differences in the UPSIT scores between those with a 
family history of PD compared to those without a family history of PD (p=0.385). The 
proportion of patients with normosmia, 3 grades of hyposmia and anosmia and classified by 
family history of PD in Table 8.3. 
 
 
Table 8.3 Olfactory status in patients (n=211) classified by family history of PD  
and gender. 
Olfactory status*  Positive FH  
median (IQR) 
Negative FH 
median (IQR) 
Number of cases 52 159 
Age* ( in years) 52.1 (47.4-56.8) 52.0 (47.5-56.6) 
Sex (males) 63.5 % 63.8 % 
Disease duration (years) 6.4 (3.3-11.5) 7.4 (2.8-11.3) 
UPSIT scores M: 15 (20-25) 
F: 21 (28-31) 
M: 14 (18-25) 
F: 20 (26-30) 
Normosmia M: 0 % 
F: 10.5 % 
M: 4.9 % 
F: 8.6 % 
Mild hyposmia M: 8.8 % 
F:  26.3 % 
M: 5.9 % 
F: 19.0 % 
Moderate hyposmia M: 14.7 % 
F: 26.3 % 
M: 9.8 % 
F: 24.1 % 
Severe hyposmia M: 29.4 % 
F: 21.1 % 
M; 28.4 % 
F: 27.6 % 
Anosmia M: 47.1 % 
F: 15.8 % 
M: 51.0 % 
F: 20.7 % 
Total (hyposmia or 
anosmia) 
M: 100 % 
F: 89.5 % 
M: 95.1 % 
F: 91.4 % 
FH = family history, * using gender based cut-off scores provided in the University of Pennsylvania Smell 
Identification test kit (40 item) British version. M = male, F = female. 
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Subgroup analysis showed males with a positive family history of PD had lower UPSIT total 
scores (median 20, IQR 15-25) compared to females (median 28, IQR 21-31) (p= 0.021). 
This trend persisted in those with negative family history of PD i.e. sporadic PD with females 
achieving higher scores on UPSIT (median 26, IQR 20-30) compared to males (median 18, 
IQR 14-25) (p=0.001). 
 
There was a weak but significant positive correlation between UPSIT and MOCA test score 
(Spearman’s rho=0.177, p<0.001) and weak negative correlations between UPSIT scores and 
UPDRS3 (Spearman’s rho= -0.0272, p=<0.001), NMSS (Spearman’s rho= -0.177, p=0.010) 
and PDQ8SI (Spearman’s rho= -0.153, p=0.027). 
 
 
Discussion 
 
EOPD cases are an important subset to identify for studies of neuroprotection, given their 
longer disease duration and a tool to detect pre-morbid PD would therefore be useful. 
Olfactory loss on its own may not be a perfect tool for identifying pre-motor PD because of 
its low specificity however this can be increased by using smell tests in a 2 step combined 
approach where the presence of olfactory loss in combination with other non-motor features 
such REM sleep behaviour disorder could be a pointer towards pre-motor PD [380], thereby 
helping select at risk patients who could then be assessed for evidence of pre-synaptic 
neurodegeneration using dopamine transporter imaging. This approach has been used in 
population based studies such as the Parkinson At-Risk Syndrome (PARS) study [172]. 
Besides its diagnostic value as a test olfactory dysfunction can have prognostic value too as 
odour identification deficits are associated with increased risk of neuropsychiatric 
complications and cognitive decline in patients with Parkinson's disease [381]. Therefore the 
utility of olfactory testing in PD is twofold i.e. for diagnostic and perhaps prognostic 
purposes with the added double bonus advantage of it being ‘low tech’ and ‘low cost’ 
compared to all other screening modalities with a similar sensitivity. However if olfactory 
dysfunction is to be used as screening tool for premotor PD, it is important that this should 
not select cases with a particular subtype of PD at the expense of other subtypes. 
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The prevalence of olfactory dysfunction in PD in general is about 90-95% [382] but there are 
significant variations with lower rates in some genetic variants of PD such as those with 
Parkin and DJ1 mutations [383, 384]. While these monogenic forms of PD account for a 
small number of total PD cases, they are more likely to be present in EOPD and therefore 
affect olfactory scores. Using arbitrary single point cut-offs classifies patients into either 
normosmic and hyposmic or normosmic and anosmic, depending upon which cut-off is used, 
but the fact is olfactory loss varies by degrees in the population and exists on a spectrum from 
mild, moderate and severe hyposmia through to anosmia (and functional olfactory loss) 
influenced by age and sex [379, 385]. We therefore classified patients in all clinical subtypes 
by grades of olfactory loss and gender. The British version of the UPSIT was used as the 
standard version (North American) contains some smells such as root beer, and words such as 
gasoline, that are not familiar in the British population. 
 
There are significant differences between EOPD and LOPD in motor, non-motor, cognitive 
and quality of life domains [378]. Previous reports indicate that there are significant 
differences in olfactory acuity in the 2 major motor subtypes of PD i.e. TDPD have higher 
UPSIT scores than PIGD  in both males and females but these reports have included a mix of 
EOPD and LOPD[376, 377] cases or have not clearly demarcated cases with a ‘Mixed’ motor 
subtype [376] or failed to demarcate  by age of onset [377]. Our analysis has taken account of 
these inconsistencies and we have appropriately analysed data by age at diagnosis, used a 
more homogeneous population with only EOPD cases and motor sub-typed all patients 
without ignoring those classified as ‘Mixed’. Prior studies by classifying PD into motor 
subtypes have also shown significant differences in the rate of cognitive decline [386], motor 
impulsivity [387], psychopathological features (anxiety and depression) [388], functional 
disability [179] and even mortality [389] providing evidence that these are not artificially 
created categories but different clinical subtypes with variations in motor, non-motor and 
cognitive domains. A correlation of olfactory loss with poor cognitive performance has been 
demonstrated in LOPD cases [390], our data showed similar results with a weak but 
statistically significant correlation between UPSIT and MOCA test scores. 
 
We confirmed that patients with EOPD also have differences in olfactory scores based on 
gender as has been reported for patients with late LOPD but we failed to find any significant 
differences in the UPSIT scores in patients based on motor subtypes, age at onset of PD 
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(within the EOPD cohort) and hereditary versus sporadic PD. Females scored better than 
males in all clinical subtypes examined in this study, clearly demonstrating gender 
differences in this variable in all subgroups. 
 
There are some limitations to our study. Although head trauma can cause olfactory 
dysfunction we did not exclude cases who gave a past history of head trauma without 
specifying that it showed a temporal relationship to their subjective loss of sense of smell. 
Our study was also limited by the fact that no anterior rhinoscopy was performed to 
specifically look out for local causes of airflow obstruction in the nose. We looked at cross-
sectional data for olfaction in the EOPD cohort and don’t have data about olfaction early in 
the disease course noting that earlier research indicates no relation of olfaction to disease 
duration[63] although some researchers have drawn opposite conclusions[66].  
 
In using the more recently available British version of the UPSIT, our results are less directly 
comparable to other studies in the United Kingdom [374] which have used the traditional 
North American version, but are more readily comparable to North American studies of 
olfaction in PD, or other country or region-specific versions of UPSIT. We consider the use 
of normative data based on the North American version to be reasonable, in the absence of 
similar data for the United Kingdom, as there is significant overlap between the smells used 
(30 of 40 odours are common to the 2 versions). 
 
Conclusion 
  
In early onset PD, motor subtyping, age at onset and hereditary versus sporadic nature of PD 
do not show significant differences in olfactory sores on the University of Pennsylvania smell 
identification test. More detailed studies are required to establish if there is a link in the 
pathology underlying the olfactory and cognitive dysfunction given the correlation in scores 
on tests recording these variables. 
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Chapter 9. Variation in cognitive problems in EOPD 
 
 
 
 
9.1 Objective 
 
The objective in this chapter is to analyse the variation in the cognitive problems in a cohort 
of patients with early onset Parkinson’s disease.  
 
9.2 Introduction 
 
Cognitive problems are common in Parkinson’s disease (PD) patients, the impairments 
caused affect quality of life and the ensuing problems with activities of daily living add 
significantly to the burden of disease. These problems exist on a spectrum from mild 
cognitive impairment to PD dementia (PDD). Longitudinal studies such as the Sydney 
multicentre study suggest that up to 80% of patients with PD eventually develop dementia 
[115]. PDD is treatable with cognition enhancers (cholinesterase inhibitors) and research in 
this field is an on-going enterprise in an effort to develop more specific therapies for PD-
related cognitive problems. 
 
 
9.3 Methods 
 
Patients attended 6 monthly clinic visits as per study protocol described in detail in Chapter 3. 
They were asked to fill in questionnaires for demographic data at baseline (visit 0). Patients 
were asked about their subjective feelings of impaired memory and concentration at visit 1 as 
part of their NMSS questionnaire. This was then compared with the results of objective 
testing with the Montreal cognitive assessment (MOCA) test at the same visit. Details of 
schooling or education for collation to MOCA test scores was obtained at visit 3 as part of a 
social history questionnaire.  
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Normal cognition based on MOCA test score was defined as greater than or equal to 26, 
cognitively impaired as defined as a score less than 26 which was further sub classified into 
mild cognitive impairment (MCI)  with a score less than  26 [391] but greater than or equal to 
20 and dementia with a score of less than 20 [392]. 
 
In order to analyse for the variation in non-motor phenotype of PD with respect to historical 
and examination findings all cases with EOPD were classified in 4  ways: according to motor 
subtypes (TDPD, PIGD and ‘Mixed’), gender, age at onset of PD symptoms and family 
history of Parkinson’s disease as described in Chapter 4. 
 
Statistical analysis: 
 
Descriptive data are presented as median and inter-quartile range (IQR) as data in most 
instances failed tests of normality (Shapiro Wilk). Kruskal Wallis test was used for inter-
group comparisons of numerical data in scenarios where cases where classified into 3 groups 
e.g. motor subtypes with post hoc comparisons between groups using Mann Whitney U if the 
Kruskal Wallis test statistic showed a significant difference between the 3 groups. Mann 
Whitney U test was used for inter-group comparisons of numerical data where cases were 
classified into 2 groups e.g. males and females. Chi square tests or Fisher’s exact tests were 
used for comparing groups for categorical data as appropriate. 
 
Generalised linear modelling, based on ANCOVA, was used with age ,disease duration and 
years of schooling as covariates to determine the effect of the motor subtype, gender, age at 
onset and hereditary versus sporadic parkinsonism (independent variables) on the MOCA test 
scores (dependent variable). Logarithmic transformations (log 10) of numerical data were 
used where tests of normality (Shapiro Wilk) failed.  
 
All statistical analyses were two-sided and significance level was set at 5%. Statistical tests 
were performed using Prism software (version 4.0 for Windows; CA, USA) and SPSS 
software (version 23 for Windows; IL, USA). 
 
190 
 
9.4 Results 
 
276 patients had completed all questionnaires relevant to this analysis and are included here 
(Figure 9.1). Their demographic details have been presented in Table 5.1 in Chapter 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1 shows the disoposition of cases prior to data analysis for this chapter. No data 
imputation was allowed. Those who had incomplete questionnaires relevant to this analysis 
were not included. 
 
The variation in the prevalence of cognitive problems in these patients, classified by motor 
subtype, is presented in Tables 9.1a and 9.1b. There were no statistically significant 
differences in the median MOCA test total scores (Figure 9.2) between the three motor 
subtypes (Table 9.1a) but using cut-offs to define “normal”, mild cognitive impairment and 
dementia, as defined in the methods section, showed significant differences between the 3 
motor subtypes (Figure 9.3). 
Initial recruitment 
target 
N= 240 
Incomplete 
questionnaires 
N=50 
Additional cases 
recrutited 
N= 86 
Full dataset 
available 
N= 276 
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Figure 9.2 shows the Montreal cognitive assessment (MOCA) test score (on the y-axis) and 
the motor subtype (on the x-axis). The line in the centre of the boxes represent the medians, 
the ends of the whiskers 2 standard deviations on either side and outliers are represented by 
dark circles. No significant differences were found in the the MOCA test scores between 
those with TDPD (n=155), PIGD (n=100) or ‘Mixed’ (n=21) motor subtypes (p=0.183) after 
adjusting for age, disease duration and years of schooling. 
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Figure 9.3 shows the proportion of patients who were cognitively normal, had mild cognitive 
impairment (MCI) or dementia (on the y-axis) as recorded on the MOCA test with respect to 
their motor subtype. 
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Post hoc tests showed more PIGD patients to be affected with cognitive impairment 
compared to TDPD (p=0.015) but not between TDPD and ‘Mixed’ (p=1.000) or between 
PIGD and ‘Mixed’ (p=0.339). Dementia was also more prevalent in the PIGD group 
compared to the TDPD group (p=0.013). No patients in the ‘Mixed’ subgroup were classified 
as demented (Table 9.1a). 
 
Table 9.1a Variation in cognitive profiles in patients (n=276) classified by motor subtype. 
 
Variable   TDPD  
mean (SD) 
  PIGD 
mean (SD) 
Mixed  
mean (SD) 
p- 
value 
Number of cases 155 100 21 - 
Age (at registration, in years) 49.8 (6.7)  54.4 (9.0) 50.5 (5.8) <0.001 
Sex (males) 67.7 % 59.0 % 65.0 % 0.356 
Disease duration (years) 6.2 (5.2)  10.8 (9.3) 7.8 (6.7)  <0.001 
Age at leaving school (years) 16.6 (1.0) 16.2 (1.0) 16.6 (1.1) 0.030 
Impaired concentration (s) 65.6 % 73.7 % 70.0 % 0.391 
Impaired memory (s) 75.5 % 82.8 % 80.0 % 0.380 
MOCA test score 25.9 (2.9) 24.4 (4.5) 26.4 (2.3) 0.183 
  Normal (≥ 26) 63.9 % 48.5 % 61.9 % - 
  Cognitive impairment (< 26) 36.1 % 51.5 % 38.1 % 0.049 
  MCI PD (≥ 20, < 26) 33.5 % 43.4 % 38.1 % 0.140 
  Dementia (< 20) 2.6 % 9.1 % 0 0.013 
SD= standard deviation.  MCI PD= Mild cognitive impairment Parkinson’s disease. Data are presented 
as mean (standard deviation) for comparison with normative data provided by the test publisher. (s) = 
self-reported 
 
 
Detailed analysis of the MOCA test scores showed significant differences between the 3 
motor subtypes in the domains of  language [sub-domains naming (p=0.001), category 
fluency (p=0.031)],  registration (p=0.020), short term memory as represented by delayed 
recall (p=0.029) but not working memory as represented by the forward and backward digit 
span (p=0.522). There were also statistically significant differences between the 3 sub-groups 
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in the domains of executive function [subdomain abstraction (p=0.022)] and visuospatial 
abilities as represented by copying a cube (p=0.042). 
 
 
Table 9.1b is a continuation of Table 9.1a and shows detailed analysis of MOCA test scores 
of patients (n=276) classified by motor subtype. 
Variable   TDPD  
mean (SD) 
  PIGD 
mean (SD) 
Mixed  
mean (SD) 
p- 
value 
Number of cases 155 100 21 - 
MOCA test scores     
         Trail 0.89 (0.31) 0.83 (0.38) 0.81 (0.40) 0.302 
         Cube 0.87 (0.34) 0.75 (0.44) 0.86 (0.36) 0.042 
         Clock 3.00 (1.00) 2.59 (0.73) 2.86 (0.36) 0.063 
         Pentagons*  0.93 (0.26) 0.89 (0.31) 1.00 (0.00) 0.199 
         Naming 2.99 (0.11) 2.87 (0.42) 3.00 (0.00) 0.001 
         Registration 4.75 (0.68) 4.40 (1.13) 4.71 (0.72) 0.020 
         Memory
†
      3.32 (1.39) 2.72 (1.78) 3.52 (1.36) 0.029 
         Digit span
‡
 1.86 (0.34) 1.84 (0.44) 1.95 (0.22) 0.522 
         Vigilance 0.90 (0.30) 0.89 (0.31) 0.99 (0.30) 0.939 
         Serial 7’s (attention) 2.37 (0.76) 2.22 (0.77) 2.48 (0.75) 0.116 
         Repetition 1.81 (0.47) 1.70 (0.59) 1.71 (0.64) 0.290 
         Lexical fluency 0.66 (0.47) 0.74 (0.44) 0.71 (0.46) 0.433 
         Category fluency* 
§
 23.97 (7.25) 21.44 (6.82) 23.1 (6.64) 0.031 
         Abstraction 1.75 (0.54) 1.53 (0.73) 1.81 (0.51) 0.022 
         Orientation 5.75 (0.77) 5.72 (0.79) 5.81 (0.40) 0.930 
SD = standard deviation.  Data are presented as mean (standard deviation) for comparison with 
normative data provided by the test publisher. * not part of Montreal cognitive assessment test, † delayed 
recall, ‡ working memory, §over 90 seconds 
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Post hoc analysis showed significant differences in naming between TDPD and PIGD 
(p<0.001) but not between PIGD and ‘Mixed’ (p=0.209) or TDPD and ‘Mixed’ (p=0.999). 
Similar results were obtained on post hoc tests for registration and delayed recall with 
significant differences between TDPD and PIGD (p=0.005, p=0.015) but not between PIGD 
and ‘Mixed’ (p=0.239, p=0.072) or TDPD and ‘Mixed’ (p=0.892, p=0.535). 
 
There were no differences in the median MOCA test total scores (Figure 9.4) and the 
proportion of patients with normal or impaired cognition, including dementia, between males 
and females (Figure 9.5, Table 9.2a) 
 
 
 
 
 
 
 
 
Figure 9.4 shows the Montreal cognitive assessment (MOCA) test score (on the y-axis) and 
the gender (on the x-axis) of the patients (n=276) in the EOPD cohort of the PRoBaND study. 
The line in the centre of the boxes represent the medians, the ends of the whiskers 2 standard 
deviations on either side and outliers are represented by dark circles. No significant 
differences were found in the MOCA test scores between males (n=177) and females (n=99) 
after adjusting for age, disease duration and years of schooling (p=0.331). 
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Table 9.2a Variation in cognitive profiles in patients (n=276) classified by gender. 
 
Variable Males 
    mean (SD) 
 Females 
    mean (SD) 
p- 
value 
Number of cases 177 99 - 
Age* (years) 51.6 (7.9) 51.4 (7.8) 0.968 
Age at leaving school (years) 16.5 (1.0) 16.5 (1.1) 0.737 
Disease duration (years) 7.9 (6.3) 8.1(7.3) 0.922 
Impaired concentration (s) 68.9 % 57.6 % 0.058 
Impaired memory (s) 76.3 % 70.7 % 0.311 
MOCA test score 25.4 (3.3) 25.8 (3.4)  0.331 
    Normal (≥ 26) 56.3 % 61.6 % 0.386 
    Cognitive impairment (< 26) 43.7 % 38.4 % 0.386 
    MCI PD (≥ 20, < 26) 38.1 % 36.4 % 0.602 
    Dementia (< 20) 5.7 % 2.0 % 0.214 
* Age at registration, SD = standard deviation.  MCI PD = Mild cognitive impairment Parkinson’s 
disease. Data are presented as mean (standard deviation) for comparison with normative data provided 
by the test publisher, (s) = self-reported 
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Figure 9.5 shows the proportion of patients who were cognitively normal, had mild cognitive 
impairment (MCI) or dementia (on the y-axis) as recorded on the MOCA test with respect to 
their gender. 
 
 
Detailed analysis of the MOCA test scores showed significant differences between the 2 
genders only in the visuospatial domain (p=0.042) as represented by asking the patients to 
copy a cube (Table 9.2b). 
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Table 9.2b is a continuation of Table 9.2a and shows detailed analysis of MOCA test scores 
of patients (n=276) classified by gender. 
 
Variable Males 
mean (SD) 
  Females 
    mean (SD) 
p- 
value 
Number of cases 177 99 - 
MOCA test scores    
         Trail 0.86 (0.35) 0.88 (0.33) 0.715 
         Cube 0.86 (0.34) 0.77 (0.42) 0.042 
         Clock 2.72 (0.57) 2.73 (0.62) 0.582 
         Pentagons* 0.92 (0.27) 0.93 (0.26) 0.791 
         Naming 2.95 (0.22) 2.97 (0.17) 0.547 
         Registration 4.57 (0.94) 4.76 (0.61) 0.116 
         Memory
†
      3.01 (1.59) 3.35 (1.48) 0.081 
         Digit span
‡
 1.90 (0.30) 1.82 (0.44) 0.139 
         Vigilance 0.90 (0.30) 0.91 (0.29) 0.835 
         Serial 7’s (attention) 2.35 (0.74) 2.31 (0.78) 0.802 
         Repetition 1.74 (0.53) 1.83 (0.50) 0.069 
         Lexical fluency 0.69 (0.46) 0.72 (0.45) 0.607 
         Category fluency* 
§
 23.17 (7.19) 22.90 (6.69) 0.653 
         Abstraction 1.65 (0.65) 1.73 (0.55) 0.512 
         Orientation 5.76 (0.73) 5.77 (0.55) 0.628 
SD = standard deviation.  Data are presented as mean (standard deviation) for comparison with 
normative data provided by the test publisher, * not part of Montreal cognitive assessment test, †delayed 
recall, ‡ working memory, §over 90 seconds 
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Classifying patients by age at onset of PD into those who had onset of PD age less than (or 
equal to) 40 years and those who had onset of PD after the age of 40 years also showed no 
differences in the median MOCA test total scores (Figure 9.6) and the proportion of patients 
with normal or impaired cognition, including dementia, between males and females (Figure 
9.7, Table 9.3a) 
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Figure 9.6 shows the Montreal Cognitive Assessment (MOCA) test score of the cases (on the 
y-axis) and age at onset of PD symptoms (on the x-axis). The line in the centre of the boxes 
represent the medians, the ends of the whiskers 2 standard deviations on either side and 
outliers are represented by dark circles. No significant differences were found in the MOCA 
test scores between those with age at onset of PD ≤ 40 years (n=64) and those with age at 
onset of PD > 40 years (n=212) after adjusting for age, disease duration and years of 
schooling (p=0.966). 
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Table 9.3a Variation in cognitive profiles in patients (n=276) classified by age at onset 
 of PD. 
Variable Age  onset  ≤ 40y 
mean (SD) 
Age  onset > 40y 
mean (SD) 
p- 
value 
Number of cases   64     212 - 
Age* ( years) 45.8 (9.4) 53.3 (6.4) <0.001 
Sex (males)   67.2 % 63.2 % 0.561 
Age at leaving school (years) 16.4 (1.1) 16.5 (1.1) 0.354 
Disease duration (years) 7.9 (8.6) 6.6 (5.8) 0.707 
Impaired concentration (s) 77.8 % 66.5 % 0.082 
Impaired memory (s) 81.0 % 77.5 % 0.591 
MOCA test score 25.03 (4.47) 25.53 (3.36) 0.966 
   Normal (≥ 26) 54.7 % 59.2 % 0.517 
   Cognitive impairment (< 26) 45.3 % 40.8 % 0.517 
   MCI PD (≥ 20, < 26) 43.8 % 35.5 % 0.325 
   Dementia (< 20) 3.1 % 5.2 % 0.737 
* Age at registration, SD = standard deviation.  MCI PD = Mild cognitive impairment Parkinson’s 
disease. Data are presented as mean (standard deviation) for comparison with normative data provided 
by the test publisher, (s) = self-reported 
 
 
 
 
 
Detailed analysis of the MOCA test scores showed no significant differences between the 2 
subgroups classified by age at onset of PD (Table 9.2b). 
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Table 9.3b is a continuation of Table 9.3a and shows detailed analysis of MOCA test scores 
of patients (n=276) classified by age at onset of PD. 
 
Variable Age onset ≤ 40 yrs. 
    mean (SD) 
Age onset > 40 yrs. 
      mean (SD)     
p- 
value 
Number of cases   64     212 - 
MOCA test scores    
         Trail 0.88 (0.33) 0.86 (0.35) 0.838 
         Cube 0.82 (0.39) 0.83 (0.38) 0.852 
         Clock 2.68 (0.71) 2.71 (0.61) 0.954 
         Pentagons*  0.89 (0.31) 0.93 (0.26) 0.431 
         Naming 2.91 (0.42) 2.94 (0.29) 0.600 
         Registration 4.57 (0.95) 4.61 (0.92) 0.463 
         Memory
†
      3.29 (1.47) 3.04 (1.61) 0.412 
         Digit span
‡
 1.78 (0.48) 1.87 (0.36) 0.100 
         Vigilance 0.83 (0.38) 0.92 (0.28) 0.057 
         Serial 7’s  2.34 (0.67) 2.31 (0.80) 0.759 
         Repetition 1.74 (0.59) 1.76 (0.53) 0.894 
         Lexical fluency 0.62 (0.49) 0.71 (0.45) 0.124 
         Category fluency* 
§
 22.82 (7.45) 23.00 (7.26) 0.917 
         Abstraction 1.62 (0.65) 1.68 (0.62) 0.324 
         Orientation 5.54 1.17) 5.78 (0.68) 0.070 
SD = standard deviation.  Data are presented as mean (standard deviation) for comparison with 
normative data provided by the test publisher, * not part of Montreal cognitive assessment test, †delayed 
recall, ‡ working memory, §over 90 seconds 
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Figure 9.7 shows the proportion of patients who were cognitively normal, had mild cognitive 
impairment (MCI) or dementia (on the y-axis) as recorded on the MOCA test with respect to 
their age at onset of PD. 
 
There were no statistically significant differences in the MOCA test scores between those 
with and without a positive family history of PD (Figure 9.8)  and the proportion of patients 
with normal or impaired cognition, including dementia, between the 2 sub-groups ( Figure 
9.9, Table 9.4a). 
 
 
Figure 9.8 shows the Montreal Cognitive Assessment (MOCA) test score of the cases (on the 
y-axis) and the family history of PD (on the x-axis). The line in the centre of the boxes 
represent the medians, the ends of the whiskers 2 standard deviations on either side and 
outliers are represented by dark circles. No significant differences were found in the MOCA 
test scores between those with familial PD (n=64) and those with sporadic PD (n=212) after 
adjusting for age, disease duration and years of schooling (p=0.486). 
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Table 9.4a Variation in cognitive profiles in patients (n=276) classified by family history 
 of PD. 
Variable         Positive FH 
   mean (SD) 
     Negative FH 
      mean (SD) 
p- 
value 
Number of cases 64 212 - 
Age (at registration, in years) 52.1 (7.8)  51.3 (7.8)  0.582 
Sex (males) 65.6% 63.7% 0.776 
Age at leaving school (years*) 16.6 (1.1)  16.5 (1.0)  0.444 
Disease duration (years) 8.7 (7.1)  7.8 (6.5)  0.312 
Impaired concentration (s) 68.2% 67.5% 0.968 
Impaired memory (s) 72.7% 77.8% 0.466 
MOCA test score 25.9 (2.6)  25.3 (3.9) 0.486 
     Normal (≥ 26) 62.1% 56.9% 0.424 
    Cognitive impairment (< 26) 37.9% 43.1% 0.424 
    MCI PD (≥ 20, <26) 35.9 % 37.9 % 0.620 
    Dementia (< 20) 1.6 % 5.7 % 0.306 
FH = family history, * = standard deviation.  MCI PD = Mild cognitive impairment Parkinson’s disease. Data are 
presented as mean (standard deviation) except where indicated, * median (inter-quartile range), (s) = self-reported. 
 
 
 
 
 
Detailed analysis of the MOCA test scores showed significant differences between the 2 sub-
groups only in the visuospatial domain (p=0.038) as represented by asking the patients to 
copy a cube (Table 9.4b). This was also evident in the item of copying 2 intersecting 
pentagons adapted from the mini mental status exam (p=0.033) (Table 9.4 b) 
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Table 9.4b is a continuation of Table 9.4a and shows detailed analysis of MOCA test  
scores of patients (n=276) classified by family history of PD. 
 
Variable Positive FH 
mean (SD) 
Negative FH 
mean (SD) 
p- 
value 
Number of cases 64 212 - 
MOCA test scores    
         Trail 0.94 (0.24) 0.84 (0.37) 0.060 
         Cube 0.74 (0.44) 0.85 (0.35) 0.038 
         Clock 2.82 (0.43) 2.68 (0.65) 0.246 
         Pentagons*  0.98 (0.12) 0.90 (0.30) 0.033 
         Naming 2.97 (0.17) 2.94 (0.29) 0.506 
         Registration 4.76 (0.58) 4.58 (0.95) 0.215 
         Memory
†
      3.30 (1.51) 3.05 (1.59) 0.230 
         Digit span
‡
 1.86 (0.35) 1.86 (0.39) 0.906 
         Vigilance 0.95 (0.21) 0.88 (0.32) 0.154 
         Serial 7’s (attention) 2.38 (0.63) 2.31 (0.80) 0.959 
         Repetition 1.74 (0.54) 1.77 (0.53) 0.701 
         Lexical fluency 0.61 (0.49) 0.72 (0.45) 0.087 
         Category fluency* 
§
 23.67 (7.25) 22.84 (7.15) 0.499 
         Abstraction 1.77 (0.52) 1.64 (0.65) 0.128 
         Orientation 5.79 (0.41) 5.73 (0.83) 0.581 
FH = family history, SD = standard deviation.  Data are presented as mean (standard deviation) for 
comparison with normative data provided by the test publisher, * not part of Montreal cognitive 
assessment test, †delayed recall, ‡ working memory, §over 90 seconds 
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Figure 9.9 shows the proportion of patients who were cognitively normal, had mild cognitive 
impairment (MCI) or dementia (on the y-axis) as recorded on the MOCA test with respect to 
their family history (FH) of PD. 
 
9.5 Discussion 
 
 
Cognitive impairment is common in Parkinson’s disease (PD), with long-term longitudinal 
studies reporting that most patients will develop dementia if they live long enough. The long-
term  prevalence of dementia in PD from the Sydney multicentre study at 10 years was 38% , 
67% at 15 years and 80 % at 20 years in those who were still alive [115]. In the world of 
dementia, few phrases are more likely to polarise opinion than ‘mild cognitive impairment’ 
(MCI) [393]. Some have argued that while cognitive deficits in PD could be due to Lewy 
body pathology and represent the earliest stages of PD dementia (PDD), but these deficits 
theoretically could also occur due to dynamic changes in neurotransmitter networks (e.g. 
dopaminergic pathways) and/or non-PD pathology. As such, defining a PD patient as having 
MCI (MCI-PD) may not necessarily help in predicting prognosis or clinical course [393]. 
Others have argued exactly the opposite, that the identification of MCI-PD is important, 
because it can predict the future development of PDD [394]. Irrespective of the ‘baggage’ 
associated with the term MCI and its definition in PD, there seems little doubt that early 
cognitive impairment in PD, insufficient to merit a diagnosis of PDD, impacts adversely upon 
patients’ self-perceived health status, their ability to undertake activities of daily living and 
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the strain placed upon their caregivers [395]. MCI-PD is a significant, independent factor 
contributing to poorer quality of life in patients with newly diagnosed PD. Those classified 
with greatest impairment (2.0 SD below normal values) have lower quality of life. This has 
implications for clinical practice and future interventions targeting cognitive impairments 
[395]. MCI-PD is common in non-demented patients with PD (mean prevalence: 27%; range: 
19%–38%) [396] affecting a range of cognitive domains, including memory, visual-spatial, 
and attention/executive abilities with slightly higher figures emerging from more recent data 
such as the ICICLE-PD study. This study reported figures of 42.5% even in newly diagnosed 
patients [397]. In the Norwegian Park West study, using the same criteria i.e. 1.5 standard 
deviation (SD) below mean for normal healthy controls, this roughly translated to a twofold 
increase in the proportion with cognitive impairment in subjects with early, untreated PD 
compared to normal healthy controls [398].  Our study, in the absence of normal healthy 
controls used the original criteria proposed by the MOCA test authors assigning a cut off 
value of 26 to define MCI [391] and < 20 to define dementia which have been validated in a 
PD population [392] , the comparison between groups was adjusted for age, disease duration 
and educational status . The prevalence of MCI- PD in the EOPD cohort from PRoBaND 
ranged from 33.5%- 43.8% based on sub-group analysed (Tables 9.1-9.4) ) The prevalence of 
PD dementia in the EOPD cohort from PRoBaND ranged from 0-9.1% based on sub-group 
analysed  (Tables 9.1-9.4 ) 
 
This variation in the prevalence of cognitive impairment partly reflects differences in disease 
duration but there is also recognition that there are differences in cognitive impairment 
between motor subtypes. The PIGD motor subtype is associated with a faster rate of 
cognitive decline in PD and may be considered a risk factor for incident dementia in PD 
[386]. Our results replicated this finding and showed the prevalence of cognitive impairment 
(p= 0.049) and dementia (p=0.013) were highest in this motor subtype (Table 9.1) 
 
Sub-item analysis of the MOCA test scores showed significant differences were found on 
five of six domains, specifically visuospatial, executive, language, memory and attention 
(concentration) with no significant differences in orientation scores (Table 9.2). 
 
MOCA test was used specifically because the alternative instrument, mini mental status 
examination (MMSE) is handicapped by a lack of adequate representation of executive 
function tests and these deficits can occur in about a third of patients with PD [399] 
206 
 
Impairments in executive function, attention, visuospatial skills, and memory characterize the 
“typical” cognitive profile in PD, whereas language and praxis are thought to be relatively 
spared [400].  
 
In the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD) of 
873 PD patients there were no differences on the  MMSE or the  Parkinson 
Neuropsychometric Dementia Assessment (PANDA) total score between males and females 
[127], however,  subtle differences emerge when more detailed psychometric tests are 
administered [401-403]. We found no statistically significant differences in the MOCA test 
scores or the proportion of cases classified as cognitively normal, MCI-PD and demented 
between the 2 sub-groups.  
 
Sub-item analysis of the MOCA test scores showed significant differences were found in 
only one of six  domains, specifically visuospatial domain (Table 9.2b) with males 
performing better on the visuospatial task compared to females(p=0.042). 
 
The age of onset of PD is reported to influence the development of cognitive problems with 
older age onset significantly associated with the development of dementia [370] . Our results 
showed no significant differences in the proportion of patients with either mild cognitive 
impairment (p=0.325) or dementia (p=0.737) between those who had onset of disease before 
40 years of age compared to those who had onset of disease between the ages of 40 and 50 
years in the EOPD cohort. 
 
Sub-item analysis of the MOCA test scores also showed no significant differences in any of 
the six domains assessed (Table 9.3b). 
 
The influence of family history in PD on the onset of dementia has been previously reported. 
The onset of dementia was significantly earlier in those with no family history of PD 
compared to those with a family history of PD [404]. Our results showed no statistically 
significant differences in the MOCA test scores or the proportion of cases classified as 
cognitively normal, MCI-PD and demented between the 2 sub-groups. Sub-item analysis of 
the MOCA test scores showed significant differences in only one of six domains, specifically 
visuospatial domain. Cases with a positive family history of PD performed poorly on the 
visuospatial task compared to those with sporadic PD (p=0.038) (Table 9.2b). 
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The mechanisms responsible for the variation in the cognitive scores, beyond the effects of 
age, disease duration and education levels are largely not known. One hypothesis suggests 
that the heterogeneous cholinergic denervation, in addition to the well-recognised 
dopaminergic denervation, may account for some of the variability. Previous studies have 
reported cognitive correlates of cortical cholinergic denervation [405, 406]. On the other hand 
dopamine levels in frontal regions may influence the fronto-striatal cognitive circuits which 
may contribute to some of the cognitive deficits. The catechol-O-methyltransferase (COMT) 
Val (158) Met polymorphism modulates fronto-cortical dopamine turnover in early PD 
according to a PET study.  COMT is the main mode of inactivation for dopamine in frontal 
areas. Met homozygotes have higher presynaptic dopamine levels in frontal regions than Val 
homozygotes, which may also help to explain how genotypic variation may influence the 
fronto-striatal cognitive deficits of PD [407]. Some have investigated brain volumetric 
correlates of memory in early PD and found right parietal cortical grey matter volume is 
related to free recall memory deficits [408]. The same group also found striatal volume being 
related to phonemic verbal fluency in another study [409]. A final piece of evidence for the 
differences in the biological substrates of PD is that the levels alpha-synuclein, the protein 
that is central to the degenerative process in PD, measured in the more advanced PD stages 
decreased in men, but not in women. Further, in men only, plasma alpha-synuclein 
concentration was associated with cognitive impairments, hallucinations, and sleep disorders 
in this study underlining  the gender-related differences [410]. One could therefore 
conceptualise that natural variation that might occur in the expression of all these underlying 
biological substrates could explain at least in part if not all of the variability. Further studies 
would be required to determine the other so far unexplained determinants of the 
heterogeneity of cognitive dysfunction in PD. 
 
9.6 Conclusion 
 
Dementia in the late stages of PD is common. MCI-PD almost always precedes the onset of 
dementia but there is some debate as to whether all those with MCI-PD go on to develop 
dementia. Nevertheless, recognition of MCI-PD is important but more importantly some 
phenotypes of PD e.g the PIGD group are even at a greater risk than others. Focussing on this 
group at its initial stage will enable clinicians to better inform patients about prognosis and to 
allow these patients the benefits of therapeutic intervention.  
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Chapter 10. Variation in neuropsychiatric symptoms in EOPD 
 
 
 
 
10.1 Objective 
 
The objective in this chapter is to analyse the variation in the neuropsychiatric and 
behavioural characteristics and risk factors in a cohort of patients with early onset 
Parkinson’s disease.   
 
10.2 Introduction 
 
Behavioural symptoms such as anxiety and neuropsychiatric problems like depression and 
psychosis are common in PD. While anxiety and depression can arise de novo and can be part 
of the premotor syndrome, psychosis and impulse control problems are usually seen as a 
complication of dopaminergic therapy .These symptoms can sometimes cause more distress 
to the patents than the motor dysfunction caused by PD. They negatively impact on the 
quality of life, can cause caregiver distress and may lead to care home placement [411].  
 
10.3 Methods 
 
Patients attended 6 monthly clinic visits as per study protocol described in detail in Chapter 3. 
They were asked to fill in questionnaires for demographic data at baseline (visit 0). Data 
required for determining the prevalence of important depressive screening features such as 
anhedonia and flat affect and important psychotic phenomena such as delusions and 
hallucinations were collected from patient filled NMSS at visit 1. Patients also filled in a 
questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) [412] at visit 
1 and the responses were used as a measure of the prevalence of impulse control symptoms 
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such as overeating, overspending, hyper sexuality and gambling  in this cohort. A subjective 
assessment of patient’s perspective whether they believe to suffered from anxiety and 
depression was determined from responses to relevant questions in the NMSS, this was then 
more objectively contrasted with the scores obtained on validated Leeds Scales for the Self-
Assessment of Anxiety  (Leeds SAA) and Depression (Leeds SAD) [413]. Each of these 
scales has 6 questions with 4 responses and these are scored 1-4. A total score for each scale 
is obtained by adding the individual scores to each question. Further, those with scores <7 on 
each scale are classified as normal while those with scores ≥ 7 on the Leeds SAD scale are 
classified as depressed while those with a score ≥ 7 on the Leeds SAA scale are classified as 
suffering from anxiety.  
 
In order to analyse the variation in clinical phenotype of PD with respect to historical and 
objective examination based findings all cases with EOPD were classified according to motor 
subtypes (TDPD, PIGD, ‘Mixed’), gender, age at onset and heritability of the parkinsonian 
trait as described in Chapter 4. 
 
Statistical analysis: 
 
Descriptive data are presented as median and inter-quartile range (IQR) as data in most 
instances failed tests of normality (Shapiro Wilk). Kruskal Wallis test was used for inter-
group comparisons of numerical data in scenarios where cases where classified into 3 groups 
e.g. motor subtypes with post hoc comparisons between groups using Mann Whitney U if the 
Kruskal Wallis test statistic showed a significant difference between the 3 groups. Mann 
Whitney U test was used for inter-group comparisons of numerical data where cases were 
classified into 2 groups e.g. males and females. Chi square tests or Fisher’s exact tests were 
used for comparing groups for categorical data as appropriate. 
 
All statistical analyses were two-sided and significance level was set at 5%. Statistical tests 
were performed using Prism software (version 4.0 for Windows; CA, USA). 
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10.4 Results 
 
276 patients had completed all questionnaires relevant to the behavioural symptoms and 269 
of those patients had completed all questionnaires related to the neuropsychiatric symptoms 
(Figure 10.1). Their demographic details have been presented in Table 5.1 in Chapter 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
 
        Behavioural symptoms                                                        Neuropsychiatric symptoms 
 
 
Figure 10.1 shows the disoposition of cases prior to data analysis for this chapter. No data 
imputation was allowed. Those who had incomplete questionnaires relevant to this analysis 
were not included. 
Initial recruitment 
target 
N = 240 
Incomplete 
questionnaires 
N = 57 
Additional cases 
recrutited 
N = 86 
Incomplete 
questionnaires 
N = 50 
Full dataset 
available 
N = 269 
Full dataset 
available 
N = 276 
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The variation in the prevalence of neuropsychiatric problems in these patients, classified by 
motor subtype, is presented in Table 10.1a. There were no statistically significant differences 
in the prevalence of neuropsychiatric symptoms of anhedonia (Figure 9.2) or delusions 
(Figure 9.3) between the three motor subtypes. 
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Figure 10.2 shows the proportion of patients who reported anhedonia, using the NMSS 
questionnaire, (on the y-axis) and their motor subtype (on the x-axis). The top of the boxes 
represent the proportion of cases reporting anhedonia, as indicated on the y-axis, and the 
whiskers represent the 95% confidence limits of proportion. 
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Figure 10.3 shows the proportion of patients who reported delusions, using the NMSS 
questionnaire, (on the y-axis) and their motor subtype (on the x-axis). The top of the boxes 
represent the proportion of cases with delusions, as indicated on the y-axis, and the whiskers 
represent the 95% confidence limits of proportion. 
 
There were no significant differences in the proportion of cases reporting impulse control 
problems such as gambling, overeating, overspending, hypersexuality or self-medicating 
behaviours in between the three groups (Figures 10.4 and 10.5, Table 10.1b) 
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Figure 10.4 shows the proportion of patients who reported overspending, using the QUIP 
questionnaire, (on the y-axis) and their motor subtype (on the x-axis). The top of the boxes 
represent the proportion of cases who reported over spending, as indicated on the y-axis, and 
the whiskers represent the 95% confidence limits of proportion 
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Figure 10.5 shows the proportion of patients who reported hypersexuality, using the QUIP 
questionnaire, (on the y-axis) and their motor subtype (on the x-axis). The top of the boxes 
represent the proportion of cases who reported hypersexuality, as indicated on the y-axis, and 
the whiskers represent the 95% confidence limits of proportion. 
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Table 10.1a Variation in prevalence of neuropsychiatric symptoms in patients (n=269) 
classified by motor-subtype. 
 
Variable  TDPD 
 median (IQR) 
 PIGD 
median (IQR) 
Mixed  
median (IQR) 
p- 
value 
Number of cases 151 98 20  
Age* ( in years) 50.4 (45.1-54.2) 54.6 (48.8-59.7) 49.1 (46.8-52.2) <0.001 
Sex (males) 66.9 % 58.2 % 65.0 % 0.373 
Duration (years) 4.7 (1.9-9.6) 9.1 (4.6-15.2) 6.5 (2.4-11.8) <0.001 
 Anhedonia 39.1 % 44.9 % 60.0 % 0.178 
 Flat affect 51.7 % 56.1 % 55.0 % 0.781 
 Delusions 7.3 % 15.3 % 10.0 % 0.129 
 Hallucinations(visual) 30.5 % 40.8 % 40.0 % 0.218 
Anxiety  
  Subjective 43.0 % 53.1 % 55.0 % 0.238 
  Objective✝  31.6% 33.6% 12.8% 0.002 
Depression  
  Subjective 59.6% 59.2% 55.0% 0.925 
  Objective
‡
 27.4% 29.9% 11.4% 0.006 
* Age at registration, IQR = inter-quartile range, † using Leeds SAA general scale for anxiety as follows:  
normal (0-6), abnormal (≥7); ‡ using Leeds SAD general scale scoring for depression as follows: normal 
(0-6), abnormal (≥7) [413]  
 
 
 
 
 
Post-hoc analysis showed the prevalence of anxiety symptoms using the Leeds SAA general 
scale was greater in the TDPD compared to the Mixed motor subtype (p=0.001), greater in 
the PIGD compared to the Mixed motor subtype (p <0.001) but there were no statistically 
significant differences between TDPD and PIGD subtypes (p=0.692). 
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Post-hoc analysis showed the prevalence of depressive symptoms using the Leeds SAD 
general scale was greater in the TDPD compared to the Mixed motor subtype (p=0.001), 
greater in the PIGD compared to the Mixed motor subtype (p <0.001) but there were no 
statistically significant differences between TDPD and PIGD subtypes (p=0.692). 
 
 
Table 10.1b Variation in prevalence of behavioural symptoms in patients (n=269) classified 
by motor-subtype. 
 
 
Variable    TDPD  
median (IQR)  
   PIGD 
median (IQR)  
Mixed subtype 
 median (IQR) 
p- 
value 
Number of cases 155 100 21  
Age* ( in years) 50.4 (45.1-54.3) 54.6 (48.8-59.8) 49.6 (46.9-52.5) <0.001 
Sex (males) 67.7 %  59 %  65 %  0.356 
Duration (years) 5.1 (2.0-9.6) 9.1 (4.6-15.0) 7.4 (2.5-11.8) <0.001 
  Over-eating 17.4 % 21.0 % 19.0 % 0.775 
  Over-spending 24.5 % 20.0 % 38.1 % 0.203 
  Hypersexuality 23.2 % 21.0 % 38.1 % 0.242 
  Gambling 16.8 % 22.0 % 33.3 % 0.165 
  Self-medication 5.8 % 10.0 % 4.8 % 0.407 
DA (%) 63.9 % 63.0 % 42.9 % 0.171 
LEDD (mg/day) 599 (300-965) 840 (532-1043) 738 (538-1053) 0.003 
* Age at registration, IQR = inter-quartile range, DA = dopamine agonists, LEDD = levodopa equivalent 
daily dose 
 
216 
 
There were no differences in any of the neuropsychiatric symptoms subjectively or 
objectively (Table 10.2a, Figures 10.6 and 10.7) between males and females. 
 
Figure 10.6 shows the Leeds SAA scale score (on the y-axis) and the gender (on the x-axis). 
The line in the centre of the boxes represent the medians, the ends of the whiskers 2 standard 
deviations on either side and outliers are represented by dark circles. No significant 
differences were found between males (n=171) and females (n=98) (p=0.442). 
 
 
 
 
Figure 10.7 shows the Leeds SAD scale score (on the y-axis) and the gender (on the x-axis). 
The line in the centre of the boxes represent the medians, the ends of the whiskers 2 standard 
deviations on either side and outliers are represented by dark circles. No significant 
differences were found between males (n=171) and females (n=98) (p=0.988). 
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Table 10.2a Variation in prevalence of neuropsychiatric symptoms in patients (n=269) 
classified by gender. 
 
Variable Males 
   median (IQR) 
   Females 
   median (IQR) 
p- 
value 
Number of cases 171 98 - 
Age* (years)     51.4 (46.2-56.4)    51.0 (47.2-55.5) 0.945 
Disease duration (years)     7.3 (2.7-11.5)    6.1 (2.5-12.2) 0.852 
 Anhedonia 45.6 % 37.8 % 0.209 
 Flat affect 53.2 % 67.4 % 0.891 
 Delusions 10.5 % 10.2 % 1.000 
 Hallucinations (visual) 36.3 % 32.7 % 0.596 
Anxiety  
  Subjective 48.6% 52.5% 0.530 
  Objective† 35.1% 30.5% 0.351 
Depression  
  Subjective 56.5% 65.7% 0.136 
  Objective
‡
 32.0% 25.8% 0.194 
* Age at registration, IQR = inter-quartile range, † using Leeds SAA general scale for anxiety as follows:  
normal (0-6), abnormal (≥7); ‡ using Leeds SAD general scale scoring for depression as follows: normal 
(0-6), abnormal (≥7) [413]. 
 
 
 
The were no significant differences in the proportion of cases reporting impulse control 
problems such as gambling, overeating, overspending, hypersexuality or self-medicating 
behaviours in between the two groups (Table 10.2b). 
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Table 10.2b Variation in prevalence of behavioural symptoms in patients (n=269) classified 
by gender. 
 
Variable    Males 
     median (IQR)  
    Females 
     median (IQR)  
p- 
value 
Number of cases   177  99 - 
Age *  (years)       51.7 (46.5-56.8)     51.1 (47.2-55.6) 0.968 
Disease duration (years)       7.3 (2.8-11.5)      6.5 (2.6-11.9) 0.737 
  Over-eating 19.8 % 17.2 % 0.937 
  Over-spending 23.2 % 25.3 % 0.696 
  Hypersexuality 15.9 % 13.1 % 0.535 
  Gambling 21.5 % 13.1 % 0.087 
  Self-medication 9.0 % 4.0 % 0.124 
DA (%) 58.2 % 68.7 % 0.085 
LEDD (mg/day) 760 (400-1030) 600 (328-986) 0.136 
 * Age at registration, IQR = inter-quartile range, DA = dopamine agonists, LEDD = levodopa equivalent 
daily dose. 
 
 
 
 
 
 
There were no differences in any of the neuropsychiatric symptoms (Table 10.3a) 
subjectively or objectively (Figures 10.8 and 10.9), between those diagnosed with PD before 
the age of 40 years and those diagnosed with PD after the age of 40 years except the 
prevalence of anxiety, objectively recorded using the Leeds SAA scale, was greater in those 
diagnosed with PD after the age of 40 years (p=0.027). 
 
 
 
 
 
 
219 
 
A g e  o n s e t   4 0 y A g e  o n s e t >  4 0 y
0
5
1 0
1 5
2 0
L
e
e
d
s
 S
A
A
 s
c
o
r
e
A g e  o n s e t   4 0 y
A g e  o n s e t >  4 0 y
 
 
Figure 10.8 shows the Leeds SAA scale score (on the y-axis) and the age at onset of PD (on 
the x-axis). The line in the centre of the boxes represent the medians, the ends of the whiskers 
2 standard deviations on either side and outliers are represented by dark circles. No 
significant differences were found between those with age at onset of PD ≤ 40 years (n=63) 
compared to those with age at onset of PD > 40 years (n=206) (p=0.737). 
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Figure 10.9 shows the Leeds SAD scale score (on the y-axis) and the age at onset of PD (on 
the x-axis). The line in the centre of the boxes represent the medians, the ends of the whiskers 
2 standard deviations on either side and outliers are represented by dark circles. No 
significant differences were found between those with age at onset of PD ≤ 40 years (n=63) 
compared to those with age at onset of PD > 40 years (n=206) (p=0.539). 
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Table 10.3a Variation in prevalence of neuropsychiatric symptoms in patients (n=269) 
classified by age at onset of PD. 
 
Variable Age onset ≤ 40 yrs. 
   median (IQR) 
   Age onset > 40yrs 
   median (IQR)     
p- 
value 
Number of cases  63    206 - 
Age* ( in years) 44.6 (40.2-50.8) 52.9 (48.8-57.0) <0.001 
Sex (males)  67.2% 63.2% 0.559 
Disease duration (years)  7.9 (3.7-15.0) 6.6 (2.5-11.3) 0.049 
 Anhedonia 50.8 % 40.3 % 0.140 
 Flat affect 61.9 % 51.0 % 0.127 
 Delusions 12.7 % 9.7 % 0.486 
 Hallucinations (visual) 34.9 % 45.6 % 0.133 
Anxiety  
  Subjective 50.8 % 46.6 % 0.559 
  Objective† 25.4 % 37.0 % 0.027 
Depression  
  Subjective 60.3 % 58.7 % 0.823 
  Objective‡  22.9 % 32.6 % 0.055 
* Age at registration, IQR = interquartile range,† using Leeds SAA general scale for anxiety as follows:  
normal (0-6), abnormal (≥7); ‡ using Leeds SAD general scale scoring for depression as follows: normal 
(0-6), abnormal (≥7) [413].  
 
 
 
 
The were no significant differences in the proportion of cases reporting impulse control 
problems such as gambling, overeating , overspending or self-medicating behaviours in 
between the two groups. The only significant difference was that about one third of patients 
diagnosed with PD before the age of 40 years reported hyper sexuality compared to about one 
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fifth of those diagnosed with PD after the age of 40 years in the EOPD cohort (p=0.046) 
(Table 10.3 b) 
 
Table 10.3b Variation in subjective and objective assessment of neuropsychiatric symptoms 
in patients (n=269) classified by age at onset of PD. 
 
Variable  Age onset ≤ 40 yrs Age onset > 40 yrs p- value 
Number of cases  64    212 - 
Age* ( in years) 44.6 (40.2-50.8) 52.9 (48.8-57.0) <0.001 
Sex (males)    67.2%  63.2% 0.561 
Disease duration (years)    7.9 (3.7-15.0)   6.6 (2.5-11.3) 0.707 
  Over-eating 21.9 % 17.9 % 0.479 
  Over-spending 23.4 % 24.1 % 0.919 
  Hypersexuality 32.8 % 20.8 % 0.046 
  Gambling 21.9 % 19.3 % 0.721 
  Self-medication 12.5 % 5.7 % 0.094 
DA (%) 60.9 % 62.3 % 0.848 
LEDD (mg/day) 700 (363-998) 715 (400-1008) 0.659 
* Age at registration, IQR = interquartile range, DA = dopamine agonists, LEDD = levodopa equivalent 
daily dose 
 
 
 
 
 
There were statistically significant differences in the prevalence of anxiety (p=0.022) and 
depression (p=0.014) recorded objectively using the Leeds SAA and SAD scales (Figures 
10.10 and 10.11), in between those cases with a positive family history PD compared to those 
with negative family history of PD, both symptom complexes being more prevalent in those 
with sporadic PD i.e. no family history of PD (Table 10.4a). 
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Figure 10.10 shows the Leeds SAA scale score (on the y-axis) and the family history of PD 
(on the x-axis). The line in the centre of the boxes represent the medians, the ends of the 
whiskers 2 standard deviations on either side and outliers are represented by dark circles. No 
significant differences were found between those with familial PD (n=63) compared to those 
with sporadic PD (n=206) (p=0.664). 
 
 
 
Figure 10.11 shows the Leeds SAD scale score (on the y-axis) and the family history of PD 
(on the x-axis). The line in the centre of the boxes represent the medians, the ends of the 
whiskers 2 standard deviations on either side and outliers are represented by dark circles. No 
significant differences were found between those with familial PD (n=63) compared to those 
with sporadic PD (n=206) (p=0.899). 
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Table 10.4a Variation in prevalence of neuropsychiatric symptoms in patients (n=269) 
classified by family history of PD. 
 
Variable    Positive FH 
  median (IQR) 
   Negative FH 
     median (IQR) 
p- 
value 
Number of cases 63 206 - 
Age *( in years) 52.3 (47.4-56.8) 51.0 (46.9-55.7) 0.296 
Sex (males) 65.1% 63.1% 0.776 
Disease duration (years) 6.9 (3.5-12.3) 6.7 (2.3-11.3) 0.239 
 Anhedonia 42.9 % 42.7 % 0.985 
 Flat affect 54.0 % 53.4 % 0.937 
 Delusions 9.5 % 10.7 % 1.000 
 Hallucinations (visual) 34.9% 33.0% 0.779 
Anxiety  
  Subjective 50.8 % 46.6 % 0.559 
  Objective† 25.0% 36.9% 0.022 
Depression  
  Subjective 57.1 % 59.7 % 0.717 
  Objective‡  21.0% 33.5% 0.014 
FH = family history, * Age at registration, IQR= inter-quartile range.  Data are presented as median 
(inter-quartile range) except where indicated. † using Leeds SAA general scale for anxiety as follows:  
normal (0-6), abnormal (≥7); ‡ using Leeds SAD general scale scoring for depression as follows: normal 
(0-6), abnormal (≥7) [413].  
 
 
 
 
 
The were no significant differences in the proportion of cases reporting impulse control 
problems such as gambling, overeating , overspending or self-medicating behaviours in 
between the two groups (Table 10.4b). 
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Table 10.4b Variation in prevalence of behavioural symptoms in patients (n=269) classified 
by family history of PD. 
 
Variable    Positive FH 
  median (IQR) 
   Negative FH 
     median (IQR) 
p- 
value 
Number of cases 63 206 - 
Age *( in years) 52.3 (47.4-56.8) 51.0 (46.9-55.7) 0.582 
Sex (males) 65.1% 63.1% 0.776 
Disease duration (years) 6.9 (3.5-12.3) 6.7 (2.3-11.3) 0.312 
  Over-eating 18.8 % 18.9 % 0.983 
  Over-spending 23.4 % 24.1 % 0.125 
  Hyper sexuality 29.7 % 21.7 % 0.187 
  Gambling 18.8 % 20.3 % 0.859 
  Self-medication 3.1 % 8.5 % 0.178 
DA (%) 60.9 % 62.3 % 0.848 
LEDD (mg/day) 824 (460-1033) 655 (400-1000) 0.135 
FH = family history, * Age at registration, IQR = interquartile range, DA = dopamine agonists, LEDD = 
levodopa equivalent daily dose 
 
 
 
10.5 Discussion 
 
Using rigid criteria such as DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition ) may miss a substantial number of cases with neuropsychiatric symtpoms 
[414], particularly those with a sub-syndromal diagnosis, who may end up not being treated 
even when symptoms are significantly affecting quality of life, therefore a more inclusive 
approach is advocated, nevertheless some objective measures and clinimetric scales to 
quantify the prevalence and severity of these problems in the PD population are are required 
for practical purposes. There are several scales that can be used for each diagnostic category. 
The choice of scale depends on several factors like ease of use, applicability to the population 
in question and the research question being answered. The scales for depression and anxiety 
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i.e. Leeds SAA and SAD scales used in this chapter had been chosen as these are validated 
instruments that are used in similar large scale epidemiological studies such as the Oxford 
Parkinson disease centre (OPDC) discovery cohort such that datasets could be shared for 
cross-comparisons and meta-analysis, while recognising the fact that other research groups 
have used different scales. 
 
The influence of the motor subtype on neuropsychiatric features such as depression and mood  
has been investigated, with the PIGD subtype reported to have a greater association with 
depression compared to TDPD [415] but other studies such as the PROMS-PD study found 
no statistically significant difference in the proportion of patients classified as depressed or 
anxious using the HADS scales [416]. Our results, however, showed the prevalence of 
depression using the Leeds SAD scale was greater in both TDPD (p = 0.001) and PIGD (p 
<0.001) compared to the ‘Mixed’ motor subtype but no significant differences were found 
between the TDPD and PIGD subtypes (p=0.692). Using the Leeds SAA scale, we also found 
the prevalence of depression using the Leeds SAD scale was greater in both TDPD (p=0.001) 
and PIGD (p <0.001) compared to the ‘Mixed’ motor subtype but no significant differences 
were found between the TDPD and PIGD subtypes (p=0.692). 
 
In one previous study of neuropsychiatric symptoms in PD gender did not seem to have an 
influence on the prevalence of symptoms in the mood and apathy clusters from the NPI [417] 
but another study, using GDS found the female gender to be significantly associated with 
depressive symptoms [418]. Our results showed no statistically significant differences in the 
prevalence of either anxiety or depressive symptoms both subjectively and objectively 
between the two genders (Table 10.2a). 
 
The age of onset of PD is reported to influence the development of  behavioural and 
neuropsychiatric symptoms with old-age onset significantly associated with the development 
of hallucinations, loss of interest and impaired concentration [370]. Our results also indicated 
a greater proportion of patients diagnosed with PD after the age of 40 years to be affected 
with depression, using the Leeds SAD scale, compared to those diagnosed with PD before the 
age of 40 years (p=0.027) but there was no significant difference in the proportion of patients 
diagnosed with anxiety using the Leeds SAA scale between the two groups (p=0.055). One 
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could hypothesize that the biologic mechanisms for these two different, yet overlapping, set 
of symptoms may be different. 
 
The association of neuropsychiatric features such as depression in PD with a positive family 
history of PD is reported [56]. Our study, however, found a greater prevalence of anxiety 
(p=0.014) and depression (p=0.022) objectively in those with a negative family history of PD 
(sporadic PD) compared to those with a positive family history of PD despite there being no 
statistically differences in the age and disease duration between the 2 groups (Table 10.4a). 
 
There were no significant differences in the proportion of cases reporting impulse control 
problems such as gambling, overeating, overspending or self-medicating behaviours in 
between cases classified by motor subtype  (Table 10.1b), gender (Table 10.2b), age at onset 
of PD (Table 10.3b) and hereditary versus sporadic PD (Table 10.4b). This is in keeping with 
previous studies showing no relationship between motor phenotypes and impulse control 
behaviour symptoms [419]. The only significant differences noted, in our analysis, were in 
the proportion of patients reporting hyper sexuality between those with age at diagnosis of 
PD less than 40 years (30.8%) compared to those with age at diagnosis of PD greater than 40 
years (20.8%) (p=0.046), even though there was no significant difference in the proportion of 
cases on dopamine agonists in the two groups (p=0.848).  
 
The mechanisms leading to neuropsychiatric problems and behavioural symptoms remain 
largely unknown however there has been some evidence to suggest that both sets of problems 
are associated with aberrations in ventral striatal dopamine signalling and concomitant 
dysfunction of the limbic cortico-striatal-thalamocortical circuit. Depression in PD seems 
associated with decreased activity in the limbic cortico-striatal-thalamo-cortical  circuit, 
whereas impulse control problems seem associated with increased limbic cortico-striatal-
thalamo-cortical circuit activity, usually after commencing dopamine replacement therapy 
[420]. Besides the role of monoamine neurotransmitter circuits, there is evidence from other 
sources of possible contribution of the cholinergic system and white-matter change, in older 
depressed patients [416]. The determinants of psychosis in a study of 755 PD patients were a 
combination of age, disease duration, H&Y stage and medication (dopamine agonists and 
COMT inhibitors) usage [421]. 
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10.6 Conclusion 
 
The variation in the underlying biological substrates and environmental influences such as 
drug side effects could account for some of the variability in the neuropsychological profiles 
in the subgroups of PD, however, more work is required to explain other possible 
determinants of this heterogeneity. 
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Chapter 11. Variation in QoL and determinants of QoL in EOPD 
 
 
 
 
 
 
11.1 Objective 
 
The objective in this chapter is to analyse the variation in the quality of life (QoL) scores and 
its determinants in a cohort of patients with early onset Parkinson’s disease.  
 
 
11.2 Introduction 
 
Measurement of quality of life has become increasingly relevant as an outcome parameter in 
almost all clinical trials of PD [422]. Quality of life is a multidimensional concept that in the 
broadest sense encompasses a subjective evaluation by a person of his or her satisfaction with 
life and concerns, among others, the relationships with family or relatives, the person’s own 
health, the health of another close person, finances, housing, independence, religion, social 
life, and leisure activities [423]. Health and independence in activities of daily living 
contribute to quality of life, and this domain is often referred to as health related quality of 
life which we will abbreviate as QoL. 
  
 
11.3 Methods 
 
Patients attended 6 monthly clinic visits as per study protocol described in detail in Chapter 3. 
They were asked to fill in questionnaires for demographic data at baseline (visit 0). Patients 
filled in questionnaires about their independence in  activities of daily living (ADL) using 
Schwab and England scale [424] and Parkinson’s disease quality of life  eight items (PDQ-8) 
[130] at study visit 1. The final scores obtained on PDQ-8 were converted into a PDQ8 
summary index (PDQ8SI) score by using the following formula PDQ8 score/32 x100. Data 
required for determining the motor and non-motor symptoms that impact on quality of life 
(QoL) were assimilated from UPDRS scores, NMSS and their HY stage documented at the 
same study visit [425].  
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In order to analyse the variation in motor complications of PD with respect to historical and 
examination findings all cases with EOPD were classified in 4  ways: according to motor 
subtypes (TDPD, PIGD and ‘Mixed’), gender, age at onset of PD symptoms and heritability 
of the Parkinsonian trait as described in Chapter 4. 
 
Statistical analysis: 
 
Descriptive data are presented as median and inter-quartile range (IQR) as data in most 
instances failed tests of normality (Shapiro Wilk). Kruskal Wallis test was used for inter 
group comparisons of numerical data in scenarios where cases where classified into 3 groups 
e.g. motor subtypes (pairwise comparisons between groups were made adjusting for multiple 
comparisons with Dunn’s correction). Post hoc comparisons between groups were done using 
Mann Whitney U if the Kruskal Wallis test statistic showed a significant difference between 
the 3 groups. Mann Whitney U test was used for inter-group comparisons of numerical data 
where cases were classified into 2 groups e.g. males and females. Chi square tests or Fisher’s 
exact tests were used for comparing groups for categorical data as appropriate. 
 
As a first step, the factors that would be used in generalised linear models, deemed to have an 
impact on the PDQ8SI, would be determined by correlation analysis, using Spearman's 
correlation coefficients.  
 
Generalized linear models, based on ANCOVA, with age, disease duration, UPDRS3 scores, 
HY stages, NMSS scores and ADL scores as covariates were employed to determine any 
significant differences in subgroups classified by  motor subtype, gender, age at onset and 
hereditary versus sporadic parkinsonism (independent variables) on quality of life scores 
(dependent variable). Log10 transformations were used where data distributions failed the 
Shapiro Wilk test of normality.  
 
All statistical analyses were two-sided and significance level was set at 5%. Statistical tests were 
performed using Prism software (version 4.0 for Windows; CA, USA) and SPSS software (version 23 
for Windows; IL, USA). 
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11.4 Results 
 
269 patients had completed all questionnaires relevant to this analysis and are included here 
(Figure 11.1). Their demographic details are presented in Tables 11.2 to 11.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.1 shows the disoposition of cases prior to data analysis for this chapter. No data 
imputation was allowed. Those who had incomplete questionnaires relevant to this analysis 
were not included. 
 
 
 
The factors that were deemed to have an impact on the quality of life scores (PDQ8SI), 
determined by correlation analysis, using Spearman's correlation coefficients are shown in 
Table 11.1. 
 
 
 
Initial recruitment 
target 
N= 240 
Incomplete 
questionnaires 
N=57 
Additional cases 
recrutited 
N= 86 
Full dataset 
available 
N= 269 
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Table 11.1 Factors that had an influence on the quality of life scores in patients. 
 
Variable Median (IQR) 
n=269 
Correlation with PDQ8SI 
(Spearman’s rho) 
p-value 
Age (years) 51.5 (46.9-56.5) 0.217 <0.001 
Disease duration (years) 6.8 (2.7-11.5) 0.351 <0.001 
UPDRS1 16 (14-18) 0.482 <0.001 
UPDRS2 15 (9-22) 0.740 <0.001 
UPDRS3 24 (15-37) 0.449 <0.001 
UPDRS4 2 (0-7) 0.486 <0.001 
HY stage 2.0 (1.5-2.5) 0.441 <0.001 
NMSS score 39 (24-71) 0.707 <0.001 
ADL 80 (60-90) -0.577 <0.001 
UPDRS = Movement disorder society (MDS) unified Parkinson’s disease rating scale, UPDRS1 = Part 1 
of the MDS-UPDRS scale, UPDRS2 = Part 2 of the MDS-UPDRS scale, UPDRS3= Part 3 of the MDS-
UPDRS scale, UPDRS4 = Part 4 of the MDS-UPDRS scale, HY = modified Hoehn Yahr scale, NMSS = 
non- motor symptoms scale for PD, ADL = independence in activities of daily living recorded on the 
Schwab and England scale 
 
 
The variation in the activities of daily living (Figure 11.2), the quality of life scores (Figure 
11.3 and 11.4) and the factors that influence the quality of life in these patients classified by 
motor subtype are presented in Tables 11.1. There were statistically significant differences in 
the quality of life scores between the three motor subtypes (Table 11.2).  
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Figure 11.2 shows the Schwab and England (SE) scale score (on the y-axis) and the motor 
subtype (on the x-axis). The line in the centre of the boxes represent the medians, the ends of 
the whiskers 2 standard deviations on either side and outliers are represented by dark circles. 
SE scale scores were greater in those with TDPD (n=151) compared to those with PIGD  
(n=98) (p<0.001). 
 
 
 
Figure 11.3 shows the movement disorder society unified Parkinson’s disease Part 2 (UPDRS 
2) score (on the y-axis) and the motor subtype (on the x-axis). The line in the centre of the 
boxes represent the medians, the ends of the whiskers 2 standard deviations on either side and 
outliers are represented by dark circles. UPDRS 2 scores were greater in those with PIGD 
(n=98) compared to those with TDPD (n=151) (p=0.028). 
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Figure 11.4 shows the Parkinson’s disease quality of life summary index (PDQ8SI) score (on 
the y-axis) and the motor subtype (on the x-axis). The line in the centre of the boxes represent 
the medians, the ends of the whiskers 2 standard deviations on either side and outliers are 
represented by dark circles. No significant differences were found between those with TDPD 
(n=151), PIGD (n=98) and ‘Mixed’ motor subtypes (n=20) (p=0.796). 
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11.2 Variation in the activities of daily living (ADL), quality of life (QoL) scores and 
determinants of QoL in patients (n=269) classified by motor subtype. 
 
Variable/ Scale   TDPD  
median (IQR) 
  PIGD 
median (IQR) 
Mixed subtype 
median (IQR) 
p- value 
Number of cases 151 98 20 - 
Age* (years) 50.4 (45.1-54.2) 54.6 (48.8-59.7) 49.1 (46.8-52.2) <0.001 
Sex (males) 66.9 % 58.2 % 65.0 % 0.373 
Duration (years) 4.7 (1.9-9.6) 9.1 (4.6-15.2) 6.5 (2.4-11.8) <0.001 
UPDRS score  
UPDRS Part 1  16 (14-17) 17 (14-20) 16 (14-17) 0.924 
UPDRS Part 2  13 (8-20) 19 (11-26) 16 (8-21) 0.028 
UPDRS Part 3  22 (14-36) 28 (19-38) 15 (10-22) 0.007 
UPDRS Part 4  2 (0-6) 5 (2-10) 4 (0-10) 0.452 
Hoehn Yahr stage 2.0 (1.0-2.0) 2.0 (2.0-3.0) 1.5 (1.0-2.0) <0.001
¥
 
NMSS score  
Autonomic  10 (4-18) 12 (5-22) 12 (8-19) 0.486 
Sleep/fatigue  8 (4-16) 12 (4-21) 7 (3-14) 0.140 
Mood/apathy  4 (1-10) 4 (1-14) 11 (2-17) 0.132 
Percept. /halluc. 0 (0-1) 1 (0-3) 0 (0-1) 0.073 
Attention/memory 3 (1-8) 4 (2-8) 5 (2-6) 0.843 
Total score 36 (21-65) 48 (25-77) 43 (26-84) 0.433 
ADL score 90 (75-90) 80 (60-90) 85 (60-90) <0.001 
PDQ8SI score 29.7 (15.6-46.9) 37.5 (25.0-53.1) 31.3 (21.9-46.9) 0.796 
* Age at registration, IQR = inter-quartile range, UPDRS = Movement disorder society unified Parkinson’s disease 
rating scale, NMSS = non motor symptoms scale, PDQ8SI = Parkinson’s disease quality of life summary index, ADL 
= activities of daily living using Schwab and England scale  
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Post hoc tests showed the difference in the UPDRS2 scores was between TDPD and PIGD 
(P<0.001) with PIGD subtype having higher scores but not between TDPD and ‘Mixed’ 
(p=0.526) or between PIGD and ‘Mixed’ (p=0.114). 
 
There were also significant differences in the UPDRS 3 scores between PIGD and ‘Mixed’ 
(p=0.004) with PIGD subtype having the higher scores, between TDPD and ‘Mixed’ 
(p=0.035) with TDPD having the higher scores but there were no significant differences 
between TDPD and PIGD (p=0.055) UPDRS3 scores on post hoc tests. 
 
Further, post hoc tests showed the differences in ADL scores between TDPD and PIGD 
(p<0.001) with TDPD having higher scores but no significant differences between PIGD and 
‘Mixed’ (p=0.213) as well as between TDPD and ‘Mixed’ (p=0.188). 
 
Classifying patients by gender, however, showed no differences in either the activities of 
daily living (Figure 11.5) or quality of life scores (Figures 11.6 and 11.7, Table 11.3). 
 
 
 
 
 
Figure 11.5 shows the Schwab and England scale score (on the y-axis) and the gender (on the 
x-axis). The line in the centre of the boxes represent the medians, the ends of the whiskers 2 
standard deviations on either side and outliers are represented by dark circles. No statistically 
significant differences were found between males (n=171) and females (n=98) (p=0.987). 
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Figure 11.6 shows the movement disorder society unified Parkinson’s disease part 2 (UPDRS 
2) score (on the y-axis) and the gender (on the x-axis). The line in the centre of the boxes 
represent the medians, the ends of the whiskers 2 standard deviations on either side and 
outliers are represented by dark circles. No statistically significant differences were found 
between males (n=171) and females (n=98) (p=0.152). 
 
 
 
Figure 11.7 shows the Parkinson’s disease quality of life summary index (PDQ8SI) score (on 
the y-axis) and the gender (on the x-axis). The line in the centre of the boxes represent the 
medians, the ends of the whiskers 2 standard deviations on either side and outliers are 
represented by dark circles. No statistically significant differences were found between males 
(n=171) and females (n=78) (p=0.213). 
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11.3 Variation in the activities of daily living (ADL), quality of life (QoL) scores  
and determinants of QoL in patients (n=269) classified by gender. 
 
Variable/ Scale  Males 
    median (IQR) 
   Females 
    median (IQR) 
p- value 
Number of cases   171  98 - 
Age* ( in years)     51.4 (46.2-56.4)    51.0 (47.2-55.5) 0.945 
Duration (years)     7.3 (2.7-11.5)    6.1 (2.5-12.2) 0.852 
UPDRS score  
UPDRS Part 1  16 (14-19) 15 (14-17) 0.335 
UPDRS Part 2  16 (10-22) 13 (8-23) 0.152 
UPDRS Part 3  24 (15-36) 23 (14-36) 0.456 
UPDRS Part 4  3 (0-8) 4 (0-8) 0.842 
Hoehn Yahr stage 2.0 (1.5-2.5) 2.0 (1.0-2.5) 0.566 
NMSS score  
Autonomic  11 (4-19) 10 (5-18) 0.958 
Sleep/fatigue  8 (4-17) 11(4-17) 0.391 
Mood/apathy  4 (1-13) 4 (1-12) 0.580 
Percept. /halluc. 0 (0-2) 0 (0-2) 0.858 
Attention/memory 4 (2-8) 3 (1-7) 0.118 
Total score 41 (24-70) 36 (24-73) 0.743 
ADL score 80 (70-90) 90 (60-90) 0.987 
PDQ8SI score 34.4 (17.2-46.9) 29.7 (15.6-47.7) 0.213 
* Age at registration, IQR= interquartile range.  Data are presented in median (inter-quartile range) except where 
indicated. UPDRS= Movement disorder society unified Parkinson’s disease rating scale, NMSS= non motor 
symptoms scale, PDQ8SI= Parkinson’s disease quality of life summary index, ADL=activities of daily living using 
Schwab and England scale  
 
 
There was no differences in either the activities of daily living (Figure 11.8) or the quality of 
life scores (Figure 11.9 and 11.10) in those diagnosed with PD before the age of 40 years 
compared to those diagnosed after the age of 40 years (Table 11.4). 
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Figure 11.8 shows the Schwab and England scale score (on the y-axis) and the age at onset of 
PD (on the x-axis). The line in the centre of the boxes represent the medians, the ends of the 
whiskers 2 standard deviations on either side and outliers are represented by dark circles. No 
statistically significant differences were found between those with age at onset of PD ≤ 40 
years (n=63) compared to those with age at onset of PD > 40 years (n=206) (p=0.095). 
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Figure 11.9 shows the movement disorder society unified Parkinson’s disease part 2 (UPDRS 
2) score (on the y-axis) and the age at onset of PD (on the x-axis). The line in the centre of 
the boxes represent the medians, the ends of the whiskers 2 standard deviations on either side 
and outliers are represented by dark circles. No statistically significant differences were 
found between those with age at onset of PD ≤ 40 years (n=63) compared to those with age at 
onset of PD > 40 years (n=206) (p=0.315). 
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Figure 11.10 shows the Parkinson’s disease quality of life summary index (PDQ8SI) score 
(on the y-axis) and the age at onset of PD (on the x-axis) of the patients (n=276) in the EOPD 
cohort of the PRoBaND study. The line in the centre of the boxes represent the medians, the 
ends of the whiskers 2 standard deviations on either side and outliers are represented by dark 
circles. No statistically significant differences were found between those with age at onset of 
PD ≤ 40 years (n=63) compared to those with age at onset of PD > 40 years (n=206) 
(p=0.285). 
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11.4 Variation in the activities of daily living (ADL), quality of life (QoL) scores and 
determinants of QoL in patients (n=269) classified by age at onset of PD. 
Variable/ Scale  Age onset ≤ 40 yrs. 
    median (IQR) 
Age of onset > 40 yrs. 
    median (IQR)     
p- value 
Number of cases  63    206 - 
Age *(in years) 44.7 (40.2-50.9) 52.8 (48.7-56.8) <0.001 
Sex (males)  66.7% 62.6% 0.559 
Duration (years)  8.1 (3.7-15.0) 6.0 (2.4-11.2) 0.049 
UPDRS score  
UPDRS Part 1  16 (14-19) 16 (14-18) 0.978 
UPDRS Part 2  19 (11-26) 14 (9-22) 0.315 
UPDRS Part 3  25 (17-41) 23 (14-34) 0.588 
UPDRS Part 4  4 (0-10) 3 (0-8) 0.180 
Hoehn Yahr stage 2 (1-3) 2 (2-3) 0.871 
NMSS score  
Autonomic  10 (5-23) 10 (5-18) 0.868 
Sleep/fatigue  10 (4-18) 8 (4-16) 0.635 
Mood/apathy  6 (1-17) 4(1-12) 0.832 
Percept. /halluc. 0 (0-1) 0 (0-2) 0.986 
Attention/memory 4 (1-12) 4 (1-6) 0.842 
Total score 45 (26-74) 37 (23-70) 0.801 
ADL score 80 (60-90) 80 (63-90) 0.095 
PDQ8SI score 34.4 (25.0-57.8) 31.3 (15.6-46.9) 0.285 
* Age at registration, IQR = interquartile range UPDRS = Movement disorder society unified Parkinson’s disease 
rating scale, NMSS = non motor symptoms scale, Percept. = perception, Halluc. = hallucinations, ADL = activities of 
daily living using Schwab and England scale, PDQ8SI = Parkinson’s disease quality of life summary index. 
 
 
There were also no difference in either the activities of daily living (Figure 11.11) or the 
quality of life scores (Figure 11.12 and 11.13) in those with a positive family history of PD 
compared to those with sporadic PD i.e. no family history of PD (Table 11.5). 
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Figure 11.11 shows the Schwab and England scale score (on the y-axis) and the family 
history (FH) of PD (on the x-axis). The line in the centre of the boxes represent the medians, 
the ends of the whiskers 2 standard deviations on either side and outliers are represented by 
dark circles. No statistically significant differences were found between those with familial 
PD compared to those with sporadic PD (p=0.371).  
 
 
 
Figure 11.12 shows the movement disorder society unified Parkinson’s disease part 2 
(UPDRS 2) score (on the y-axis) and the family history (FH) of PD (on the x-axis). The line 
in the centre of the boxes represent the medians, the ends of the whiskers 2 standard 
deviations on either side and outliers are represented by dark circles. No statistically 
significant differences were found between those with familial PD compared to those with 
sporadic PD (p=0.995). 
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Figure 11.13 shows the Parkinson’s disease quality of life summary index (PDQ8SI) score 
(on the y-axis) and the family history (FH) of PD (on the x-axis). The line in the centre of the 
boxes represent the medians, the ends of the whiskers 2 standard deviations on either side and 
outliers are represented by dark circles. No statistically significant differences were found 
between those with familial PD compared to those with sporadic PD (p=0.584). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
243 
 
 
11.5 Variation in variation in the activities of daily living (ADL), quality of life (QoL) 
 scores and determinants of QoL in patients (n=269) classified by family history of PD. 
Variable/ Scale    Positive FH 
   median (IQR) 
       Negative FH 
      median (IQR) 
p- value 
Number of cases 63 206 - 
Age* (years) 52.3 (47.4-56.8) 51.0 (46.9-55.7) 0.296 
Sex (males) 65.1% 63.1% 0.776 
Duration (years) 6.9 (3.5-12.3) 6.7 (2.3-11.3) 0.239 
UPDRS score  
UPDRS Part 1  16 (15-18) 16 (14-19) 0.998 
UPDRS Part 2  15 (11-21) 15 (9-24) 0.995 
UPDRS Part 3  25 (16-37) 24 (15-35) 0.671 
UPDRS Part 4  5 (1-8) 3 (0-8) 0.112 
Hoehn Yahr stage 2 (1-2) 2 (1-3) 0.711 
NMSS score  
Autonomic  10 (4-18) 10 (5-19) 0.786 
Sleep/fatigue  9 (5-17) 9 (4-16) 0.335 
Mood/apathy  4 (1-12) 4 (1-13) 0.907 
Percept. /halluc. 0 (0-2) 0 (0-2) 0.913 
Attention/memory 3 (2-6) 4 (1-8) 0.752 
Total score 41 (26-70) 39 (23-73) 0.831 
ADL score 80 (65-90) 90 (60-90) 0.371 
PDQ8SI score 32.8 (21.9-44.5) 34.4 (15.6-50.0) 0.584 
FH = family history, * Age at registration, IQR = interquartile range. UPDRS = Movement disorder 
society unified Parkinson’s disease rating scale, NMSS = non motorsymptoms scale, PDQ8SI = 
Parkinson’s disease quality of life summary index, ADL = activities of daily living using Schwab and 
England scale.  
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11.5 Discussion 
 
 
There is a complex mix of motor, non-motor, cognitive and neuropsychiatric symptoms that 
impact on the quality of life in patients with PD besides the social and personal circumstances 
of individual patients. 
 
Besides its utility in clinical research, measuring or recording QoL scores in the health 
records of patients assumes importance as the overall aim of treatment in PD should be to 
minimize the negative impact of the disease on functioning in an attempt to maintain or 
improve the quality of life of these patients. There are several questionnaires to measure QoL, 
some universal that can be used for several diseases, others specific for one disease [422]. In 
our study we have employed a specific questionnaire: the Parkinson`s Disease Questionnaire 
8 items (PDQ-8). 
 
The PDQ-8 scale is an abbreviated version and derived from the Parkinson`s Disease 
Questionnaire 39 items (PDQ-39) scale [426]. The PDQ-8 has eight items (questions) 
measuring the physical and psychosocial impact of the disease. Each item represents one 
domain corresponding to the PDQ-9 scale. These domains are mobility, activities of daily 
living, emotional well-being, stigma of the disease (‘stigma’), social support, cognitive 
impairment (‘cognitions’), communication and bodily discomfort. The respondent (patient or 
carer) has to choose one of five possible answers: never (score 0), occasionally (score 1), 
sometimes (score 2), often (score 3) or always (score 4). The final score is obtained by adding 
the scores obtained from all 8 items. The range of scores on this scale is 0-32. In order to 
covert the score to a percentage, a summary index score based on answers to all the 8 
questions - the PDQ-8 Summary Index (PDQ-8 SI) - can be derived as explained in the 
methods section [130]. 
 
A previous systematic review to compare and contrast the disease specific instruments to 
measure QoL in PD suggested that although the selection of an instrument partly depends on 
the goal of the study, in many situations the PDQ-39, of which PDQ-8 is a shortened form, is 
probably the most appropriate HRQoL instrument in PD based on the clinimetric properties 
and test-retest reliability of the scale [427]. 
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The influence of the motor subtype on quality of life scores has been reported. Patients with 
the PIGD  motor subtype reported worse QoL, compared with those with TDP [361]. This 
may be due the fact that patients with the PIGD subtype rate their mobility, ability to perfrom 
activities of daily living and communication worse than those with TDPD patients [428]. 
However, these reported differences need to be interpreted in the light of other deteminants of 
QoL such as disease duration and stage. Our results showed no differences in the quality of 
life scores (p=0.796) between the 3 motor subtypes having adjusted for differences between 
age, disease duration, UPDRS3, HY stages and ADL scores. 
 
Gender based differences in the quality of life scores in PD has also been investigated. 
Females had lower quality of life scores [429] but paradoxically after DBS surgery [430] 
females emerge with higher quality of life scores, the suggestion being women have better 
coping strategies in the aftermath of surgery. Our results showed no differences in the quality 
of life scores between the two genders (p=0.213) 
 
A previous study reported that quality of life scores were higher in those with younger onset 
(<55 years) compared to those with older onset (>55 years) of PD. Our results, however, 
showed no differences in the quality of life scores between those with onset of  PD aged less 
than (or equal to) 40 years and those after the onset of 40 years in the EOPD cohort (p=0.285) 
In a study of familial PD (n= 30) versus sporadic PD (n=104) no differences were found in 
the quality of life scores between the 2 groups [323]. Our results replicated those results and  
showed no differences in the quality of life scores between  those with a positive family 
history of PD compared to those with no family history of PD  (p=0.584). 
 
The variation in the prevalence of  motor (examined in Chapter 5), non-motor (examined in 
Chapter 7) and neuropsychiatric symptoms like depression, apathy and impulsivity, 
(examined in Chapter 10),  can explain part of the variation in activities of daily living and 
quality of life scores [431]. Even the place  where care is provided to patients can be a 
contributor to the quality of life in PD suggesting that best practices in managing patients to 
improve their quality of lives may vary [432].   
 
In summary, besides details obtained from the physical examination for assessment of the 
motor severity and a questionnaire survey to detect non-motor symptoms, quality of life  
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scoring tools can provide valuable insight into the health burden of PD and contribute to a 
more comprehensive picture of the total disease impact [433].  
 
11.6 Conclusion 
 
The variation in the quality of life scores are influenced by several factors including a mix of 
motor and non-motor symptoms however after making adjustments for co-variates such as 
age, disease duration, UPDRS3, HY stages and ADL scores, the differences in quality of life 
scores in a pre-selected, nearly homogeneous group of patients, the differences in the quality 
of life scores can even out. Adequate management of all these aspects of PD that impact on 
the quality of life require holistic care from clinicians and carers.   
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Chapter 12. Genetic influences causing variation in early onset Parkinson’s 
disease 
 
 
 
12.1 Objectives 
 
The objectives of this chapter are to analyse the prevalence of genetic cases in early onset 
Parkinson’s disease and the influence of genetic factors causing variation in the clinical 
phenotype. 
 
 
12.2 Introduction 
 
Identifying factors influencing phenotypic heterogeneity in PD is crucial for understanding 
variability in disease characteristics. Age, disease duration and gender are only the most basic 
epidemiological characteristics, that can influence the variation  in the clinical expression of 
PD.[434]  In the last decade and a half there has been substantial progress in our 
understanding of the genetics of PD. Highly-penetrant mutations in several genes (SNCA, 
LRRK2, VPS35, Parkin, PINK1, and DJ-1) can cause rare monogenic forms of the disease. 
Less penetrant mutations in the LRRK2 and the GBA gene are strong risk factors for PD, and 
are especially prevalent in some ethnic groups. More recently, common variants of small 
effect size, modulating the risk for PD, have been identified by genome-wide association 
studies in more than 20 chromosomal loci [435]. Further details of how these mutations lead 
to alterations in the normal biochemical pathways and machinery of the cell that results in 
cellular damage leading to a parkinsonian phenotype are just emerging. As a corollary of 
their disease causing potential, mutations in these genes and single nucleotide polymorphisms 
at several other genetic loci together with epigenetic phenomena, contribute to the variation 
or heterogeneity in the phenotypic expression of PD. A summary of the genetic loci 
associated with PD are tabulated below. 
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Table 12.1 PARK loci linked with the Parkinson’s disease phenotype. 
Locus Gene  Chromosome Protein product Inheritance Reference 
PARK1 SNCA 4q21.3-q22 Alpha-synuclein AD [6] 
PARK2 Parkin 6q25.2-q27 Parkin AR [300] 
PARK3 NA 2p13 NA AD [436] 
PARK4 SNCA 4q21.3-q22 Alpha-synuclein AD [437] 
PARK 5 UCHLI-1 4p13 Ubiquitin 
carboxyl-terminal 
esterase L1  
AD [438] 
 
PARK6 PINK1 1p36.12 PTEN induced 
kinase 1 
AR [301] 
PARK7 DJ1 1p36.23 DJ1 AR [439] 
PARK8 LRRK2 12q12 Leucine rich 
repeat kinase 2 
AD [440] 
PARK9 ATP13A2 1p36 ATPase 13 A2 AR [441] 
PARK10 Sus. loc. 1p32 NA NA [442] 
PARK11 GIGYF2 2q36-q37 GRB10 
interacting GYF 
protein 2  
AD [443] 
PARK12 NA Xq21-q25 NA X-linked [444] 
PARK13 HTRA2 2p13.1 HtrA serine 
peptidase 2  
AD [445] 
PARK14 PLA2G6 22q13.1 Phospholipase A2 AR [446] 
PARK15 FBX07 22q12.3 F-box protein 7 AR [447] 
PARK16 Sus. loc. 1q32 NA NA [448] 
PARK17 VPS35 16q12 Vacuolar protein 
sorting 35 
AD [449] 
PARK18 EIF4G 3q27.1 Eukaryotic 
translation IF 4 
gamma 
AD [450] 
PARK19 DNAJC6 1p31.3  Auxilin AR [451] 
AD = autosomal dominant, AR = autosomal recessive, NA = not available, Sus. loc = Susceptibility locus 
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Mutations in GIGYF2 [443] and HTRA 2 [445] were found in PD cases, but subsequent 
studies have found such mutations in controls as well.[452, 453] . 
 
Genetic testing for early onset Parkinson’s disease (EOPD) is now offered by several centres 
in the United Kingdom. In Scotland as part of the services offered to NHS patients, 
Molecular Genetic Testing Laboratory at Ninewells hospital in Dundee offers a screen for 
Parkin copy number variation, direct sequencing of coding exons of Parkin  and targeted 
sequencing of the most common LRRK2 gene mutation in the northern European population. 
It is important to contrast what is offered as part of the standard NHS testing protocol in order 
to understand what PRoBaND seeks to determine in a research set-up.  
 
12.3 Methods 
 
Patients attended 6 monthly clinic visits as per study protocol described in detail in Chapter 3. 
They were asked to fill in questionnaires for demographic data at baseline (visit 0). Data 
required for the description of motor and non-motor symptoms using appropriate validated 
questionnaires including MDS-UPDRS [454], modified HY staging [455], NMSS [352], 
Schwab and England scale [424] , Leeds SAD [413], Leeds SAA [413], MOCA test [391], 
UPSIT [456], GCSI [351], PDSS[356] , ESS [355] , RBD [357]  (as described in the earlier 
chapters) and medication requirements in LEU [333, 334] were recorded  at study visit 1. 
 
Genomic DNA was isolated from peripheral blood samples that were collected from patients 
at the baseline visit (visit 0) and shipped to Cardiff using standard protocols. In Cardiff, 
whole-genome DNA amplification was performed and then used for mutational screening by 
direct sequencing in Parkin and GBA.  LRRK2 genotyping for the G2019S point mutation 
using a ‘Kompetitive’ alelle specific polymerase chain reaction (KASP) assay (LGC 
Genomic solutions). Copy dosage analysis of Parkin was performed by multiplex ligation-
dependent probe amplification (MLPA) on the genomic DNA obtained from blood samples 
using MLPA kits (obtained from MRC Holland) according to the manufacturer's protocol. 
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To analyse for the variation in demographic characteristics, motor, non-motor and cognitive 
descriptors all cases with EOPD were classified into gene test positive ‘cases’ and gene test 
negative ‘controls’ (comparator group) . Further analysis of the gene test positive cases was 
performed by classifying these cases into subgroups defined according to the genes that 
contained the pathogenic mutations i.e. Parkin, GBA and LRRK2.  
 
Statistical analysis: 
Descriptive data are presented as median and inter-quartile range (IQR) as data in most 
instances failed tests of normality (Shapiro Wilk).  Independent sample t-tests were used for 
inter-group comparisons of normally distributed continuous numerical data and Mann 
Whitney U test of continuous numerical data that was not normally distributed. Chi square 
tests or Fisher’s exact tests were used for comparing groups for categorical data as 
appropriate. 
 
In generalised linear models, based on ANCOVA, having adjusted for covariates (age , 
disease duration), a comparison was done between the two factors (independent variables) i.e. 
“cases” (gene test positive) and “controls” (gene test negative) with respect to all dependent 
variables (MDS-UPDRS scores). Additionally, when comparing MDS-UPDRS part 3 and 
MDS-UPDRS part 4 scores (dependent variables) daily anti-parkinsonian medication 
requirements in levodopa equivalent units were also used as a covariate. Logarithmic 
transformations (base 10) of numerical data were used where tests of normality (Shapiro 
Wilk) failed. 
 
Finally binary logistic regression analysis was used to determine whether age of onset of PD 
in the EOPD cohort (less than 40 years versus greater than 40 years) had any association to 
the genes causing PD, gender, ethnicity or family history of PD. 
 
All statistical analyses were two-sided and significance level was set at 5%. Statistical tests 
were performed using Prism software (version 4.0 for Windows; CA, USA) and SPSS  
software (version 23 for Windows; IL, USA). 
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12.4 Results 
178 patients with EOPD had genetic tests done for Parkin, GBA and LRRK2 mutations. 18 
tested positive for mutations in one of these 3 genes. 16 of these 18 patients had all 
questionnaires completed for the data analysis and are included here. 160 cases with EOPD 
tested negative for these genes. 134 of these had all questionnaires complete, for comparing 
their phenotypic characteristics with the gene test positive “cases”, and are included in the 
“control” group (Figure 12.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.1 shows the disoposition of cases prior to data analysis for this chapter. No data 
imputation was allowed. Those who had incomplete questionnaires relevant to this analysis 
were not included. 
 
Number of cases 
tested 
N= 178 
Incomplete 
questionnaires 
N=26 
Number of gene test 
positive cases 
N= 18 
Full dataset 
available 
N= 16 
Incomplete 
questionnaires 
N=2 
Number of gene test 
negative cases 
N= 160 
Full dataset 
available 
N= 134 
252 
 
The individual gene test results for the 16 cases and their demographic details are presented 
in Table 12.2. 
 
Table 12.2 Demographics, motor disability and medication requirements of mutation carriers 
in the EOPD cohort from the PRoBaND study. 
 Gene Mutation Age * Gender HY UPDRS3 LEDD(mg/d) FH 
1. Parkin Ex 4 hz del / 
R275W 
20.1 y Male 3.0 32 2262 -ve 
2. Parkin P113Xfs / 
R275W 
40.0 y Male 2.0 60 800 -ve 
3. GBA N409S 48.2 y Male 1.5 14 280 -ve 
4. GBA D419A 38.7 y Male 2.0 15 1320 +ve 
5. GBA R502C 43.7 y Male 2.0 20 925 -ve 
6. GBA N409S 30.5 y Female 1.0 9 1036 +ve 
7. GBA D419A 45.7 y Male 2.0 34 520 +ve 
8. GBA P305Xfs 40.5 y Male 2.5 28 1245 -ve 
9. GBA L483P / 
A495P 
42.0 y Female 1.5 17 833 +ve 
10. GBA L483P 32.9 y Female 4.0 66 660 -ve 
11. GBA L483P 43.4 y Male 2.5 12 620 -ve 
12. LRRK2 G2019S 41.5 y Male 2.0 30 1011 +ve 
13. LRRK2 G2019S 40.5 y Male 1.5 22 2840 -ve 
14. LRRK2 G2019S 37.1 y Male 1.5 11 1164 +ve 
15. LRRK2 G2019S 47.9 y Male 1.0 25 100 +ve 
16. LRRK2 G2019S 44.0 y Male 2.5 66 314 -ve 
* Age at registration in years (y), HY = Hoehn Yahr stage, UPDRS3 = modified unified Parkinson’s 
disease rating scale Part 3, LEDD = Levodopa equivalent daily dose, FH = family history, +ve = positive,  
-ve = negative,  Ex = exon, hz = heterozygous, del = deletion 
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The demographics of the gene test positive patients (n=16), classified by gene of interest i.e. 
Parkin, GBA and LRRK2  compared to the gene test negative patients (n=134) are shown in 
Table 12.3. 
 
Table 12.3 Demographics of ‘cases’ classified by gene mutation versus “controls” 
Variable  LRRK2 
median (IQR) 
GBA 
median (IQR) 
Parkin 
median (IQR) 
“Controls” 
(Gene- test negative) 
median (IQR) 
Number 5 9 2 134 
Age* (years) 52.1 (50.5-53.3) 50.2 (47.1-55.5) 52.7 (50.7-54.8) 53.4 (48.6-57.4) 
Duration (years) 10.0 (6.2-15.0) 7.3 (4.8-16.4) 22.7 (19.8-25.6) 8.4 (5.4-12.4) 
Sex (males) 100 % 66.7 % 100 % 66.2 % 
Ethnicity     
   Caucasian 100 % 88.9 % 100 % 95.5 % 
   Asian - 11.1 % - 3.0 % 
   African - - - - 
   Caribbean - - - 0.8% 
Positive FH 60.0 % 44.4 % - 25.9 % 
ADL
‡
 80 (60-90) 90 (80-90) 55 (42.5-67.5) 80 (60-90) 
* Age at registration, LRRK2 = Leucine rich repeat kinase 2 gene test positive, GBA = Glucocerebrosidase 
gene test positive, Parkin = Parkin gene test positive, FH= family history ‡ADL=activities of daily living 
score is based on Schwab and England scale 
 
 
The disease duration was longest in the Parkin patients compared to the other groups 
(p=0.037) and keeping in with the autosomal recessive nature of inheritance of this gene 
mutation, there was no family history of PD in the preceding or succeeding generations. 
 
The variation in mentation, behaviour and mood symptoms, recorded using MDS- UPDRS 
scale Part 1 (figure 12.2), activities of daily living, recorded using MDS- UPDRS scale Part 2 
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(figure 12.3), motor features recorded using MDS- UPDRS scale Part 3 (figure 12.4), and 
complications of PD treatment, recorded using MDS- UPDRS scale Part 4 (figure 12.5)  are 
shown  in Table 12.4 by classifying “cases” (gene test positive) according to gene test 
abnormality versus “controls” (gene test negative). 
 
 
 
 
Figure 12.2 shows the movement disorder society unified Parkinson’s disease rating scale 
(MDS-UPDRS) Part 1 scores on the y-axis and the two groups EOPD subjects classified by 
gene test mutation and “controls” (gene test negative) on the x-axis. The top of the bar 
column graphs represents the median and the whiskers represent the inter-quartile range 
(bottom whisker is hidden within the boxes). Due to very small sample sizes (n=2) in some 
groups, no inferences have been made about inter-group differences. 
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Figure 12.3 shows the movement disorder society unified Parkinson’s disease rating scale 
(MDS-UPDRS) Part 2 scores on the y-axis and the two groups EOPD subjects classified by 
gene test mutation and “controls” (gene test negative) on the x-axis. The top of the bar 
column graphs represents the median and the whiskers represent the inter-quartile range 
(bottom whisker is hidden within the boxes). Due to very small sample sizes (n=2) in some 
groups, no inferences have been made about inter-group differences. 
 
Figure 12.4 shows the movement disorder society unified Parkinson’s disease rating scale 
(MDS-UPDRS) Part 3 scores on the y-axis and the two groups EOPD subjects classified by 
gene test mutation  and “controls” (gene test negative) on the x-axis. The top of the bar 
column graphs represents the median and the whiskers represent the inter-quartile range 
(bottom whisker is hidden within the boxes). Due to very small sample sizes (n=2) in some 
groups, no inferences have been made about inter-group differences. 
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Figure 12.5 shows the movement disorder society unified Parkinson’s disease rating scale 
(MDS-UPDRS) Part 4 scores on the y-axis and the  EOPD subjects classified by gene test 
mutation  and “controls” (gene test negative) on the x-axis. The top of the bar column graphs 
represents the median and the whiskers represent the inter-quartile range (bottom whisker is 
hidden within the boxes). Due to very small sample sizes (n=2) in some groups, no inferences 
have been made about inter-group differences. 
 
  
 
There were no significant differences in the MDS-UPDRS total and sub-scores between the 
pooled data for the gene test positive cases and gene test negative cases when adjustments 
were made for age, disease duration and medication requirements in the statistical model for 
any baseline differences in these variables (not shown in tables). 
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Table 12.4 MDS-UPDRS scores, Hoehn Yahr stages and medication requirements in “cases” 
classified by genotype versus “controls”. 
Variable  LRRK2 
  median (IQR) 
GBA 
 median (IQR) 
Parkin 
 median (IQR) 
“Controls” 
(Gene- test 
negative) 
median(IQR) 
Number 5 9 2 134 
UPDRS 1 15 (14-15) 18 (17-20) 19 (18-20) 16 (14-19) 
UPDRS 2  16 (11-27) 14 (13-24) 26 (24-28) 16 (10-24) 
UPDRS 3  25 (22-30) 17 (14-28) 46 (39-53) 24 (17-39) 
UPDRS 4  4 (1-8) 5 (4-6) 6 (3-8) 5 (1-10) 
UPDRS total  70 (43-71) 61 (54-74) 98 (96-99) 65 (47-84) 
HY stage 1.5 (1.5-2.0) 2.0 (1.5-2.5) 2.5 (2.25-2.75) 2.0 (1.5-2.5) 
LEU(mg/day) 1011 (314-1164) 833 (620-1036) 1530 (1165-1896) 798 (524-1023) 
MDS-UPDRS = Movement disorder society unified Parkinson’s disease rating scale,  LRRK2 = Leucine 
rich repeat kinase 2 gene test positive, GBA = Glucocerebrosidase gene test positive, Parkin = Parkin gene 
test positive, UPDRS = Movement Disorder Society Unified Parkinson’s disease rating scale, UPDRS1 = 
UPDRS Part 1 score, UPDRS 2 = MDS-UPDRS Part 2 score, UPDRS 3 = MDS-UPDRS Part 3 score, 
UPDRS 4 = MDS-UPDRS Part 4 score, HY = Hoehn Yahr stage, LEU= Levodopa equivalent dose, HY = 
Hoehn Yahr stage, LEU= Levodopa equivalent unit dose 
 
The number of cases in some groups were so small (n=2) that the results of non-parametric 
statistical tests such as the chi-square test for categorical data comparing 3 groups would not 
be valid. The power of any test to detect any significant differences between groups is 
handicapped when the numbers are small. This was, therefore, not attempted in Tables 12.3, 
12.4 and 12.5. 
 
A detailed analysis of the non-motor symptoms of  dysfunction sleep such as excessive and 
REM sleep behaviour disorder; neuropsychiatric symptoms such as anxiety and depression; 
autonomic features such as constipation and bladder dysfunction; cognitive problems   
including dementia recorded using appropriate and validated scales, described in the methods 
section, are  shown  in Table 12.5 by classifying patients into ‘‘cases’’ (gene test positive ) 
according to gene test abnormality versus ‘‘controls’’ (gene test negative). 
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Table 12.5 Non-motor features in “cases” classified by genotype versus “controls”. 
Variable  LRRK2 
 
GBA Parkin “Controls” 
(Gene- test negative) 
Number 5 9 2 134 
EDS 60 % 55.6 % 100 % 49.7 % 
Disrupted sleep  60 % 22.2 % 100 % 35.7 % 
RBD 100 % 55.6 % 50 % 53.8 % 
Anxiety* 40.0 % 44.4 % 50.0 % 46.9 % 
Depression** 20.0 % 55.6 % 50.0 % 43.4 % 
Anosmia
£
 M: 60 %  
F: NC 
M: 50 % 
F: 50 % 
M: 0 %  
F: NC 
M: 50.6 % 
F: 15.0 % 
Constipation 20.0 % 44.4 % 50.0 % 53.0 % 
Bladder dysfunction† 100 % 100 % 100 % 93.3 % 
Cognitive impairment§ 100 % 88.9 % 50 % 83.8 % 
Dementia
 ‡
 20 % 11.1 % 0 % 9.7 % 
LRRK2 = Leucine rich repeat kinase 2 gene test positive, GBA = Glucocerebrosidase gene test positive, 
Parkin = Parkin gene  test positive, EDS = Excessive daytime sleepiness based on an Epworth Sleep Scale 
score >=9 , Disrupted sleep based on a  Parkinson’s disease sleep score (PDSS) >= 100,  *based on Leeds 
scale  for self-assessment of anxiety (SAA) score >= 7, **based on Leeds for self-assessment of depression 
(SADS) score >=7, † Bladder dysfunction= Bladder dysfunction= difficulty retaining urine, feeling 
bladder not completely empty, weak stream, pis en deux or nocturia, § based on Montreal cognitive 
assessment (MOCA) test score <26 , ‡ based on a MOCA test score < 20, £ based on  University of 
Pennsylvania Smell Identification test ( UPSIT)  score <19 in males and  females, NC = no cases. 
 
 
Binary logistic regression analysis showed age of onset of PD in the EOPD cohort (less than 
40 years versus greater than 40 years) was  not related to the  genes causing PD (p=0.948 ), 
gender (p=0.420 ), ethnicity (p=0.894) or family history of PD (p=0.234). 
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12.5 Discussion 
 
The detailed molecular mechanisms of the pathogenesis leading to neuronal death in PD 
remain largely unknown; however, it is becoming increasingly clear that genetic factors have 
a role to play in the inheritance patterns and the underlying neuronal degeneration in the brain 
of this complex trait. In the past 15 years, the genetic basis of rare forms of PD with 
Mendelian inheritance, which represent less than 10% of total cases, has been investigated. 
More than 16 loci, identified through linkage analysis or genome wide association studies 
(GWAS), and eight validated genes have been identified so far (Table 12.1). Several studies 
have shed light on the influence of these genes not only in familial but also in sporadic forms 
of PD [302]. 
  
The prevalence of genetic cases of PD overall is reported to be 5-10% [457]. Our study 
showed a prevalence of 10.1% of genetic cases of PD in the EOPD cohort randomly tested 
for mutations in 3 genes Parkin, GBA and LRRK2. This is likely to under report the number 
of cases with a genetic basis to PD given that there are other genes such as PINK1, DJ1 and 
SNCA that we didn’t test (Table 12.1) in this phase of our study but have been tested in other 
studies [458-460] . In our study only 2 genes were sequenced (Parkin and GBA) and only 
targeted mutational analysis was performed on LRRK2 (G2019S ) at this stage  based on the 
frequencies of these genes being implicated in the general PD population [166, 435], the 
other genes being less prevalent in the overall population, while recognising the fact that 
certain gene mutations such as PINK1 may be more common in certain ethnic backgrounds 
[458]. 
 
The most common mutation in our study was in GBA (5.6%) and the least common was in 
Parkin (1.7%) with LRRK2 mutations somewhere in between (2.8%). GBA is the most 
common cause for genetic cases of PD in the British population and has been reported before 
[166] but we believe this is the first time this has been replicated in an EOPD cohort. This 
may have implications for genetic testing offered locally for NHS patients. The east of 
Scotland regional molecular genetics service based in the molecular genetics department at 
Ninewells Hospital, Dundee, has been offering, a free at the point of care, service to NHS 
patients in the whole of Scotland. Over the years the testing that has been offered is restricted 
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to Parkin whole gene sequencing and targeted mutation analysis of G2019S (p.Gly2019Ser) 
mutation in the LRRK2 gene supplemented by a gene dosage analysis of the Parkin gene 
using MPLA kits. Restricting the genetic testing to Parkin and LRRK2 in the EOPD misses 
the largest segment of patients with genetic PD i.e. GBA mutation carriers and should be 
included as this has implications for genetic counselling of families given this is an autosomal 
dominant gene with 1:2 chance of passing the mutated gene to the offspring. The importance 
of GBA testing is not overstated given GBA mutations can influence the natural history of 
Parkinson's disease in a community-based incident cohort on longitudinal follow up. The 
hazard ratio for progression both to dementia and Hoehn and Yahr stage 3 were significantly 
greater in GBA mutation carriers than those who were wild-type homozygotes [461]. This is 
reported to be the first time a genetic locus has been shown to influence motor progression in 
PD and therefore a potential prognostic marker but needs to be confirmed in other studies 
such as PRoBaND over time.  
 
Few large scale studies have ever been performed in homogeneous populations to explore the 
contribution of known PD-causing genes in patients with EOPD. In a previous study of 38 
patients with PD in southern Africa (18% with positive familial history of PD) with an 
average onset age 54.9 ± 12.2 years, all SNCA exons and LRRK2 exons 29 to 48 were 
sequenced in every patient. In those patients with a family history of PD and those with age at 
onset <55 years (n = 22) the whole LRRK2 coding region was sequenced (51 exons). In the 
patients with onset <50 years (n = 12), all Parkin, PINK1, and DJ-1 exons were sequenced, 
and dosage analysis of Parkin, PINK1, DJ-1, LRRK2, and SNCA was performed. The LRRK2 
p.Gly2019Ser mutation was not detected. A novel LRRK2 missense variant (p.Ala1464Gly) 
of possible pathogenic role was found in one case [459]. In our study however p.Gly2019Ser 
mutation was the second most common mutation detected (5/18) in the EOPD cohort. 
G2019S (p.G2019S) in LRRK2 is the most common mutation in this gene [462] but screening 
for only a single mutation (targeted mutation analysis) suggests a great disparity in the 
proportion of patients with LRRK2 mutations amongst different groups (42% in Tunisian 
families and 2.6% in U.S. families [463]. In the southern African study no case with this 
mutation was found, in our study this accounted for 2.8% of cases.  While it is completely 
plausible that different mutations segregate in different populations due to a founder effect, 
the overall reported frequency of mutations in this gene will understandably be deflated 
unless all the exons are sequenced as several other mutations in LRRK2 can cause PD [462]. 
261 
 
This may be one of the weaknesses of our study as well at this stage given only targeted 
mutational analysis has been performed for  G2019S LRRK2 mutation rather than sequencing 
the whole gene. 
 
The study recruiting patients in sub-Saharan Africa reported two heterozygous, likely 
disease-causing deletions of Parkin (exon 2 and exon 4) in the early-onset cases [459]. In our 
study one patient had a hemizygous deletion on exon 4 along with R275W mutation, both 
previously reported. Parkin mutations (3/18) were the least common cause for genetic cases 
of PD in the PRoBaND EOPD cohort. In the southern African study no pathogenic mutations 
were detected in SNCA, PINK1, or DJ-1, another hint that some mutations segregate in 
certain ethnic groups. In fact no common disease-causing mutations were detected in the 5 
genes tested, suggesting that further investigations in PD patients from different populations 
might unravel the role of additional, still unknown genes [459]. 
   
The methodology used in the southern African study and our study has important 
implications in the reporting of the genetic contributions to PD. Direct sequencing of genes 
for point mutations or targeted sequencing for point mutations would miss copy number 
variations (gene dosage). Genomic rearrangements account for a substantial number of the 
genetic cases of PD [460]. MLPA (multiplex ligation-dependent probe amplification), is an 
alternative technique, based on a  multiplex polymerase chain reaction (PCR) method can 
detect abnormal copy numbers such as duplications and (partial) deletions. These techniques 
are therefore complimentary when screening genes for PD and studies reporting the use of 
only of the 2 techniques will under report the genetic cases of PD.  
 
The second point to note is some studies have reported novel mutations that have later turned 
out to be non-pathogenic and considered variant polymorphisms, for example, the R275W 
variant in Parkin is still controversial because this mutation was found to occur as frequently 
in control subjects (3 of 192) as in patients (5 of 313) [464], unless a second mutation is also 
identified. In light of the above, in our study R275W missense mutation in combination with 
exon 4 hemizygous deletion (Case 1 in Table 12.2) and mutation P113Xfs (Case 2 in Table 
12.2) can explain the disease state in both patients. In the PRoBaND EOPD cohort all 
mutations reported in the 3 genes sequenced have previously been reported except a novel 
P305Xfs mutation in GBA that has not been previously reported. 
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A systematic review and UK-based study of PARK2 (Parkin), PARK6 (PINK1), PARK7 
(DJ-1) and PARK8 (LRRK2) in EOPD showed an increased likelihood of mutations in 
patients with lower age at onset, family history, or parental consanguinity [458]. Our study, 
however, showed that the age at onset (less than 40 years versus greater than 40 years) was 
not related to the genes causing PD (p = 0.948), gender (p = 0.420), ethnicity (p = 0.894) or 
family history of PD (p = 0.234) using binary logistic regression. The age of onset considered 
in that systematic review dichotomised patients into those with age of onset < 30 years versus 
age at onset > 30 years. Only 1 patient in our EOPD cohort who tested positive for any gene 
mutation had an age of onset < 30 years, all others had age at onset > 30 years, hence the 
rationale for considering the split between the 2 groups at 40 years to test this hypothesis. 
 
In our study the results suggest it would clinically not be possible to distinguish gene test 
positive cases from gene test negative cases in the EOPD cohort based simply on the 
phenotype given that the differences in clinimetric measures (Tables 12.4) between the 2 
groups, when the pooled data was analysed (not shown in tabulated form) for all those with 
gene test mutation positive status compared to those with gene test mutation status, did not 
show any significant differences after adjusting for the effects of age, disease duration and 
medication, except for Parkin mutation carriers. Parkin mutation carriers had an earlier onset 
and longer disease duration (Table 12.3) which has also been reported before [169]. The 
limitation placed by the small numbers of cases who tested positive for mutations in each PD 
causing gene that was analysed in this study when analysing differences between groups, to 
search for statistically significant differences, was recognised. This was therefore not 
attempted, in order to avoid drawing erroneous conclusions based on a dataset with small 
number of genetically proven PD cases, which could not be replicated by other research 
groups. 
 
The implications, therefore, are that clinical phenotypes of gene mutation carriers overlap 
with those who test negative for the genes involved in PD, with the exception of Parkin 
carriers, to such an extent that it would not be possible predict genotype based on phenotype, 
however, that should not cloud the importance that gene mutation carrier status has on 
disease course and prognosis; therein lies the main utility of gene testing, in addition to its 
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relevance in inheritance risks and genetic counselling. However, genetic testing in PD can 
raise ethical issues as well as issues of informed consent if presymptomatic testing is 
performed and if this testing is offered to first degree relatives of patients with  autosomal 
dominant PD genes. 
 
12.6 Conclusion 
 
Patients with EOPD should be offered genetic testing in order to further understand their 
disease, to enable them to make informed life decisions and with a more secure diagnosis 
they can be enrolled in trials for specific treatments such as LRRK2 kinase inhibitors.  
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Chapter 13. Environmental influences causing variation in Parkinson’s 
disease 
  
 
 
13.1 Objective 
 
The objective of this chapter is to analyse the variation in environmental risk factors in a 
cohort of patients with early onset Parkinson’s disease.  
 
 
13.2 Introduction 
 
The link between PD and environmental influences grew after a mini-epidemic of  cases 
exposed to the synthetic meperidine (pethidine in the United Kingdom) derivative 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) emerged in the San Francisco Bay area in 
intravenous drug users [465]. MPTP induces parkinsonism in humans by selectively 
destroying nigrostriatal dopaminergic neurons [466].  This discovery not only helped 
establish animal models of PD [467] but also stimulated an interest in finding chemically 
similar molecules that could replicate the effects of MPTP on the substantia nigra. Numerous 
population based epidemiological surveys have looked at the possibility of one or more 
environmental exposures that could either increase or decrease the lifetime risk of developing 
PD. 
 
13.3 Methods 
 
Patients from the EOPD cohort of the PRoBaND study were the subject of analysis for the 
environmental influences in PD. They attended 6 monthly clinic visits as per study protocol 
described in detail in Chapter 3. They were asked to fill in questionnaires for demographic 
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data at baseline (visit 0). They were asked to fill in a modified mini environmental risk 
questionnaire for Parkinson’s disease patients’ baseline (MERQ-PD-B) at study visit 2 as 
described in detail in Chapter 4. 
In order to analyse for variation in environmental influences affecting PD phenotypic 
expression  with respect to medication exposure , all cases with EOPD were classified in 4  
ways: according to motor subtypes i.e. TDPD, PIGD and ‘Mixed’ , gender, age at onset of 
PD symptoms and heritability of the Parkinsonian trait as described in Chapter 4. 
 
Statistical analysis: 
 
Descriptive data are presented as median and inter-quartile range (IQR) as data in most 
instances failed tests of normality (Shapiro Wilk). Kruskal Wallis test was used for inter-
group comparisons of numerical data in scenarios where cases where classified into 3 groups 
e.g. motor subtypes with post hoc comparisons between groups using Mann Whitney U test if 
the Kruskal Wallis test statistic showed a significant difference between the 3 groups. Mann 
Whitney U test was used for inter-group comparisons of numerical data where cases were 
classified into 2 groups e.g. males and females. Chi square tests or Fisher’s exact tests were 
used for comparing groups for categorical data as appropriate. 
 
All statistical analyses were two-sided and significance level was set at 5%. Statistical tests were 
performed using Prism software (version 4.0 for Windows; CA, USA) and SPSS software (version 23 
for Windows; IL, USA). 
 
13.4 Results 
210 patients had completed all questionnaires relevant to environmental exposures analysis 
(Figure 13.1) and this is indicated in the relevant tables (Tables 13.1-13.4). Their 
demographic details have been presented in Table 4.2 in Chapter 4.   
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Figure 13.1 shows the disoposition of cases prior to data analysis for this chapter. No data 
imputation was allowed. Those who had incomplete questionnaires relevant to this analysis 
were not included. 
 
 
The variation in the exposure to environmental risk factors, classified by motor subtype, is 
presented in Table 13.1. There were no statistically significant differences in any of the 
environmental risk exposures that are considered to either decrease the risk of developing PD 
(Figure 13.2) or increase the risk of developing PD (Table 13.1) between the three motor 
subtypes. 
 
 
Initial recruitment 
target 
N = 240 
Incomplete 
questionnaires 
N = 116 
Additional cases 
recrutited 
N = 86 
Full dataset 
available 
N = 210 
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Figure 13.2 shows the proportion of patients who smoked or consumed caffeine in significant 
amounts (≥ 3 cups of coffee/tea per day) before the diagnosis of PD, as recorded on the 
MERQ-PD baseline questionnaire (on the y-axis) and their motor subtype (on the x-axis). 
There were no significant differences in the exposure to smoking (p=0.268) or caffeine 
(p=0.992, p=0.370) between the three motor subtypes. 
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Table 13.1 Variation in environmental exposures (as risk factors) in cases (n=210)  
from the EOPD cohort classified by motor subtype 
 
Variable/ 
Exposure 
  TDPD 
median (IQR) 
  PIGD 
median (IQR) 
Mixed 
median (IQR) 
p- 
value 
Number  116 79 15 - 
Age*(years) 51.2 (46.0-54.7) 55.0 (50.0-59.4) 51.2 (45.9-52.3) <0.001 
Sex (males) 65.5 % 59.5 % 60.0 % 0.675 
Duration (years) 5.7 (2.9-10.1) 9.5 (5.4-15.1) 7.7 (3.9-11.2) <0.001 
Solvents✝
‡
 21.6 % 27.4 % 14.3 % 0.480 
Pesticides§ 52.6 % 53.4 % 28.6 % 0.214 
Heavy metals✝
‡
  13.4 % 12.3 % 0 % 0.837
¶ 
Smoking✝ 28.9 % 34.2 % 50.0 % 0.268 
Caffeine intake✝     
  < 3 cups/ day 14.4 % 15.1 % 14.3 % 0.992 
  ≥  3 cups/ day 65.5 % 65.8 % 73.3 % 0.370 
TDPD = tremor dominant Parkinson’s disease, PIGD = postural instability gait difficulty, * age at 
registration, ✝ before diagnosis, ‡ exposure for more than 6 months,  § includes herbicides, insecticides, 
fungicides and fumigants, ¶ Fisher’s exact test between TDPD and PIGD groups (chi-square not valid 
when comparing cells with values less than 5 therefore mixed subtype not used in the equation) 
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Classifying patients by gender showed no statistically significant differences in any of the 
environmental risk exposures that are considered to decrease the risk of developing PD 
(Table 13.2) but amongst risk factors that are reported to increase the risk of developing PD, 
exposure to solvents (p<0.001) and heavy metals were more commonly reported by males 
compared to females (Figure 13.3).  
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Figure 13.3 shows the proportion of patients who were exposed to solvents, pesticides or 
heavy metals before the diagnosis of PD, as recorded on the MERQ-PD baseline 
questionnaire (on the y-axis) and their gender (on the x-axis). Exposure to solvents (p<0.001) 
and heavy metals (p<0.001) were more commonly reported by males compared to females 
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Table 13.2 Variation in environmental exposures (as risk factors) in cases (n=210)  
from the EOPD cohort classified by gender. 
 
Variable  Males 
  median (IQR) 
  Females 
   median (IQR) 
p- value 
Number of cases 132 78 - 
Age*(years) 52.5 (47.4-56.7) 52.2 (47.4-56.5) 0.906 
Disease duration (years) 7.7 (3.7-11.6) 6.7 (3.3-11.3) 0.362 
Solvents✝
‡
 31.4 % 7.9 % <0.001 
Pesticides
§
 53.7 % 46.0 % 0.332 
Heavy metals✝
‡
  18.2 % 0 % <0.001 
Smoking✝ 37.2 % 23.8 % 0.070 
Caffeine intake✝    
       < 3 cups/ day 12.4 % 19.0 % 0.273 
       ≥ 3 cups/ day 66.7 % 65.4 % 0.849 
* Age at registration, ✝ before diagnosis, ‡ exposure for more than 6 months, § includes herbicides, 
insecticides, fungicides and fumigants. 
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There were no statistically significant differences in any of the environmental risk exposures 
that are considered to either decrease the risk of developing PD or increase the risk of 
developing PD (Figure 13.4) between those diagnosed with PD aged less than (or equal to) 40 
years and those diagnosed with PD after the age of 40 years (Table 13.3).  
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Figure 13.4 shows the proportion of patients who were exposed to solvents, pesticides or 
heavy metals  before the diagnosis of PD, as recorded on the MERQ-PD baseline 
questionnaire (on the y-axis) and their age at onset of PD (on the x-axis). There were no 
significant differences in the exposure to solvents (p=0.685), pesticides (p=0.492) or heavy 
metals (p=0.788) between those with age at onset ≤ 40 years and those with age at onset > 40 
years. 
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Table 13.3 Variation in environmental exposures (as risk factors) in cases (n=210)  
from the EOPD cohort classified by age at onset of PD. 
 
Variable  Age onset ≤ 40 yrs.                     
   median (IQR) 
Age onset > 40 yrs. 
    median (IQR) 
p- 
value 
Number of cases 50 160 - 
Age* (years) 47.2 (41.6-51.9) 53.5 (49.7-57.0) <0.001 
Sex (males) 72.0 % 60.0 % 0.135 
Disease duration (years) 8.4 (4.7-15.0) 7.2 (3.1-11.2) 0.031 
Solvents✝
‡
 25.6 % 22.7 % 0.685 
Pesticides
§
 55.8 % 49.6 % 0.492 
Heavy metals✝
‡
  9.3 % 12.8 % 0.788 
Smoking✝ 39.5 % 30.5 % 0.271 
Caffeine intake✝    
       < 3 cups/ day 14.0 % 14.9 % 0.879 
       ≥ 3 cups/ day 58.0 % 68.8 % 0.161 
* Age at registration, ✝ before diagnosis, ‡ exposure for more than 6 months, § includes herbicides, 
insecticides, fungicides and fumigants. 
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There were no statistically significant differences in any of the environmental risk exposures 
that are considered to either decrease the risk of developing PD or increase the risk of 
developing PD (Figure 13.5) between those with a positive family history of PD compared to 
those with a negative family history of PD (Table 13.4).  
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Figure 13.5 shows the proportion of patients who were exposed to solvents, pesticides or 
heavy metals  before the diagnosis of PD, as recorded on the MERQ-PD baseline 
questionnaire (on the y-axis) and their family history (FH) of PD (on the x-axis). 
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Table 13.4 Variation in environmental exposures (as risk factors) in cases (n=210)  
from the EOPD cohort classified by family history of PD. 
 
Variables Positive FH  
median (IQR) 
Negative FH  
median (IQR) 
p- 
value 
Number of cases 52 158 - 
Age* (years) 52.0 (47.4-55.9) 52.7 (47.5-56.6) 0.586 
Sex (males) 63.5 % 62.7 % 1.000 
Disease duration (years) 6.0 (3.7-11.3) 7.6 (3.7-11.7) 0.602 
Solvents✝
‡
 20.5 % 24.3 % 0.686 
Pesticides
§
 50.0 % 51.4 % 0.869 
Heavy metals✝
‡
  6.8 % 13.6 % 0.294 
Smoking✝ 38.6 % 30.7 % 0.359 
Caffeine intake✝    
       < 3 cups/ day 13.6 % 15.0 % 0.824 
       ≥  3 cups/ day 61.5 % 67.7 % 0.414 
FH = family history, * age at registration, ✝ before diagnosis, ‡ exposure for more than 6 months, § 
includes herbicides, insecticides, fungicides and fumigants. 
 
 
 
13.5 Discussion 
 
Environmental influences that have been linked to PD include pesticides [468], heavy metals 
[469] , solvents [470] , smoking [471] , coffee [472] , rural living [473] and well water [474]. 
Although some of the findings have not been replicated across all surveys but exposure to 
pesticides increasing the risk of PD while smoking and coffee consumption decreasing the 
risk seem to stand out even in meta-analyses [194].  
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The influence of gender vis a vis environmental risk factors such as coffee drinking has been 
reported  in a meta-analysis of 8 case–control studies and 5 cohort studies on coffee drinking 
[475]. Interestingly, the two cohort studies in this meta-analysis that included only men (i.e., 
the Honolulu Heart Study and the Health Professionals' Follow-up Study) [472, 476] found a 
strong inverse linear relation between cups of coffee and risk of PD (pooled relative risk per 
three additional cups/day, 0.51; 95% confidence intervals, 0.31–0.83), whereas the cohort 
study that included only women (i.e., the Nurses' Health Study) [475] found a virtually null 
linear relation (relative risk per three additional cups/day, 1.00; 95% confidence intervals, 
0.74–1.34). Our results didn’t show any differences in coffee intake between the genders 
(Table 13.2). The only difference in exposure to any of the environmental risk factors  was 
the prevalence of exposure to solvents which was reported more by males compared to 
females (p<0.001). 
 
The influence of environmental factors on the age of onset of PD has also been investigated. 
In a study of 80 patients with LOPD (> 60 years), 69 EOPD (<40 years), and 149 age- and 
sex-matched control subjects, there were no significant differences in early life experiences 
or environmental exposures between the EOPD and LOPD patients [477]. Our results also 
showed no differences in the exposure to environmental agents considered in this study in 
between the two groups (Table 13.3). 
 
The influence of environmental risk factors on the motor subtype of PD has been reported. In 
a study of 212 PD patients and 175 age- and gender-matched controls    showed that the 
inverse association of smoking (p=0.046) and alcohol consumption (p=0.07) was only seen in 
PIGD cases and not in TDPD cases, which was similar to controls [478]. Our results, 
however, showed no significant differences in the exposure to environmental agents 
considered in this study in between the three groups (Table 13.1) suggesting that the motor 
subtypes of PD are not influenced by environmental risk factors, considered in this analysis, 
preceding the diagnosis of PD. 
 
Those with a positive family history of PD, particularly across more than 2 generations, 
would very likely to point to a heritable trait and therefore genetic factors responsible for the 
aetiology , however, for those with sporadic PD one can hypothesize that there must be some 
environmental risk factor that is related to the disease process in question. Surprisingly there 
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was no difference in exposure to environmental agents considered in this study in between 
the two groups (Table 13.4). 
 
We did not attempt to analyse whether certain environmental influences increase or decrease 
the chances of developing PD during a person’s lifetime for that would require a much larger 
cohort of patients and controls to draw any definite conclusions, perhaps some of those 
answers can only be gained from meta-analyses of datasets from several large studies pooled 
together. In this study, our aim was only to find out whether certain environmental influences 
were more or less likely to be associated with certain subtypes of PD, and more specifically 
to analyse this issue within an EOPD cohort. On their own each of these environmental risk 
factors, that we analysed, can not be sufficient to explain all the heterogeneity of PD and 
recent studies have tried to explore the mechanisms of gene-environment interactions 
(discussed further in Chapter 15). 
 
It may also be pertinent to point out, this analysis doesn’t consider iatrogenic factors as 
environmental influences to determine their role in explaining the heterogeneity in the 
clinical expression of PD but these are analysed in more detail in Chapter 14.  
 
13.6 Conclusion 
 
The subtypes of PD analysed in this thesis are not significantly influenced by environmental 
risk factors preceding the diagnosis of PD with the exception of solvent exposure being more 
commonly reported by males compared to females. This does not, however, take into 
consideration the influence of environmental factor such as drug effects, analysed in detail in 
the next chapter, on the clinical heterogeneity of PD or the fact that the predominant basis for 
the sub-typing could be due to internal biological factors rather than external influences. 
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Chapter 14. Iatrogenic influences causing variation in Parkinson’s disease 
 
 
  
 
14.1 Objectives 
 
The primary objective of this chapter is to analyse the variation in the medication 
prescriptions (iatrogenic influence) in a cohort of patients with early onset Parkinson’s 
disease from the PRoBaND study. A secondary objective is to explore system specific side 
effects, using the cardiovascular system as an example, of dopaminergic drugs and other 
medications prescribed for comorbid conditions. We analysed a separate incidental cohort of 
360 Parkinson’s disease patients specifically for cardiac side effects. 
 
14.2 Introduction 
 
Levodopa initially provides good symptomatic control of parkinsonian symptoms. As 
symptomatic control deteriorates other classes of anti-parkinsonian drugs including dopamine 
agonists, catechol-O-methyl transferase inhibitors, or monoamine oxidase type B inhibitors 
are then added as adjuvant therapy [479]. The variation in medication requirements is largely 
determined by disease severity and duration [480], however, we wished to explore this 
further to find whether the motor subtype, gender, age at onset of Parkinson’s disease (PD) 
and heritability of the parkinsonian trait also contributed to the variation. Iatrogenic problems 
in PD can have several manifestations ranging from the well-recognised side effects of 
dopaminergic medications such as nausea and orthostatic symptoms in the short term to 
dyskinesia in the long term. This spectrum of iatrogenic adverse events seems to be 
expanding with more recently reported associations such as peripheral neuropathy , reversible 
corneal oedema and the dopamine dysregulation syndrome[481-483]. In order to explore the 
variation in system specific adverse effects we analysed a separate incidental cohort of 
patients, without any preselection bias of study protocol, for cardiac side effects of anti-
parkinsonism drugs and other medications prescribed for comorbid conditions.  
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14.3 Methods 
 
The assessment for iatrogenic influence in PD was done in two stages. Patients from the 
EOPD cohort of the PRoBaND study were the subject of analysis for the iatrogenic 
influences in PD in the first stage. They attended 6 monthly clinic visits as per study protocol 
described in detail in Chapter 3. They were asked to fill in questionnaires for demographic 
data and a medication list at baseline (visit 0). Levodopa equivalent daily doses (LEDD) in 
mg/day were calculated using the formula described in detail in Chapter 5.  
 
In order to analyse the variation in the medication requirements as an indicator of iatrogenic 
influences, all cases with EOPD were classified in 4  ways: according to motor subtypes 
(TDPD, PIGD and ‘Mixed’), gender, age at onset of PD symptoms and heritability of the 
Parkinsonian trait as described in Chapter 4. 
 
Further analysis of the iatrogenic influences in PD was done using a different cohort of 360 
recently attending patients at 3 movement disorder clinics across Glasgow to specifically look 
at the cardiac side effects induced by drug prescription, as an example of unintended 
detrimental side effects of therapy. The results of the latter study are presented as a stand-
alone paper that was published in the journal Parkinsonism and Related Disorders and is 
added as an appendix to this chapter. 
 
Statistical analysis: 
 
Descriptive data are presented as median and inter-quartile range (IQR) as data in most 
instances failed tests of normality (Shapiro Wilk). Kruskal Wallis test was used for inter-
group comparisons of numerical data in scenarios where cases where classified into 3 groups 
e.g. motor subtypes with post hoc comparisons between groups using Mann Whitney U if the 
Kruskal Wallis test statistic showed a significant difference between the 3 groups. Mann 
Whitney U test was used for inter-group comparisons of numerical data where cases were 
classified into 2 groups e.g. males and females. Chi square tests or Fisher’s exact tests were 
used for comparing groups for categorical data as appropriate. 
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Generalised linear models, based on ANCOVA, were  used with age ,disease duration and 
Hoehn Yahr stages as covariates to determine the effect of the motor subtype, gender, age at 
onset and hereditary versus sporadic parkinsonism (independent variables) on the LEDD 
(dependent variable). Hoehn Yahr staging was used as a covariate in preference to MDS-
UPDRS part 3 scores as the latter are influenced by the time during the day these are 
recorded, before or after taking PD medications, ‘on’ or ‘off’ state and there is greater inter-
individual variation in clinical scoring. Logarithmic transformations (base 10) of numerical 
data were used where tests of normality (Shapiro Wilk) failed.  
 
All statistical analyses were two-sided and significance level was set at 5%. Statistical tests were 
performed using Prism software (version 4.0 for Windows; CA, USA) and SPSS software (version 23 
for Windows; IL, USA). 
 
14.4 Results 
 
276 patients had completed all questionnaires relevant to medication exposures analysis 
(Figure 14.1) and this is indicated in the relevant tables (Tables 14.1- 14.4). Their 
demographic details have been presented in Table 5.1 in Chapter 5.  
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Figure 14.1 shows the disoposition of cases prior to data analysis for this chapter. No data 
imputation was allowed. Those who had incomplete questionnaires relevant to this analysis 
were not included. 
 
 
The variation in anti-parkinsonian medication (PDMED) prescription as a risk factor for 
iatrogenic adverse events in these patients, classified by motor subtype, is presented in Table 
14.1. There were statistically significant differences in PDMED prescription between the 
three motor subtypes (p=0.003) (Figure 14.2). Post hoc analysis showed the differences to be 
between TDPD and PIGD (p<0.001)   but not between PIGD and ‘Mixed’ (p= 0.616) or 
between TDPD and ‘Mixed’ (p=0.134). 
Initial recruitment 
target 
N = 240 
Incomplete 
questionnaires 
N = 50 
Additional cases 
recrutited 
N = 86 
Full dataset 
available 
N = 276 
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Figure 14.2 shows the proportion of patients who were prescribed one, two, three or four 
classes of PD medications (PDMED) (on the y-axis) and their motor subtype (on the x-axis). 
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Table 14.1 Variation in anti-parkinsonism medication exposure in cases (n=276) from the 
EOPD cohort classified by motor subtype. 
Medications     TDPD 
   median (IQR) 
     PIGD   
  median (IQR) 
    Mixed 
median (IQR) 
p- 
value 
Number of cases 155 100 21 - 
Age *(years) 50.4 (45.1-54.3) 54.6 (48.8-59.8) 49.6 (46.9-52.5) <0.001 
Sex (males) 64.1 % 59.0 % 65.0 % 0.356 
Duration (years) 5.1 (2.0-9.6) 9.1 (4.6-15.0) 7.4 (2.5-11.8) <0.001 
L-DOPA 65.2 % 88.0 % 90.5 % 0.222 
DA 45.8 % 49.0 % 33.3 % 0.669 
MAOBI 45.8 % 39.0 % 33.3 % 0.385 
COMTI 23.9 % 42.0 % 33.3 % 0.624 
Amantadine 14.2 % 26.0 % 23.8 % 0.622 
1 class of  PDMED 25.2 % 16.0 % 28.6 % 0.172 
2 classes of PDMED 38.7 % 41.0 % 38.1 % 0.927 
3 classes of PDMED 22.6 % 34.0 % 19.0 % 0.095 
4 classes of PDMED 7.1 % 8.0 % 9.5 % 0.909 
LEDD (mg/day) 599 (300-965) 840 (532-1043) 738 (538-1053) 0.003 
HY stage 2.0 (1.0-2.0) 2.0 (2.0-3.0) 1.5 (1.0-2.0) <0.001 
* Age at registration, IQR = inter-quartile range.  Data are presented in median (inter-quartile range) except 
where indicated, DA = dopamine agonists, MAOBI = monoamine oxidase B inhibitors, COMTI= catechol-o-methyl 
transferase inhibitors, PDMED = Parkinson’s disease medication, LEDD = levodopa equivalent daily dose, HY = 
Hoehn Yahr stage. 
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Classifying patients by gender showed no differences in the classes of anti-parkinsonsian 
medications prescribed (Figure 14.3) but more males were prescribed COMTI (p=0.016) 
while more females were prescribed Amantadine (p=0.011) (Table 14.2). 
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Figure 14.3 shows the proportion of patients who were prescribed one, two, three or four 
classes of PD medications (PDMED) classified by gender. 
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Table 14.2 Variation in anti-parkinsonism medication exposure in cases (n=276) from the 
EOPD cohort classified by gender. 
 
Variable 
 
           Males 
        median (IQR) 
        Females 
     median (IQR) 
p- 
value 
Number of cases         177         99 - 
Age*( years)    51.7 (46.5-56.8)   51.1 (47.2-55.6) 0.968 
Duration (years)    7.3 (2.8-11.5)   6.5(2.6-11.9) 0.737 
L-DOPA 75.1 % 75.8 % 0.909 
DA 42.9 % 51.5 % 0.170 
MAOBI 41.2 % 44.4 % 0.606 
COMTI 36.2 % 22.2 % 0.016 
Amantadine 14.7 % 27.3 % 0.011 
1 class of PDMED 22.6 % 21.2 % 0.790 
2 classes of PDMED 38.4 % 41.4 % 0.625 
3 classes of PDMED 26.6 % 26.3 % 0.958 
4 classes of PDMED 7.9 % 7.1 % 0.801 
LEDD (mg/day) 760 (400-1030) 600 (328-986) 0.453 
HY stage     2.0 (1.5-2.5)   2.0 (1.3-2.5) 0.513 
* Age at registration, IQR = inter-quartile range.  Data are presented in median (inter-quartile range) except 
where indicated, DA = dopamine agonists, MAOBI= monoamine oxidase B inhibitors, COMTI = catechol-o-methyl 
transferase inhibitors, PDMED = Parkinson’s disease medication, LEDD = levodopa equivalent daily dose, HY = 
Hoehn Yahr stage. 
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There were no differences in anti-parkinsonism medication prescription between those 
diagnosed with PD aged less than (or equal to) 40 years compared to those diagnosed after 
the age of 40 years (Figure 14.4) except more patients in the latter sub-group were prescribed 
COMTI (p=0.014) (Table 14.3). 
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Figure 14.4 shows the proportion of patients who were prescribed one, two, three or four 
classes of PD medications (PDMED) classified by age at onset of PD. 
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Table 14.3 Variation in anti-parkinsonism medication exposure in cases (n=276) from the 
EOPD cohort classified by age at onset of PD. 
 
Variable     Age onset ≤ 40 yrs. 
        median (IQR) 
    Age onset > 40 yrs. 
       median (IQR) 
p- 
value 
Number of cases 64   212 - 
Age* ( years) 44.6 (40.2-50.8) 52.9 (48.8-57.0) <0.001 
Sex (males) 67.2 % 63.2 % 0.561 
Duration (years) 7.9 (3.7-15.0) 6.6 (2.5-11.3) 0.707 
L-DOPA 79.7 % 74.1 % 0.411 
DA 46.9 % 45.8 % 0.887 
MAOBI 46.9 % 41.0 % 0.408 
COMTI 18.8 % 34.9 % 0.014 
Amantadine 23.4 % 17.9 % 0.366 
1 class of PDMED 21.9 % 22.2 % 0.870 
2 classes of PDMED 43.8 % 38.2 % 0.427 
3 classes of PDMED 28.1 % 25.9 % 0.748 
4 classes of PDMED 3.1 % 9.0 % 0.178 
LEDD (mg/day) 700 (363-998) 715 (400-1008) 0.171 
HY stage 2.0 (1.0-2.5) 2.0 (1.5-2.5) 0.016 
* Age at registration, IQR = inter-quartile range.  Data are presented in median (inter-quartile range) except 
where indicated, DA = dopamine agonists, MAOBI = monoamine oxidase B inhibitors, COMTI = catechol-o-methyl 
transferase inhibitors, PDMED = Parkinson’s disease medication, LEDD = levodopa equivalent daily dose, HY = 
Hoehn Yahr stage 
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There were no differences in anti-parkinsonism medication prescription between those with a 
positive family history of PD compared to those with a negative family history of PD (Figure 
14.5) except more patients in the former sub-group were prescribed 3 classes of anti-
parkinsonian medications (p=0.009) compared to the latter (Table 14.4). 
 
 
 
1  P D M E D 2  P D M E D s 3  P D M E D s 4  P D M E D s
0
2 0
4 0
6 0
P
ro
p
o
rt
io
n
 o
f 
c
a
s
e
s
 (
%
)
P o s it iv e  F H
N e g a tiv e  F H
Figure 14.5 shows the proportion of patients who were prescribed one, two, three or four 
classes of PD medications (PDMED) classified by family history (FH) of PD.  
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Table 14.4 Variation in anti-parkinsonism medication exposure in cases (n=276) from the 
EOPD cohort classified by family history of PD. 
Variable   Positive FH 
median (IQR) 
     Negative FH 
    median (IQR) 
p- 
value 
Number of cases 64 212 - 
Age* (years) 52.2 (47.3-56.8) 51.2 (46.9-56.1) 0.582 
Sex (males) 65.6 % 63.7 % 0.776 
Duration (years) 6.7 (3.5-12.1) 6.8 (2.5-11.3) 0.312 
L-DOPA 81.3 % 73.6 % 0.249 
DA 43.8 % 46.7 % 0.679 
MAOBI 59.4 % 37.3 % 0.002 
COMTI 34.4 % 30.2 % 0.526 
Amantadine 18.8 % 19.3 % 0.916 
1 class of PDMED 18.8 % 23.1 % 0.607 
2 classes of PDMED 31.3 % 42.0 % 0.124 
3 classes of PDMED 39.1 % 22.6 % 0.009 
4 classes of PDMED 9.4 % 7.1 % 0.591 
LEDD (mg/day) 824 (460-1033) 655 (400-1000) 0.191 
HY stage 2.0 (1.5-2.0) 2.0 (1.5-2.5) 0.583 
FH = family history, * Age at registration, IQR = inter-quartile range.  Data are presented in median (inter-
quartile range) except where indicated, DA = dopamine agonists, MAOBI = monoamine oxidase B inhibitors, 
COMTI = catechol-o-methyl transferase inhibitors, PDMED = Parkinson’s disease medication, LEDD = Levodopa 
equivalent daily dose, HY = Hoehn Yahr stage. 
 
 
 
14.5 Discussion 
 
 
Iatrogenic influences in the general population due the prescription of drugs with dopamine 
receptor blocking potential can cause drug induced parkinsonism (DIP) which is the most 
prevalent cause of secondary parkinsonism in clinical practice in the western world [484]. 
More importantly subclinical Lewy body disease in some cases may provide a pathologic 
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substrate for an individual’s susceptibility to DIP and the persistence of parkinsonian 
symptoms even after the withdrawal of dopamine receptor blockers in such cases may 
represent drug unmasked parkinsonism (DUP). Latent disruption of the dopaminergic 
nigrostriatal projections, as evident on L-6-[F
l8
] fluorodopa positron emission tomography 
(
18
F-dopa PET), in DUP is different from DIP which has normal presynaptic dopaminergic 
uptake [485]. 
 
Drugs that are used to treat PD can have both dose related side effects as well as idiosyncratic 
and novel side effects such as dopamine dysregulation syndrome. Therefore, as an unintended 
consequence of the art of healing, physicians expose their patients to the double edged sword 
of anti-parkinsonism drugs. It is also reported that patients with PD are vulnerable to cardiac 
adverse effects of drugs due to inherent autonomic dysfunction compounded by similar side 
effects of a number of prescribed medications and this is analysed separately. 
 
The prescription of these drugs is primarily determined by the motor disability of PD but 
influenced by other factors such as patient preference, side effects and drug interactions. In 
order to analyse the variation in prescription of these drugs to see whether this is influenced 
by the clinical subtypes of PD after adjusting for confounding variables such as age, disease 
duration and motor disability we classified patients as described in Chapter 3. Our results 
showed that the medication requirements in LEDD (mg/day), after adjusting for differences 
in age, disease duration and motor disability, were significantly greater in those with the 
PIGD phenotype and TDPD (p<0.001) but there were no significant differences in LEDD 
between the TDPD and ‘Mixed’ or PIGD (p=0.616) and ‘Mixed’(p=0.134) phenotypes. This 
is not surprising given that PIGD is less treatment responsive than the TDPD phenotype as 
levodopa had marked symptomatic effects on all features, but low potency for effect on PIGD 
(ED50 of 1237 mg/ day compared with 7–24 mg/ day
 
 for other motor and non-motor features) 
[486].  
 
The influence of gender on medication requirements has not been directly investigated, 
however, several previous studies looking at gender differences in  non-motor characteristics 
reported no differences in LEDD in males and females while analysing their baseline 
characteristics[327, 487]. Our results showed no significant differences in medication 
requirements in LEDD (mg/day), after adjusting for differences in age, disease duration and 
motor disability, between the two groups (p=0.453). 
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The influence of age at onset of PD on medication requirements (levodopa daily dose) was 
investigated in the Sydney multicentre study. There was no significant difference in the 
levodopa requirements at 5 years in those diagnosed with PD at age less than 70 years 
compared to those diagnosed with PD after the age of 70 years but this was not corrected for 
disease stage [488]. Another study comparing 43 patients with old onset (age onset >78 
years) compared to 81 middle age onset (age onset 43-66 years) patients found no significant 
differences in the dose of levodopa or dopamine agonists between the 2 groups at 2 years but 
this was also not corrected for disease stage. We adjusted for disease duration and differences 
in UPDRS 3 scores and found no significant differences in medication requirements in LEDD 
(mg/day), after adjusting for differences in age, disease duration and motor disability, 
between the two groups (p=0.171). 
 
The influence of family history of PD on medication requirements has not been investigated. 
Our results showed no significant differences in medication requirements in LEDD (mg/day), 
after adjusting for differences in age, disease duration and motor disability, between the two 
groups (p=0.191). 
 
 
14.6 Conclusion  
 
 
The major determinants of medication requirements in PD are age, disease duration and 
motor disability. Patients with the PIGD phenotype have motor symptoms that are less 
responsive to dopamine replacement and therefore require significantly greater anti-
parkinsonian medications compared to TDPD. Levodopa was the most frequently prescribed 
medication (75% of cases) followed by dopamine agonists (60%), MAOBI (42%) and 
COMTI (32%). Most patients required 2 or 3 classes of PD medications at a median disease 
duration of 6.8 (2.7-11.5) years. 
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Original observations: Study of drug usage and iatrogenic influences on the 
cardiovascular system in PD. 
 
Abstract 
 
Introduction 
 Epidemiological studies report an association of ventricular arrhythmias with medication 
through prolongation of the cardiac QT interval. This has implications in the management of 
Parkinson’s disease, as commonly prescribed drugs for non-motor symptoms and 
comorbidities have QT prolonging potential. 
Objectives 
 To review prescribed medication in Parkinson’s disease patients, in particular the use of 
drugs that may prolong the cardiac QT interval, in relation to other risk factors for QT 
prolongation. 
 
Methods 
Medication prescription and doses, presence of underlying cardiac disease, patient age, and 
sex were recorded in a cross-sectional sample of 360 current PD patients attending two 
district and one regional specialist hospital based movement disorder clinics. 
 
Results 
We sampled 360 consecutive patients with PD, median age 66.5 years (interquartile range 
58.5-74.8) and median disease duration 4.2 years (interquartile range 1.2 -8.0 years).  125 
(34.7%) were taking one or more drugs with definite potential to prolong QT, including 
domperidone in 91 (25.2%), citalopram or escitalopram in 47 (13.1%), and concurrent 
antibiotics in 5 (1.3%). Cofactors increasing the risk for QT interval prolongation were: age 
over 60 years 71.7%, female sex 46.9% and presence of cardiac disease 19.2%. In patients 
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with combined risk factors, the rate of prescription of at least one definite QT prolonging 
drug was between 34.5 and 42.1%. 
 
Conclusion 
 Combination therapy and comorbidity relevant to cardiac QT prolongation are common in 
patients with Parkinson’s disease. Strategies to reduce the proportion of patients at risk from 
iatrogenic adverse cardiac events are warranted. 
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Introduction 
 
The therapeutic management of Parkinson’s disease (PD) has broadened with increased 
recognition and treatment of non-motor symptoms affecting quality of life, such as 
depression and bladder dysfunction [489]. Epidemiological studies show an association of 
some of these treatments with cardiac arrhythmia, through prolongation of the corrected 
cardiac QT interval (QTc), resulting in torsades de pointes or ventricular tachycardia, which 
are often fatal [490, 491]. Those studies have led to regulatory alerts from government and 
federal  drug regulatory agencies, in particular for citalopram and domperidone[492, 493]. 
In general terms, QT prolongation predicts cardiovascular mortality and may be an 
independent risk factor for stroke [494, 495]. The issue of drugs with adverse potential on 
cardiac conduction requires particular consideration, because of an inherent propensity to 
autonomic dysregulation in PD worsened by extraneous factors, which may collectively 
contribute to patient morbidity and even premature death. Concern about these drugs is not 
restricted to the rare congenital long QT syndromes caused by mutations in genes encoding 
cardiac ion channels. In the management of patients with Parkinson’s disease, acquired 
factors of relevance which can impact on cardiac conduction include iatrogenic autonomic 
disturbances, cardiovascular comorbidities such as cardiac ischemia or ventricular 
hypertrophy, and the concurrent use of other drugs such as diuretics resulting in electrolyte 
imbalance [496]. 
 
Several classes of drugs are implicated in QTc prolongation, including anti-emetics, 
antidepressants, and antibiotics. Domperidone is frequently used in PD in Europe and 
elsewhere, both for its licensed antiemetic indication, and ‘off-label’ to treat symptomatic 
postural hypotension. It is not approved in the US, and was the subject of a 2004 warning by 
the Food and Drug Administration (FDA) against unregulated use to increase lactation, 
because of safety concerns regarding the cardiac QT interval. The association of 
domperidone in epidemiological studies with a small but significant increased risk (odds ratio 
1.6-3.7) of ventricular arrhythmias and sudden cardiac death, resulted in safety updates in 
2011-12 by the United Kingdom Medicines Health Regulatory Agency (MHRA), and Canada 
Health. The need to review the patient’s on-going requirement for domperidone and to avoid 
doses higher than 30mg per day whenever possible, are emphasized. 
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Citalopram and escitalopram may also prolong the QT interval and a recent MHRA safety 
update has reduced the maximal safe dose of citalopram to 20mg daily in patients older than 
65 years. 
 
Combination of these agents with some antipsychotics (e.g. haloperidol), tricyclic 
antidepressants, antimicrobial agents (e.g. intravenous erythromycin), antihistamines (e.g. 
astemizole) and anti-retrovirals (e.g. ritonavir) have additive influences on QT interval 
prolongation.  
A second FDA safety alert also highlights that patients with hepatic impairment, the elderly, 
poor CYP2C19 metabolizers (i.e. the cytochrome P450 isoform that metabolizes citalopram), 
or patients taking cimetidine or other CYP2C19 inhibitors should not receive citalopram 
above 20mg daily as the resulting increased citalopram concentration increase the risk of QTc 
prolongation and subsequent torsade de pointes.  
We examined the usage of drugs with the potential to prolong the cardiac QT interval, and 
the presence of other risk factors, in a broadly representative sample of Parkinson’s disease 
patients from the local community, to determine an estimate of the prevalence of this issue 
and if changes in clinical practice could improve patient safety. 
 
Methods 
 
Medication prescription and doses, presence of underlying cardiac disease, patient age, and 
sex were recorded in a cross-sectional sample of 360 current PD patients attending two 
district and one regional specialist hospital based movement disorder clinics. 
 
Drugs with potential to prolong the cardiac QT interval were tabulated according to the 
classification as definite, possible, and conditional, according to the Arizona Center for 
Education and Research on Therapeutics (ACERT) which includes agents not approved by 
the FDA, and is recognised by other groups. Drugs that inhibit the metabolism of 
domperidone and citalopram, and increasing their arrhythmogenic potential from elevated 
plasma levels were also noted. Drugs relevant only to congenital QT syndromes e.g. 
salbutamol were not included. 
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Risk factors for cardiac QT interval prolongation besides drugs were used from the third 
national health and nutrition examination survey of the Food and Drug Administration (FDA) 
of the United Sates. 
 
Fisher’s exact test was used to compare groups, using Prism (version 5.0, GraphPad 
Software, CA, USA). 
 
Results 
 
We sampled 360 consecutive PD patients (191 male, 53 %), median age 66.5 years 
(interquartile range 58.5-74.8), median disease duration 4.2 years (interquartile range 1.2 -8.0 
years) in this study. 125 (34.7%) were taking one or more drugs with definite potential to 
prolong QT, including domperidone in 91 (25.2%), citalopram or escitalopram in 47 (13.1%), 
and concurrent antibiotics in 5 (1.3%). Prescription rates for drugs with possible and 
conditional effects on QT were lower (Table 14.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
296 
 
Table 14.5 Number of drugs prescribed in 360 patients with Parkinson’s disease, by drug 
class, according to risk grading for prolongation of the cardiac QT interval.  
Drug class        Potential for QT prolongation  
  
  
Definite Possible Conditional 
Total 
N (%) 
Antibiotics     
Clarithromycin 3   3 
Erythromycin 2   2 
Trimethoprim   9 9 
Ciprofloxacin   3 3 
 sub-total 5   12 17 (5.9) 
Cardiac 
     
Sotalol 2   2 
Dronaderone  1  1 
 sub-total 2 1   3 (1.4) 
Gastrointestinal 
     
 Domperidone 91     91 (31.4) 
Neurological     
 Amantadine   30   30 (10.3) 
Psychiatric 
     
  Antidepressants     
Citalopram 46   46 
Escitalopram 1   1 
Venlafaxine  4  4 
Amitriptyline   25 25 
Fluoxetine   22 22 
Sertraline   8 8 
Dothiepin   4 4 
Paroxetine   2 2 
Trazodone   1 1 
 sub-total 47 4 62 113 (39) 
 Antipsychotics     
Quetiapine  11  11 
Lithium  5  5 
  sub-total    16   16 (5.5) 
Genitourinary     
Alfuzosin  3  3 
Solifenacin   17 17 
 sub-total   3 17 20 (6.9) 
Total number of drugs 145 54 91 290 
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One definite QT prolonging drug was prescribed in 106 patients (29.4%), while there was co-
prescription of 2 such drugs in 19 patients (5.0%) and 3 such drugs in 1 patient (0.3%) (Table 
14.6). 
 
Table 14.6 Number of QT prolonging drugs prescribed per patient according to ACERT risk 
grading. 
QT effect         
 
Number of QT prolonging drugs prescribed 
 Patients, n (%) 
     
1 2 3 
    
Definite 106 18 1 125 (34.7%) 
Possible  46 4 - 50 (13.9%) 
Conditional 75 8 -  83 (23.1%) 
ACERT= Arizona Center for Education and Research on Therapeutics 
 
The prevalence of cofactors, individually and combined, and the number of drugs with 
definite QT prolonging effect are shown in Table 14.7. Cofactors increasing the risk for QT 
interval prolongation were: age greater than 60 years 71.7%, female sex 46.9%, and presence 
of cardiac disease 19.2%. Considering a combination of these risk factors, the rate of 
prescription of at least one definite QT prolonging drug was between 34.5 and 42.1%, 
although this involved progressively fewer patients (Table 14.7). While older patients were 
more likely to have cardiac disease (p=0.0234) and to be prescribed diuretics (p=0.0006), 
they were no more likely to be on drugs with definite or possible QT prolonging effects than 
younger patients. 
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Table 14.7 Individual and combined risk factors in patients (n=360) prescribed one or more 
drug with definite potential to prolong the cardiac QT interval  
Risk factor N (% ) 
Number of definite QT prolonging drugs 
 
1 2 3 Total n (%) 
Age over 60 years 262 (71.7%) 74 13 1 88 (33.6%) 
Female 169 (46.9%) 54 13 0 67 (39.6%) 
Cardiac disease 69 (19.2%) 19 2 0 21 (30.4%) 
Over 60 + female 126 (35.0%) 40 10 0 50 (39.7%) 
Over 60 + cardiac disease 58 (16.1%) 18 2 0 20 (34.5%) 
Over 60 + female + 
cardiac disease 19 (5.3%) 7 1 0 8 (42.1%) 
 
Four of 47 patients (8.5%) aged over 65 years were prescribed citalopram above the new 
recommended maximum of 20mg daily, and 16 of 91 (17.5%) were on domperidone 
exceeding 30mg daily.  There was no evidence of increased prescription of domperidone in 
patients taking dopamine agonists (35/136, 25.7%) versus other anti-parkinsonian therapy 
(56/205, 27.3%), p=0.803. 
 
Prescription of other medications with drug-drug interactions that may increase plasma levels 
of domperidone or citalopram through interaction with the hepatic cytochrome P450 system 
were absent in relation to domperidone, as no patients had concomitant use of agents 
metabolized by the CYP3A4 system (e.g. ketoconazole); however, 16 of 47 patients 
prescribed citalopram (34%) were co-prescribed agents that share its CYP2C19 metabolic 
pathway, consisting of proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, 
pantoprazole) in 15/16 (93.8%) and modafinil in 1/16 (6.3%).  
 
Discussion 
 
Prolongation of the QT interval, which is usually multifactorial, can lead to torsades de 
pointes, a specific and often self-limiting arrhythmia which may progress to fatal ventricular 
arrest [497, 498]. The epidemiological association of co-prescription of more than one drug 
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with adverse cardiac events to PD patients, through the mechanism of cardiac QT 
prolongation and resultant arrhythmia, have not been previously examined in this population. 
Domperidone was the most frequently prescribed agent with definite potential to prolong the 
QT interval in our study. Patients taking domperidone at a daily dose exceeding 30mg are 
highlighted as a risk group in the MHRA safety update based on large epidemiological 
studies. A population-based case control study found that 10 of 1304 cases of sudden cardiac 
death were in domperidone treated patients, giving an odds ratio (OR) of domperidone for 
sudden cardiac death of 3.72 (95% CI 1.72-8.08) [492]. A retrospective case control study of 
83212 individuals exposed to domperidone or a proton pump inhibitor found 1608 serious 
cardiac events (1559 sudden deaths; 49 ventricular arrhythmias), giving an OR for current 
domperidone use of 1.59 (95% CI 1.28-1.98) [493]. Domperidone is also the subject of 449 
reports through the UK ‘yellow card’ system of adverse drug event reporting, which included 
14 fatalities, half of those related to cardiac arrhythmia.  
 
It has been widely prescribed to PD patients in licensed areas including Europe, as a first 
choice antiemetic to avoid central postsynaptic dopamine receptor blockade. It has also been 
frequently used to treat symptomatic orthostatic hypotension in PD. The presence of 
orthostatic hypotension has often, paradoxically, been a potential indication for increasing the 
dose of domperidone for symptomatic management. If such treatment contributes to adverse 
cardiac events from self-limiting torsades de pointes which manifests as syncopal episodes 
and is misinterpreted by the clinician as persistent or worsening symptomatic orthostatic 
hypotension, dose escalation of domperidone could aggravate an already problematic 
situation. In such a scenario, the symptoms arising from orthostatic hypotension and cardiac 
dysrhythmia can also have a broader phenotype than typical pre-syncopal or syncopal events, 
with episodes of generalized weakness and mental ‘clouding’ being recognised as 
manifestations [499]. 
 
Given the increased risks of cardiac adverse events from domperidone (>30 mg /day) in the 
presence of autonomic dysfunction caution is clearly indicated however the question arises as 
to the level of risk in patients when such features are absent. 
 
In practical terms, the absence of orthostatic hypotension or syncope as markers of autonomic 
dysfunction does not remove the risk from drugs with potential to prolong the QT interval, as 
the mechanisms for peripheral and cardiac autonomic dysfunction differ; while around half of 
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those with orthostatic hypotension also have cardiac sympathetic dysfunction [500]. 
Randomized clinical trial evidence for domperidone having beneficial effects on orthostatic 
hypotension is very limited. In a crossover study with fludrocortisone in 17 patients without a 
placebo group, any positive effects noted were relative to non-pharmacological 
measurements in the run-in period of the study, and not performed on an intent-to-treat 
basis[501]. However, clinical experience of reduced side-effects when co-prescribing 
domperidone with dopamine agonists, in particular Apo morphine, is supported by autonomic 
measurements [502]. These competing elements of clinical management need to be 
considered in individual patient treatment decisions. Total daily doses of domperidone should 
be limited to 30 mg/day in PD patients and co-prescription of other QT prolonging drugs 
avoided. 
 
Citalopram was the second commonest drug with QT prolonging effects in our cohort. It is 
widely used to treat depression, in patients with and without PD, and has a convenient dosing 
schedule, but the problem of QT interval prolongation and torsades de pointes even at 
conventional doses has emerged [503].
 
Other selective serotonin reuptake inhibitors have 
lesser potential to prolong the cardiac QT interval, and are therefore graded possible rather 
than definite in the QT interval prolonging drugs risk classification. The balance of benefits 
and risks of citalopram and escitalopram should be considered carefully, particularly at 
higher doses, in patients with pre-existing risk factors for QT interval prolongation, such as 
significant bradycardia, recent acute myocardial infarction, or decompensated heart failure 
[492]. 
 
Several classes of antimicrobial drugs including macrolides (e.g. erythromycin, azithromycin, 
and clarithromycin), azoles (e.g. fluconazole, ketoconazole) and fluoroquinolones (e.g. 
ciprofloxacin) also have the potential to prolong the cardiac QT interval and thereby increase 
the risk of torsades. Given the intermittency of antibiotic use, our point estimate of 1.3% 
based on prevailing antibiotic therapy at the time of last clinic review is an underestimate of 
such exposure, and the overall rate of 5.2% patients receiving 2 or more QT prolonging drugs 
concurrently is therefore likely to be an underestimate. 
 
A case control study from a medical record database of 500000 people compared 775 cases 
of sudden cardiac death to 6297 matched controls; current use of non-cardiac QTc-prolonging 
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drugs was associated with an almost three-fold increased risk of sudden cardiac death [504].
 
Our study bridges the gap between such large epidemiological studies (none of which is 
specific to PD) and small PD studies examining drug effects on the cardiac QT interval. The 
findings from both types of study are relevant as a perspective to the current work. 
These large studies indicate that the detection of transient self-terminating ventricular 
arrhythmia causing syncopal events (potentially from QT prolonging drugs), would be 
difficult in the setting of outpatient movement disorder clinics as there would be too few 
events to recognise or adequately quantify. However cardiovascular events are one of the 5 
most frequent causes for hospital admission in PD patients [505]. While torsades de pointes is 
estimated to occur in 1-5% of patients treated with cardiac antiarrhythmic drugs that prolong 
QT, a much lower though inexactly quantified risk for non-cardiac drugs, that we studied, is 
expected, with epidemiological estimates of the population attributable risk of non-cardiac 
QTc-prolonging drugs being around 2% [504]. 
 
Although electrocardiographic recordings were not obtained in our study, which might be 
considered a limitation, they are perhaps surprisingly not central to the issues under 
consideration. ECG measurement is not definitive, as there is diurnal variation (often 
exceeding drug effects), correction is required for heart rate, and there are gender differences 
(a longer QT interval in females), meaning that the QT interval has varying definitions for 
normal, borderline, and prolonged [506, 507].
 
Further, a normal baseline QT interval (e.g. to 
screen pre-treatment) does not preclude the emergence of QT prolongation, exemplified by 
some congenital QT syndrome cases developing QT prolongation only while on an offending 
drug [508]. The large epidemiological studies used diagnostic coding for cardiac arrhythmia 
and sudden death, rather than ECG measurements, on the presumption that QT prolongation 
through drug exposure was the causative mechanism. ECG screening or monitoring is 
therefore not central to regulatory guidance [493]. Although it may be part of the assessment 
in patients with cardiac disease or cardiovascular symptoms, review of therapeutic need for 
particular treatments is the primary focus, noting upper dose limits (regardless of ECG 
findings) in relation to risk factors such as patient age. We therefore followed this practical 
approach in the present assessment of risk in PD patients. A prospective ECG study to 
provide more quantifiable information of the cardiac risk is now underway, to determine QT 
interval changes in relation to drugs, doses, and adjustments in therapy. 
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There is limited data on cardiac causes of death in PD. Autonomic effects or drug interactions 
were not considered causative of excess mortality found in one study in patients treated with 
levodopa and selegiline [161]. Prolonged cardiac QT intervals (451 and 470 msec in the year 
preceding death) in 2 of 48 PD patients who died suddenly were reported, but causation was 
not conclusive [509].
 
The QT interval has also been studied more directly in relation to 
autonomic function in PD patients. The QTc was prolonged in 30 PD patients, and correlated 
with the Valsalva ratio, patient age, and disease staging [510]. Similar observations regarding 
QTc and Valsalva, but not other markers of autonomic dysfunction, were made in 34 PD 
patients, selected to exclude cases with electrolyte imbalance, cardiac disease, or using QT 
prolonging drugs. Standard anti-parkinsonian medication did not affect the QT interval. 
Therefore caution is indicated in the prescription of other drugs for co- morbidities and non-
motor symptoms of PD that have QT prolonging properties. Both direct and indirect effects 
of these drugs may lead to adverse cardiac events. 
 
Conclusion 
 
As risk factors for acquired QT prolongation are common in PD, extra caution is often 
required when making treatment decisions for non-motor symptoms of PD such as orthostatic 
hypotension or depression. Adding or increasing the dose of drugs which may prolong the 
cardiac QT interval, in particular domperidone and citalopram, requires care in PD patients, 
taking due consideration of comorbidity, and concomitant drug therapy. This is of particular 
concern in PD patients compared to the general population due to the added dimension of 
autonomic dysfunction in PD and related disorders. 
 
 
 
 
 
 
Note: Additional references for this paper are available online in the journal: Parkinsonism 
Relat Disord. 2013 Jun; 19(6):586-9.  
303 
 
Chapter 15. Conclusions and future directions of PRoBaND 
 
 
 
Parkinson’s disease (PD) is a complex trait, and several molecular pathways and pathogenic 
mechanisms can lead to the clinical picture of parkinsonism. At the individual level there are 
several determinants of PD risk, and within populations, the causes of PD can be diverse 
[511]. Although mutations in many different genes are recognized to cause PD, these account 
for roughly about 10% or less of PD cases in the general population. Population based 
epidemiological studies suggest environmental factors may also be involved. Indeed, it may 
turn out that the interplay of environmental factors and our genetic makeup not only 
influences the risk of developing PD but also influences the variation in the phenotypic 
expression of PD.  
 
Early onset Parkinson’s disease (EOPD) is a recognised subset of patients with PD which 
differs from late onset Parkinson’s disease (LOPD) patients in several ways. EOPD cases 
tend to have a more gradual progression of parkinsonian signs and symptoms, earlier 
appearance of levodopa related dyskinesia and dose related motor fluctuations, as well as the 
more frequent presentation to clinicians with dystonia as an early sign [512]. 
 
The seminal study of Zetusky et al established the idea of clinical subtyping of patients with 
PD because of prognostic implications. In this study of patients with idiopathic PD (n=334), 
deterioration in mental status was correlated with the PIGD subtype while the TDPD subtype 
was associated with  relative preservation of mental status, earlier age at onset, family history 
of parkinsonism, and generally a more favourable prognosis [324]. Clinical subtyping of PD 
patients can be done in more than one way, to analyse the heterogeneity in their phenotypic 
characteristics [320].  
 
With this in mind we subtyped patients according to their motor presentation, gender, age at 
onset and family history of PD. We analysed the clinical data for variation in the motor, non-
motor, cognitive and quality of life domains of PD. We found heterogeneity in the phenotypic 
expression of PD across all domains, in some characteristics, while finding no statistically 
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significant differences in other variables. These differences are tabulated and presented in the 
relevant chapters in the thesis.  
 
While recognising that some of these differences may not have a direct impact on the way we 
manage PD cases, the stated aim of this research was not to change clinical practice but to 
analyse, quantify and document the heterogeneity in PD as well as to test hypothetical models 
of the factors responsible for this heterogeneity. 
 
The heterogeneity that we found in our EOPD cohort, is very likely to be an expression of the 
underlying differences in the mechanisms, both genetic and environmental, that culminate in 
the expression of disease in individual patients. This is the substrate on which a mix of 
iatrogenic factors in the form of dopaminergic and non-dopaminergic medications that these 
patients are prescribed generate a plethora of phenotypes, each with subtle differences from 
case to case but allowing for patients at a group level, to be classified under clinical subtypes.  
 
The drivers of variation can be summarised under the following 5 headings:  
 
i. Environmental influences 
 
Although no single environmental agent besides MPTP has been conclusively linked to PD, 
the influence of several environmental agents, both positively linked to the risk of developing 
PD such as pesticides [468],  heavy metals [469], solvents [470], rural living [473] and 
negatively linked to the risk of developing PD such as smoking [471], coffee [472], has come 
up in large scale epidemiological studies. Our research showed some differences in the 
exposure to environmental agents such as solvents and smoking amongst the various 
subgroups of patients, however, this was not in a case control study format, as our study did 
not recruit ‘normal controls’. We wanted to determine whether environonmental influences 
could account for some of the variation in the phenotypic characteristics as epigenetic factors 
i.e. interact with genes to change the odds of modifying the clinical characteristics of this 
disease [513]. While this may turn out to be true but environmental influences on their own 
can not explain all the variation. 
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ii. Genetic influences 
 
Mutations in several genes (SNCA, LRRK2, VPS35, Parkin, PINK1, LRRK2, GBA and DJ-1) 
can cause rare monogenic forms of the disease. Our research showed a prevalence of 10.1% 
of genetic cases of PD in the EOPD cohort randomly tested for mutations in 3 genes Parkin, 
GBA and LRRK2. Besides the mutation in these genes that are inherited in a Mendelian 
fashion recent work has focussed on, common variants of small effect size, called single 
nucleotide polymorphisms (SNP), at several loci identified in genome wide association 
studies (GWAS) which may not only modulate the risk for developing PD, but also influence 
the variation in its clinical characteristics [435]. Such influences include the recently reported 
findings of an association of certain SNPs and the age at onset of PD symptoms.  The most 
robust association reported was for rs10889162 polymorphism in a transcription factor 
binding site -582 bp from CYP2J2 arachidonic acid epoxygenase. Each variant allele was 
associated with 5.04 years older diagnosis age of patients (95% confidence interval 2.28-7.80, 
p=0.0003) in 258 newly diagnosed non-hispanic caucasian cases in Washington state, USA 
[514]. There are hundreds and thousands of such SNPs at numerous loci that are the focus of 
current research in PD and the protocol of the PRoBaND envisages genotyping all DNA 
samples using the Illumina Human Core Exome array, supplemented with custom content. 
This will allow the analysis of approximately 250,000 common and 250,000 rare variants, 
across the human genome. These SNPs have been selected because of their previous 
implication in a range of neurodegenerative, neurologic, and psychiatric disorders. 
 
iii. Gene-environment and gene-gene interactions 
 
The interaction of genes and environmental influences modifying the risk of developing PD 
has been studied. In one study pairwise interactions between environmental exposures and 18 
variants (16 SNPs and two variable number tandem repeats, or "VNTRs") in SNCA, MAPT 
and LRRK2 genes, were investigated using data from 1098 PD cases and 1098 matched 
controls. Five pairwise interactions had uncorrected p-values < 0.05. These included pairings 
of pesticides and SNCA rs3775423 or MAPT rs4792891; coffee drinking and MAPT H1/H2 
haplotype or MAPT rs16940806; alcohol drinking and MAPT rs2435211 [515].   
Several other studies have analysed gene environment interactions using different sets of 
genetic markers [516, 517]. This is an active field of research and in the years to come will 
306 
 
shed more light into how these interactions influence the variation in the clinical 
characteristics of this disorder. The analysis of gene-environment interactions was not done at 
this stage in PRoBaND as this would require the analysis of dozens of SNPs across the genes 
linked to PD; as alluded to above sequencing for these SNPs will be done in the next phase of 
the study. 
 
Besides gene environment interactions, current research also delves into the influence of 
gene-gene interactions in PD, for example, polymorphic variants in MAPT show a significant 
association with age of onset in individuals with LRRK2 mutations [518]. This finding has 
been replicated in different populations [519] and indicates an association of mutation-
affected protein domain and mutation-extrinsic genetic factors, suggesting that gene-gene 
interactions could influence the phenotypic heterogeneity observed in PD. Future research 
projects based on PRoBaND could analyse polymorphic variants in MAPT and other genes to 
study these influences.  
 
iv. Iatrogenic influences 
 
A significant contributor to variation in the clinical characteristics of PD, including motor 
complications such as dyskinesia and non-motor problems such as cognitive dysfunction and 
syncope, is the influence of prescribed medication. This includes medications specific for PD 
such as dopaminergic drugs and non-PD medications for comorbidities. We analysed the 
prescription of non-PD medications in a cohort of 360 patients to analyse system specific 
effects on the cardiovascular system and the results are presented at the end of Chapter 13. 
 
v. Multiple ‘hit’ hypothesis 
 
The focus of research has always been on the dopaminergic system as being ‘hit’ by the 
disease process in PD, however, evidence is emerging that other neurotransmitter systems are 
also ‘hit’ and contribute to the symptomatology of PD, particularly the non-motor aspects of 
this disease. Results of post mortem and molecular imaging studies reveal parallel 
degenerations of cortical noradrenaline (NA) and serotonin (5-HT) innervations, which may 
contribute to affective and cognitive changes of PD [520]. One could hypothesise that part of 
the variation in the clinical phenotype of PD may also result from how much the other 
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neurotransmitter systems are affected in different individuals and at different stages of PD. 
Looking at the depletion of non-dopaminergic systems in PD was not part of my remit in this 
research thesis but the imaging sub-studies of PRoBaND can provide a research platform for 
future scientific studies of how these influences contribute to the variation in the phenotypic 
expression of PD. 
 
A single model of population attributable risk factors for causing PD and explaining the 
variation in the phenotypic expression of PD would have to include environmental, lifestyle 
and genetic factors, individually and collectively. Several variables such as environmental 
exposures to chemicals, lifestlye factors such as smoking and genetic factors that include both 
monogenic disorders such as LRRK2 and polymorphic variants in other genes such as MAPT 
have been analysed by other groups using stepwise logistic regression [196]. Individually 
these influences contribute to small population attributable risks for PD but collectively they 
can contribute to a substantial proportion of the population attributable risk for developing 
PD [196]. 
 
In conclusion, there is a compelling need to further understand how all these influences 
converge and interact to bear upon the clinical expression of PD in individuals, their response 
to treatment, their risk of developing complications and prognosis. That PRoBaND can be a 
platform for this endeavour is a stated aim and future direction for this study and the 
researchers involved in it.  
 
The study protocol has a lab based component to look for proteomic and genetic biomarkers 
and the study set up allows collaboration with other similar studies such as OPDC. Pooling 
data on the genetic cases of PD can lead to more detailed phenotype-genotype correlations 
given the number of genetic cases in individual studies may not be large enough. 
 
The most important contribution, one could therefore argue, is that PRoBaND can provide 
access to a wealth of information and biological material about a very big cohort of cases, 
both EOPD and LOPD, for longitudinal follow up over years and decades which can help 
answer questions about the natural history, progression and prognosis of PD.   
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Limitations of methodology of the EOPD arm of the PRoBaND study  
 
One could argue that the lack of a control group in this arm would be a serious limitation to 
analyse the prevalence of some of the non-motor symptoms such as loss of sense of smell or 
depression that can be unrelated to EOPD and are common in the general population. 
However, one needs to bear in mind that the primary research goal as stated in the opening 
pages of this thesis is not to estimate the prevalence of non-motor symptoms in EOPD vis a 
vis the general population or to determine whether smoking is a protective influence on 
EOPD but to analyse the variation within an EOPD cohort. The analytical approach adopted 
for the EOPD arm was to analyse intraclass differences within several subtypes of EOPD 
replicating previous work done in LOPD. Nevertheless, we acknowledge that the lack of 
probability sampling is an important and obvious limitation to our research because it will 
prevent us from making any generalisations about the EOPD population. In the main arm of 
the PRoBaND study, a ten times larger datset will be avaialbe (n= 2000), with a control 
group (n=750) who will be age and sex-matched. This will then provide ample opportunities 
to answer specific hypothetical questions that could not be answered using data from the 
EOPD arm of the study. While every opportunity has been taken to minimise bias, there will 
be certain inherent selection biases that will exist in every prospective or retrospective study 
with pre-defined inclusion ansd exclusion criteria as well as a personal interface between 
recruiter, usually a clinician, and the recruit, usually a patient with the exception of controls.  
 
The accuracy of diagnosis of PD in life, when recruiting patients to studies, based on clinical 
criteria alone has been challenged and can not be absolute but when the Queen Square Brain 
Bank criteria (asymmetrical onset, no atypical features, and no possible etiology for another 
parkinsonian syndrome), are used as we have done in this study,  the proportion of true PD 
cases correctly identified is close to 95% compared to their autopsy pathologic diagnosis 
[521]. While most recent studies have used these as part of their inclusion criteria for 
classifying cases as PD, the same can not be said about historical studies. This limitation is 
recognised as a significant problem but is not specific to our study, our aim of linking with 
the Brain Bank study will provide avenues for further analysing clincopathologic data to 
provide a means of better defining clinical criteria for PD and this may include imaging 
modalities as a surrogate for autopsy brain tissue specimens. 
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